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Abstract 
Carnosine (β-alanyl-L-histidine), a histidine containing dipeptide, is one of the most 
abundant small-molecular compounds in human skeletal muscle. Supplementation with the rate 
limiting amino acid, β-alanine, has resulted in significant improvements to high-intensity exercise 
performance. The role of carnosine as an intracellular pH buffer is undisputable, yet other 
physiological roles have been proposed, including the potential influence of increased carnosine 
content on regulation of skeletal muscle calcium (Ca
2+
) kinetics. The movement of Ca
2+
 is vital 
during both skeletal muscle contraction and relaxation phases. The overall aim of this thesis was to 
investigate the effect of β-alanine supplementation on voluntary and electrically evoked contractile 
properties of in-vivo human skeletal muscle. To examine this research question, there were several 
aims of this thesis, initially to examine the effect of β-alanine supplementation on intrinsic in-vivo 
isometric knee extensor force production and skeletal muscle contractility in both fresh and 
fatigued human skeletal muscle in young (Studies 1 and 2; Chapters 4 and 5) and older (Study 3; 
Chapter 6) adults. The distribution of the carnosine molecule across subcellular fractions within rat 
skeletal muscle tissue was explored, as well as the impact of increased carnosine availability on 
ATPase activity, a measure associated with skeletal muscle relaxation, estimated by Pi generation. 
In young adults, 28-days of β-alanine supplementation did not significantly influence voluntary and 
evoked force responses, or the force-frequency relationship, the in-vivo analogue of the force-Ca
2+
 
relationship, in either fresh (Studies 1 and 2; Chapters 4 and 5) or fatigued (Study 2; Chapter 5) 
skeletal muscle. Furthermore, older adults experiencing pre-existing declines in skeletal muscle 
function due to ageing, demonstrated no beneficial effect of 28-days β-alanine supplementation on 
voluntary or electrically evoked skeletal muscle contractions (Study 3; Chapter 6). In young adults, 
there was, however, a significant decline in skeletal muscle half-relaxation time (HRT) during 
electrically evoked octet contractions, resting and potentiated twitches (Studies 1 and 2; Chapters 4 
and 5). Two possible steps influence skeletal muscle relaxation speed include the Ca
2+
 removal 
from the myoplasm and Ca
2+
 dissociation from troponin followed by cross-bridge detachment. 
Based on the in-vivo research, it was proposed that there was a direct or indirect mechanism 
associated with activity of the sarcoplasmic/endoplasmic reticulum Ca
2+
 ATPase (SERCA) pump, 
the proposed rate-limiting step of muscle relaxation. In-vitro analysis of ATPase activity 
demonstrated that SERCA activity was unaffected by increased carnosine concentrations, although 
there was a significant increase in overall ATPase activity (Study 4; Chapter 7). The results in this 
thesis showed that β-alanine supplementation was effective in improving skeletal muscle HRT in 
young adults, although not in healthy older adults. The exact mechanism associated with the in-vivo 
decline in skeletal muscle HRT remains unclear, yet raising the availability of carnosine in-vitro, 
does increase overall ATPase activity, although not Ca
2+
-dependent or SERCA activity. 
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1.1 Introduction 
Carnosine, is a histidine containing dipeptide, found in high-concentrations in the skeletal 
muscle of vertebrates and non-vertebrates. Following ingestion from the diet, carnosine is broken 
down into its two constituent amino acids, β-alanine and L-histidine (Sadikali et al., 1975). Upon 
entering the skeletal muscle, carnosine is formed by the bonding of β-alanine and L-histidine, in a 
reaction catalysed by carnosine synthase (Harding & Margolis, 1976; Horinishi, Grillo & Margolis, 
1978). The availability of β-alanine is the rate limiting factor of skeletal muscle carnosine synthesis 
(for a brief review, see Harris et al., 2012). Supplementation with β-alanine is regarded as the most 
beneficial means of increasing muscle carnosine content (Asatoor et al., 1970). In young adults, 
daily doses of β-alanine have been shown to raise skeletal muscle carnosine content in a dose-
dependent manner, with 40 to 80% increases evident over a 4 to 10-week duration, almost without 
exception, on an individual-by-individual basis (Harris et al., 2006; Hill et al., 2007; Baguet et al., 
2010; Sale et al., 2013). Increasing skeletal muscle carnosine content, with β-alanine 
supplementation, has been shown to be ergogenically beneficial to high-intensity exercise 
performance, as highlighted by several reviews (see Artioli et al., 2010; Sale et al., 2010; 2013). 
Two meta-analyses have supported the positive effect of β-alanine supplementation on high-
intensity exercise performance (Hobson et al., 2012; Saunders et al., 2017). Tasks lasting between 
60 and 240 s have gained the largest beneficial effect, specifically when the tasks include open 
ended exercise bouts, such as time to exhaustion tests (TTE) (Hobson et al., 2012; Saunders et al., 
2017). Supplementation with daily doses of β-alanine in older adults (60-80 y) have also shown to 
significantly increase skeletal muscle carnosine content, alongside improvements in physical 
exercise capacity (Stout et al., 2008; del Favero et al., 2012; McCormack et al., 2013; Glenn et al., 
2016). That said, β-alanine supplementation has been shown to not significantly benefit measures 
of muscle function or quality of life (del Favero et al., 2012; Glenn et al., 2016). Due to the small 
number of investigations examining the impact of β-alanine supplementation in this population, the 
impact of increased skeletal muscle carnosine content on skeletal muscle function remains 
undetermined.  
 
Carnosine was first described as an intracellular pH buffer (Bate-Smith, 1938; Deutsch & 
Eggleton, 1938), due to the imidazole ring of carnosine having a pKa of 6.83, making carnosine a 
suitable intracellular buffer over the whole exercise induced intramuscular pH transit-range (Bate-
Smith et al., 1938; Harris et al., 2006). The role of carnosine as a pH buffer, explains some of the 
ergogenic effects of β-alanine supplementation on exercise performance and capacity (Hobson et 
al., 2012; Saunders et al., 2017). This does not, however, exclude the possibility that carnosine may 
have other physiological roles. One such role, is the potential influence of carnosine on regulating 
Ca
2+
 kinetics within the skeletal muscle (Lamont & Miller, 1992; Batrukova & Rubtsov, 1997; 
Dutka & Lamb, 2004; Dutka et al., 2011; Everaert et al., 2013). In-vitro research has suggested that 
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increased skeletal muscle carnosine content may impact the amount of Ca
2+
 released during skeletal 
muscle contraction and/or the sensitivity of contractile properties to Ca
2+
 (Lamont & Miller, 1992; 
Batrukova & Rubtsov, 1997; Dutka & Lamb, 2004; Dutka et al., 2011; Everaert et al., 2013). 
Carnosine may interact with the Ca
2+
-channel itself (Batrukova & Rubstov, 1997), through the 
existence of saturable binding site(s) on the Ca
2+
-channel. In-vitro research indicated that 
increasing skeletal muscle carnosine content, via β-alanine supplementation, could alter the Ca2+ 
kinetics properties of the muscle. It remains unclear, however, if this proposed in-vitro mechanism 
is apparent during in-vivo skeletal muscle contractions. Any improvements in skeletal muscle 
function following increased skeletal muscle carnosine content, via β-alanine supplementation, 
would possibly benefit overall skeletal muscle performance.  
 
The overall aim of this programme of work was to investigate the effect of β-alanine 
supplementation on voluntary and electrically evoked contractile properties of in-vivo human 
skeletal muscle. The impact of increased skeletal muscle carnosine content, via 28-days of β-
alanine supplementation, on in-vivo neuromuscular performance, in young and older healthy adults 
was examined. In-vitro research was undertaken to examine the potential effect of increased 
carnosine concentrations on SERCA activity, a mechanism possibly associated with the 
improvements in skeletal muscle relaxation reported in-vivo.  
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1.2 Overview 
Brief outlines of the experimental chapters reported within this thesis are as follows; the 
research reported within study 1 (Chapter 4) examined the effect of 28-days β-alanine 
supplementation on the intrinsic contractile properties of human skeletal muscle in-vivo, as well as 
on voluntary muscle function in young (18 - 30 y) healthy males. Neuromuscular performance was 
examined using measures such as the force-frequency relationship, pre- and post- β-alanine 
supplementation, providing an in-vivo analogue of the force-Ca
2+
 relationship (Balnave & Allen, 
1996). 
 
Study 2 (Chapter 5) examined the effect of β-alanine supplementation on intrinsic in-vivo 
isometric knee extensor force production and muscle contractility in both fresh (rested conditions) 
and fatigued human skeletal muscle. These data in young adults provide support to the previous 
research (Study 1; Chapter 4), whilst also examining the influence of increased skeletal muscle 
carnosine content on neuromuscular function following the completion of an isometric knee 
extensor endurance task (IKET).  
 
Following studies 1 and 2 (Chapter 4 and 5) conducted in young adults, study 3 (Chapter 6) 
investigated the effect of β-alanine supplementation on intrinsic in-vivo isometric knee extensor 
force production and muscle contractility in both fresh and fatigued human skeletal muscle in older 
(60 - 80 y) healthy adults. These data extend the currently limited β-alanine supplementation 
research in this population, investigating the potential impact of increased carnosine content on 
skeletal muscle function in older adults.  
 
The in-vivo data within the thesis explored the influence of 28-days β-alanine supplementation 
on neuromuscular function in young and older adults, under fresh and fatigued skeletal muscle 
conditions. Study 4 (Chapter 7) isolated the microsomal fraction of rat skeletal muscle tissue and 
examined the impact of increased carnosine concentrations on ATPase activity, a factor related to 
skeletal muscle relaxation. These data also included analysis of the distribution of the carnosine 
molecule, and its constituents, β-alanine and L-histidine within the nucleic, mitochondrial, 
cytosolic and microsomal fractions of the skeletal muscle cell. The in-vitro findings reported within 
study 4 (Chapter 7) are supported by the development of several methodological processes, as 
reported in appendix 1.  
  
Chapter 2: Review of literature 
 
  5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Review of literature 
  
Chapter 2: Review of literature 
 
  6 
2.1 Carnosine 
Carnosine, a dipeptide consisting of β-alanine and L-histidine (Krimberg, 1906; 1908) 
characterised by three ionisable groups: the carboxyl group (pKa 2.76), the amino group of the β-
alanine residue (pKa 9.32), and the nitrogen of the imidazole ring (pKa 6.83; Vistoli et al., 2012). 
Carnosine was first isolated by Gulewitsch and Amiradzhibi (1900) in the early 1900s from Liebigs 
meat extract, and is now known to be one of the most abundant small-molecular compounds in 
human skeletal muscle (Fig. 2.1). In addition to its high content within in human skeletal muscle, 
over the last 100 years’ carnosine has been identified in numerous other animal species (Boldyrev, 
2013), most prominently in those involved in athletic performance, including horses, greyhounds, 
and camels (Harris et al., 1990; Dunnett & Harris, 1997). It has been suggested that animal species 
where a periodical demand from anaerobic exercise, or tolerance to imposed hypoxic condition 
elevates muscle carnosine content (Abe, 2000; Harris et al., 1990). Cetaceans’ mammals have 
some of the largest reported skeletal muscle carnosine contents (Suyama et al., 1977), theoretically 
due to experiencing prolonged periods of hypoxia when diving. The concentration of skeletal 
muscle carnosine of vertebrates varies according to the species from 0.6 mM in mice, up to 10 and 
30 mM in humans and horses (Crush, 1970).  
 
 
Fig. 2.1: Molecular structure of carnosine, β-alanine and L-histidine 
 
2.1.1 Carnosine transport into human skeletal muscle 
In humans, carnosine enters the small intestine following dietary intake, where it is 
transported across the cellular membrane by a peptide transporter (PEPT1; Fig. 2.2). PEPT1 is 
characterised as a high-capacity, low-affinity transporter and plays a major nutritive role in the 
intestinal absorption of peptides. The presence of carnosinase, an enzyme that hydrolyses carnosine, 
in the enterocytes of humans (Sadikali et al., 1975) suggests that carnosine is broken down into its 
constituent amino acids (β-alanine and L-histidine) via tissue/jejunal carnosinase enzyme (CNDP2) 
prior to entering the blood stream. Nonetheless, due to the low activity of CNDP2 in the jejunum 
Carboxyl group 
Amino group of 
the β-alanine 
residue 
Imidazole ring 
Carnosine 
Carnosinase 
Carnosine 
synthase 
β-alanine L-histidine 
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(Sadikali et al., 1975), parts of the ingested carnosine reach the blood stream via peptide 
transporters (Fig. 2.2). Upon entering the blood stream, the remaining carnosine is rapidly 
hydrolysed due to the presence of the highly active serum carnosinase enzyme (CNDP1) (Asatoor 
et al., 1970; Perry et al., 1967). Small amounts (<14% of ingested carnosine) of intact carnosine 
have, however, been shown in urine in the 5 h following carnosine ingestion (Block et al., 1965; 
Perry et al., 1967; Gardner et al., 1991). β-alanine and L-histidine enter the blood stream from the 
enterocytes, via amino acid transporters, ready for transportation into the skeletal muscle by a 
Taurine transporter (Tau-t; Fig. 2.2). Upon entering the skeletal muscle, β-alanine and L-histidine 
are re-synthesised into carnosine by the enzyme carnosine synthase (Harding & Margolis, 1976; 
Horinishi, Grillo & Margolis, 1978; Fig. 2.1). Carnosine synthetase is a member of the adenosine 
triphosphate (ATP)-grasp family of ATPases, which catalyses ATP, β-alanine and L-histidine into 
carnosine, phosphate and adenosine diphosphate (ADP). The process of skeletal muscle carnosine 
synthesis is limited by the availability of β-alanine from the diet (for a brief review see Harris et al., 
2012).  
Fig. 2.2: A schematic illustration of the pathways of intestinal absorption of carnosine, β-alanine 
(BA) and L-histidine in humans. Highlighting potential roles of carnosine in skeletal muscles cells. 
CNDP2: Jejunal carnosinase enzyme; CNDP1: Serum carnosinase enzyme. PEPT1: Peptide 
transporter 1. PHT: Peptide histidine transporter. Tau-t: Taurine transporter (Adapted from 
Boldyrev, 2013). 
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2.1.2 Determinants of skeletal muscle carnosine content 
2.1.2.1 Diet 
In humans, carnosine can be ingested directly through several dietary sources, including 
red and white meats (e.g., beef and poultry) and fish (e.g., salmon) (Abe, 2000). Neither dairy nor 
vegetable food products contain L-histidine containing dipeptides or β-alanine, except for the very 
small presence of β-alanine in vegetable oils, at ~100 to 1,000 times lower than those in meat 
(Sanchez-Hernandez, Marina & Crego, 2011). In an omnivorous Western diet, due to the ingestion 
of animal products, the average daily intake of β-alanine has been calculated at ~330 mg.day-1 
(Everaert et al., 2010). This estimate is likely to be highly variable given that the cooking method is 
a critical factor in maintaining meat carnosine content, with some cooking procedures resulting in a 
complete carnosine loss (Harris et al., 2012). Individuals who do not consume animal products 
(vegans or vegetarians) rely solely on endogenous sources of β-alanine, with ~20% lower muscle 
carnosine content compared to omnivores counterparts (Everaert et al., 2010). Long term 
vegetarianism (>8 y) has been associated with declined carnosine content in the m. soleus (-17%; P 
= 0.05), m. gastrocnemius (-26%; P = 0.01) and m. tibialis anterior (20%; P = 0.07), when 
compared to omnivorous. Short term dietary restriction of β-alanine (5 weeks) through transiently 
switching omnivores onto vegetarian diets, reported a 9% reduction in m. soleus carnosine 
concentrations. Highlighting the highly sensitive and dependant nature of skeletal muscle carnosine 
concentrations upon the availability of dietary β-alanine in humans.  
 
2.1.2.2 Muscle fibre type 
Carnosine is evident in both slow (Type I) and fast (Type II) skeletal muscle fibres, with 
greater content in Type II fibres compared to Type I (Dutka et al., 2012; Stellingwerff et al., 2011; 
Harris et al., 2012). Within the same human skeletal muscle (m. vastus lateralis) carnosine content 
can vary widely, with Type I muscle fibres around half the carnosine content of those in Type II 
muscle fibres (Type I: 10.5 mmol
.
kg
-1
 dry muscle (DM); Type II: 23.2 mmol
.
kg
-1
 DM; Harris et al., 
1998). A similar distribution of muscle carnosine concentration between fibre type in the human m. 
vastus lateralis was replicated by Hill et al., (2007), with Type II fibres displaying 1.7 times greater 
than those reported in Type I fibres (Type I; 17.8 mmol
.
kg
-1
 DM, Type II; 29.6 mmol
.
kg
-1
 DM). 
Larger carnosine content in Type II muscle fibres are also been shown in numerous other species, 
with content reaching 4 – 5 times those in Type I fibres (Dunnett & Harris, 1995; Dunnett et al., 
1997). β-alanine supplementation over a 10-week period does, however, increase muscle fibre 
carnosine content in both Type I and II muscle fibres to a similar extent (16.5 mmol
.
kg
-1
, and 17.0 
mmol
.
kg
-1
), thereby maintaining the muscle carnosine content ratio between muscle fibre types. 
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2.1.2.3 Sex  
In humans, males have a ~21% greater skeletal muscle carnosine content (21.3 ± 4.2 
mmol
.
kg
-1
) than those reported in females (17.5 ± 4.8 mmol
.
kg
-1
; Mannion et al., 1992; Everaert et 
al., 2011). These sex-related differences are dependent on muscle fibre type, with males displaying 
a 30% increase in carnosine content in skeletal muscles that are predominantly Type I fibres (m. 
soleus and m. gastrocnemius; Everaert et al., 2011). The magnitude is increased to 82% in skeletal 
muscles predominantly Type II fibres, such as the m. tibialis anterior (Everaert et al., 2011). The 
differences between sexes may also be associated with a significantly higher plasma carnosinase 
activity in females (P < 0.001). Nonetheless, during the period of skeletal muscle carnosine loading, 
sex and body mass variances have only a minimal effect on the absolute increases in skeletal 
muscle carnosine content (Stegen et al., 2014). 
 
2.1.2.4 Training  
Compared to untrained individuals, skeletal muscle carnosine content are significantly 
higher in elite athletes (Parkhouse et al., 1985; Tallon et al., 2005), specifically in competitive 
bodybuilders where carnosine contents were twice that of those in their age-matched untrained 
counterparts (Tallon et al., 2005). These contents are some of the largest human skeletal muscle 
carnosine content reported (Tallon et al., 2005), possibly due to these individuals experiencing 
prolonged repetitive exposure to low muscle pH, alterations to their diet, ingestion of dietary 
supplements, and/or the use of anabolic steroids (Tallon et al., 2005). Exercise training may also be 
responsible for these increased skeletal muscle carnosine concentration (Suzuki et al., 2004), yet 
there are limited exercise intervention studies to support this theory (Kendrick et al., 2008; Baguet 
et al., 2011). Research combining 10 weeks of β-alanine supplementation (6.4 g.day-1) and 
resistance training reported increased skeletal muscle carnosine content only following β-alanine 
supplementation (+12.81 ± 7.97 mmol
.
kg
-1 
DM; Kendrick et al., 2008). Furthermore, no change in 
skeletal muscle carnosine content was evident within the placebo group, even after the completion 
of the resistance training programme (Kendrick et al., 2008). Nonetheless, resistance trained 
individuals are likely to partake in extended periods of training, over several months and years, 
rather than participating in short training programmes. It could be speculated that the current 
resistance training protocols were not of sufficient duration to illicit increased muscle carnosine 
contents. It could also be hypothesised that elite athletes have higher skeletal muscle carnosine 
contents compared to untrained individuals’ due to increased muscle mass, specifically more Type 
II muscle fibres where larger carnosine content are reported (see section 2.1.2.2; page 8).  
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2.1.2.5 Ageing 
The research examining the impact of ageing on skeletal muscle carnosine content is 
limited, with no longitudinal research to support the negative correlation evident in cross-sectional 
investigations (Peñafiel et al., 2004; Tallon et al., 2007; Everaert et al., 2011; Fig. 2.3). Current 
research reports large reductions in skeletal muscle carnosine content (~53%) in Type II muscle 
fibres of older participants, compared to younger adult counterparts (Tallon et al., 2007). Cross-
sectional data from the m. soleus of individuals aged 19 - 47 y demonstrated a negative correlation 
between age and skeletal muscle carnosine content, with carnosine content declining at a rate of 
1.2% per year (Everaert et al., 2011; Fig. 2.3). These data, however, are largely focused on 
individuals under the age of 30 y, with no data in adults over the age of 60 y, limiting the 
interpretation of these analyses. The negative correlation between carnosine concentrations and 
ageing, reported previously (Everaert et al., 2011), is weak (r= -0.26). As such, to fully understand 
this relationship additional confirmation data is required, specifically in older adults. Furthermore, 
the current data is undertaken in Type I muscle fibres (Everaert et al., 2013), Type I muscle fibres 
are known to contain around half the carnosine content of those in Type II muscle fibres (Harris et 
al., 1998; Section 2.1.2.2), to support the reported decline in carnosine concentrations with ageing, 
and understand this relationship, analysis of both Type I and Type II muscle fibres would be 
essential The exact reasons for the decline in skeletal muscle carnosine content remains unclear 
(Peñafiel et al., 2004; Tallon et al., 2007; Everaert et al., 2011). Although numerous potential 
mechanisms have been proposed, including a decline in physical activity, the amount of meat 
consumed by older individuals (Harris et al., 2006), an overall reduction in muscle mass, and/or 
lower levels of circulating free testosterone (Peñafiel et al., 2004).  
Fig. 2.3: Skeletal muscle carnosine content of the m. soleus in male and female adult human 
omnivores (P < 0.05, r = -0.26, n = 58). Redrawn from Everaert et al., (2011). 
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2.1.3 Increasing muscle carnosine content 
Increasing the availability of free β-alanine, either via dietary or supplemental means, 
results in significantly increased in skeletal muscle carnosine content (Harris et al., 2006; Hill et al., 
2007; Derave et al., 2007; Baguet et al., 2009; Baguet et al., 2010). In humans, carnosine does not 
remain under tight homeostatic control, unlike other intracellular buffers (Gollnick et al., 1991), 
therefore, the ability to significantly alter carnosine content making it highly valuable. 
Supplementation with β-alanine is regarded as the most beneficial means of increasing muscle 
carnosine content, above that of supplementation with carnosine (Asatoor et al., 1970), potentially 
due to the mechanism by which carnosine is transported and formed within the skeletal muscle 
(Perry et al., 1967; Asatoor et al., 1970). The relationship between β-alanine supplementation and 
skeletal muscle carnosine content occurs in a dose dependent manner, with increases in carnosine 
content of between 40 and 80%, dependent upon β-alanine supplemental dose (between 3.2 and 6.4 
g
.
d
-1
) and duration (between 4 - 10 weeks; Harris et al., 2006; Derave et al., 2007; Hill et al., 2007; 
Baguet et al., 2010; Sale et al., 2013; Saunders et al., 2017; Fig. 2.4). Harris and colleagues (2006) 
were the first to report this relationship, with human skeletal muscle carnosine content increasing 
by ~65% following 28-days of β-alanine supplementation (6.4 g.d-1). Parallel increases in the m. 
vastus lateralis carnosine content of 60% are reported by Hill et al., (2007) following a similar 28-
day β-alanine supplementation protocol (6.4 g.d-1). The supplementation period was extended for 
an additional six weeks, where skeletal muscle carnosine content continued to increase (~20%), 
Fig. 2.4: Percentage increase in skeletal muscle carnosine concentration following β-alanine 
supplementation, data from muscle biopsy or proton magnetic resonance spectroscopy (
1
H-MRS) 
analysis. Data from Harris et al., (2006); Derave et al., (2007); Hill et al., (2007); Kendrick et al., 
(2008; 2009); Baguet et al., (2010); Stellingwerff et al., (2011); del Favero et al., (2012); Bex et 
al., (2013); Sale et al., (2013); Chung et al., (2014); Gross et al., (2014); Stegen et al., (2014); 
Danaher et al., (2014); Saunders et al., (2016). 
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increasing baseline skeletal muscle carnosine content by ~80% (Hill et al., 2007). These data have 
been extended by numerous investigations, consistently reporting increased skeletal muscle 
carnosine contents following β-alanine ingestion (Derave et al., 2007; Kendrick et al., 2008; 
Baguet et al., 2010; Stellingwerff et al., 2011; del Favero et al., 2012; Bex et al., 2014; Chung et 
al., 2014; Gross et al., 2014; Stegen et al., 2014; Danaher et al., 2014; Saunders et al., 2017; Fig. 
2.4). Increased skeletal muscle carnosine content, following β-alanine supplementation, was 
examined using either muscle biopsies, or proton magnetic resonance spectroscopy (
1
H-MRS) 
(Harris et al., 2006; Hill et al., 2007; Derave et al., 2007; Kendrick et al., 2008; Baguet et al., 
2010; Stellingwerff et al., 2011; del Favero et al., 2012; Bex et al., 2014; Chung et al., 2014; Gross 
et al., 2014; Stegen et al., 2014; Danaher et al., 2014). To date, only one participant has displayed 
no increase in carnosine content following β-alanine ingestion (Harris et al., 2006). The longest 
duration of β-alanine supplementation to assess skeletal muscle carnosine concentration was 
undertaken by Saunders et al., (2017), with individuals completing a total of 24-weeks of β-alanine 
supplementation (5.2 g
.
d
-1
). Skeletal muscle carnosine content significantly increased from baseline 
at all assessed time points during the 24-week β-alanine supplementation protocol (all P < 0.001; 
Week 4: +11 ± 7 mmol·kg
-1
DM, Week 8: +14 ± 8 mmol·kg
-1
DM, Week 12: +17 ± 9 mmol·kg
-1
DM, 
Week 16: +18 ± 8 mmol·kg
-1
DM, Week 20: +21 ± 8 mmol·kg
-1
DM, Week 24: +20 ± 8 mmol·kg
-
1
DM). The current body of β-alanine supplementation research has largely been conducted in 
younger adult males (18 – 30 y; see reviews Sale et al., 2010; 2013; Hobson et al., 2012; Saunders 
et al., 2017), and although these data suggest a dose-dependent relationship there remains limited 
understanding of the impact of β-alanine supplementation on skeletal muscle carnosine contents in 
older adults.  
 
The impact of β-alanine supplementation on skeletal muscle carnosine content in older 
individuals (60 – 80 y) has recently been investigated (del Favero et al., 2012). Skeletal muscle 
carnosine content of the m. gastrocnemius, assessed via 
1
H-MRS measurements in older adults 
significantly increased (β-alanine: + 85%, PLA: +7%; P = 0.004) following 12-weeks of β-alanine 
supplementation (3.2 g
.
d
-1
; total dose; ~269 g). The ingestion of β-alanine at 3.2 g.d-1 is currently 
the largest daily dose reported in older adults (del Favero et al., 2012; McCormack et al., 2013; 
Glenn et al., 2016), half that currently implemented in similar investigations in younger adults 
(~6.4 g
.
d
-1
; see review Sale et al., 2010; 2013). Ingestion of β-alanine at the lower daily dose of 3.2 
g
.
d
-1 
is sufficient in significantly raising skeletal muscle carnosine content, with an 85% increase 
evident following 12-weeks of supplementation (total dose: 269 g; del Favero et al., 2012). The 
smaller daily dosing strategies are largely undertaken due to the associated declines in muscle mass 
experienced by older individuals, and the potential risk of experiencing the negative side effect of 
β-alanine supplementation, paraesthesia. Currently there has only been one documented case of 
older individuals experiencing feelings of paraesthesia with β-alanine supplementation at 3.2 g.d-1 
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(Glenn et al., 2016). There was, however, no change between research findings with and without 
this individual’s data (Glenn et al., 2016). Based on the present literature, supplementation with β-
alanine at a daily dose of 3.2 g
.
d
-1
 is suitable for adults aged 60 to 80 y, without the risk of 
paraesthesia, maintaining the double-blind status of research investigations. Currently, it remains 
unknown if older adults can tolerate daily doses of β-alanine above 3.2 g.d-1, without experiencing 
the negative side effect of paraesthesia.  
 
Short term (4-weeks) β-alanine supplementation has been widely undertaken to raise 
skeletal muscle carnosine content (Derave et al., 2007; Kendrick et al., 2008; Baguet et al., 2010; 
Stellingwerff et al., 2011; del Favero et al., 2012; Bex et al., 2014; Chung et al., 2014; Gross et al., 
2014; Stegen et al., 2014; Danaher et al., 2014). Recently long-term (24 weeks) β-alanine 
supplementation protocols have been undertaken showing that skeletal muscle carnosine content 
may not increase continuously until maximal in all individuals, with skeletal muscle carnosine 
content declining at certain times points, despite maintaining ingestion (Saunders et al., 2017). 
Interestingly, a fifth of the participants (5 out of 25) reported their highest carnosine content at the 
24-week time-point, suggesting that for these individuals further increases in skeletal muscle 
carnosine content would have been evident if β-alanine supplementation was maintained. 
 
Based on the current short term (~ 28-days) β-alanine supplementation data, maintenance 
of increased muscle carnosine concentration is achievable with a much smaller concentration of β-
Fig. 2.5: The relative change in muscle carnosine concentrations after six weeks of loading (3.2 g
.
d
-
1
), proceeded by five different maintenance phases. *P < 0.05 from post-loading levels. Redrawn 
using data from Stegan et al., (2014), Stellingwerff et al., (2012) and Baguet et al., (2009).  
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alanine (1.2 g
.
d
-1
; Stegen et al., 2014; Fig. 2.5). Upon discontinuation of β-alanine supplementation, 
carnosine synthesis returns to normal, resulting in a 2 to 4% decline in skeletal muscle carnosine 
content per week (Baguet et al., 2009); a process referred to as carnosine washout (Baguet et al., 
2009; Stellingwerff et al., 2012; Stegen et al., 2014; Fig. 2.5). Based on current literature, an 
individual with increased muscle carnosine content of greater than 55% following β-alanine 
supplementation would require a washout period of up to 15 weeks. To ensure that participants are 
all starting investigations at a normal skeletal muscle carnosine content, researchers must confirm 
that all individuals refrain from β-alanine supplementation for a minimum of almost four months 
before participating. This significant period required for skeletal muscle carnosine washout 
demonstrates the impracticality of implementing cross-over research designs when implementing 
β-alanine supplementation protocols.  
 
2.1.4 Side effects of β-alanine supplementation 
Ingestion of β-alanine in powder form at a single dose of > 10 mg.kg-1 BM rapidly 
increases blood plasma content, associated with symptoms of paraesthesia, which can continue for 
> 60 min (Harris et al., 2006; Fig. 2.6). Paraesthesia is a neuropathic pain, resulting in the 
experience of a prickly sensation affecting areas of the face, neck, shoulders, chest and buttocks 
(Harris et al., 2012; Decombaz et al., 2012). To reduce the incidence of paraesthesia, a sustained 
release formulation was developed by Natural Alternatives International (NAI; Carnosyn, San 
Marcos, California, USA). The sustained release formulation imposes a physical restriction on the 
Fig. 2.6: Mean plasma β-alanine concentration following ingestion of 10, 20 and 40 mg.kg-1 bwt β-
alanine. For clarity SE of the means is shown only for measurements following 20 and 40 mg
.
kg
-1
 
bwt β-alanine. Redrawn from Harris et al., (2006).  
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amount of β-alanine released into the gut, slowing the release of β-alanine into the blood stream 
(~6 h), and reducing the peak plasma concentration from a single dose (Decombaz et al., 2012). 
Due to the reduced symptoms of paraesthesia, even at larger single doses of β-alanine, ingestion of 
sustained release tablets is now more commonplace (Sale et al., 2011; Saunders et al., 2012). 
Participants appear to be unable to differentiate between the β-alanine and matched placebo tablets 
in this sustained release form (Decombaz et al., 2012). Apart from paraesthesia, no other side 
effects of β-alanine have been reported (Harris et al., 2006). 
 
2.2 β-alanine supplementation and exercise performance 
In the last 10 years, there has been significant research examining the influence of 
increased skeletal muscle carnosine content on exercise performance (see meta-analyses Hobson et 
al., 2012; Saunders et al., 2017). Due to the undeniable role of carnosine as an intracellular pH 
buffer (see section 2.3; see reviews Sale et al., 2010; 2013), exercise performances that are likely to 
experience the generation of large quantities of H
+
, and thus disruption to acid-base balance, have 
been significantly improved following β-alanine supplementation (Hill et al., 2007; Sale et al., 
2011). The current review will specifically focus on the literature surrounding β-alanine 
supplementation to increase skeletal carnosine concentrations and neuromuscular performance, in 
line with the aim of the current body of work.  
 
2.2.1 Younger individuals  
Stout et al., (2006) investigated the effect of 28-days of β-alanine and creatine 
monohydrate supplementation on the onset of neuromuscular fatigue as assessed by the physical 
working capacity at neuromuscular fatigue threshold test (PWCFT). In untrained males, β-alanine 
supplementation at 1.6 g
.
d
-1
 for 28-days, delayed the onset of neuromuscular fatigue during the 
PWCFT, with cycling performance times increasing by ~17%. A similar 14% increase in ventilatory 
threshold was shown in physically active women following 28-days of β-alanine supplementation; 
3.2 g
.
d
-1
 in week one, increasing to 6.4 g
.
d
-1
 in weeks two to four. It is likely that these reported 
improvements in performance are associated with the increase in skeletal muscle carnosine content, 
thereby a greater capacity to buffer H
+
 during high-intensity exercise. To explore this mechanism in 
an isolated condition, Ponte and colleagues (2006) examined the effect of β-alanine 
supplementation (6.4 g
.
d
-1
; total dose of 179 g) on an IKET at 45 – 50% maximal voluntary 
isometric force (MVIF). Twenty-eight days of β-alanine supplementation improved IKET 
performance by 10 - 15%, equating to around 8-s (Ponte et al., 2006). Sale et al., (2012) reported a 
similar increase in IKET hold times, around 10 s (13%), following 28-days of β-alanine 
supplementation at 6.4 g
.
d
-1
 (total dose: 179.2 g). The IKET hold time were within 3 - 4 s of the 
expected hold duration of 78 s (Ahlborg et al., 1972), as predicted by the Rohmert equation 
(Rohmert, 1960). These hold times indicated that participants completed the IKET at the hold 
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target of 45% MVIF. Research examining the influence of β-alanine supplementation on IKET 
hold time in trained sprinters, however, showed no significant improvement following 28-days of 
supplementation (4.8 g
.
d
-1
; total dose: 134.4 g; Derave et al., 2007). The duration of the IKET hold 
times were markedly above those expected at a hold intensity of 45% MVIF (~78 s; Ahlborg et al., 
1972). Furthermore, based on the hold times reported, it has been speculated that the trained 
sprinters were completing the IKET at ~25% MVIF (Sale et al., 2012); much lower than instructed 
(Derave et al., 2007). Completion of the IKET at this intensity may have restricted skeletal muscle 
blood flow, yet complete occlusion of the skeletal muscle would have been unlikely (Sale et al., 
2012). As such, this hold intensity would have allowed maintenance of H
+
 transport from the 
skeletal muscle, prolonging the duration of the task.  
 
A recent meta-analysis by Hobson et al., (2012) demonstrated that supplementation with β-
alanine for 28-days, at 6.4 g
.
d
-1
, significantly improved exercise measures by ~3% when compared 
to the placebo condition. A significant overall ES of 0.18 (95% CI 0.08 to 0.28) following β-
alanine supplementation was reported, based on 40 individual studies, employing 65 different 
exercise protocols, totalling 70 exercise measures, in 1461 participants. The majority of these data 
however, were undertaken in recreationally active individuals, rather than elite athletes, who may 
not experience the same levels of ergogenic effect (Hobson et al., 2012). Disparity between 
investigations may be associated with variations in methodological design, such as, exercise 
intensity and duration, supplementation dosage, publication bias, training status, and lack of 
familiarisation (Hobson et al., 2012).  
 
There is currently a large body of evidence to support the ergogenic effect of increased 
skeletal muscle carnosine content, via β-alanine supplementation, on high-intensity exercise 
performance. Nonetheless, there remains limited support for the beneficial effect of β-alanine 
supplementation on maximal strength performance measures (Hoffman et al., 2006; Kendrick et al., 
2008). One of the few studies to explore this was undertaken in physically active males, 
supplemented with either placebo, creatine, or creatine and β-alanine in combination with a 
resistance training programme, over a 10-week period (3.2 g
.
d
-1
; total dose: 224 g; Hoffman et al., 
2006). Resistance training significantly improved free weight squat one-repetition maximum 
(1RM), and individuals supplemented with either creatine or creatine plus β-alanine improved to a 
greater extent, that those in the placebo group (P < 0.05; ES > 0.89). Bench press performance 
increased two-fold greater in the creatine and β-alanine group, and two and a half-fold greater with 
creatine supplementation, compared to the placebo group. Creatine supplementation increased 
strength performance, although there was no additional benefit to co-ingestion of creatine and β-
alanine supplementation. The effect of 10 weeks resistance training and β-alanine (6.4 g.day-1) 
demonstrated no beneficial effect on whole-body strength (box squat, bench press and dead lift) 
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and isokinetic dynamometer strength, even though skeletal muscle carnosine content increased by 
13 ± 8 mmol
.
kg
-1
 DM (Kendrick et al., 2008). These types of strength activities are not limited by 
the buffering capacity of the skeletal muscle; therefore, it seems expected that β-alanine 
supplementation would not result in improved muscular strength. 
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2.2.2 Older individuals  
The current literature examining the impact of β-alanine supplementation, on high-intensity 
exercise performance and muscular strength have been predominately conducted in young healthy 
adults (see meta-analyses Hobson et al., 2012; Saunders et al., 2017). Emerging, although limited 
research has shown similar improvements in exercise performance measures following β-alanine 
supplementation in older adults (Stout et al., 2008; del Favero et al., 2012; McCormack et al.,2013; 
Glenn et al., 2015; 2016; Table 2.1). Older individuals experience declined cross-sectional area of 
Type II muscle fibres (Verdijk et al., 2010), loss of both Type I and II muscle fibres (Lexell, 1995; 
Doherty 2003; Tallon et al., 2007), as well as reductions in skeletal muscle carnosine content 
(Stuerenburg & Kunse, 1999; Tallon et al., 2007). Older adults, may therefore, experience declines 
in their ability to complete anaerobic activity, during which reduced intracellular pH limits 
performance (Stout et al., 2008). The amalgamation of these factors increases the sense of frailty in 
older adults, associated with impairments in balance, gait speed, and an increased risk of falls 
(Madureira et al., 2010). As such, it is imperative to find techniques to maintain and even improve 
physical function in older individuals. Supplementation with β-alanine over 12-weeks (3.2 g.d-1; 
total dose 269 g) in older adults, has been shown to significantly increase skeletal muscle carnosine 
content (85%; del Favero et al., 2012). Furthermore, these increases in skeletal muscle carnosine 
content were positively correlated with improved TTE performance, in both the constant-load 
submaximal (r = 0.62; P = 0.01) and incremental tests (r = 0.48; P = 0.02; del Favero et al., 2012). 
Supplementation with β-alanine in older adults has also been associated with delayed onset of 
neuromuscular fatigue (Stout et al., 2008). Ninety days of β-alanine supplementation significantly 
improved PWCFT (28.6%) in older adults, with no change to the placebo group performances. 
Interestingly, the improvements in exercise performance, were two-fold greater than those 
previously reported in young healthy adult males (younger; 12 – 15% vs. older; 29%; Stout et al., 
2006). There were however, clear differences in supplemental dosing strategies. Whilst the older 
participants ingested a lower daily dose of β-alanine, compared to the younger counterparts (older; 
2.4 g
.
d
-1
; young; 6.4 g
.
d
-1
), supplementation was provided over an additional 62 days. Therefore, 
total dose ingested by the older adults was around 30 g more (younger; ~179 g, older; 216 g). 
Ingestion of shorter 28-day β-alanine supplementation periods at 3.2 g.d-1 have also been shown to 
improve older female physical function (Glenn et al., 2015; 2016). Female masters athletes 
following 28-days of β-alanine supplementation, exhibited improved TTE (23%) performance and 
total work completed (21%) during a cycling performance at 120% aerobic capacity (Glenn et al., 
2015). These data are in-line with the improvements in exercise performance lasting between 60 
and 240 s reported in young healthy adults (see meta-analysis, Hobson et al., 2012).  
 
Although several investigations have shown improved exercise performance following β-
alanine supplementation (Stout et al., 2008; del Favero et al., 2012; Glenn et al., 2015), measures 
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associated with skeletal muscle function (timed-stand and timed-up-and-go, hand-grip strength), 
and quality of life parameters (del Favero et al., 2012; Glenn et al., 2016) have remained 
unaffected. The lack of change in quality of life and skeletal muscle function variables, may be due 
to the healthy and physically active status of these older individuals. Alterations to functional and 
health related measures may be more apparent in older individuals whom have already experienced 
declines in physical function, activity and quality of life, such the frail elderly.  
 
The current research highlights the efficiency of β-alanine supplementation in raising 
skeletal muscle carnosine content in older individuals, as well as the potential beneficial effect of 
supplementation on improving exercise performance. Furthermore, these data suggest that older 
individuals may experience a greater beneficial effect following increased skeletal muscle 
carnosine content in comparison to younger adult counterparts. It can also be proposed that the 
positive effects of β-alanine supplementation may be to an even greater degree in older adults 
whom already have declined muscle function.   
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Table 2.1: Overview of current research examining the effect of β-alanine supplementation on older adult’s physical performance measures. 
Participants Supplementation Methodology 
Author 
(year) 
Supplementation groups 
(n) 
Age 
(y) 
Gender 
Dose 
(g.d
-1
) 
Duration 
(days) 
Total 
Intake 
(g) 
Placebo Performance Measure 
Glenn et al., 
(2016) 
β-alanine (11) 
Placebo (11) 
54 ± 2 
53 ± 1 
F 3.2 28 89.6 Dextrose Isokinetic flexor and 
extensor strength, 
isometric grip strength. 
Glenn et al., 
(2015) 
β-alanine (11) 
Placebo (11) 
54 ± 2 
53 ± 1 
F 3.2 28 89.6 Dextrose Time to exhaustion, 
total work completed 
McCormack 
et al., (2013) 
ONS (16) 
ONS+ β-alanine 800 (15) 
ONS+ β-alanine 1200 (13) 
71 ± 7 
71 ± 6 
72 ± 6 
 
5F/11M 
10F/5M 
7F/6M 
1.6 
or 
3.2 
84 134.4 
or 
268.8 
N/A PWCFT, hand 
dynamometer, 30 s sit 
to stand. 
del Favero et 
al., (2012) 
β-alanine (12) 
Placebo (6) 
65 ± 4 
64 ± 7 
Mixed 
(8F/10M) 
3.2 84 268.8 Maltodextrin PWCFT, timed stands, 
timed up and go. 
Stout et al., 
(2008) 
β-alanine (12) 
Placebo (14) 
72 ± 10 
73 ± 11 
Mixed 
(9M/17F) 
2.4 90 216 Cellulose PWCFT. 
F: Females. M: Males. PWCFT: Physical working capacity at neuromuscular fatigue threshold test. ONS: Oral nutritional supplement
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2.3 Potential roles of carnosine in the skeletal muscle 
Although carnosine is evident within excitable tissues, including the cardiac muscle and 
neuronal tissue, based on the objectives of the present thesis, this section will discuss the potential 
roles of carnosine within the skeletal muscle (Fig. 2.7). Furthermore, it has been suggested that 
carnosine may not display the same functions in different tissues, and may even fulfil several 
functions within one tissue (Boldyrev et al., 2013).  
 
2.3.1 Proton buffer 
Carnosine was first described as an intracellular pH buffer in 1938 by two independent 
research groups (Bate-Smith, 1938; Deutsch & Eggleton, 1938), following the isolation of the 
molecule in the early 1900s (Gulewitsch & Amiradzhibi, 1900). Research by Severin et al., (1953), 
showed that, in the presence of 10 mM carnosine, there was a greater accumulation of lactate 
within the isolated frog nerve and muscle without limiting muscle performance. In the absence of 
carnosine, lactate accumulation occurred, and resulted in rapid muscle fatigue and acidosis. Due to 
its molecular structure, the role of carnosine as an intracellular pH buffer is undisputable (Bate-
Smith et al., 1938; Sale et al., 2010; 2013; Fig. 2.7), furthermore with the imidazole ring of 
carnosine having a pKa of 6.83, carnosine is a suitable intracellular buffer over the whole exercise 
induced intramuscular pH transit-range (Bate-Smith et al., 1938; Harris et al., 2006). In untrained 
human individuals, carnosine can neutralise between 2 and 10 mmol H
+.
kg
-1
dm as intramuscular 
pH declines, as a minimum estimate this can add at least 7 to 10% to total intramuscular buffering 
capacity (Bate-Smith, 1938; Mannion et al., 1992; Cairns, 2006). These analyses, however, were 
conducted in skeletal muscle samples approaching rigour, likely resulting in an underestimation of 
the true contribution carnosine has to total muscle buffering capacity.  The ability of carnosine to 
buffer H
+
 is dependent on both animal species and muscle fibre type (Bate-Smith, 1938; Abe, 
2000). The improvements in high-intensity exercise performance following β-alanine 
supplementation, specifically at durations of 60 to 240 s where H
+
 accumulation is evident (for a 
review see Hobson et al., 2012) are associated with the role of carnosine as an intracellular pH 
buffer (see review; Sale et al., 2010; 2013), and therefore increased buffering capacity (Hill et al., 
2007; Sale et al., 2011; Fig. 2.7). Although the role of carnosine as an intracellular pH buffer is 
undisputable, this does not exclude the possibility of other physiological roles. 
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2.3.2 Calcium kinetics 
Raising skeletal muscle carnosine content is suggested to influence the regulation of Ca
2+
 
kinetics within the sarcoplasmic reticulum (SR) of the skeletal muscle, through increased Ca
2+
 
release during skeletal muscle contraction and/or improved sensitivity of contractile properties to 
Ca
2
 (Lamont & Miller, 1992; Batrukova & Rubtsov, 1997; Dutka & Lamb, 2004; Dutka et al., 
2011; Everaert et al., 2013). The SR has three key functions regarding Ca
2+
 movement; 1) storage 
of Ca
2+
 pending excitation (Tripathy et al., 1995); 2) Ca
2+
 release through Ca
2+
 specific channel 
proteins (Ryanodine Receptor; RyR); and 3) Ca
2+
 reuptake initiating muscle relaxation via Ca
2+
-
dependent ATPases. The carnosine molecule can bind to both Ca
2+
 and H
+
, potentially acting to 
serve as a cytoplasmic regulator of Ca
2+
 and H
+ 
coupling (Baran, 2000). In-vitro research on rabbit 
hind leg muscles showed that raising carnosine concentrations decreased the rate of Ca
2+
 
accumulation within the muscle, implying that carnosine influenced the amount of Ca
2+
 released 
during muscle contraction (Batrukova & Rubtsov, 1997). The addition of L-histidine and β-alanine, 
assessed separately and together, reported no activation of the Ca
2+
 channels (Rubstov, 2001), 
indicating that the whole carnosine molecule is required to alter Ca
2+
 release. There is also 
emerging evidence to suggest that carnosine may influence the sensitivity of the contractile 
apparatus to Ca
2+
 (Lamont & Miller, 1992; Dutka & Lamb, 2004). In rat m. extensor digitorum 
longus fibres, increased muscle carnosine concentrations improved Ca
2+
 sensitivity of the 
contractile apparatus in a concentration-dependent manner (Dutka & Lamb, 2004). Similar 
improvements in contractile properties Ca
2+
 sensitivity where shown in Type I and Type II fibres of 
skinned human m. vastus lateralis fibres following the addition of 8 and 16 mM cytoplasmic 
carnosine concentrations, with little or no change to either the Hill coefficient or maximum Ca
2+
-
activated force (Dutka et al., 2012). Improving the sensitivity of the contractile apparatus to Ca
2+ 
would potentially allow the same amount Ca
2+
 to be released, whilst either increasing force 
production, or increasing the duration a force is produced (Dutka & Lamb 2004). Currently, it 
remains unclear if these responses to increased skeletal muscle carnosine content alters the amount 
of Ca
2+
 released, and/or the sensitivity of the contractile properties to Ca
2+
 (Dutka et al., 2012). 
Nonetheless, these data highlight the potential of increasing skeletal muscle carnosine content to 
alleviate the decline in exercise performance, through a mechanism of improved Ca
2+
 kinetics. 
 
In-vivo research examining the effect of increased carnosine content, through 
supplementation of mice drinking water with 1.2% β-alanine, over eight weeks, reported 
significantly higher carnosine concentrations in the m. extensor digitorum longus (+156%, P < 
0.001) and the m. tibialis anterior (+160%, P < 0.001) compared with control mice (Everaert et al., 
2013). Furthermore, analysis of submaximal m. quadriceps femoris stimulation at a range of 
frequencies (1 – 100 Hz) was undertaken in the mice to examine the force-frequency relationship, a 
correspondent of the in-vivo force-Ca
2+
 concentration relationship (Balnave & Allen, 1996; 
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MacIntosh & Willis, 2000). The amount of relative force produced in the m. extensor digitorum 
longus of the mice supplemented with β-alanine, increased by 10 – 31%, inducing a leftward shift 
of the force–frequency relationship (Everaert et al., 2013). The alterations to the force-frequency 
relationship implied that Ca
2+
 kinetics was improved following increased carnosine concentrations, 
via β-alanine supplementation. These data highlight the possibility that increasing carnosine 
concentrations, via β-alanine supplementation, may alter in-vivo human contractile properties, and 
thus muscle performance by a Ca
2+
 related mechanism. The in-vitro nature of the current literature 
should be considered, although the saturable binding sites of carnosine on the Ca
2+
 release channels 
in skeletal muscle highlights the potential for carnosine to alter the Ca
2+
 channel itself (Batrukova 
& Rubtsov, 1997). It remains unclear if the association between skeletal muscle carnosine content 
and Ca
2+
 kinetics in-vitro, is apparent within a human in-vivo scenario.  
 
2.3.3 Antioxidant 
Carnosine is suggested to provide protection against exercise-induced production of 
reactive oxidant species (ROS) in skeletal muscle (Kohen et al., 1988; Boldyrev et al., 1992; 
Boldyrev, 2007; Fig. 2.7). Under normal physiological conditions ROS carry out important 
regulatory functions in the organism (Halliwell & Gutteridge, 2007; Valko et al., 2007), yet when 
an increased generation of free radicals and/or reduced physiological activity of antioxidant 
defences against free radicals is evident (Poljsak et al., 2013), oxidative stress occurs. There are 
numerous causes associated with increased ROS production, including exposure to microbial 
infections, extensive exercise, or pollutants/toxins such as cigarette smoke, alcohol, ultra-violet 
radiation and pesticides (Poljsak et al., 2013). Increased levels of oxidative stress can negatively 
impact deoxyribonucleic acid, proteins and lipids, increasing the risk of cardiovascular disease, 
cancer, autism and other diseases (Lu et al., 2010). The skeletal muscle is relatively resistant to 
exercise-induce oxidative damage, however, exposure to intense and/or prolonged muscular 
activity can negatively influence performance (Clarkson & Hubal, 2002). Antioxidants are 
substances that are existing at low concentrations, in comparison to an oxidisable substrate, and 
significantly delay or prevent the oxidation of that substrate (Halliwell & Gutteridge, 1999). 
Ingestion of antioxidants has been shown to prevent harmful effects of exercise-induced oxidative 
stress, accelerate recovery of muscle function and improve exercise performance (see review, 
Peternelj & Coombes, 2011). Carnosine is suggested to meet almost all the requirements for an 
ideal antioxidant; it is synthesised and contained in human skeletal muscle and nervous tissues, it is 
easily absorbed in the digestive tract, it can penetrate through the blood-brain barrier, and has 
membrane-stabilising actions (Prokopieva et al., 2016). The antioxidant activity of carnosine is 
supposedly multifunctional, with the ability to display a buffering effect, interact in the initial step 
of oxidation, decrease the amount of preformed peroxides and react with some secondary products 
(Kansci et al., 1997).   
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2.3.4 Metal ion chelation 
Another assumed role of carnosine in skeletal muscle tissue is as a physiological metal ion 
chelator, forming complexes with bivalent metals including ions of copper, cobalt, manganese, and 
cadmium (Brown & Antholine, 1979; Vladimirov, 1996). Of these ions, copper (Cu
2+
) and zinc 
complexes have been the most examined due to their biological relevance. These molecules are 
able to neutralise free radicals by accepting the unpaired election, inhibiting the oxidation of other 
molecules (Steinbacher & Eckl, 2015). Dobbie and Kermack (1955) was the first to suggest a 
complex formation between carnosine and Cu
2+
, although the exact structure of this molecule has 
been debated (Baran et al., 2000). In human calf muscle, the presence of carnosine has been shown 
to chelate copper when examined in-vivo through 
1
H-MRS (Schröder et al., 2008). Although 
carnosine at pH 7.84 ± 0.18, displayed a much lower binding constant with Cu
2+
 ions (1.1 M
-1
) 
compared with that of L-histidine (71 M
-1
; Velez et al., 2008). There is currently very limited 
research within this area, with most of the studies examining this potential mechanism conducted 
in-vitro, implemented during un-physiological conditions.  
 
2.3.5 Inhibitor of protein glycation  
When elevated glucose levels are evident, formation of covalent adducts with plasma 
proteins occurs, through a non-enzymatic process known as glycation. Protein glycation reactions 
leading to advanced glycation end products; thought to be a critical factor in ageing, 
neurodegeneration, diabetes and its related complications (Kikuchi et al., 2003; Miller et al., 2003; 
Chen et al., 2004; Davydov et al., 2004; Ahmed, 2005). A large majority of these secondary 
complications from diabetes are associated with protein glycation and oxidation (Brownlee, 2001; 
Ahmed, 2005). Glycation of proteins interferes with their normal functions by disrupting molecular 
conformation, altering enzymatic activity, and interfering with receptor functioning (Singh et al., 
2014). The carnosine molecule may provide protection of proteins against glycation, by either 
acting as a sacrificial peptide (Hipkiss et al., 1995), or though prevention of the formation of 
protein-protein cross-links via reactions with protein-carbonyl groups (Hipkiss et al., 2001; Fig. 
2.7). Evaluation of plasma carnosine levels in diabetic rats demonstrated significantly lower 
concentrations when compared to those of normal animals (Nagai et al., 2003). The authors 
proposed that carnosine provides a regulatory effect on the blood glucose levels within the rats. In-
line with the current proposed mechanism, Ahmed (2005) indicated that carnosine has the 
properties required to act as a putative glycation inhibitor, including carnosine’s role as a metal ion 
chelator (Browan & Antholine, 1979; Vladimirov, 1996; Baran, 2000) and anti-oxidant (Kohen et 
al., 1988; Boldyrev et al., 1993; Boldyrev, 2007). 
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2.3.6 Conclusion  
Based on the existing body of literature, the carnosine molecule may perform several roles 
within the skeletal muscle (Fig. 2.7), albeit based on varying levels of scientific support. The role 
of carnosine as an intracellular pH buffer is undisputable, although it is possible that some of the 
associated improvements in exercise performance are due to the other potential mechanisms of 
carnosine, which are currently less well studied. The current programme of work will focus 
predominately on the suggested influence of increased carnosine content on regulating Ca
2+
 
kinetics within the SR, and the potential influence of carnosine on the amount of Ca
2+
 released 
during skeletal muscle contractions and/or the sensitivity of the contractile properties to Ca
2+
. 
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2.4 Calcium kinetics within skeletal muscle 
Given the previous body of literature, and the potential association between carnosine 
content and Ca
2+
 kinetics within the skeletal muscle, the following section will give a brief 
overview on the role of Ca
2+
 within the skeletal muscle, specifically regarding skeletal muscle 
activation and relaxation.  
 
2.4.1 Calcium kinetics during skeletal muscle activation and relaxation 
The movement of Ca
2+
 within the skeletal muscle is vital due to the involvement of Ca
2+
 
during both the contraction and relaxation phases. To activate a skeletal muscle contraction, an 
impulse (action potential) transfers from the nerve into the skeletal muscle, described as 
neuromuscular transmission, this action potential propagates change across the surface membrane 
(Allen et al., 2008; Fig. 2.8). Depolarisation of the motor end plate occurs, directing the action 
potential down the T-tubules into the skeletal muscle, and the SR. Depolarisation allows for cross-
talk between the voltage sensitive dihydropyridine receptor (DHPR), located on the T-tubule, and 
the RyR located in the SR. RYRs are the Ca
2+
 release channels of the SR, and have a high 
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permeability to Ca
2+
 (Fig. 2.8). When opened, the RYRs permit a rapid efflux of Ca
2+
 from the SR 
lumen to the myofibrils, driven by the large luminal-cytoplasmic concentration gradient. The 
junctional membrane complex between the plasma membrane and the SR is an important structural 
foundation for crosstalk between the cell surface and intracellular ionic channels (Pozzan et al., 
1994; Berridge, 1998). In a relaxed muscle state, tropomyosin obstructs the attachment site for the 
myosin cross bridge, held in place by troponin complexes, thus preventing skeletal muscle 
contraction. Troponin has three subunits within the skeletal muscle; Ca
2+
-binding protein troponin 
C (TnC), the inhibitory troponin I (TnI) and tropomyosin-binding troponin T (TnT) (Farah & 
Reinach, 1995). Upon release of Ca
2+
 by the RyRs into the SR, the Ca
2+
 binds to the TnC exposing 
a patch of hydrophobic residues located in the N-terminal domain of TnC, allowing interaction of 
TnC with both TnI and Tnt (Gomes et al., 2002). These interactions promote alterations to the 
shape and position of the troponin, freeing the tropomyosin filament (Jurkat-Rott & Lehmann-Horn, 
2005). The process of sarcoplasmic Ca
2+
 release can be directly and indirectly inhibited by H
+
 
cations during skeletal muscle contraction (Laver, Eager, Taoube & Lamb, 2000; Laver, O’Neill & 
Lamb, 2004). Myosin and actin filaments can connect through the movement of the myosin 
globular heads, forming a cross-bridge between the two proteins. ATP is broken down within the 
skeletal muscle, resulting in the release of energy, allowing the myosin globular heads to twist and 
move into position. The actin filament is pulled inwards, shortening and thus contracting the 
skeletal muscle. ATP is then required to break the bond between the actin filament and the myosin 
globular head, allowing the myosin globular head to move along the action chain, allowing 
continuation of the shortening and relaxation of the muscle. The speed of skeletal muscle relaxation 
can be impacted by the rate of: (1) dissociation of Ca
2+
 from troponin (Little et al., 2011); (2) the 
rate of translocation of Ca
2+
 to near the site of entry into the SR (Muntener et al., 1995); (3) re-
uptake of Ca
2+ 
into the SR by Ca
2+
 pumps (Nogueira et al., 2013) and cross-bridge detachment 
(Allen et al., 2008). Research conducted by Westerblad and Allen (1993), in fatigued mouse 
muscle fibres, suggested that the slowing of muscle relaxation, apparent under fatigued conditions, 
was a reflection of slowed cross-bridge kinetics, rather than a reduction in the rate of Ca
2+
 decline 
at the end of the stimulation train. Yet, when these data were repeated in Xenopus muscle fibres, 
the slowing of muscle relaxation was associated with a combination of altered cross-bridge kinetics 
and impaired Ca
2+
 kinetics, rather than just slowed cross-bridge kinetics. Whilst there is an 
adequate supply of both ATP and Ca
2+
,
 
the contraction of the skeletal muscle will continue. If the 
action potential is halted, thus no longer permitting the release of Ca
2+
 into the muscle, the 
contraction is stopped. Additionally, if there is a reduction in available ATP to make or break the 
myosin and actin filament connection, in circumstances such as muscle fatigue, the myosin 
globular head will remain bound to the actin filament, preventing muscle contraction, even if the 
action potential stimuli and Ca
2+
 levels are sufficient.  
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2.4.2 Assessment of calcium kinetics in-vivo 
There are several measures that can be implemented in-vivo to monitor skeletal muscle 
Ca
2+
 kinetics, alterations to these variables are indicative of adaptations to either the sensitivity of 
the contractile properties to Ca
2+
 and/or the amount of Ca
2+
 released from the SR lumen to the 
myofibrils. The in-vivo force-frequency relationship is the association between skeletal muscle 
force output and electrically evoked stimulation frequency, this relationship is associate with 
intracellular skeletal muscle Ca
2+
 levels (Batrukova & Rubstov 1997). Alterations to the force-
frequency relationship could be influenced by adjusted Ca
2+
 kinetics and/or sensitivity (Jones, 
1981). Research examining the intracellular Ca
2+
 in mammalian fibres, noted that for a given 
stimulation frequency there was a reduced Ca
2+
 in the fatigued fibre, although there was no 
evidence of altered intracellular buffering of Ca
2+
 (Westerblad et al., 1993). These data suggested 
that the alterations to the force-frequency relationship were due to a reduction in Ca
2+
 release from 
the SR, rather than decreased Ca
2+ 
binding. Interpretation of Ca
2+
 kinetics within the skeletal 
muscle based solely on the force-frequency relationship should be avoided, as the assessment of the 
force-frequency relationship can be influenced by the potentiation of the muscle (Jones, 1996), 
potentially altering muscle responses and thus any findings based solely on these assumptions. It 
should also be noted that there may be a compensatory mechanism occurring within the skeletal 
muscle, which would be overlooked by solely assessing the force-frequency relationship, as such, 
reductions in SR Ca
2+
 release may be obscured by an associated increase in Ca
2+
 sensitivity of the 
myofibrils, consequential the same skeletal muscle force output will be produced.  
 
The activation of a single action potential, via a 1 Hz electrical impulse, described as a 
twitch contraction, will result in a quick contraction of the skeletal muscle, generating a small force 
response (Enoka, 2008). Generation of a twitch contraction is delivered in a voluntary passive state, 
which is described as a resting or un-potentiated twitch, or shortly following a voluntary muscle 
contraction, referred to as a potentiated twitch (Rassier & MacIntosh, 2000; Hodgson et al., 2005; 
Ebben, 2006; Fukutani et al., 2013). Potentiated twitches generally generate larger forces than 
resting twitches, with possible increases of up to 100% (Kopman et al., 2001). The increases in 
force response are due to the phosphorylation of the myosin regulatory light chain, leading to a 
larger number of attached cross brides at a given Ca
2+
 concentration (Sweeney et al., 1993; Rassier 
& MacIntosh, 2000; Kamm & Stull, 2011). Both resting and potentiated twitch contractions are 
typically characterised by a few key variables including, peak force, time-to-peak tension (TPT), 
the interval between the onset of tension and the peak value, and the time it takes for the force to 
decline to one half of its peak value, half relaxation time (HRT) (Enoka, 2008; MacIntosh, 
Gardiner & McComas, 2005). There are numerous parameters used to describe skeletal muscle 
relaxation, although HRT is the most frequently used index because it considers the whole 
relaxation process (Gillis, 1985). Alterations to evoked twitch contraction time course variables 
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(TPT and HRT) are proposed to reflect changes in Ca
2+
 kinetics (Enoka, 2008). TPT is known to be 
significantly influenced by skeletal muscle fatigue, with reported increases during both electrically 
evoked resting and potentiated twitches (Klitgaard et al., 1989), potentially a reflection of declined 
efficiency of the SR to release Ca
2+
. Alongside prolonged TPT, skeletal muscle HRT significantly 
increases with the ageing process (Edstrom & Larsson, 1987; Kent-Braun & Ng, 1999), with an 
increase of 30 ms in HRT in older individuals compared to younger counterparts (130 ± 9 ms older 
vs 107 ± 7 young, P = 0.05; Kent-Braun & Ng, 1999). The negative impact of ageing on skeletal 
muscle HRT was later supported by McPhee et al., (2014), with men having faster relaxation than 
women (~12 ms), and younger adults faster than older (~19 ms). This slowing of skeletal muscle 
relaxation is potentially due to a reduced rate of dissociation of cross-bridges following the removal 
of the activating Ca
2+
 back into the SR (Edwards, Hill & Jones, 1975; Cady et al., 1989) or a 
reduced rate of Ca
2+
 pumping by the SR (Dawson, Gadian & Wilkie, 1980). Skeletal muscle HRT 
is also known to be influenced by other physiological factors including localised muscle fatigue 
(Jewell & Wilkie, 1960; Edwards, Hill & Jones, 1972, 1975; Bigland-Ritchie et al., 1983). During 
muscle exhaustion, the m. quadricep femoris displays increased HRT, associated with decreased 
Ca
2+
 uptake of ~58% of baseline measures (Gollnick et al., 1991).  
 
  
Chapter 2: Review of literature 
 
  31 
2.5 Calcium-dependent ATPase 
Ca
2+
-dependent ATPases are members of the P-type ATPase family of ion pumps, and 
responsible for the ATP dependent active transport of ions across a wide variety of cellular 
membranes. Ca
2+
 pumps, together with Ca
2+ 
release channels, form ubiquitous Ca
2+
 regulatory 
systems in muscle and non-muscle cells (McMullan et al., 1997). Ca
2+
-dependent ATPases are 
cation transporting proteins that utilise the energy of ATP hydrolysis for the transport of Ca
2+
 after 
a skeletal muscle contraction. Within the human skeletal muscle, Ca
2+
-dependent ATPases are in 
either the plasma membrane or in the internal membranes of the sarcoplasmic reticulum (SR), there 
are three types of enzymes: Plasma Membrane Ca
2+
-dependent ATPase (PMCA), Secretory 
Pathway Ca
2+
/Mn
2+
-ATPases (SPCA) and SERCA.  
 
2.5.1 Plasma membrane calcium-dependent ATPase  
PMCAs are Ca
2+
-dependent ATPases found on the plasma membrane that catalyse the 
active transport of Ca
2+
 from the cytoplasm into the extracellular space (Carafoli, 1994), and are 
critical regulators of intracellular Ca
2+
 concentrations (Jensen et al., 2004). The PMCA was 
discovered in erythrocytes (Schatzmann, 1966) and shows the same essential membrane topology 
properties of the SERCA pump. The pump operates with a 1:1 Ca
2+
/ATP stoichiometry as a Ca
2+
: 
H
+
 exchanger, yet the matter of Ca
2+/
H
+ 
stoichiometry is still controversial (Niggli et al., 1982; Hao 
et al., 1994). Due to the numerous variants and specific distribution of the PMCA, it is purposed 
that PMCA pump plays a prominent role as signalling molecules, in addition to having a 
constitutive role as Ca
2+
 housekeeping enzymes (Brini & Carafoil, 2011). Upon skeletal muscle 
relaxation, Ca
2+
 ions are pumped out of the cytosolic compartment by PMCAs and pumped into 
intracellular compartments by SERCAs, where Ca
2+
 is stored and released upon necessity 
(Kochegarov, 2003).  
 
2.5.2 Sarcoplasmic/endoplasmic reticulum calcium-ATPase 
The SERCA pump is a high-affinity low-capacity 110-kDa transmembrane protein that 
transports Ca
2+
 from the cytosolic compartment to the SR lumen (MacLennan, Rice & Green, 
1997), maintaining the Ca
2+
 gradient across the membrane of intracellular vesicles of all cells 
(MacLennan & Kranias, 2003; Rossi & Dirksen, 2006). The SERCA pumps are in the longitudinal 
SR, found in abundance in cardiac and skeletal muscle cells, and are the primary protein 
responsible for maintaining the Ca
2+
 gradient across the membrane of intracellular vesicles 
(MacLennan & Kranias, 2003; Fig 2.8 and Fig. 2.9). The SERCA serves as a dual function, (a) 
lowering the cytosolic Ca
2+
 content to induce muscle relaxation, and (b) concurrently restoring the 
SR Ca
2+
 store required for following muscle contractions (MacLennan, 1970; Gommans et al., 
2002; Rossi & Dirksen, 2006; Periasamy & Kalyanasundraam, 2007; Bers, 2008). The speed by 
which muscle relaxation occurs has been associated with the reuptake of Ca
2+
 by the SERCA 
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pumps (Gafni & Yuh, 1989), the pump is proposed to be the rate-limiting step in muscle relaxation 
(Gillis, 1985; Dux, 1993). SERCA and PMCA have the highest affinity for Ca
2+
 removal from the 
cytoplasm, and therefore set resting cytoplasmic Ca
2+
 concentrations (MacLennan, Rice & Green, 
1997). The SERCA pump is responsible for removing 80% of the Ca
2+
 within the cytoplasm into 
the lumen of the SR, generating a 10,000-fold concentration gradient across the SR membrane, and 
provides a large store of Ca
2+
 inside muscle cells. Resting SERCA activity maintains a normal 
intracellular lumen of free Ca
2+
 at concentrations of 0.3 and 1.0 mM
 
(Bers, 2001; Ginsburg et al., 
1998), which is more than 1000 times greater than free Ca
2+
 concentrations in the extracellular 
cytoplasm (~20-50 nM; Laver et al., 2007).  
 
The SERCA pump undergoes a series of structural transitions, producing a reversibly 
phosphorylated state (Kühlbrandt, 2004; Wuytack, Raeymaekers, & Missiaen, 2002), according to 
the E1-E2 model these transitions include changing the affinity of Ca
2+
-binding sites from high 
(E1) to low (E2; Toyoshima & Nomura, 2002; Fig. 2.9). This transition process is initiated by the 
binding of either Ca
2+
 or ATP to the high-affinity site on the cytoplasmic face of the SERCA pump 
(Fig. 2.9). The ATP molecule undergoes phosphorylation into ADP and Pi, and resulting in E1P-
Ca
2+
 (Fig. 2.9). This intermediate is ADP-sensitive, with the presence of ADP resulting in a 
backwards reaction occurring, thus releasing the Ca
2+
 and synthesising ATP. The Ca
2+
 binding sites 
are converted to a low affinity state, reorienting toward the luminal face, releasing the Ca
2+
 and 
inorganic phosphate (Pi), returning the molecules from the low affinity state (E2), to high affinity 
(E1; Fig. 2.9). For each ATP molecule hydrolysed, the SERCA pump transports two molecules of 
Ca
2+
 from the cytoplasm to the lumen of the SR, which takes only a few milliseconds. The re-
accumulation of Ca
2+
 through the SERCA pump is directly controlled by the mitochondrial supply 
of ATP. SERCA activity accounts for 10 - 25% of basal ATP turnover (Clasusen et al., 1991; 
Simonides et al., 2001), yet this is dependent on the cell type and the physiological state. The 
transfer of Ca
2+
 into the SR lumen by the SERCA pump is accompanied by a counter-transport of 
H
+
 out into the cytosolic (Tran et al., 2009), by acting on Ca
2+
 kinetics proteins directly or via other 
molecules, Ca
2+
 signalling can be inhibited or excited (Swietach et al., 2013). The function of the 
SERCA pump appears to be rather well adapted to the faster Ca
2+
 replenishment of releasable Ca
2+
 
stores and the decline of cytosolic Ca
2+
 transients after cell stimulation (Dode et al., 2005).  
 
2.5.3 Secretory protein ATPases  
SPCAs represent a group of ion-motive ATPases consisting of single subunit integral 
membrane enzymes specifically mediating the ATP-powered transport of either Ca
2+
 or Mn
2+
 from 
the cytosolic compartment into the Golgi lumen (Wuytack et al., 2002; van Baelen et al., 2004). 
The importance of SPCAs in suppling sufficient Ca
2+
 and Mn
2+
 to different Golgi compartments for 
the correct execution of diverse luminal functions was recently documented in clinical, genetic, and 
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functional investigations (Hu et al., 2000; Sudbrak et al., 2000; Fairclough et al., 2003). Like the 
SERCA pump, the SPCA pump undergoes a series of structural transitions producing a reversibly 
phosphorylated state (Fig. 2.9). The SPCA reaction cycle, however, transports only one Ca
2+
 per 
hydrolysed ATP rather than the two transported by the SERCA pump. The SPCA pump is a high 
affinity and low turnover rate pump can be expected to render the adjustment of the luminal Ca
2+
 
level less dependent on the cytosolic Ca
2+
 concentration, mainly by limiting the fluctuation of 
pumping activity during cytosolic Ca
2+
 transients (Dode et al., 2005).  
 
2.5.4 Calcium-dependent ATPase and carnosine 
Carnosine has been suggested to alter the Ca
2+
 kinetics within the skeletal muscle (Zaloga, 
Roberts & Nelson, 1996), possibly via the existence of saturable binding site(s) for carnosine on 
the Ca
2+
-channel (Batrukova & Rubstov, 1997). The presence of carnosine has been shown to 
improve isolated rat heart muscle contraction and increase free intracellular Ca
2+
 concentrations 
(Zaloga, Roberts & Nelson 1996). At a pH of 6.0, where a complete decline in Ca
2+
 release pump 
activity was evident, the presence of carnosine maintained ~30% of pump activity at the same pH. 
Although speculative, these data suggest that increased carnosine content might alter Ca
2+
-channel 
activity by interacting with the Ca
2+
-channel itself (Batrukova & Rubstov, 1997). These data, 
however, are limited by several methodological factors, including but not limited to, the lack of a 
Ca
2+
 buffer, the overloading of the SR with Ca
2+
 concentrations approximately ten times greater 
than normal, and the inclusion of non-physiological magnesium concentrations.  
Fig. 2.9: Simplified version of the transition of the sarcoplasmic endoplasmic reticulum calcium 
ATPase pump during the transportation of calcium (Ca
2+
) per the E1-E2 model. Redrawn from 
Toyoshima & Nomura (2002).  
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2.6 Summary  
Since 1938, carnosine, a dipeptide consisting of β-alanine and L-histidine, has been 
described as an intracellular pH buffer within the skeletal muscle (Bate-Smith, 1938; Deutsch & 
Eggleton, 1938). In the following years, the role of carnosine as an intracellular buffer has been 
supported by reported improvements in exercise performance measures, following increased 
muscle carnosine content, via β-alanine supplementation (see reviews Sale et al., 2010; 2013; 
Hobson et al., 2012; Saunders et al., 2017. In the last ten years, the role of carnosine in the skeletal 
muscle has been extended (see Begum et al., 2005; Sale et al., 2010; Fig. 2.7). One such 
mechanism is the potential influence of increased carnosine content on regulating Ca
2+
 kinetics, 
through either altered the amount of Ca
2+
 released during skeletal muscle contraction and/or the 
sensitivity of contractile properties to Ca
2+
 (Lamont & Miller, 1992; Batrukova & Rubtsov, 1997; 
Dutka & Lamb, 2004; Dutka et al., 2011; Everaert et al., 2013). The current in-vitro data highlights 
the possibility that increasing carnosine content, via β-alanine supplementation, may in turn, alter 
in-vivo human contractile properties, and thus skeletal muscle performance through a Ca
2+
 kinetics 
mechanism. Despite the importance, there remains no research examining the impact on increased 
skeletal muscle carnosine content, via β-alanine supplementation, on in-vivo measures associated 
with in-vitro Ca
2+
 kinetics. The current thesis reports on four studies that extend the previously 
limited body, evaluating the impact of increased carnosine content, via β-alanine supplementation 
on measures associated with skeletal muscle Ca
2+
 kinetics. 
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3.1 Introduction 
This chapter provides a description of the general methodologies implemented during the 
studies including within this programme of work (Chapters 4–6). Any specific protocols 
implemented during an individual investigation are described within the respective chapter. 
Development of the research specific methodologies, reported with study 4 (Chapter 7), are 
presented in Appendix 1.  
 
3.2 Ethical approval 
All invasive research conducted on human participants required ethical approval, as such, 
each individual investigation obtained permission from the Nottingham Trent University Invasive 
Human Ethical Review Committee. All approvals were obtained prior to the commencement of 
data collection. Research presented in Study 4 (Chapter 7), conducted using rat skeletal muscle 
tissue did not require institutional ethical approval, however, to comply with the principles of 
replacement, reduction and refinement, as stated in the Animals (Scientific Procedures) Act 1986 
(Amendment Regulations 2012, SI 2012/3039), the research was conducted on tissue samples 
collected as a by-product from animals sacrificed as part of another research programme. The 
researcher was not involved in the life or death of the animal, or collection of the tissue. 
 
3.3 Human participants 
All human participants were fully informed of any risks and discomforts associated with 
the research (in verbal and written form) prior to providing written informed consent and 
completing a health screen. Participants were immediately excluded from the research if they 
presented with any medical conditions documented in the exclusion criteria, or if these conditions 
arose during their participation in the study. Participants were excluded if they had ingested β-
alanine or carnosine during the previous 6 months, this time frame was due to the long washout 
period of muscle carnosine (Baguet et al., 2009). None of the participants were vegetarian/vegan, 
and would have ingested small amounts of β-alanine in their normal diet; typically 50 – 400 mg.d-1 
(Yeum et al., 2010; Jones 2011; Harris et al., 2012). Participants were excluded from partaking in 
the current research if they had undertaken a resistance training programme in the previous 6 
months. Participants were instructed to avoid strenuous/unaccustomed exercise for 48 h prior to 
each visit to the laboratory, with alcohol and caffeine prohibited on test days. Participants arrived 
to each session at least 3 h postprandial. Compliance with these requests was confirmed verbally 
with each participant prior to each session.  
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3.3.1 Young human participants 
Within this thesis, participants classified as ‘young’ adults were physically active males 
aged between 18 - 30 y. Exclusion criteria for these participants were; a) bone disorders in the 
assessed lower limb, sustained within the previous 2 y, including osteoarthritis, osteoporosis, bone 
cyst and osteopenia, b) non-arthroscopic joint surgery, or joint replacement, ever, in the assessed 
limb (knee, hip and ankle), c) lower limb leg injuries including sprains and strains, joint 
dislocations and fractures at the time of assessment and d) regular knee pain in the assessed limb 
when performing daily movement tasks.  
 
3.3.2 Older human participants 
Participants classified throughout this thesis as ‘older’ adults were male or female 
individuals aged between 60 - 80 y, and defined as ‘medically stable for exercise studies’ by Grieg 
et al., (1994; Table 3.1). These criteria were designed for safety, ensuring participants were free 
from diseases that might affect exercise performance (Greig et al., 1994).  
 
Table 3.1: Exclusion criteria, defining 'medically stable' older participants (Greig et al., 1994). 
Exclusion criteria: 
History of myocardial infarction within the previous 2 y 
Cardiac illness: symptoms of aortic stenosis, acute pericarditis, acute myocarditis, aneurysm, severe 
angina, clinically significant valvular disease, uncontrolled dysrhythmia, claudication, within the 
previous 10 y 
Thrombophlebitis or pulmonary embolus within the previous 2 y 
History of cerebrovascular disease  
Acute febrile illness within the previous 3 months 
Severe airflow obstruction  
Uncontrolled metabolic disease (e.g. diabetes, thyroid disease) 
Major systemic disease active within the previous 2 y (e.g. cancer, rheumatoid arthritis)  
Significant emotional distress, psychotic illness or depression within the previous 2 y 
Lower limb arthritis, classified by inability to perform maximal contractions of lower limbs without 
pain 
Lower limb fracture sustained within the previous 2 y 
Upper limb fracture sustained within the previous 6 months 
Non-arthroscopic lower limb joint surgery within the previous 2 y 
Any reason for a loss of mobility for greater than 1 week in the previous 2 months or greater than 2 
weeks in the previous 6 months 
Resting systolic blood pressure > 200 mmHg or resting diastolic blood pressure > 100 mmHg 
Taking beta-blockers or digoxin, or not in sinus rhythm 
On daily analgesia 
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3.4 Supplementation  
3.4.1 Supplement disclosure 
All β-alanine (CarnosynTM) and placebo (maltodextrin) supplements used as a part of this 
thesis were provided free of charge from NAI (San Marcos, California, USA), although no 
additional funding was provided. 
 
3.4.2 Supplementation protocol 
Participants were supplemented with either sustained-release β-alanine or a matched 
placebo ingested in the form of 800 mg tablets. Supplement tablets were consumed two at a time 
(dose of 1.6 g), on three (older individuals; Study 3; Chapter 6) or four occasions (young 
individuals; Studies 1 and 2; Chapters 4 and 5) per day, across the 28-day period. Older individuals 
were provided with 134.4 g of either β-alanine or placebo over the 28-day period, younger 
individuals were provided with around 45 g more, totalling 179.2 g. Supplements were supplied to 
each participant in identical white tubs, with both the participants and researchers remaining blind 
to allocations, until data analyses were completed. Participant compliance was assessed across the 
28-day period using a supplement log, with participants asked to report any feelings of paraesthesia 
during this time. Prior to use, β-alanine tablets were tested by the manufacturer and conformed to 
the label claim for β-alanine content. In addition, β-alanine and placebo supplements were 
independently tested by HFL Sports Science, UK, to ensure no contamination with steroids or 
stimulants per International Organization for Standardization 17025 accredited tests.  
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3.5 Experimental setup 
3.5.1 Height and body mass 
Upon arrival to the familiarisation session of each study, participant height was measured 
to the nearest 0.1 cm using a stadiometer (Seca, UK). Body mass was measured while wearing 
minimal clothing, to the nearest 0.1 kg using calibrated electronic scales (Seca, UK).  
 
3.5.2 Fingertip blood sampling 
Fingertip capillary blood sample preparation included wiping with an isopropyl alcohol 
wipe and puncturing the skin using a spring propelled lancet (Unistik3, Mumford, UK). Fingertip 
capillary blood lactate measurements at 5 min following exercise provided the best estimate of 
lower limb blood lactate contractions (Comeau et al., 2011). Sampling involved the collection of 
80 µL of whole blood in to a heparin-coated clinitube (Radiometer Ltd, UK); all samples were 
immediately analysed. 
  
3.5.3 Knee extensor force  
The production of voluntary muscular force is determined by a combination of motor unit 
recruitment and the firing rate of recruited motor units (Watanabe et al., 2012; Hu et al., 2014). A 
greater number of action potentials will enlarge muscle contraction, increasing force production. 
The force exerted by each motor unit depends principally on the number of muscle fibres that are 
innervated by the motor neuron and the rate at which the motor neuron discharges action potentials 
(Enoka et al., 2012). The evaluation of voluntary muscular force has been widely undertaken to 
assess physical conditioning, identify muscle weakness (due to ageing or disease), and monitor the 
influence of external factors such as training and rehabilitation programmes (Dwyer & Davis, 
2008).  
 
Participants were seated in a rigid, custom-built isometric dynamometer (Fig. 3.1) with hip 
and knee joint angles of approximately 95° and 100° (180° = full extension), previously described 
by Hannah et al., (2012; 2013). Adjustable strapping across the pelvis and shoulders prevented 
extraneous movement during skeletal muscle contractions. An ankle cuff was attached to the 
dominant leg of the participant ~2 cm proximal to the medial malleolus and in-line with a uni-
linear strain gauge (615, Tedea-Huntleigh, Herzliya, Israel) oriented perpendicular to the tibia. 
Dynamometer configuration was established during the familiarisation session and replicated 
thereafter. The force signal was amplified (×1000) in the frequency range of 0 – 500 Hz, and 
sampled at 2000 Hz using an external A/D converter (1401; CED, Cambridge, UK), interfaced with 
a computer using Spike 2 software (CED, Cambridge, UK). Force data were low-pass filtered bi-
directionally at 450 Hz using a fourth-order zero-lag Butterworth filter prior to analysis. Baseline 
resting force was subtracted from force recordings to correct for the effects of gravity and 
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background noise. The force onset was identified manually using visual identification in 
accordance with previously published methods (Tillin et al., 2010; Hannah et al., 2012). 
 
 
  
Fig. 3.1: Pictorial representation of the custom-built isometric dynamometer, including adjustable 
straps, force gauge, and anatomical positions of selected electrode sites: frontal view of the right 
quadricep. Adapted from Konrad (2006). 
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3.5.4 Electromyography 
Surface electromyography (EMG) provides quantifiable information on the relative 
contribution of the superficial muscles during muscular activity (Winter, 2005; Esquenazi & Mayer, 
2004), with varying amplitude, duration and frequency content (Basmajian & De Luca, 1985). 
Surface EMG is more suitable for recording neural activation of large muscle groups, including the 
quadriceps, rather than small or deep muscles, which may require intramuscular EMG (Tucker, 
1993). Surface EMG records the action potential travelling across the muscle fibres in response to 
neural activation (MacIntosh, Gardiner & McComas, 2006), providing information on the relative 
contribution of the superficial muscles during movement (Basmajian & DeLuca, 1985; Esquenazi 
& Mayer, 2004). This method provides a non-invasive, easy to access assessment of muscular 
responses during force generation, movement production and accomplishment of everyday tasks 
(De Luca, 1997). EMG signals are obtainable during both voluntary and electrically evoked 
contractions, although during voluntary activation interpretation of EMG signals can become 
difficult due to inconsistencies in signal formation; EMG activity is normally expressed in 
millivolts (mV). Surface EMG can be influenced by multiple intracellular and extracellular factors 
including, electrode placement, signal crosstalk, blood flow, and subcutaneous tissue (De Luca, 
1997; Farina et al., 2006). Although, the positive curvilinear relationship between EMG amplitude 
and force output, supports its implementation to interpret neuromuscular activation. Normalisation 
of the EMG signal is the process by which the values are expressed as a percentage of the muscle 
activity during a calibrated test contraction (Lehman & McGill, 1999) typically a MVIC. By 
normalising EMG signals to a supramaximal muscle action potential (M-wave), the removal of 
some confounding factors associated with EMG, such as electrode location, subcutaneous fat 
quantity, and skin impedance, may be reduced (Gandevia 2001). In addition to reducing 
confounding factors, normalisation of the EMG signal allows comparison between different 
muscles, across time and between individuals (De Luca, 1997; Knutson et al., 1994; Mathiassen, 
Winkel & Hagg, 1995). 
 
In the current thesis, surface EMG was recorded from the superficial quadricep muscles (m. 
rectus femoris, m. vastus medialis and m. vastus lateralis) of the dominant leg, with a reference 
electrode placed on the patella of the same limb (Fig. 3.1). Bipolar surface electrodes (2.5 cm inter-
electrode distance; silver/silver chloride, 95 mm
2
 area, Ambu Blue Sensor, Ambu, Ballerup, 
Denmark) were attached over each assessed muscle at standardised percentages of thigh length, as 
measured from the knee joint space to the greater trochanter (m. rectus femoris, 55%; m. vastus 
medialis, 25% and m. vastus lateralis, 45%, see Fig. 3.1). Orientation of the electrode pair were 
positioned in the direction of the muscle fibre, in accordance with the guidelines set by Konrad 
(2006). These sites were selected to avoid the innervation zones of each of the assessed muscles 
(Rainoldi et al., 2004). Preparation of the skin prior to electrode placement was achieved by 
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removing hair and cleaning of the skin with fine sandpaper and an alcohol pad (Konrad, 2006), 
attempting to reduce bioelectrical impedance.  
 
EMG signals were pre-amplified by active EMG leads (input impedance 100 MΩ, CMMR 
> 100 dB, base gain 500, 1
st
 order high pass filter set to 10 Hz; Noraxon, Scottsdale, USA) 
connected in series to a custom-built junction box and subsequently to the same A/D converter and 
computer software that enabled synchronisation with the force data. The signals were sampled at 
2000 Hz. EMG data were band-pass filtered in both directions between 20 and 450 Hz using a 
fourth-order zero-lag Butterworth filter prior to analysis. 
 
3.5.5 Electrically stimulation 
Electrical stimulation involves the use of low-amplitude electrical pulses to induce an 
involuntary muscle contraction (Maffiuletti, 2010), through the activation of the motor neuron 
axons or intramuscular axonal branches (Hultman et al., 1983). Electrical stimulation provides a 
helpful measure to investigate the physiological properties of the neuromuscular system (Merletti et 
al., 1992) in healthy and impaired muscles, in both fresh and fatigued muscle conditions (Martin et 
al., 2004; Wust et al., 2008; Horstman et al., 2008). Electrical stimulation overcomes any central 
activation failure by bypassing any spinal or voluntary inhibitions (Westing et al., 1990; Fitzgerald 
et al., 2004), allowing the activation of Type II muscle fibres, even when stimulation is at relatively 
low intensities (Maffiuletti, 2010). 
 
A constant current variable voltage stimulator (DS7AH, Digitimer Ltd, Welwyn Garden 
City, UK) was used to assess evoked knee extensor contractile properties. The frequency of 
electrical stimulation described the number of pulses delivered per s, progressing from 1 Hz 
upwards. The duration of each pulse is measured in microseconds (μs), with the intensity of the 
current recorded in milliamps (mA) or voltage (V). As an electrical evoked signal causes the 
muscle to contract, on M-wave from stimulating motor axons is produced and is used to assess 
changes in membrane excitability. As the electrical stimulus intensity is increased at rest or during 
a movement, the M-wave increases until maximum (Mmax).  
 
3.5.5.1 Femoral nerve stimulation 
The cathode (positive electrode) stimulation probe (1 cm diameter, Electro-Medical 
Supplies Ltd, Wantage, UK; Fig. 3.2) was pressed firmly onto the skin over the femoral nerve high 
in the femoral triangle. The anode (negative electrode) carbon rubber electrode (7 × 10 cm; Electro-
Medical Supplies Ltd, Wantage, UK) was coated with electrode gel and taped to the skin midway 
between the iliac crest and the greater trochanter (Sidhu et al., 2009). The precise location of the 
cathode was determined during each testing session as the position that evoked the greatest twitch 
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response for a submaximal electrical current (typically 30 – 50 mA). Femoral nerve stimulation 
was implemented for all electrically evoked resting and potentiated twitches, doublet and octet 
contractions.  
 
3.5.5.2 Percutaneous stimulation 
Two carbon rubber electrodes (14 × 10 cm; Electro-Medical Supplies Ltd, Wantage, UK; 
Fig. 3.2) were coated with electrode gel and placed on the skin directly above the assessed 
quadricep muscles (m. rectus femoris, m. vastus medialis, and m. vastus lateralis) to induce 
percutaneous stimulation. Placement of the electrodes was at standardised percentages of thigh 
length, as measured from the patella to the anterior superior iliac spine. The proximal electrode was 
placed 20% distal to the anterior superior iliac spine, and the distal electrode placed 10% proximal 
to the patella. Percutaneous stimulation was implemented to assess the force-frequency relationship, 
with electrically evoked contractions at a range of frequencies (1, 5, 10, 15, 20, 30, 40, 50, 80 and 
100 Hz) to induce submaximal muscle contractions. 
 
 
 
 
  
Fig. 3.2: Method of electrical stimulation: (A) a constant current Digitimer DS7AH electrical 
stimulator; (B) a femoral nerve stimulation probe and carbon rubber electrode; and (C) two carbon 
rubber electrodes used for percutaneous muscle stimulation.  
(B) 
(A) 
(C) 
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3.6 Protocol and measurements 
Measurements were completed in a specific order, in accordance with a consistent time 
schedule, with 3 min rest between successive measurements. Force and EMG onsets for all evoked 
and voluntary contractions were identified using manual visual identification by the same 
investigator. The method of manual visual identification has been proposed as the ‘gold standard’ 
measure to identify signal onset (Pain & Hibbs, 2007; Pulkovski et al., 2008; Tillin et al., 2010; 
Hannah et al., 2012). Manual identification is considered more valid than the use of automated 
methods (Tillin et al., 2012), with identification of the signal onsets up to 60 ms earlier than 
automated methods (Allison, 2003; Pain & Hibbs, 2007). 
 
3.6.1 Maximal voluntary isometric contraction 
Voluntary force production by a given muscle, or group of muscles, in each situation is 
referred to as muscle strength (Knuttgen & Komi, 1992). Muscle strength is specific to both the 
assessed muscle or muscle groups, and the given situation (Knuttgen & Komi 1992; Logan et al., 
2000). The ability to generate a maximal voluntary isometric contraction (MVIC) allows the 
assessment of an individual’s MVIF. MVIF is the difference between baseline force and the 
greatest peak in force production (Folland & Williams, 2007; Fig. 3.3) and is defined as the peak 
instantaneous force achieved during a given situation (Wigley & Strauss, 2000) or during a 
measurement session (Tillin et al., 2010; Hannah et al., 2012). The completion on an MVIC can 
allow the impact of muscular fatigue to be observed and quantified. Skeletal muscle fatigue is often 
described as the decline in physical performance, associated with an increase in the real and/or 
perceived difficulty of a task or exercise (MacIntosh et al., 2005). Muscle fatigue is a decline in 
MVIF or power, of either a single muscle or muscle group (Millet et al., 2012; Enoka & Duchateau, 
2008; Gandevia 2001).  
 
3.6.1.1 Protocol 
To elicit a voluntary maximal contraction, participants were instructed to kick out their 
dominant leg “as hard as possible” for a 2 - 3 s duration. In total, four separate MVIC were 
undertaken with greater than 60 s rest between each attempt, this rest period was double that 
reported in previous research (≥30 s; Folland et al., 2013; 2014; Hannah et al., 2014), ensuring 
participants remained rested throughout. During each MVIC, participants received strong and 
consistent verbal encouragement reiterating the initial instructions, together with on-screen 
feedback of the force signal and a marker of their maximum force during that session displayed on-
screen. Following the competition of each MVIC two potentiated twitch contractions were elicited.  
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3.6.1.2 Assessed variables  
MVIF was recorded during each maximal contraction, with the RMS (Equation 3.1; 
Basmaijian & De Luca, 1985) of the EMG signal for each muscle (m. rectus femoris, m. vastus 
medialis, and m. vastus lateralis) calculated over a 500 ms epoch surrounding MVIF (250 ms either 
side). The RMS value was normalised to the corresponding Mmax (Folland & Williams, 2007; 
Buckthorpe et al., 2012), before being averaged across all three sites to calculate a mean quadriceps 
value.  
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Fig. 3.3: Representative records from a single participant displaying the force response of the knee 
extensors during a maximal isometric voluntary contraction of the knee extensors. Maximal isometric 
voluntary force (MVIF) is depicted as the difference between baseline force and the greatest peak in 
produced force.  
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3.6.2 Explosive voluntary contractions 
The ability to generate force rapidly or as ‘fast and hard’ as possible from rest, is often 
described as production of explosive force (Logan et al., 2000). The production of the muscle force 
generation over a period (∆Force/∆Time) is also described as rate of force development (RFD; 
Aagaard et al., 2002; de Ruiter et al., 2004; Minshull et al., 2007). The RFD at specific time points 
from the onset of the contraction (Tillin et al., 2010) or across a time (Aagaard et al., 2002) can be 
used to quantify explosive force (Fig. 3.4). The RFD is an important descriptor of functional 
performance (Aagaard et al., 2002; de Ruiter et al., 2004), a key factor in numerous populations, 
including athletes (Luhtanen & Komi, 1979; Kuitunen, Komi, & Kyrolainen, 2002), clinical 
populations (Suetta et al., 2004) and the elderly (Hakkinen et al., 1996). RFD is considered more 
important than the production of a MVIC (Tillin et al., 2012; Aagaard et al., 2002; Anderson et al., 
2010), due to the many sporting movements occurring within a shorter time than it take to reach 
maximal force (Hernández-Davó & Sabido, 2014). There is however, a moderate-to-strong 
relationship between RFD and MVIC, especially as time increases beyond 200 ms from force onset 
(Driss et al., 2002; Anderson et al., 2006). The use of 50 ms time windows from the onset of force 
production to provide clearer understanding of the determinants of RFD (Tillin et al., 2010) with 
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Fig. 3.4: Representative records from a single participant displaying force responses of the knee 
extensors during an explosive contraction of the knee extensors. Specific time points are depicted 
every 25 ms following the onset of force (0 ms), to quantify explosive force and rate of force 
development.  
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shorter time window of 25 ms being used in more recent research (Hannah et al., 2012).  
3.6.2.1 Protocol 
Explosive contractions were generated by the participants contracting voluntarily “as fast 
and as hard as possible” on ten separate occasions. The emphasis was on the speed of voluntary 
contraction, yet participants were expected to achieve greater than 80% of MVIF. Contractions 
were performed in accordance with previously published protocols (Tillin et al., 2010; Hannah et 
al., 2012). Each contraction was held for around one second, with around 20 seconds between each 
measurement. Feedback was provided using on-screen cursors; one displaying the peak RFD 
recorded during the session, and the other displaying an 80% MVIC target level. A sensitive scale 
of resting force level was also displayed on-screen providing feedback on any countermovement or 
pre-tension (Fig. 3.5).  
 
3.6.2.2 Assessed variables  
The three explosive voluntary contractions with the greatest RFD, displaying no prior 
countermovement or pretension, with peak force ≥80% MVIF were used for analysis, criteria 
previously described by Hannah et al., (2012; 2014). Force and EMG measurements were averaged 
across the three selected contractions. Force and RFD measures (absolute and normalised to MVIF) 
were recorded at 25, 50, 75, 100, 125 and 150 ms from force onset. The RMS of the EMG signal 
from each muscle (m. rectus femoris, m. vastus medialis, and m. vastus lateralis) was measured 
over three consecutive 50 ms time periods (i.e., 0 - 50, 50 - 100 and 100 - 150 ms) from the EMG 
onset of the first activated agonist muscle. The RMS value (Equation 3.1) of each assessed 
quadricep muscle was normalized to Mmax and averaged to provide a mean quadriceps value. 
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Equation 3.1: Root mean square (RMS) equation where t is the time at the start of sampling, T is 
the time window and m is the amplitude of the surface electromyography signal. 
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Fig. 3.5: Representative records from a single participant displaying force responses of the knee 
extensors collected during an explosive contraction; (A) Channel displaying rate of force 
development, with a horizontal cursor to depict maximum rate of force development; (B) A 
sensitive scale of resting force level; and (C) Force channel displaying horizontal cursor 
displayed 80% of maximal isometric voluntary contraction target level.  
(A) 
(B) 
(C) 
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3.6.3 Sustained isometric knee extensor endurance test 
At 45% MVIF, the blood flow to the active muscle becomes occluded by the increased 
intramuscular pressure (de Ruiter et al., 2007), obstructing circulation to the contracting muscle 
with minimal efflux on lactate and H
+
 (Ahlborg et al., 1972). The active muscle becomes a closed 
system, solely dependent upon anaerobic energy provision, with physiochemical buffers providing 
the only defence against local changes in pH (Sale et al., 2012). In 1960, the Rohmert equation was 
formulated, following the discovery of a non-linear relationship between an individual’s ability to 
maintain a static force and the percentage of MVIF (Rohmert, 1960; Bloswick & Ellis, 1974). It 
was predicted, based on the following equation (Equation 3.2), that a constant isometric contraction 
of the knee extensors would fail to maintain 45% MVIF after approximately 78 s (Ahlborg et al., 
1972).  
 
 ( )       (
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Equation 3.2: The Rohmert equation (Rohmert, 1960), where P is the decimal percentage of 
maximal isometric voluntary force, T is the time window in seconds (s).  
 
3.6.3.1 Protocol 
Participants were instructed to contract their dominant leg and hold this isometric 
contraction at 45% MVIF. Individual targets were visually displayed on-screen in the form of a 
horizontal cursor, with participants asked to complete the IKET as close as possible to the target 
force. Two additional horizontal cursors were displayed to indicate 5% above and below the target 
force (Fig. 3.6). Verbal feedback was provided throughout the contraction, including “too high”, 
“too low” or “on the line”. The start of the IKET was defined as when the force response reached 
greater than 40% MVIF for more than one second (Sale et al., 2010), and ended when force fell 
below 40% MVIF (5% drop from target) for more than three seconds, despite strong verbal 
encouragement (Nordez et al., 2009; Nam et al., 2013; McPhee et al., 2014). 
 
3.6.3.2 Assessed variables  
The Rohmert equation (Equation 3.2) was used to calculate, 1) time to task failure (TTF) at 
45% of MVIF force; ~78 s (Ahlborg et al., 1972), and 2) the hold MVIF percentage based on the 
recorded TTF. The impulse (kN
.
s) of each IKET was calculated from the average force production, 
and the TTF of the fatigue hold contraction. For confirm the presence of muscle fatigue following 
the IKET, MVIF was recorded immediately following the IKET, declines in force generation 
indicated the presence of muscle fatigue (Hassanlouei et al., 2012). 
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Fig. 3.6: Representative records from a single participant displaying the force responses of the knee 
extensors during an isometric knee extensor task, including three on-screen horizontal cursors 
depicting the target force (45% maximal isometric voluntary force) and 5% above and below the 
required target.  
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3.6.4 Twitches 
Through the activation of a single action potential, via a 1 Hz (pulse per second) electrical 
impulse, the skeletal muscle contracts quickly, generating a small force response, referred to as a 
twitch contraction (Enoka, 2008; Fig. 3.7). Twitch contractions are the smallest contractile 
response in skeletal muscle and can last as little at 7.5 ms, yet can last ~100 ms (Martini, 1998). A 
twitch stimulus delivered in a voluntary passive state, generates a resting or un-potentiated twitch 
response, whilst stimulus delivered shortly following a voluntary muscle contraction, is referred to 
as a potentiated twitch (Rassier & MacIntosh, 2000; Hodgson et al., 2005; Ebben, 2006; Fukutani 
et al., 2013; Fig. 3.7). Potentiated twitches generally generate larger force responses compared to 
resting twitches, with increases up to 100% greater than those at rest (Kopman et al., 2001). These 
increases are associated with the phosphorylation of the myosin regulatory light chain, leading to a 
larger number of attached cross brides at a given Ca
2+
 concentration (Sweeney et al., 1993; Rassier 
& MacIntosh, 2000; Kamm & Stull, 2011). Potentiated twitches display increased peak force, 
twitch RFD and larger declines in TPT compared to resting twitches (Sweeney et al., 1993; 
O’Leary et al., 1997; Fig. 3.7). Potentiated twitches also demonstrate higher level of reproducibility 
compared to their resting twitch counterparts, with greater levels of sensitivity to fatigue (Kufel et 
al., 2002).  
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Fig. 3.7: Representative records from a single participant displaying force responses of the knee 
extensors following an evoked resting (before completion of a maximal voluntary isometric 
contraction) and a potentiated twitch (following a maximal voluntary isometric contraction).  
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3.6.4.1 Protocol 
A twitch contraction as defined a single electrical impulse via femoral nerve stimulation, 
was delivered in stepwise increments, separated by greater than ten seconds to allow for 
neuromuscular recovery. Twitch contractions were elicited under rested conditions until a plateau 
in twitch force and M-wave amplitude were achieved. These plateaus indicated maximal 
depolarisation of the femoral nerve, to ensure supramaximal stimulation was achieved, the current 
was increased by 25%, to account for activity dependant changes in axonal excitability (Burke, 
2001). Three discrete supramaximal stimuli were delivered to achieve a maximal resting twitch 
response. Resting twitches are defined as when the electrical stimuli are delivered under rested 
conditions. Following the completion of a MVIC, two femoral nerve supramaximal stimuli were 
delivered, the response to this stimulation resulted in a potentiated twitch response.  
 
3.6.4.2 Assessed Variables 
Resting and potentiated twitches were assessed for several force response variables 
including; peak twitch force, the time recorded between the activation of the first electrode (M-
wave onset) and force onset (electromechanical delay; EMD; Cavanagh & Komi, 1979; Fig. 3.8), 
TPT (Fig. 3.9), RFD measured at 25 ms, 50ms and peak force, and HRT (Fig. 3.9). The M-wave 
area was recorded and averaged across all quadricep muscle sites (m. rectus femoris, m. vastus 
medialis and m. vastus lateralis), with the mean M-wave area of the three supramaximal stimuli 
defined as the Mmax (Fig. 3.10). The M-wave area is a function of and incorporates both the 
amplitude and the duration of the assessed muscle. This representation of the M-wave has been 
suggested to be a more accurate estimate of the number of axons or muscle fibres firing, compared 
to assessing amplitude in isolation (Weiss et al., 2015), thus providing a better overall 
representation.  
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Fig. 3.8: Representative records from a single participant displaying knee extensor force (blue line) 
and agonist surface electromyography (EMG) (pink line) from the m. rectus femoris during the 
onset of an isometric explosive contraction. Electromechanical delay (EMD) is reported as the time 
delay between onset of EMG activity and force, identified manually. 
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Fig. 3.9: Representative record from a single participant displaying force responses of the quadricep 
muscle following an electrically evoked resting twitch. Time-to-peak tension (TPT), peak force and 
half relaxation time (HRT) are reported. 
Fig. 3.10: Representative record from a single participant displaying surface electromyography (EMG) 
response from the m. rectus femoris following an evoked resting twitch. Muscle action potential (M-
wave), stimulation artefact and peak-to-peak amplitude are reported.  
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3.6.5 Doublets  
Doublet discharges are two closely spaced action potentials (<10 ms; Simpson, 1969; 
Christie & Kamen, 2006), which can be evoked by femoral nerve electrical stimulation (Gorassini 
et al., 2000). In human skeletal muscle, doublets are shown to increase in frequency following 
exercise training, with a parallel increase in the RFD of the muscle (Van Cutsem et al., 1998). 
Eliciting an electrical evoked doublet generates a nonlinear increase in force, larger than the sum of 
two twitches (Duchateau & Hainaut, 1986).  
 
3.6.5.1 Protocol 
Electrically evoked doublet contractions (two impulses at 100 Hz) were achieved through 
femoral nerve stimulation, initially delivered at a supramaximal current (+25%) with force and 
RFD recorded. Between subsequent stimuli, current intensity was increased (~5%), until no further 
increases were shown, confirming that maximal force and RFD had been obtained. If the first 
stimuli produced a submaximal response, a fourth stimuli were delivered to ensure three maximal 
responses. A maximum of four stimuli were elicited to prevent muscle damage.  
 
3.6.5.2 Assessed Variables 
Doublets contractions were assessed for peak force (Fig. 3.9), EMD (Fig. 3.8), TPT, and 
HRT (Fig. 3.9). All measurements were averaged across the three final contractions. 
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3.6.6 Octets 
Electrically evoked supramaximal octet contractions (eight pulses at 300 Hz; Fig. 3.11) 
provide a reliable method of examining the maximal evoked explosive performance of the motor 
tendon unit and more reliable than the twitch for assessing peak RFD (de Ruiter, 2004). Octet RFD 
between 0 - 50 ms has been reported as the primary determinant of the voluntary RFD between 50 - 
100 ms, accounting for 68% of the variance once agonist activation was greater than 50 ms 
(Folland, Buckthorpe & Hannah, 2013). Evoking octet contractions declines the inter-individual 
variability noted during voluntary contractions, with voluntary responses two to three times higher 
than those of evoked octet contractions (Folland, Buckthorpe & Hannah, 2013). 
 
3.6.6.1 Protocol 
Electrically evoked octet contractions (Fig. 3.11) were achieved through femoral nerve 
stimulation, initially delivered at a supramaximal current (+25%) with force and RFD recorded. 
Between subsequent stimuli current intensity was increased (~5%), until no further increases were 
seen, confirming that maximal force and RFD had been obtained. If the first stimuli produced a 
submaximal response, a fourth stimuli was delivered to ensure three maximal responses. A 
maximum of four stimuli were elicited to prevent muscle damage.  
 
3.6.6.2 Assessed Variables 
Octet contractions were assessed for peak force (Fig. 3.9), EMD (Fig. 3.8), TPT, and HRT 
(Fig. 3.9). All measurements were averaged across the three final contractions.  
Fig. 3.9: Representative records from a single participant displaying force response of the 
quadricep muscles to an eight impulse 300 Hz octet contraction delivered via electrically evoked 
femoral nerve stimulation. 
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3.6.7 Submaximal contractions / Force-electromyography relationship 
The relationship between force and EMG amplitude provides a greater understanding of 
the association between changes in activation and force (Tillin et al., 2010; Saito & Akima 2013). 
The characteristics of the force-EMG relationship demonstrates the neuromuscular properties of the 
assessed contracting muscle (De Luca, 1997), with the movements in this relationship related to the 
recruitment and firing rate of the muscle motor units (Saito & Akima, 2013). The EMG-force 
relationship has been assessed in several muscles, including the knee extensors (Pincivero & 
Coelho, 2000; Pincivero et al., 2003; Watanabe & Akima, 2009). The relationship between force 
and EMG amplitude is directly proportional with increased force, resulting in increased EMG 
signal, this has however, been widely disputed (Bilodeau et al., 2003; Gerdle et al., 1991; Herzog 
et al., 1998; Karlsson & Gerdle, 2001; Moritani & Muro, 1987). The discrepancies in findings are 
likely due to the limitations of EMG assessments, including cross talk between signals, location of 
the electrode, and in most experiments the catchment area of the electrode does not extend 
sufficiently to detect the signal generated across the entire muscle volume (De Luca, 1997; Siegler 
et al., 1985). There are also known differences between muscle recruitment during voluntary 
contractions, assessment of EMG during these contractions provides a way to verify differences in 
the activation behaviour of the different quadriceps muscles (Pincivero et al., 2003). During 
voluntary isometric contractions, the m. vastus lateralis contributes the most to the muscle 
contraction compared to the m. vastus medialis or the m. rectus femoris, with the lowest 
contribution from the m. vastus medialis (Pincivero et al., 2003). 
 
3.6.7.1 Protocol 
Participants were instructed to produce submaximal voluntary contractions to set target 
forces (15, 30, 45, 60, 75 and 90% MVIF) as identified using on-screen horizontal cursors. 
Individuals were asked to reach the target force as quickly as possible and to maintain the 
contraction for ~3 s in duration, with each voluntary contraction separated by greater than 20 s (Fig. 
3.12).  
 
3.6.7.2 Assessed Variables 
The RMS was calculated during each voluntary contraction, with force and EMG measured 
over a 500 ms stable part of the voluntary contraction. The EMG RMS values were normalised to 
Mmax and plotted against the respective force values. Linear regression was used to assess the slope 
and intercept of the force-EMG relationship incorporating all data between 15 - 90% MVIF.  
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Fig. 3.11: Representative records from a single participant displaying force response of the 
quadricep muscle during a 5 Hz percutaneous stimuli, evoking tetanic contraction.  
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Fig. 3.11: Representative records from a single participant displaying force responses of the 
quadricep muscle during a submaximal contraction held at 60% maximal isometric voluntary force. 
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3.6.8 Force-frequency relationship  
The force-frequency relationship is the association between skeletal muscle force output 
and electrically evoked stimulation frequency. Stimulation of the assessed skeletal muscle occurs at 
frequency from 1 Hz to 100 Hz. At low levels of stimulation frequencies (<5 Hz) the quadriceps 
muscles can contract and reach near full relaxation between pulses. As stimulation frequency is 
increased, complete relaxation of the skeletal muscle is unable to occur, the twitch contractions 
therefore begin to summate, producing a greater skeletal muscle force output. The contractile 
responses when the muscle is unable to completely relax prior to the following stimulus, is referred 
to as a tetanic contraction (MacIntosh et al., 2006). Eventually maximal summation occurs, with 
the force output from the assessed muscle plateauing at maximal force (Binder-Macleod & 
McDermond, 1992). The slope and the half-maximal stimulation frequency become defining 
characteristics of the force-frequency relationship. To compare individual performances, force data 
is normalised by dividing the peak force produced at each frequency by the maximum peak force 
produced during the task, normally (but not always) produced during the 100 Hz contraction 
(Binder-Macleod & McDermond, 1992). The force-frequency relationship provides a mechanism 
to describe the contractile properties of the assessed muscle. Leftward shifts in the slope 
demonstrate the skeletal muscle force has become slower, whilst shifts in the force-frequency curve 
to the right denotes an increase skeletal muscle speed (Jones, 1996). One such example of the 
force-frequency curve shifting is during the ageing process, the relaxation properties of the triceps, 
quadriceps and adductor pollicis muscles slow, shifting the force-frequency curve to the left 
(Davies & White, 1983; Narici, Bordini & Cerretlli, 1991; Roos et al., 1999; Stevens et al., 2001). 
Alterations to the force-frequency relationship are suggested to be caused by Ca
2+
 kinetics, through 
adjustments to the sensitivity of the contractile properties to Ca
2+
 (Jones, 1981) or the amount of 
Ca
2+
 released from the SR (Westerblad et al., 1993).  
 
3.6.8.1 Protocol 
Percutaneous electrical stimulation was used to evoke tetanic contractions of the 
quadriceps muscles (m. rectus femoris, m. vastus medialis, and m. vastus lateralis). Initially an 
evoked contraction at 100 Hz was delivered, with progressively increased intensity until the current 
elicited a skeletal muscle contraction at a force output of 50% MVIF (Fig. 3.13). The current was 
then maintained to evoke a 1 Hz contraction of the assessed skeletal muscle, followed by nine 
single contractions at increasing intensities (5, 10, 15, 20, 30, 40, 50, 80, 100 Hz) of one second 
duration, each contraction was separated by around 30 s. 
 
3.6.8.2 Assessed variables  
For each evoked stimulation (1 – 100 Hz), peak force was defined as the greatest 
instantaneous force during the whole tetanic contraction. Thereafter, the force values at each 
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stimulation frequency were normalized to the force produced during the 100 Hz contraction. The 
force-frequency relationship was fitted with a Hill curve and evaluated for frequency at 50% of the 
maximum force response (Dutka et al., 2012). 
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4.1 Introduction 
Carnosine was first described as an intracellular pH buffer in 1938 (Bate-Smith, 1938; 
Deutsch & Eggleton, 1938), due to its molecular structure, the role of carnosine as an intracellular 
pH buffer is undisputable (Bate-Smith et al., 1938; Sale et al., 2010; 2013; Fig. 2.7), suitable over 
the whole exercise induced intramuscular pH transit-range (Bate-Smith et al., 1938; Harris et al., 
2006). It is unsurprising that improvements in high-intensity exercise performance following 
increased skeletal muscle carnosine content, via β-alanine supplementation, have been associated 
with improved intracellular buffering capacity, resulting in improved exercise performance (see 
review; Sale et al., 2013). Several other potential mechanisms for the enhancement in exercise 
performance following increased carnosine content via β-alanine supplementation have been 
proposed (see review; Begum et al., 2005; Sale et al., 2010). One such mechanism is the suggested 
influence of carnosine on Ca
2+
 kinetics within the skeletal muscle. Altering skeletal muscle 
carnosine content may influence the amount of Ca
2+
 released during skeletal muscle contraction, 
decreasing the inhibitory effect of low Mg
+ 
concentrations (Batrukova & Rubtsov, 1997). Evidence 
in skinned animal muscle fibres suggested that carnosine influenced the sensitivity of the 
contractile apparatus to Ca
2+
 (Lamont & Miller, 1992; Dutka & Lamb, 2004), rather than increasing 
the amount of Ca
2+
 released. In-line with these data, skinned human m. vastus lateralis muscle fibre 
research has shown similar increases in contractile property Ca
2+
 sensitivity following increased 
carnosine concentrations (Dutka et al., 2011). Raising skeletal muscle carnosine content, via β-
alanine supplementation, could influence the amount of Ca
2+
 released during skeletal muscle 
contraction and/or the sensitivity of contractile properties to Ca
2+
, thus alleviating the decline in in-
vivo exercise performance (Lamont & Miller, 1992; Batrukova & Rubtsov, 1997; Dutka & Lamb, 
2004; Dutka et al., 2011; Everaert et al., 2013). Research in nine male mice was the first to 
examine the influence of increased skeletal muscle carnosine content on in-vivo muscle contractile 
properties, through supplementation of drinking water with β-alanine (Everaert et al., 2013). 
Supplementation with β-alanine for eight-weeks significantly increased skeletal muscle carnosine 
content and relative force of the m. extensor digitorum longus by 10 to 31%, inducing a leftward 
shift of the force–frequency relationship (Everaert et al., 2013). These data highlight that increased 
skeletal muscle carnosine content, via β-alanine supplementation, may alter in-vivo human 
contractile properties and skeletal muscle performance via a Ca
2+
 kinetics mechanism. Nonetheless, 
it remains unclear if the relationship between skeletal muscle carnosine content and Ca
2+
 kinetics is 
apparent within a human in-vivo scenario.  
 
As such, the current investigation examined the effect of β-alanine supplementation on 
intrinsic in-vivo knee extensor force production and skeletal muscle contractility in human skeletal 
muscle. It was hypothesised that β-alanine supplementation would improve intrinsic contractile 
properties, creating a leftward shift in the force-frequency relationship, enhancing peak and 
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explosive force responses, and thereby increasing explosive voluntary force production. 
Furthermore, it was hypothesised that the altered contractile properties would lead to a shift in the 
force-EMG relationship towards lower EMG levels for a given level of force. 
 
4.2 Methodology 
4.2.1 Participants 
Twenty-six male participants provided written informed consent and were stratified and 
allocated into the two supplementation groups [placebo or β-alanine] based on MVIF values 
recorded during the familiarisation session. Three participants withdrew from the investigation 
(two from placebo and one from β-alanine); one due to a lack of tolerance of electrical stimulation 
and two provided no reason. As such, 23 participants completed all aspects of the investigation 
(Table 4.1). This research was approved by the Nottingham Trent University Human Ethical 
Review Committee (Application #265). All participants were ‘moderately active’ based on their 
short-form International Physical Activity Questionnaire (IPAQ) physical activity score with no 
significant difference between groups at baseline (β-alanine: 3368 ± 1600 Metabolic Equivalent of 
Task (METs); Placebo: 2429 ± 877; independent sample t-test, P = 0.13).  
 
Table 4.1: Characteristics of participants (n = 23).  
 Placebo (n = 11) β-alanine (n = 12) 
Age (years) 26 ± 6 26 ± 7 
Body mass (kg) 79.1 ± 13.0 82.4 ± 15.2 
Height (m) 1.80 ± 0.07 1.79 ± 0.06 
MVIF (N) 602 ± 108 617 ± 111 
No significant differences were reported. MVIF: Maximal voluntary isometric force. Data are mean 
± 1SD. 
 
4.2.2 Experimental design 
Over a five-week period, three experimental sessions were undertaken by each participant; 
familiarisation sessions were held around seven days prior to the baseline session, with the final 
session conducted following 28-days of supplementation with either β-alanine or placebo. 
Participants were familiarised with the voluntary and electrical evoked knee extensor contractions, 
with all assessments undertaken on the dominant leg. Baseline and the follow-up session involved 
identical protocols, performed in accordance to a strict schedule, and undertaken at a consistent 
time of day. Participants were instructed to abstain from alcohol and strenuous/unaccustomed 
exercise for 36 h before each session, with caffeine prohibited on the day of the protocol. 
Compliance with these requests was confirmed verbally with the participant before commencement 
of the protocol. All raw data analyses, exclusions, and statistical analyses were undertaken by an 
experimenter blind to supplemental group, ensuring double-blind status. 
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4.2.3 Experimental protocol  
Upon arrival to the familiarisation session participant’s height and weight were recorded. 
Participants were seated in a rigid, custom-built isometric dynamometer (Fig. 3.5.3; page 36) with 
hip and knee joint angles of approximately 95° and 100° (180° = full extension), as previously 
described (Hannah et al., 2012; 2013). Isometric knee extension force and EMG signals were 
recorded during all sessions, the details of which have been described in sections 3.5.3 and 3.5.4, 
page 38-39. Several isometric voluntary and electrically evoked contractions were undertaken 
during each session, including: 
a) MVIC; as described in section 3.6.1, page 42. 
b) Explosive voluntary contraction; as described in section 3.6.2, page 44. 
c) Twitches (resting and potentiated); as described in section 3.6.4, page 49. 
d) Octet contractions; as described in section 3.6.6, page 54. 
e) Force-EMG relationship; as described in section 3.6.7, page 55. 
f) Force-frequency relationship; as described in section 3.6.8, page 57. 
 
4.2.4 Supplementation 
Participants were supplemented with 6.4 g
.
day
-1
 of either β-alanine or a matched placebo in 
tablet form over 28-days. The supplementation protocol consisted of two 800 mg tablet ingested 
four times per day, at 2 - 4 h intervals. Compliance with the supplementation period was monitored 
with compliance logs, both groups reported a high degree of compliance, reported at 91 ± 7% in the 
β-alanine group (total dose of 163.1 ± 12.5 g) and 88 ± 10% in the placebo group (total dose of 
157.7 ± 1.8 g; independent sample t-test, P = 0.60). Participants supplemented with β-alanine 
would expect an increase in skeletal muscle carnosine content of ~15 mmol
.
kg
-1
 dry muscle (~65%) 
from baseline based on comparable β-alanine supplementation protocols (Harris et al., 2006). 
There were no reported symptoms of paraesthesia from any of the participants during the 
supplementation period. 
 
4.2.5 Statistical analysis 
The G* Power 3.1.6 software programme was used to calculate an a priori power 
calculation for sample size, having as parameters: statistical test (ANOVA), α = 0.05, β = 0.80 
(power of the sample), number of groups analysed (2 = β-alanine and placebo), and the effect of 
sample size based on previous findings (Hobson et al., 2012). According to the calculations, a 
minimum of 22 participants would be required for the study, with 26 participants being recruited to 
allow for dropouts. A three-way analysis of variance (ANOVA) (group × session × time point) was 
used to assess dependent variables (force and EMG during explosive voluntary contractions, 
evoked twitch, and octet force) and the force-frequency relationship (group × session × frequency). 
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MVIF, HRT, TPT, the force-EMG relationship, and the force-frequency relationship (at 50%) were 
evaluated using a two-way ANOVA (group × session). Assessed variables were tested for 
normality using the Shapiro-Wilks test, and for homogeneity using the Fevene test. A Greenhouse-
Geisser correction was applied when the ANOVA assumption of sphericity was violated, and 
significant interaction effects were followed-up by independent sample t-tests on the individual 
percentage change values for each condition. ES for multiple comparisons was calculated using 
partial (  
 ) and generalised (  
 ) eta squared (Lakens, 2013). Providing two ESs is suggested to 
yield a greater understanding of a specific effect (Preacher & Kelly, 2011). Post hoc comparisons 
to explain any significant interactions are reported with Cohen’s d and Hedges g ES. An ES of 0.2 
– 0.5 was defined as small, 0.5 – 0.8 as medium and ≥ 0.8 as a large effect (Schünemann et al., 
2008). Intra-individual variability was calculated using the mean intra-individual coefficient of 
variation (CV) between the pre- and post-supplementation sessions for the placebo group [(SD / 
mean) × 100]. Statistical analyses were completed using SPSS version 22 (SPSS Inc., Chicago, IF, 
USA) and Microsoft Excel (Microsoft Inc., USA). Statistical significance was accepted at P ≤ 0.05, 
with data presented as mean ± 1 SD. 
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4.3 Results 
4.3.1 Maximum and explosive voluntary contractions 
MVIF was unaffected by 28-days of supplementation in fresh skeletal muscle (P = 0.17; f 
(1, 21) = 1.99,   
  = 0.1,   
  < 0.1; Fig. 4.1). The mean CV within the placebo group was 3%. 
Correspondingly, β-alanine supplementation showed no effect on explosive voluntary force 
measured at 25 ms intervals (P = 0.82; f (5, 105) = 0.44,   
  < 0.1,   
  < 0.1 (group × session × time 
point); P = 0.56; f (1, 21) = 0.36,   
  = 0.2,   
  < 0. 1 (group × session); Fig. 4.1). The mean CV in 
the placebo group, across 25 - 50 ms window was 13 - 17%, decreasing to 4 - 7% in the 75 - 150 
ms window.  
Agonist EMG normalized to Mmax during MVICs and explosive contractions were not 
influenced by supplementation (P = 0.69; f (3, 36) = 0.50,   
  < 0.1,   
  < 0.1 (group × session × 
time point); P = 0.55; f (1, 21) = 0.36,   
  < 0.1,   
  < 0.1 (group × session); Fig. 4.1). The mean CV 
for the placebo group was 26% for the 0 - 50 ms window, 23% for the 50 - 100 ms window, 9% for 
the 100 - 150 ms window, and 13% for MVIF.  
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Fig. 4.1: Explosive and maximal isometric voluntary force (MVIF) (A), and agonist surface 
electromyography (EMG) normalised to maximum muscle action potential (Mmax) during 
explosive contractions (0 - 50, 50 - 100 and 100 - 150 ms from onset) and at MVIF (B) for the 
β-alanine (BA) and placebo (PLA) groups pre- and post-supplementation. RMS: Root mean 
square. Data are mean ± 1SD. 
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4.3.2 Twitches 
Resting twitches: Supplementation did not significantly influence resting twitch force (P = 
0.45; f (2, 40) = 0.82,   
  < 0.1,   
  < 0.1 (group × session × time point); P = 0.70; f (1, 21) = 0.16, 
  
  < 0.1,   
  < 0.1 (group × session); Table 4.2), EMD (P = 0.55; f (1, 20) = 0.38,   
  < 0.1,   
  < 
0.1; Table 4.2), or TPT (P = 0.79; f (1, 20) = 1.12,   
  < 0.1,   
  = 0.1 Table 4.2) in fresh skeletal 
muscle. There was, however, a significant group × session interaction for HRT (P = 0.02; f (1, 20) 
= 6.68,   
  = 0.2,   
  < 0.1; Fig. 4.2). Post hoc analysis showed that the percentage change in HRT 
was greater for the β-alanine group (-8 ± 10 ms; -10 ± 11%) compared with the increased responses 
in the placebo group (+3 ± 13 ms; 5 ± 12%; P = 0.006; t (21) = -3.0; 95% confidence interval [-
24.3, -4.5], Cohen’s d = 1.3; Hedge’s g = 1.2). The confidence interval ES indicated that there was 
an 81% chance of a randomly selected pair of individuals would experience a decline in HRT 
following β-alanine supplementation. Mean CV values for fresh skeletal muscle in the placebo 
group: force at 25 and 50 ms and peak were 14, 9 and 8%, EMD was 7%, TPT was 3% and HRT 
was 7%. 
 
Potentiated twitches: Supplementation did not significantly influence resting twitch force 
(P = 0.43; f (2, 42) = 0.87,   
  < 0.1,   
  < 0.1; Table 4.2 (group × session × time point)), EMD (P = 
0.47; f (1, 21) = 0.54,   
  < 0.1,   
  < 0.1; Table 4.2), or TPT (P = 0.29; f (1, 21) = 1.17,   
  = 0.1, 
  
  < 0.1 Table 4.2). There was, however, a significant group × session interaction for HRT (P = 
0.04; f (1, 21) = 5.27,   
  = 0.2,   
  < 0.1; Fig. 4.2). Post hoc analysis showed that the change in 
HRT was greater for the β-alanine group (-12 ± 28 ms; -7 ± 11%) compared with the increased 
responses in the placebo group (+1 ± 5 ms; 1 ± 8%; P = 0.05 t (21) = -1.9; 95% confidence interval 
[-32.1, 0.9], Cohen’s d = 0.8; Hedge’s g = 0.8). The confidence interval ES indicated that there was 
a 71% chance of a randomly selected pair of individuals would experience a decline in HRT 
following β-alanine supplementation. Mean CV values for fresh skeletal muscle in the placebo 
group: force at 25 and 50ms and peak were 6, 3 and 3%, EMD was 6%, TPT was 3% and HRT was 
4%.  
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4.3.3 Octet contractions 
In fresh skeletal muscle, supplementation did not significantly alter octet EMD or TPT 
(Table 4.2). There was, however, a trend towards significance for HRT (P = 0.08;   
 =0.1;   
 =0.1). 
In fresh skeletal muscle, supplementation did not significantly alter octet force at 25 ms, 50 ms and 
peak (P = 0.62; f (2, 42) = 0.48,   
  < 0.1,   
  < 0.1 (group × session × time point); P = 0.45; f (1, 
21) = 0.60,   
  < 0.1,   
  < 0.1 (group × session); Table 4.2). Mean CV for the placebo group were 
10, 3 and 4% for force at 25 ms, 50 ms and peak.  
 
Fig. 4.2: Electrically evoked half relaxation time of β-alanine (BA) and placebo (PLA) groups pre- 
and post-supplementation, in fresh and fatigued skeletal muscle during: resting twitch (a), 
potentiated twitch (b), and octets (c). Data are mean ± 1SD. **P = 0.006 and *P = 0.04 for post hoc 
independent t-test between β-alanine and placebo groups. 
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Table 4.2: Electrically evoked force responses, time-to-peak tension (TPT) and electromechanical delay (EMD) in β-alanine and placebo groups pre- and 
post-supplementation, in fresh skeletal muscle.  
Data are mean ± 1SD. 
   Pre-supplementation Post-supplementation 
   Force (N) EMD 
(ms) 
TPT 
(ms) 
Force (N) EMD 
(ms) 
TPT 
(ms)       25 ms 50 ms Peak 25 ms 50 ms Peak 
Resting Twitch Fresh β-alanine 31 ± 7 98 ± 21 127 ± 27 10 ± 1 86 ± 11 32 ± 7 100 ± 21 126 ± 25 10 ± 1 83 ± 7 
 Fresh Placebo  34 ± 12 107 ± 34 135 ± 43 10 ± 2 82 ± 5 36 ± 9 106 ± 24 130 ± 30 10 ± 1 80 ± 3 
Potentiated Twitch Fresh β-alanine 69 ± 17 159 ± 29 193 ± 39 8 ± 1 82 ± 11 70 ± 18 164 ± 27 199 ± 34 9 ± 1 82 ± 11 
 Fresh Placebo  81 ± 23 171 ± 37 203 ± 45 9 ± 1 80 ± 9 79 ± 18 172 ± 33 204 ± 43 9 ± 1 83 ± 8 
Octet Fresh β-alanine 86 ± 16 241 ± 29 384 ± 56 13 ± 1 134 ± 8 82 ± 16 244 ± 29 390 ± 57 12 ± 2 135 ± 9 
 Fresh Placebo  87 ± 18 238 ± 41 372 ± 89 14 ± 2 122 ± 18 79 ± 27 216 ± 76 344 ± 127 14 ± 3 118 ± 39 
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4.3.4 Force-electromyography relationship  
 The slope and y-intercept of the force-EMG relationship were unaffected by 
supplementation in fresh skeletal muscle (slope: P = 0.13; f (1, 21) = 2.55,   
  = 0.1,   
  = 0.1; y-
intercept: P = 0.39; f (1, 21) = 0.79,   
  < 0.1,   
  < 0.1 (group × session); Fig. 4.3). The mean CV 
in the placebo group for the slope of the force-EMG relationship was 15%. 
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Fig. 4.3: Force-surface electromyography (EMG) relationship measured during submaximal 
voluntary contractions (15 – 90% maximal voluntary isometric force) for the β-alanine (BA) and 
placebo (PLA) groups pre- and post-supplementation. Mmax: Maximum muscle action potential; 
RMS: Root mean square. Data are mean ± 1SD. 
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4.3.5 Force-frequency relationship 
Supplementation did not significantly influence peak force at each frequency of stimulation 
(P = 1.31; f (9, 189) = 6.24,   
  = 0.1,   
  < 0.1 (group × session × frequency); P = 0.50; f (1, 21) = 
0.48,   
  < 0.1,   
  < 0.1 (group × session); Fig. 4.4). The frequency at 50% of the force response 
(Table 4.3) in fresh skeletal muscle was unaffected by supplementation. The mean CV for the 
placebo responses for relative force were 6 – 8% at 1 - 10 Hz, 1 – 3% at 15 – 80 Hz, and 6% at the 
maximum 100 Hz (50% of MVIF).  
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Fig. 4.4: Force-frequency relationship measured during percutaneous contractions pre- and post-
supplementation with either β-alanine (BA) or placebo (PLA). Data are mean ± 1SD. 
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Table 4.3: Characteristics of the force-frequency and force-electromyography (EMG) relationships pre- and post-supplementation with either β-
alanine or placebo.  
 Pre-supplementation Post-supplementation 
 β-alanine Placebo β-alanine Placebo 
Force-frequency relationship 
Frequency at 50% of response, Hz 17.3 ± 2.4 18.8 ± 1.5 16.8 ± 1.7 18.0 ± 1.9 
Force-EMG relationship 
Intercept (RMS:Mmax) -0.49 ± 0.74 -0.70 ± 0.47 -0.53 ± 0.91 -0.56 ± 0.43 
Slope (RMS:Mmax/N) 0.018 ± 0.005 0.018 ± 0.004 0.017 ± 0.004 0.017 ± 0.004 
RMS: Root mean square. Mmax: Maximum muscle action potential. Data are mean ± 1SD.  
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4.4 Discussion 
There was no effect of 28-days β-alanine supplementation on the force-frequency 
relationship, the in-vivo analogue of the force-Ca
2+
 relationship (Balnave & Allen, 1996), at either 
relatively low (1 - 15 Hz) or high (20 - 80 Hz) frequencies. Supplementation with β-alanine 
resulted in no significant alterations to voluntary force responses during maximal and explosive 
contractions, or electrically evoked resting and potentiated twitches or octet contraction variables 
(EMD, peak force and TPT). These in-vivo data imply that β-alanine supplementation to increase 
skeletal muscle carnosine content, does not significantly influence Ca
2+
 kinetics or skeletal muscle 
performance. β-alanine supplementation did significantly decline skeletal muscle HRT, during 
electrically evoked resting and potentiated twitches (7 - 12%). The percentage change in skeletal 
muscle relaxation speed was greater for the β-alanine group than the placebo group, displaying a 
large effect in both resting and potentiated twitch responses (Cohen’s d = 0.8 and 1.3). 
 
The current findings are in contrast with previous research, where increased skeletal 
muscle carnosine content resulted in enhanced Ca
2+
 sensitivity in both human (Dutka et al., 2012) 
and murine (Everaert et al., 2013) skeletal muscle fibres. The discrepancies in outcomes may be 
associated with the nature of these investigations. The present research was conducted in in-vivo 
human skeletal muscle, whilst previous research reporting enhanced Ca
2+
 sensitivity with increased 
carnosine content were undertaken in in-vitro skinned muscle fibres (Dutka et al., 2012; Everaert et 
al., 2013). The manner in which in-vitro muscle fibres respond to increased carnosine content 
could have been directly influenced by the method and distribution of carnosine, influencing the 
contractile property responses. The proposed alterations to Ca
2+
 kinetics reported in in-vitro may 
have minor impact in an in-vivo scenario (Dutka et al., 2012). The current investigation is limited 
by the lack of a direct skeletal muscle carnosine measurement following the β-alanine 
supplementation protocol. Nonetheless, it can be expected that participants would have experienced 
a 65% increase in skeletal muscle carnosine content from baseline, based on previous research 
(Harris et al., 2006).  
 
Voluntary contraction variables remained unaffected by β-alanine supplementation, which 
was unsurprising, due to the lack of effect that improved Ca
2+
 sensitivity of the contractile 
apparatus and/or the amount of Ca
2+
 released would potentially have on MVIF production 
(MacIntosh & Willis, 2000). There was also no significant influence of β-alanine supplementation 
on explosive force or the force-EMG relationship. Any potential changes in these measures could 
have been indicative of modifications to the neuromuscular activation required to produce a set 
amount of skeletal muscle force. Due to the lack of change in neural drive during both voluntary 
maximal and explosive contraction, it can also be suggested that β-alanine supplementation did not 
alter neuromuscular activation. The voluntary and electrically evoked data implied that increased 
Chapter 4: Effect of β-alanine supplementation on neuromuscular performance  
 
  76 
skeletal muscle carnosine content, achieved via β-alanine supplementation does not significant 
influence Ca
2+
 kinetics within a human in-vivo model. 
 
There was, however, a significant decline in skeletal muscle relaxation speed, with a 7 – 
12% decrease in HRT during both electrically evoked resting and potentiated twitch contractions. 
The interaction effect between groups over the supplementation period resulted in a medium effect 
during both resting and potentiated twitch contractions, with the percentage change in skeletal 
muscle relaxation speed greater for the β-alanine group than the placebo group. Alterations to the 
relaxation speed of the contracting skeletal muscle could prove beneficial, in regard to reducing the 
total energy expenditure and improving efficiency of joint movements experienced during high-
intensity cyclic exercises. The speed at which skeletal muscle relaxes can be impacted by the rate 
of: (i) dissociation of Ca
2+
 from troponin (Little et al., 2011); (ii) translocation of Ca
2+
 to near the 
site of entry into the SR (Muntener et al., 1995); and (iii) re-uptake of Ca
2+ 
into the SR by Ca
2+
 
pumps (Nogueira et al., 2013). No previous research has shown that carnosine influences these 
aspects of excitation-contraction coupling, although, Everaert et al., (2013) did show decreased in 
fatigue related increases in skeletal muscle relaxation times following β-alanine supplementation in 
murine m. soleus. These findings in murine muscles, however, did not show any changes in resting 
rates of relaxation, and thus these findings could have been impacted by enhanced buffering 
capacity, rather than improved Ca
2+
 kinetics. Due to this unexpected finding, future research should 
examine the reproducibility of this proposed mechanism. There also needs to be greater 
examination of the impact of skeletal muscle fatigue on the contractile properties, providing 
improved understanding of the influence of β-alanine supplementation on skeletal muscle 
contractility, and the implications for metabolic and movement efficiency.  
 
4.5 Conclusion 
There was no effect of 28-days β-alanine supplementation, on the force-frequency 
relationship, suggesting a lack of influence of increased skeletal muscle carnosine concentration on 
the improved Ca
2+
 sensitivity of the contractile apparatus and/or the amount of Ca
2+
 released. There 
was no significant influence of β-alanine supplementation on voluntary and evoked force responses. 
These findings suggested that the improvements in exercise performance and capacity following β-
alanine supplementation are not due to alterations to Ca
2+
 kinetics (sensitivity and/or release) in the 
skeletal muscle. There was, however, a significant decline in resting and potentiated twitch HRT 
following β-alanine supplementation. The reduction in skeletal muscle HRT could be explained by 
enhanced reuptake of Ca
2+
 into the SR, a factor known to alter muscle relaxation speed.  
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5.1 Introduction 
The data reported in study 1 (Chapter 4) was the first research to comprehensively examine 
the effect of 28-days of β-alanine supplementation on the electrically evoked contractile properties 
and voluntary force production of human skeletal muscle in-vivo. These data proposed that β-
alanine supplementation did not alter the force-frequency relationship at either relatively low (1 - 
15 Hz) or high (20 - 80 Hz) frequencies, with no significant alteration to voluntary force responses 
during maximal and explosive contractions, or electrically evoked resting or potentiated twitches 
and octets variables (EMD, peak force and TPT). These findings were in-line with the hypothesis 
arising from previous exercise performance studies (Sale et al., 2010; 2013), that the main 
physiological role for carnosine in improving high-intensity exercise performance related to 
intracellular pH buffering, and not increased Ca
2+ 
sensitivity of the in-vivo contractile apparatus. An 
unexpected finding was the significant reduction in skeletal muscle HRT during both resting and 
potentiated twitches following β-alanine supplementation. The finding was not an a-priori 
hypothesis, making it important to confirm these findings before exploring potential underlying 
mechanisms.  
 
Swietach et al., (2013) suggested that there may also be a mediating effect of pH on the 
interaction between L-histidine containing dipeptides (such as carnosine) and Ca
2+
. High-intensity 
exercise leads to a more pronounced accumulation of H
+
, a metabolic factor that might be involved 
in skeletal muscle fatigue, but in combination with other fatigue-induced changes or in an indirect 
manner (Westerblad, 2016). It should also be highlighted that skeletal muscle fatigue is multi-
factorial phenomenon and can include alterations in neuromuscular transmission, muscle action 
potential propagation, excitation-contraction coupling and related contractile mechanisms (Boyas 
& Guevel, 2011). Skeletal muscle fatigue is generally accompanied by a marked slowing of 
relaxation (Allen, Lamb & Westerblad, 2008). H
+
 are proposed to directly or indirectly inhibit 
sarcoplasmic Ca
2+
 release during skeletal muscle contraction (Laver, Eager, Taoube & Lamb, 2000; 
Laver, O’Neill & Lamb, 2004). Carnosine has the potential to serve as a cytoplasmic regulator of 
Ca
2+
 and H
+
 coupling, since it binds to both ions (Baran, 2000). As such, it could be hypothesised 
that increasing skeletal muscle carnosine content, via β-alanine supplementation, would have a 
more pronounced beneficial effect on HRT when the skeletal muscle is fatigued. 
 
Therefore, the present study aimed to examine the effect of β-alanine supplementation on 
intrinsic in-vivo isometric knee extensor force production and skeletal muscle contractility in both 
fresh and fatigued human skeletal muscle. It was hypothesised that 28-days of β-alanine 
supplementation would significantly decline in skeletal muscle HRT in fresh skeletal muscle, 
similar to findings in study 1 (Chapter 4). Additionally, due to the relationship between H
+
 and 
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Ca
2+
 kinetics within the skeletal muscle it is hypothesised that there will be a decline in skeletal 
muscle HRT under fatigued conditions.  
 
5.2 Methodology 
5.2.1 Participants 
Twenty-four male participants provided written informed consent and were then stratified 
and allocated into the two supplementation groups [placebo or β-alanine] based on MVIF values 
recorded during the familiarisation session. One participant withdrew from the investigation 
(placebo group) with no reason provided. As such, 23 participants completed all aspects of the 
investigation (Table 5.1). This research was approved by the Nottingham Trent University Human 
Ethical Review Committee (Application #369). Self-reported sleep quality categorised by the PSQI 
(Pittsburgh Sleep Quality Index), reported participants as good sleepers, with no differences 
between groups or following supplementation (Table 5.2). There was no significant difference 
between groups or pre- to post-supplementation regarding participant mood scores (Brunel 
University Mood Scale), or physical activity levels (International Physical Activity Questionnaires) 
with all participants categorised as ‘moderately active’ (Table 5.2). These additional questionnaires 
were included in-line with the development of the university sport science laboratory regulations, 
due to the potential impact of sleep, mood and physical activity of an individual’s performance.  
 
Table 5.1: Characteristics of participants (n = 23).  
 Placebo (n = 11) β-alanine (n = 12) 
Age (years) 22 ± 1 22 ± 2 
Body mass (kg) 81.4 ± 14.2 76.0 ± 7.3 
Height (m) 1.83 ± 0.06 1.80 ± 0.05 
MVIF (N) 600 ± 149 565 ± 86 
No significant differences were reported. MVIF: Maximal voluntary isometric force. Data are mean 
± 1SD. 
 
5.2.2 Experimental design 
Over a five-week period, three experimental sessions were undertaken by each participant; 
familiarisation sessions were held around seven days prior to the baseline session, with the final 
session conducted following 28-days of supplementation with either β-alanine or PLA. Participants 
were familiarised with the voluntary and electrical evoked knee extensor contractions, with all 
assessment undertaken on the dominant leg. Baseline and the follow-up session involved identical 
protocols, performed in accordance to a strict schedule, and undertaken at a consistent time of day. 
Participants were instructed to abstain from alcohol and strenuous/unaccustomed exercise for 36 h 
before each session, with caffeine prohibited on the day of the protocol. Compliance with these 
requests was confirmed verbally with the participant before commencement of the protocol. All 
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raw data analyses, exclusions, and statistical analyses was undertaken by an experimenter blind to 
supplemental group, ensuring double-blind status. 
 
5.2.3 Experimental protocol  
Upon arrival to the familiarisation session participant’s height and weight were recorded. 
Participants were seated in a rigid, custom-built isometric dynamometer (Fig. 3.5.3; page 36) with 
hip and knee joint angles of approximately 95° and 100° (180° = full extension), as previously 
described (Hannah et al., 2012; 2013). Isometric knee extension force and EMG signals were 
recorded during all sessions, the details of which have been described in sections 3.5.3 and 3.5.4, 
page 38-39. Several isometric voluntary and electrically evoked contractions were undertaken 
during each session, including: 
a) MVIC; as described in section 3.6.1, page 42. 
b) Explosive voluntary contraction; as described in section 3.6.2, page 44. 
c) IKET; as described in section 3.6.7, page 47.  
d) Twitches (resting and potentiated); as described in section 3.6.4, page 49. 
e) Octet contractions; as described in section 3.6.6, page 54. 
f) Force-EMG relationship; as described in section 3.6.7, page 55. 
g) Force-frequency relationship; as described in section 3.6.8, page 57. 
 
Fingertip blood lactate was recorded via fingertip capillary blood samples taken at rest, 
immediately prior to and 5 minutes following the IKET (as described in 3.5.2, page 37). The IKET 
was completed in accordance to the description within section 3.6.3, page 47. 
 
5.2.4 Supplementation 
Participants were supplemented with 6.4 g
.
day
-1
 of either β-alanine (sustained-release 
CarnoSyn
TM
, NAI, USA) or a matched placebo (maltodextrin; NAI, USA) in tablet form over 28-
days. All supplements were provided in identical white tubs by an individual not directly involved 
in testing or data analysis. The supplementation protocol consisted of two 800mg tablet ingested 
four times per day, at 2 - 4 h intervals. Compliance with the supplementation period was monitored 
with compliance logs, both groups reported a high degree of compliance, reported at 91 ± 7% in the 
β-alanine group (total dose of 163.1 ± 12.5 g) and 88 ± 10% in the placebo group (total dose of 
157.7 ± 1.8 g; independent sample t-test, P < 0.60). Participants supplemented with β-alanine 
would expect an increase in skeletal muscle carnosine content of ~15 mmol
.
kg
-1
 DM (~65%) from 
baseline based on comparable β-alanine supplementation protocols (Harris et al., 2006). There 
were no reported symptoms of paraesthesia from any of the participants during the supplementation 
period.  
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Table 5.2: Participant questionnaire scores.  
 Placebo (n = 11) β-alanine (n = 12) 
 Pre-
supplementation 
Post-
supplementation 
Pre-
supplementation 
Post-
supplementation 
PSQI 3 ± 1 3 ± 1 3 ± 1 3 ± 1 
BRUMS     
Anger 6 ± 2 6 ± 2 5 ± 1 5 ± 1 
Confusion 6 ± 2 6 ± 2 5 ± 1 4 ± 1 
Depression 5 ± 1 5 ± 2 5 ± 2 5 ± 1 
Fatigue 8 ± 1 7 ± 2 7 ± 2 7 ± 2 
Tension 6 ± 2 6 ± 2 6 ± 3 6 ± 3 
Vigour 12 ± 3 12 ± 4 12 ± 3 12 ± 3 
IPAQ (METs) 2599 ± 1897 2770 ± 1979 3257 ± 1769 2876 ± 1760 
No significant differences were reported. PSQI: Pittsburgh Sleep Quality Index. BRUMS: Brunel University Mood Scale. IPAQ: International Physical 
Activity Questionnaires. MET: Metabolic equivalent of task. Data are presented mean ± 1SD. 
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5.2.5 Statistical analysis 
The G* Power 3.1.6 software programme was used to calculate an a priori power 
calculation for sample size, having as parameters: statistical test (ANOVA), α = 0.05, β = 0.80 
(power of the sample), number of groups analysed (2 = β-alanine and placebo), and the effect of 
sample size based on previous findings (Hobson et al., 2012). According to the calculations, a 
minimum of 22 participants would be required for the study, with 24 participants being recruited to 
allow for dropouts. Dependent variables (MVIF, EMD, HRT, TPT, slope and intercept of force-
EMG relationship, frequency at 50% of force response for the force-frequency relationship) were 
evaluated using a two-way mixed-model (group × session) ANOVA. Dependent variables 
measured over several time points (force and EMG during explosive voluntary contractions, 
evoked twitch, and octet force) were analysed using a three-way mixed-model (group × session × 
time) ANOVA. All variables were assessed during both fresh and fatigued conditions. IKET 
variables (TTF and impulse) were analysed using a two-way mixed-model ANOVA. 
 
The impact of the IKET contraction on dependant variables (MVIF, EMD, HRT, TPT, 
slope and intercept of force-EMG relationship, frequency at 50% of force response for the force-
frequency relationship) were analysed using a three-way mixed-model (group × session × fatigue) 
ANOVA. Dependent variables measured over several time points (force and EMG during 
explosive voluntary contractions, evoked twitch and octet force) were analysed using a three-way 
mixed-model (group × session × percentage change) ANOVA based on percentage change between 
fresh and fatigued values.  
 
Assessed variables were tested for normality using the Shapiro-Wilks test, and for 
homogeneity using the Fevene test. A Greenhouse-Geisser correction was applied when the 
ANOVA assumption of sphericity was violated, and significant interaction effects were followed-
up by independent sample t-tests on the individual percentage change values for each condition. ES 
for multiple comparisons was calculated using   
  and   
  eta squared (Lakens, 2013). Providing 
two ESs is suggested to yield a greater understanding of a specific effect (Preacher & Kelly, 2011). 
Post hoc comparisons to explain any significant interactions are reported with Cohen’s d and 
Hedges g ESs. An ES of 0.2 – 0.5 was defined as small, 0.5 – 0.8 as medium and ≥ 0.8 as a large 
effect (Schünemann et al., 2008). Intra-individual variability was assessed using the mean intra-
individual CV between the pre- and post-supplementation sessions for the placebo group [(SD / 
mean) × 100]. Statistical analyses were completed using SPSS version 22 (SPSS Inc., Chicago, IF, 
USA) and Microsoft Excel (Microsoft Inc., USA). Statistical significance was accepted at P ≤ 0.05, 
with data presented as mean ± 1 SD. 
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5.3 Results 
5.3.1 Maximum and explosive voluntary contractions 
Twenty-eight days of β-alanine supplementation had no effect on MVIF in fresh (P = 0.71; 
f (1, 21) = 0.29,   
  < 0.1,   
  < 0.1) or fatigued skeletal muscle (P = 1.0; f (1, 21) < 0.001,   
  < 0.1, 
  
  < 0.1; Fig. 5.1A). The mean CV in the placebo group was 3% and 5% in fresh and fatigued 
skeletal muscle. Following the completion of the IKET, MVIF significantly declined (P < 0.001; f 
(1, 21) = 216.85,   
  = 0.9,   
  = 0.2), with no differences between sessions (P = 0.73; f (1, 21) = 
0.12,   
  < 0.1,   
  < 0.1) or groups (P = 0.78; f (1, 21) = 0.08,   
  < 0.1,   
  < 0.1) (β-alanine: 17 – 
18%; PLA: 21%; Fig. 5.1A). There was no effect of β-alanine supplementation on force measures 
at 25 ms intervals during explosive voluntary contractions in either fresh (P = 0.54; f (5, 105) = 
0.82,   
  < 0.1,   
  < 0.1 (group × session × time point); P = 0.91; f (1, 21) = 0.01,   
  < 0.1,   
  < 0.1 
(group × session)) or fatigued skeletal muscle (P = 0.31; f (5, 105) = 1.20,   
  = 0.1,   
  < 0.1 (group 
× session × time point); P = 0.67; f (1, 21) = 0.18,   
  < 0.1,   
  < 0.1 (group × session); Fig. 5.1A). 
The percentage change in explosive force between fresh and fatigued conditions was not altered 
between sessions (P = 0.75; f (1, 21) = 0.46,   
  < 0.1,   
  = 0.1) with no group × session interaction 
(P = 0.50; f (1, 21) = 0.46,   
  < 0.1,   
  < 0.1). The mean CV in the placebo group during explosive 
contractions was 15 - 20% at 25 - 50 ms and 4 - 8% from 75 - 150 ms during a fatigued condition 
and 18 - 22% at 25-50 ms and 6 - 12% from 75 - 150 ms during the fatigued condition. 
 
Agonist EMG normalised to Mmax during MVICs and explosive contraction was 
uninfluenced by β-alanine supplementation in fresh (P = 0.86; f (3, 63) = 1.39,   
  < 0.1,   
  < 0.1 
(group × session × time point); P = 0.90; f (1, 21) = 0.02,   
  < 0.1,   
  < 0.1 (group × session)) and 
fatigued skeletal muscle (P = 0.10; f (3, 51) = 6.95,   
  < 0.1,   
  = 0.1 (group × session × time 
point); P = 0.26; f (1, 17) = 1.36,   
  = 0.1,   
  < 0.1 (group × session); Fig. 5.1B). The mean CV 
values in the placebo group for agonist EMG in fatigued skeletal muscle were 26% at 0 - 50 ms, 
21% at 50 - 100 ms and 20% at 100 - 150 ms time windows, and 12% at MVIF. The mean CV 
values in the placebo group for agonist EMG in fatigued skeletal muscle were 27% at 0 - 50 ms, 
29% 50 - 100 ms and 21% at 100 - 150 ms time windows, and 19% at MVIF. The percentage 
change in agonist EMG normalised to Mmax during MVICs and explosive contraction was not 
significantly altered between sessions (P = 0.29; f (1, 21) = 0.59,   
  < 0.1,   
  < 0.1), with no group 
× session interaction (P = 0.77; f (1, 17) = 0.09,   
  < 0.1,   
  < 0.1). 
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Fig. 5.1: Explosive and maximal voluntary isometric force (MVIF) voluntary force (A), and agonist 
Surface electromyography (EMG) normalised to maximum muscle action potential (Mmax) during 
explosive contractions (0 - 50, 50 - 100 and 100 - 150 ms from onset) and at MVIF (B) for the β-
alanine (BA) and placebo (PLA) groups pre- and post-supplementation, in fresh and fatigued 
skeletal muscle. RMS: Root mean square. Data are mean ± 1SD. 
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5.3.2 Twitches  
Resting twitches: Supplementation did not significantly influence fresh or fatigued twitch 
force (Fresh: P = 0.88; f (2, 42) = 0.13,   
  < 0.1,   
  < 0.1; Fatigued: P = 0.66; f (2, 42) = 0.42,   
  
< 0.1,   
  < 0.1 (group × session × time point); Fresh: P = 0.66; f (2, 42) = 0.12,   
  < 0.1,   
  < 0.1; 
Fatigued: P = 0.21; f (2, 42) = 1.67,   
  = 0.1,   
  < 0.1 (group × session); Table. 5.3), EMD (Fresh: 
P = 0.21; f (1, 21) = 1.71,   
  = 0.1,   
  = 0.2; Fatigued: P = 0.84; f (1, 21) = 0.04,   
  < 0.1,   
  = 
0.4; Table. 5.3) or TPT (Fresh: P = 0.35; f (1, 21) = 0.91,   
  < 0.1,   
  < 0.1; Fatigued: P = 0.95; f 
(1, 21) = 0.004,   
  < 0.1,   
  < 0.1; Table. 5.3). There was, however, a significant group × session 
interaction for HRT in both fresh (P = 0.04; f (1, 21) = 4.88,   
  = 0.2,   
  < 0.1) and fatigued 
skeletal muscle (P = 0.03; f (1, 21) = 5.57,   
  = 0.2,   
  = 0.1; Fig. 5.2). Post hoc analysis showed 
that the percentage change in fresh skeletal muscle HRT was not significantly different between the 
β-alanine (-2 ± 10 ms; -3 ± 13%) and placebo group (+8 ± 16 ms; 8 ± 16%) with a large effect 
reported (P = 0.06; t (21) = -2.0; 95% confidence interval [-32.8, 1.1], Cohen’s d = 0.9; Hedge’s g 
= 0.8). The confidence interval ES indicated that there was a 72% chance of a randomly selected 
pair of individuals would experience a decline in HRT following β-alanine supplementation. In 
fatigued skeletal muscle, post hoc analysis showed that the percentage change in fatigued skeletal 
muscle HRT was significantly different between the β-alanine (-25 ± 34 ms; -19 ± 26%) and 
placebo group (8 ± 16 ms; 0 ± 15%) with a large effect reported (P = 0.05; t (21) = -2.1; 95% 
confidence interval [-37.6, -0.9], Cohen’s d = 0.9; Hedge’s g = 0.9). The confidence interval ES 
indicated that there was a 74% chance of a randomly selected pair of individuals would experience 
a decline in HRT following β-alanine supplementation. Mean CV values for fresh skeletal muscle 
in the placebo group: force at 25 and 50ms and peak were 12, 11, and 12%, EMD was 5%, TPT 
was 4% and HRT was 13%. Mean CV values for fatigued skeletal muscle in the placebo group: 
force at 25 and 50ms and peak were 13, 16, and 15%, EMD was 13%, TPT was 7% and HRT was 
10%. 
 
The percentage difference between fresh and fatigued resting twitch force remained similar 
between sessions (P = 0.20; f (1, 21) = 1.74,   
  = 0.1,   
  < 0.1) with no group × session interaction 
(P = 0.69; f (1, 21) = 0.17,   
  < 0.1,   
  < 0.1). Resting twitch TPT declined following completion 
of the IKET (P = 0.001; f (1, 21) = 14.80,   
  = 0.4,   
  = 0.2; Table. 5.3), with no group × fatigue 
(P = 0.31; f (1, 21) = 1.09,   
  = 0.1,   
  < 0.1) or group × session × fatigue interactions (P = 0.38; f 
(1, 21) = 0.82,   
  < 0.1,   
  < 0.1). EMD remained similar following the IKET (P = 0.35; f (1, 21) = 
0.91,   
  < 0.1,   
  < 0.1) with no group × fatigue (P = 0.43; f (1, 21) = 0.65,   
  < 0.1,   
  < 0.1) or 
group × session × fatigue interactions (P = 0.69; f (1, 21) = 0.16,   
  < 0.1,   
  < 0.1; Table. 5.3). 
Resting twitch HRT significantly increased following the completion of the IKET (P < 0.001; f (1, 
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21) = 41.36,   
  = 0.7,   
  = 0.3; Fig. 5.2). There was no group × fatigue (P = 0.11; f (1, 21) = 
2.86,   
  = 0.1,   
  < 0.1) or group × session × fatigue interactions (P = 0.75; f (1, 21) = 0.10,   
  < 
0.1,   
  < 0.1). 
 
Potentiated twitches: Supplementation with β-alanine did not significantly influence fresh 
or fatigued skeletal muscle twitch force (Fresh: P = 0.31; f (2, 42) = 1.19,   
  = 0.1,   
  < 0.1; 
Fatigued: P = 0.97; f (2, 42) = 0.03,   
  < 0.1,   
  < 0.1; (group × session × time point); Fresh: P = 
0.32; f (1, 21) = 1.03,   
  = 0.1,   
  < 0.1; Fatigued: P = 0.29; f (1, 21) = 1.18,   
  = 0.1,   
  < 0.1 
(group × session); Table. 5.3), EMD (Fresh: P = 0.47; f (1, 21) = 0.53,   
  < 0.1,   
  < 0.1; 
Fatigued: P = 0.56; f (1, 21) = 0.35,   
  < 0.1,   
  < 0.1; Fig. 5.2D) or TPT (Fresh: P = 0.78; f (1, 
21) = 0.08,   
  < 0.1,   
  < 0.1; Fatigued: P = 0.68; f (1, 21) = 0.17,   
  < 0.1,   
  < 0.1; Table. 5.3). 
There was, however, a significant group × session interaction for HRT in both fresh (P = 0.03; f (1, 
21) = 5.27,   
  = 0.2,   
  < 0.1) and fatigued skeletal muscle (P = 0.03; f (1, 21) = 5.20,   
  = 0.2, 
  
  < 0.1; Fig. 5.2). Post hoc analysis showed that the percentage change in fresh skeletal muscle 
HRT was not significantly different between the β-alanine (0 ± 9 ms; +1 ± 15%) and placebo group 
(+7 ± 10 ms; (+12 ± 15%) with a medium effect reported (P = 0.10; t (21) = -1.7; 95% confidence 
interval [-23.9, 2.5], Cohen’s d = 0.7; Hedge’s g = 0.7). The confidence interval ES indicated that 
there was a 69% chance of a randomly selected pair of individuals would experience a decline in 
HRT following β-alanine supplementation. In fatigued skeletal muscle, post hoc analysis showed 
that the percentage change in fatigued skeletal muscle HRT was significantly different between the 
β-alanine (-2.7 ± 16 ms; -2 ± 20%) and placebo group (12 ± 12 ms; 16 ± 17%) with a large effect 
reported (P = 0.03; t (21) = -2.2; 95% confidence interval [-33.8, -1.4], Cohen’s d = 1.0; Hedge’s g 
= 0.9). The confidence interval ES indicated that there was a 75% chance of a randomly selected 
pair of individuals would experience a decline in HRT following β-alanine supplementation. Mean 
CV values for fresh skeletal muscle in the placebo group: force at 25 and 50 ms and peak were 10, 
8, and 9%, EMD was 7%, TPT was 6% and HRT was 9%. Mean CV values for fatigued skeletal 
muscle in the placebo group: force at 25 and 50 ms and peak were 17, 15, and 15%, EMD was 11%, 
TPT was 6% and HRT was 10%. 
 
The percentage change in potentiated twitch force was unaffected by supplementation (P = 
0.85; f (1, 21) = 0.03,   
  < 0.1,   
  < 0.1) with no group × session interaction (P = 0.08; f (1, 21) = 
3.21,   
  < 0.1,   
  < 0.1). Potentiated twitch TPT declined following completion of the IKET (P < 
0.001; f (1, 21) = 18.80,   
  = 0.5,   
  = 0.5; Table. 5.3), with no group × fatigue (P = 0.25; f (1, 21) 
= 1.38,   
  = 0.1,   
  < 0.1) or group × session × fatigue interactions (P = 0.88; f (1, 21) = 0.02,   
  < 
0.1,   
  < 0.1). Potentiated EMD was significantly prolonged following the IKET (P = 0.001; f (1, 
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21) = 16.82,   
  = 0.5,   
  = 0.2) with no group × fatigue (P = 0.42; f (1, 21) = 0.67,   
  < 0.1,   
  < 
0.1) or group × session × fatigue interactions (P = 0.99; f (1, 21) = 0.00,   
  < 0.1,   
  < 0.1). 
Potentiated HRT significantly increased following the completion of the IKET (P < 0.001; f (1, 21) 
= 42.35,   
  = 0.7,   
  = 0.4; Fig. 5.2). There was no group × fatigue (P = 0.72; f (1, 21) = 0.14,   
  = 
0.1,   
  < 0.1) or group × session × fatigue interactions (P = 0.47; f (1, 21) = 0.54,   
  < 0.1,   
  < 
0.1). 
 
5.3.3 Octet contractions 
In both fresh (P = 0.40; f (2, 42) = 0.95,   
  < 0.1,   
  < 0.1 (group × session × time point); 
P = 0.16; f (1, 21) = 2.15,   
  < 0.1,   
  < 0.1 (group × session)) and fatigued (P = 0.84; f (2, 42) = 
0.18,   
  < 0.1,   
  < 0.1 (group × session × time point); P = 0.83; f (1, 21) = 0.05,   
  < 0.1,   
  < 0.1 
(group × session)) skeletal muscle, supplementation did not significantly alter octet force, EMD or 
TPT (Table. 5.3). There was, however, a significant group × session interaction for octet HRT in 
both fresh (P = 0.05;   
  = 0.2;   
  = 0.1) and fatigued (P = 0.01;   
  = 0.3;   
  = 0.2) skeletal muscle 
(Fig. 5.2). Post hoc analysis showed that the percentage change in fresh skeletal muscle was 
significantly different between the β-alanine (-26 ± 30 ms; -20 ± 22%) and placebo (0 ± 32 ms; 1 ± 
34%) group with a large effect reported (P = 0.05, Cohen’s d = 0.8). In fatigued skeletal muscle, 
post hoc analysis showed that HRT percentage change was significantly different between the β-
alanine (-11 ± 20 ms; -11 ± 20%) and placebo (12 ± 19 ms; 7 ± 13%) groups with a large effect 
reported (P = 0.01, Cohen’s d = 1.2; Fig. 5.2). 
 
The percentage change in octet force between fresh and fatigued conditions was not 
significantly affected by supplementation (P = 0.20; f (1, 21) = 1.74,   
  = 0.1,   
  < 0.1), with no 
group × session interaction (P = 0.69; f (1, 21) = 0.17,   
  < 0.1,   
  < 0.1). Octet TPT (P = 0.05,   
  
= 0.2,   
  = 0.1; Table. 5.3) and HRT (P = 0.008,   
  = 0.3,   
  = 0.2; Fig. 5.2), declined following 
completion of the IKET, with no group × fatigue or group × session × fatigue interactions. Octet 
EMD was not significantly influenced following the IKET, with no group × fatigue or group × 
session × fatigue interactions (Table. 5.3). Mean CV values for fresh skeletal muscle in the placebo 
group were 15, 12 and 12% for force at 25, 50 ms and peak. Mean CV values for fatigued skeletal 
muscle in the placebo group were 20, 13 and 17% for force at 25, 50 ms and peak. 
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Table 5.3: Electrically evoked force responses, time-to-peak tension (TPT) and electromechanical delay (EMD) of β-alanine and placebo groups pre- and 
post-supplementation, in fresh and fatigued skeletal muscle.  
 Data are mean ± 1SD. 
   Pre-supplementation Post-supplementation 
   Force (N) EMD 
(ms) 
TPT 
(ms) 
Force (N) EMD 
(ms) 
TPT 
(ms)       25 ms 50 ms Peak 25 ms 50 ms Peak 
Resting Twitch Fresh β-alanine 23 ± 5 73 ± 14 88 ± 17 10 ± 1 79 ± 11 24 ± 6 73 ± 17 90 ± 19 10 ± 1 81 ± 9 
 Fresh Placebo 28 ± 4 79 ± 19 99 ± 26 11 ± 1 82 ± 8 29 ± 5 82 ± 16 104 ± 24 10 ± 1 83 ± 9 
 Fatigued β-alanine 22 ± 7 61 ± 22 68 ± 25 11 ± 2 72 ± 16 26 ± 8 71 ± 22 79 ± 23 10 ± 1 74 ± 13 
 Fatigued Placebo 25 ± 6 58 ± 20 65 ± 24 11 ± 1 69 ± 8 24 ± 4 60 ± 15 67 ± 18 10 ± 2 71 ± 9 
Potentiated Twitch Fresh β-alanine 55 ± 13 142 ± 24 159 ± 26 9 ± 1 79 ± 6 53 ± 8 136 ± 14 155 ± 9 9 ± 1 81 ± 6 
 Fresh Placebo 60 ± 16 138 ± 37 163 ± 43 9 ± 1 79 ± 9 59 ± 10 142 ± 34 167 ± 38 9 ± 1 82 ± 8 
 Fatigued β-alanine 37 ± 11 92 ± 27 101 ± 29 11 ± 1 74 ± 9 40 ± 9 101 ± 19 110 ± 18 10 ± 1 73 ± 10 
  Fatigued Placebo 42 ± 10 93 ± 25 105 ± 30 10 ± 1 74 ± 4 38 ± 9 93 ± 23 106 ± 28 10 ± 1 74 ± 8 
Octet Fresh β-alanine 52 ± 15 165 ± 42 223 ± 47 7 ± 2 117 ± 25 64 ± 18 196 ± 37 274 ± 53 7 ± 2 120 ± 24 
 Fresh Placebo 66 ± 17 190 ± 62 285 ± 94 6 ± 1 127 ± 19 64 ± 17 199 ± 60 296 ± 94 7 ± 2 137 ± 7 
 Fatigued β-alanine 62 ± 23 191 ± 49 221 ± 72 7 ± 2 100 ± 23 62 ± 17 182 ± 47 244 ± 68 7 ± 2 114 ± 25 
  Fatigued Placebo 69 ± 20 191 ± 49 273 ± 72 7 ± 1 123 ± 14 64 ± 16 198 ± 49 283 ± 79 7 ± 2 125 ± 15 
Chapter 5: β-alanine supplementation on neuromuscular performance in fresh and fatigued muscle 
90 
 
Fig. 5.2: Electrically evoked half relaxation time of β-alanine (BA) and placebo (PLA) groups pre- 
and post-supplementation, in fresh and fatigued skeletal muscle during: resting twitch (a), 
potentiated twitch (b), and octets (c). Data are mean ± 1SD. **P≤0.01 and *P≤0.05 for post hoc 
independent t-test between β-alanine and placebo groups. 
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5.3.4 Force-electromyography relationship  
The slope and y-intercept of the force-EMG relationship were unaffected by 
supplementation in both fresh (slope: P = 0.80; f (1, 21) = 0.07,   
  < 0.1,   
  < 0.1; y-intercept: P = 
0.52; f (1, 21) = 0.44,   
  < 0.1,   
  < 0.1 (group × session)) and fatigued skeletal muscle (slope: P = 
0.74; f (1, 21) = 0.11,   
  < 0.1,   
  < 0.1; y-intercept: P = 0.51; f (1, 21) = 0.46,   
  < 0.1,   
  < 0.1) 
(Fig. 5.3 and Table 5.4). There was also no influence of the IKET on the slope and y-intercept of 
the force-EMG relationship (slope: P = 0.32; f (1, 21) = 1.03,   
  = 0.1,   
  = 0.1; y-intercept: P = 
0.17; f (1, 21) = 2.05,   
  = 0.1,   
  < 0.1), with no group × fatigue interaction (slope: P = 0.32; f (1, 
21) = 1.03,   
  = 0.1,   
  = 0.1; y-intercept: P = 0.63; f (1, 21) = 0.08,   
  < 0.1,   
  < 0.1). The mean 
CV in the placebo group for the slope of the force-EMG relationship was 17% (fresh skeletal 
muscle) and 15% (fatigued skeletal muscle). 
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Fig. 5.3: Force-surface electromyography (EMG) relationship measured during submaximal 
voluntary contractions (15 - 90% maximal voluntary isometric force) for the β-alanine (BA) and 
placebo (PLA) groups pre- and post-supplementation, in fresh and fatigued skeletal muscle. Mmax: 
Maximum muscle action potential; RMS: Root mean square. Data are mean ± 1SD. 
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5.3.5 Force-frequency relationship 
Supplementation did not significantly influence peak force at each frequency of stimulation 
(fresh: P = 0.26; f (9, 189) = 1.28,   
  < 0.1,   
  < 0.1; fatigued: P = 0.94; f (9, 189) = 0.38;   
  < 0.1, 
  
  < 0.1 (group × session × frequency); fresh: P = 0.72; f (9, 189) = 1.81,   
  < 0.1,   
  < 0.1; 
fatigued: P = 0.97; f (9, 189) = 1.91;   
  = 0.1,   
  < 0.1 (group × session); Fig. 5.4). The frequency 
at 50% of the force response (Table 5.4) in fresh (peak force: P = 0.93; f (1, 21) = 0.01,   
  < 0.1, 
  
  < 0.1; frequency at 50%: P = 0.22; f (1, 21) = 1.58,   
  = 0.1,   
  < 0.1 (group × session)) and 
fatigued skeletal muscle were unaffected by supplementation (peak force: P = 0.76; f (1, 21) = 
0.09,    
  < 0.1,   
  < 0.1; frequency at 50%: P = 0.61; f (1, 21) = 0.27,    
  < 0.1,   
  < 0.1). 
Following the completion of the IKET peak force significantly declined (P = 0.001; f (1, 21) = 
111.97,   
  = 0.8,   
  = 0.2), with no group × fatigue interaction (P = 0.52; f (1, 21) = 0.45,   
  < 0.1, 
  
  < 0.1). The frequency at 50% of the force response remained unaffected by the IKET (P = 0.60; 
f (1, 21) = 0.28,   
  < 0.1,   
  < 0.1), with no group × fatigue interaction (P = 0.97; f (1, 21) = 
0.00,   
  < 0.1,   
  < 0.1). 
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Fig. 5.4: Force-frequency relationship assessed during submaximal percutaneous stimulation for β-
alanine (BA) and placebo (PLA) groups pre- and post-supplementation, in fresh and fatigued 
skeletal muscle. Data are mean ± 1SD. 
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Table 5.4: Characteristics of the force-frequency and force-electromyography (EMG) relationships in β-alanine and placebo groups in fresh and fatigued 
skeletal muscle, pre- and post-supplementation. 
 
 
Pre-supplementation Post-supplementation 
 
β-alanine Placebo β-alanine Placebo 
 
Fresh Fatigued Fresh Fatigued Fresh Fatigued Fresh Fatigued 
Force-frequency relationship 
Frequency at 50% of response, Hz 14.3 ± 2.5 14.2 ± 2.6 13.9 ± 2.2 13.6 ± 2.0 14.1 ± 2.4 14.0 ± 2.3 13.5 ± 2.5 13.6 ± 2.6 
Force-EMG relationship 
Intercept (RMS:Mmax) -0.52 ± 0.91 -0.19 ± 0.62 -0.88 ± 1.07 -0.35 ± 0.61 -0.25 ± 0.42 -0.36 ± 0.59 -0.34 ± 0.35 -0.33 ± 0.46 
Slope (RMS:Mmax/N) 0.022 ± 0.007 0.021 ± 0.007 0.022 ± 0.006 0.024 ± 0.007 0.021 ± 0.006 0.022 ± 0.006 0.020 ± 0.005 0.023 ± 0.007 
Data are mean ± 1SD. Mmax: Maximum muscle action potential; RMS: Root mean square. 
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5.3.6 Sustained isometric knee extensor endurance test 
There was no group × session interaction for TTF (β-alanine: pre: 63 ± 13 s; post: 63 ± 15 
s; Placebo: pre: 77 ± 25 s; Post: 75 ± 19 s; P = 0.85; f (1, 21) = 0.04,   
  < 0.1,   
  < 0.1; Fig. 5.5). 
Based upon the recorded TTF, the Rohmert equation (Rohmert, 1960) was used to calculate 
estimated percentage of MVIF. Individuals within the β-alanine group were estimated to be holding 
the IKET at ~51% MVIF (~6% greater than asked), as denoted by slightly shorter hold times of~63 
s. Individuals within the placebo group were estimated to be holding the IKET contraction at ~45% 
MVIF, with a hold time of ~77 s. There was no group × session interaction for impulse values (β-
alanine: pre: 16 ± 4 kN
.
s
-1
; post 16 ± 5 kN
.
s
-1
; Placebo: pre: 20 ± 4 kN
.
s
-1
; post 19 ± 3 kN
.
s
-1
; P = 
0.58; f (1, 21) = 0.30,   
  < 0.1,   
  < 0.1).  
 
Blood lactate concentrations displayed a significant session × time × group interaction (P = 
0.05; f (2, 20) = 3.41,   
  = 0.3,   
  = 0.1). Blood lactate concentrations significantly increased 5 
minutes following the IKET compared to both rest and prior to values (P < 0.001; f (2, 20) = 
38.17,   
  = 0.8,   
  = 0.6), with no influence of session (P = 0.20; f (2, 20) = 1.90,   
  = 0.2,   
  < 
0.1) or group (P = 0.73; f (1, 10) = 0.13,   
 < 0.1,   
  < 0.1; Table 5.5).  
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Fig. 5.5: Time to task failure (s; A) and impulse (kN
.s; B) of β-alanine (BA) and placebo (PLA) 
groups pre- and post-supplementation. Data are mean ± 1SD. Individual data are presented as 
squares (BA), and triangles (PLA).  
Table 5.5: Blood lactate concentrations (mmol
.
l
-1) for the β-alanine and placebo groups pre- and 
post-supplementation, at rest, prior to and 5 mins following the completion of the isometric knee 
extensor task (+5 mins). Significant differences between concentrations are denoted by * (rest and 
+5 mins) and 
X
 (prior to and +5 mins).  
 Pre-supplementation Post-supplementation 
 
Rest 
(mmol
.
l
-1
) 
Prior to 
(mmol
.
l
-1
) 
+5 mins 
(mmol
.
l
-1
) 
Rest 
(mmol
.
l
-1
) 
Prior to 
(mmol
.
l
-1
) 
+5 mins 
(mmol
.
l
-1
) 
β-alanine 1.0 ± 0.3 1.1 ± 0.2 3.8 ± 1.1
* X
 1.2 ± 0.3 1.3 ± 0.4 3.7 ± 1.3
* X
 
Placebo 1.0 ± 0.3 1.1 ± 0.4 3.8 ± 1.3
* X
 1.3 ± 0.3 1.2 ± 0.2 4.2 ± 1.0
* X
 
Data are mean ± 1SD. 
Chapter 5: The effect of β-alanine supplementation on neuromuscular performance in fresh and fatigued 
muscle 
96 
5.4 Discussion 
The main findings from the current investigation are a) β-alanine supplementation had no 
effect on isometric force production capacity in fresh or fatigued skeletal muscle, b) 28-days of β-
alanine supplementation altered fresh skeletal muscle relaxation speed, confirming the data 
reported in Study 1 (Chapter 4), and c) reduced relaxation speed was also evident in fatigued 
skeletal muscle following β-alanine supplementation, with no change to peak force production or 
contraction time. The present research is the first to comprehensively examine the effect of 28-days 
β-alanine supplementation on voluntary and electrically evoked contractile properties of fatigued 
in-vivo human skeletal muscle. 
 
β-alanine supplementation had no effect on voluntary isometric force production during 
fresh and fatigued conditions, including maximal and explosive force variables. Consistent with the 
lack of change in voluntary peak force, electrically evoked peak force responses, reported during 
twitch and octet contractions, were unaffected by 28-days of β-alanine supplementation during both 
fresh and fatigued conditions. Neural drive responses during both MVICs and explosive 
contractions in fresh and fatigued skeletal muscle pre- and post-supplementation remained similar. 
The present data in fresh skeletal muscle are consistent with the findings reported in Study 1 
(Chapter 4 if β-alanine supplementation influenced Ca2+ related function, improvements in 
explosive voluntary force and/or alterations in the force-EMG relationship would be apparent. 
 
There was no leftward shift of the force-frequency curve, the associated measure of 
intracellular Ca
2+
 levels (Batrukova & Rubstov, 1997), in either fresh or fatigued in-vivo human 
skeletal muscle, implying that elevated skeletal muscle carnosine content did not significantly alter 
Ca
2+
 related function. There may, however, have been a decrease in SR Ca
2+
 release which was not 
recognised in the force-frequency curve, due to an associated increase in Ca
2+
 sensitivity of the 
myofibrils, thereby equating to the same skeletal muscle force production. The data in fresh 
skeletal muscle is in-line with previous in-vivo research reported in this thesis (Study 1; Chapter 4), 
where increased skeletal muscle carnosine content following 28-day of β-alanine supplementation 
did not alter the force-frequency curve. It should be highlighted, that during both investigations 
there were no direct measures of skeletal muscle carnosine content. Numerous investigations have 
demonstrated increased skeletal muscle carnosine content following 28-days β-alanine 
supplementation in this adult population, almost without exception, on an individual-by-individual 
basis (Harris et al., 2006; Hill et al., 2007). It is therefore likely the current 28-day β-alanine 
supplementation protocol, significantly increased skeletal muscle carnosine concentration.  
 
There was no significant influence of increased skeletal muscle carnosine content on TPT 
and force production following 28-days β-alanine supplementation. Based on previous in-vitro 
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research in chemically skinned muscle fibres from frogs (Lamont & Miller, 1992), mechanically 
skinned rat muscle fibres (Dutka & Lamb, 2004) and, Type I and Type II human skeletal muscle 
fibres (Dutka et al., 2012), an alteration to submaximal action potential-mediated force responses 
via increased Ca
2+
 sensitivity, could have been expected. There was also no significant alteration to 
potentiated twitch contractions following β-alanine supplementation. Given that the 
phosphorylation of the myosin head during these twitch contractions, is due to the increased 
sensitivity of the contractile properties to Ca
2+
, any alterations to Ca
2+
 sensitivity via increased 
carnosine content would have been apparent during these contractions. In-vitro data in mice 
showed that increased carnosine (+156%) and anserine content (+46%) in the m. extensor 
digitorum longus, alongside a marked leftward shift of the force-frequency relationship following 
β-alanine supplementation (Everaert et al., 2013). These in-vitro data in skinned muscle fibre are 
interesting, yet due to the current in-vivo research (Studies 1 and 2; Chapter 4 and 5) it is suggested 
that these responses might not be significant enough to effect whole muscle contraction. It is also 
important to consider that the in-vitro research is performed outside the normal intracellular 
environment, with several in-vitro protocols performed with free magnesium, an inhibitor of 
skeletal muscle RyR (Laver, O’Neill & Lamb, 2004). During in-vitro investigations, solutions are 
added to regulate the pH level allowing analysis of the isolated effect of carnosine, whilst this is 
important, current research has yet to examine the impact of carnosine content and varying pH 
levels. The current in-vivo research should be considered separate from the in-vitro data, since it 
might be unrealistic to expect similar outcomes between research designs.  
 
Twenty-eight days of β-alanine supplementation to increase skeletal muscle carnosine 
content, resulted in a shorter HRT (relative to equivalent placebo times) in fresh and fatigued 
skeletal muscle during both resting and potentiated twitch contractions. The beneficial effect of β-
alanine supplementation on skeletal muscle HRT evident, are in-line with those reported in Study 1 
(Chapter 4; 7 - 12%). Muscle relaxation speed has been associated with both Ca
2+
 removal from the 
myoplasm and Ca
2+
 dissociation from troponin followed by cross-bridge detachment (Westerblad 
et al., 1997). Westerblad and Allen (1993) suggested that declines in skeletal muscle relaxation 
speed, apparent under fatigued conditions, reflected either reduced cross-bridge kinetics, or 
potentially a combination of impaired cross-bridge kinetics and Ca
2+
 kinetics. Muscle relaxation 
speed has been associated with Ca
2+
 re-uptake by the SERCA pump (Gafni & Yuh, 1989), the 
proposed rate-limiting step in skeletal muscle relaxation (Gillis, 1985; Dux, 1993). Acting on Ca
2+
 
kinetics proteins directly or via other molecules provided a mechanism by which Ca
2+
 signalling 
can be inhibited or excited (Swietach et al., 2013). Examination of isolated rat heart muscle, 
demonstrated improved contractile function and increased free intracellular Ca
2+
 concentrations in 
the presence of carnosine (Zaloga, Roberts & Nelson, 1996). Although speculative, these data 
propose that increased carnosine content might alter Ca
2+
-channel activity by interacting with the 
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Ca
2+
-channel itself (Batrukova & Rubstov, 1997), possibly via the existence of saturable binding 
site(s) for carnosine on the Ca
2+
-channel. These in-vitro analysis are, however, limited by several 
methodological factors, including but not limited to, the lack of a Ca
2+
 buffer, the overloading of 
the SR with Ca
2+
, concentrations ~10 times greater than normal, and the addition of un-
physiological magnesium concentrations. Therefore, consideration needs to be taken regarding 
interpretations based on these data. Alternatively, the beneficial effect of increased carnosine 
content on skeletal muscle relaxation time, evident within the current investigation, may also be 
associated with an indirect mechanism. Carnosine may modify the protein interactions with the 
Ca
2+
-channels and/or bind with the proteins themselves, given the quantity of additional proteins 
that bind to Ca
2+
-channels (Berchtold, Brinkmeier & Muntener, 2000); both mechanisms could 
impact the activity of the Ca
2+
-channel.  
 
The mechanism for reduced skeletal muscle relaxation time following β-alanine 
supplementation remains uncertain, yet, could be beneficial for exercise performance, specifically 
those involving short, repeated contractions, where skeletal muscle relaxation comprises an 
important proportion of total energy consumption (Bergström & Hultman, 1988). The current 
findings are predominantly significant for activities where fast, repetitive contractions and 
relaxations occur, with no period of rest. It would be beneficial to replicate these data in an older 
adult population, where pre-existing declines in skeletal muscle function are evident, meaning that 
any improvement in skeletal muscle function would be proportionally more valuable. Due to the 
possible interaction between carnosine and SERCA activity, exploring the impact of increased 
skeletal muscle carnosine content on SERCA activity could provide a number of clinical avenues 
of research. It could be speculated that increased skeletal muscle carnosine content via β -alanine 
supplementation, may benefit individuals with Brody disease, where SERCA1 activity is 
significantly reduced (Guglielmi et al., 2013) or Duchenne Muscular Dystrophy, where an excess 
of cytosolic Ca
2+ 
occurs (Ohlendieck, 2000). 
 
The IKET hold times within the present investigation were not significantly influenced by 
28-days β-alanine supplementation, directly conflicting previous research, which demonstrated a 
13% (10 ± 9 s) increase in 45% MVIF hold-times (Sale et al., 2012). The reason for a lack of a 
significant effect is uncertain, given that IKET hold times reported by both investigations were 
similar and aligned to hold times predicted by the Rohmert equation (78 s; Ahlborg et al., 1972). 
Blood lactate sampled from the finger 5 min post-exercise is indicative of the lower extremity 
lactate release (Comeau et al., 2011), with both supplemental groups in the present research 
displaying similar levels of lactate accumulation. To further understand the relationship between 
skeletal muscle relaxation, skeletal muscle carnosine content and skeletal muscle fatigue, additional 
research examining dynamic fatiguing protocols are required, since contractile slowing (i.e., 
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prolonged half-relaxation time) would affect shortening velocity and power output (Jones et al., 
2006). 
5.5 Conclusion 
The current research demonstrated that 28-days of β-alanine supplementation improved 
skeletal muscle relaxation, with declines in half relaxation time in both fresh and fatigued 
conditions. Reducing skeletal muscle relaxation rates is associated with improvements in skeletal 
muscle power output and exercise performance. It remains unclear however, whether the reported 
improvements in skeletal muscle relaxation time would be sufficient to result in improved exercise 
performance, particularly in the absence of any changes to the force-frequency relationship, peak 
force production, or contraction time. The mechanism for the ergogenic effect on skeletal muscle 
relaxation following increased carnosine content remains unclear. It could, however, be proposed 
that Ca
2+
 reuptake via direct or indirect mechanisms associated with SERCA pump activity is 
involved, as this is the rate-limiting step of skeletal muscle relaxation (see Study 4; Chapter 7).  
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6.1 Introduction 
The research reported within this thesis (Studies 1 and 2; Chapters 4 and 5) has examined 
the influence of 28-days of β-alanine supplementation on the electrically evoked contractile 
properties and voluntary force production of human skeletal muscle in-vivo in young healthy males. 
No alterations to maximal or explosive voluntary isometric force production, or the force-
frequency relationship under both fresh and fatigued conditions following β-alanine 
supplementation was shown. Given that explosive voluntary force and the force-EMG relationship 
are influenced by Ca
2+
 related functions, if β-alanine supplementation did alter Ca2+ kinetics in the 
skeletal muscle, improvements in these measures would have been apparent. It can therefore be 
implied that increased carnosine content does not significantly influence Ca
2+
 related function. 
There was, however, a significant reduction in skeletal muscle resting and potentiated twitch HRT 
following 28-days of β-alanine supplementation during both fresh and fatigued conditions (Studies 
1 and 2; Chapters 4 and 5). Additionally, β-alanine supplementation significantly reduced skeletal 
muscle octet HRT in both fresh and fatigued conditions (Study 2; Chapter 5). One explanation for 
an improvement in the skeletal muscle relaxation speed is the reuptake of Ca
2+
 in the skeletal 
muscle (Gafni & Yuh, 1989), with enhanced relaxation rates associated with improved skeletal 
muscle power output and exercise performance. Data reported in Studies 1 and 2 (Chapters 4 and 
5) suggested that increased skeletal muscle carnosine content, via β-alanine supplementation, may 
be able to alter exercise performance through a Ca
2+
 kinetics mechanism, specifically during 
skeletal muscle relaxation phase.  
 
Throughout the ageing process, there is a significant decline in skeletal muscle cross-
sectional area, muscle fibre quantity, and carnosine concentrations (Lexell, 1995; Stuerenburg & 
Kunse, 1999; Doherty 2003; Tallon et al., 2007; Verdijk et al., 2010). The amalgamation of these 
factors increases the sense of frailty in older adults, impairing balance, gait speed, and increasing 
risk of falling (Madureira et al., 2010), with one in three older individuals falling annually (Tinetti 
et al., 1988). Declines in skeletal muscle power and strength are most notable in the lower-
extremities, including the knee extensor muscles (Sieri & Beretta, 2004; Skelton et al., 2002). 
Maintaining lower-extremity muscular strength is vital in preserving independence and quality of 
life in older adults. Although limited research exists, β-alanine supplementation has also been 
shown to increase skeletal muscle carnosine content in older adults, by 85% in twelve weeks (del 
Favero et al., 2012). Ingestion of β-alanine in this older population has been associated with 
significant positive improvements in exercise performance (Stout et al., 2008; del Favero et al., 
2012; McCormack et al., 2013; Glenn et al., 2015; 2016). Research by Stout et al., (2008) reported 
improvements in the PWCFT that were two-fold greater in older individuals than those reported in 
younger participants (younger; 12 – 15% vs. older; 29%; Stout et al., 2006). Highlighting the 
possibility that older adults may experience a greater beneficial effect of β-alanine supplementation 
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compared to younger counterparts. Nonetheless, disparity remains, since β-alanine supplementation 
in older adults has not significantly improved measures of skeletal muscle function or quality of 
life (del Favero et al., 2012). Due to the limited research in this population, it remains unclear how 
β-alanine supplementation alters skeletal muscle performance, and whether the mechanisms 
associated with increased skeletal muscle carnosine content in younger adults are similar to those in 
older individuals.  
 
The current investigation investigated the effects of 28-days of β-alanine supplementation 
on intrinsic in-vivo isometric knee extensor force production and skeletal muscle contractility in 
both fresh and fatigued human skeletal muscle in healthy older adults (60 – 80 y). It was 
hypothesised that increased skeletal muscle carnosine content, via β-alanine supplementation, 
would subsequently improve the speed of skeletal muscle relaxation compared to the responses 
following placebo supplementation.  
 
6.2 Methodology 
6.2.1 Participants 
Sixteen participants provided written informed consent and were then stratified and 
allocated into the two supplementation groups [placebo or β-alanine] based on MVIF values 
recorded during the familiarisation session. All participants completed all aspects of the study 
(Table 6.1), which was approved by the Nottingham Trent University Human Ethical Review 
Committee (Application #343). Self-reported sleep quality categorised by the PSQI, reported 
participants as good sleepers, with no differences between groups or following supplementation 
(Table 6.2). There were no significant differences between groups or pre- to post-supplementation 
regarding participant mood scores (BRUMS), physical activity levels (Modified Baecke 
Questionnaire for Older Adults), depression (Geriatric Depression Scale), falls efficacy (Falls 
Efficacy Scale) or pain scores (Global Pain Scale) (Table 6.2).  
 
Table 6.1: Characteristics of participants (n = 16). 
 Placebo (n = 8) β-alanine (n = 8) 
Age (years) 64 ± 3 65 ± 3 
Body mass (kg) 83.4 ± 10.4 74.0 ± 11.2 
Height (m) 169 ± 11 171 ± 12 
MVIF (N) 334 ± 117 321 ± 132 
Gender (M/F) 4/4 3/5 
Data are mean ± 1SD. No significant differences were reported. MVIF: Maximal voluntary 
isometric force 
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6.2.2 Experimental design 
Over a five-week period, three experimental sessions were undertaken by each participant; 
familiarisation sessions were held around seven days prior to the baseline session, with the final 
session conducted following 28-days of supplementation with either β-alanine or placebo. 
Participants were familiarised with the voluntary and electrical evoked knee extensor contractions, 
with all assessment undertaken on the dominant leg. Baseline and the follow-up session involved 
identical protocols, performed in accordance to a strict schedule, and undertaken at a consistent 
time of day. Participants were instructed to abstain from alcohol and strenuous/unaccustomed 
exercise for 36 hr before each session, with caffeine prohibited on the day of the protocol. 
Compliance with these requests was confirmed verbally with the all participants before 
commencement of the protocol. All raw data analyses, exclusions, and statistical analyses was 
undertaken by an experimenter blind to supplemental group, ensuring double-blind status. 
 
6.2.3 Experimental protocol  
Upon arrival to the familiarisation session participant’s height and weight were recorded. 
Participants were seated in a rigid, custom-built isometric dynamometer (Fig. 3.5.3; page 36) with 
hip and knee joint angles of approximately 95° and 100° (180° = full extension), as previously 
described (Hannah et al., 2012; 2013). Isometric knee extension force and EMG signals were 
recorded during all sessions, the details of which have been described in sections 3.5.3 and 3.5.4, 
page 38-39. Several isometric voluntary and electrically evoked contractions were undertaken 
during each session, including: 
a)  MVIC; as described in section 3.6.1, page 42. 
b) Explosive voluntary contraction; as described in section 3.6.2, page 44. 
c) IKET; as described in section 3.6.3, page 47. 
d) Twitches (resting and potentiated); as described in section 3.6.4, page 49. 
e) Doublet contractions; as described in section 3.6.5, page 53. 
f) Force-EMG relationship; as described in section 3.6.7, page 55. 
g) Force-frequency relationship; as described in section 3.6.8, page 57. 
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Table 6.2: Participant questionnaire scores.  
 Placebo (n = 8) β-alanine (n = 8) 
 Pre-
supplementation 
Post-
supplementation 
Pre-
supplementation 
Post-
supplementation 
PSQI 4 ± 3 5 ± 3 5 ± 3 5 ± 3 
BRUMS     
Anger 5 ± 1 5 ± 1 5 ± 1 5 ± 1 
Confusion 4 ± 2 4 ± 1 5 ± 2 4 ± 2 
Depression 4 ± 2 4 ± 2 4 ± 1 4 ± 1 
Fatigue 5 ± 2 4 ± 1 7 ± 3 6 ± 2 
Tension 5 ± 2 5 ± 1 5 ± 2 4 ± 1 
Vigour 14 ± 2 13 ± 4 13 ± 3 13 ± 3 
MBQOA Physical activity     
Household 22 ± 5 21 ± 5 23 ± 6 23 ± 4 
Sport 4 ± 2 4 ± 2 2 ± 2 2 ± 2 
Leisure 3 ± 4 3 ± 3 2 ± 3 3 ± 3 
Overall  29 ± 8 28 ± 7 27 ± 7 27 ± 5 
Generic depression score 0 ± 0 0 ± 1 0 ± 1 1 ± 1 
Falls efficacy scale score 10 ± 0 10 ± 0 10 ± 1 10 ± 1 
Global Pain Score 3 ± 2 3 ± 6 6 ± 6 6 ± 4 
No significant differences were reported. PSQI: Pittsburgh Sleep Quality Index. BRUMS: Brunel University Mood Scale. MBQOA: Modified Baecke 
questionnaire for older adults. Data are mean ± 1SD. 
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6.2.4 Supplementation 
Participants were supplemented with 4.8 g
.
day
-1
 of either β-alanine or a matched placebo in 
tablet form over 28-days. All supplements were provided in identical white tubs by an individual 
not directly involved in testing or data analysis. The supplementation protocol consisted of two 
800mg tablet ingested three times per day, at 2 - 4 h intervals. Compliance with the 
supplementation period was monitored with compliance logs, both groups reported a high degree of 
compliance, reported at 95 ± 4% in the β-alanine group (total dose of 128 ± 6 g) and 93 ± 4% in the 
placebo group (total dose of 125 ± 5 g; independent sample t-test, P = 0.36). Participants consumed 
a total dose of ~130 g β-alanine, increasing skeletal muscle carnosine content by an expected ~40% 
from baseline (del Favero et al., 2012). There were no reported symptoms of paraesthesia from any 
of the participants. 
 
6.2.5 Statistical analysis 
The G* Power 3.1.6 software programme was used to calculate an a-priori power 
calculation for sample size, having as parameters: statistical test (ANOVA), α = 0.001, β = 0.50 
(power of the sample), number of groups analysed (2 = β-alanine and placebo), and the effect of 
sample size based on previous findings two investigations (Stout et al., 2008; Hobson et al., 2012). 
Based on the effect size reported in Stout et al., (2008) a minimum of 8 participants would be 
required. Dependent variables (MVIF, EMD, HRT, TPT, slope and intercept of force-EMG 
relationship, frequency at 50% of force response for the force-frequency relationship) were 
evaluated using a two-way mixed-model (group × session) ANOVA. Dependent variables 
measured over several time points (force and EMG during explosive voluntary contractions, 
evoked twitch, and doublet force) were analysed using a three-way mixed-model (group × session 
× time) ANOVA. All variables were assessed during both fresh and fatigued conditions. IKET 
variables (TTF and impulse) were analysed using a two-way mixed-model ANOVA. 
 
The impact of the fatigue hold contraction on dependant variables (MVIF, EMD, HRT, 
TPT, slope and intercept of force-EMG relationship, frequency at 50% of force response for the 
force-frequency relationship) was analysed using a three-way mixed-model (group × session × 
fatigue) ANOVA. Dependent variables measured over several time points (force and EMG during 
explosive voluntary contractions, evoked twitch and doublet force) were analysed using a three-
way mixed-model (group × session × percentage change) ANOVA based on percentage change 
between fresh and fatigued values.  
 
Assessed variables were tested for normality using the Shapiro-Wilks test, and for 
homogeneity using the Fevene test. A Greenhouse-Geisser correction was applied when the 
ANOVA assumption of sphericity was violated, and significant interaction effects were followed-
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up by independent sample t-tests on the individual percentage change values for each condition. 
Effect size for multiple comparisons was calculated using   
  and   
  eta squared (Lakens, 2013). 
Providing two effect sizes is suggested to yield a greater understanding of a specific effect 
(Preacher & Kelly, 2011). Post hoc comparisons to explain any significant interactions are reported 
with Cohen’s d and Hedges g effect sizes. An effect size of 0.2 – 0.5 was defined as small, 0.5 – 
0.8 as medium and ≥ 0.8 as a large effect (Schünemann et al., 2008). Intra-individual variability 
was assessed using the mean intra-individual CV between the pre- and post-supplementation 
sessions for the placebo group [(SD / mean) × 100]. Statistical analyses were completed using 
SPSS version 22 (SPSS Inc., Chicago, IF, USA) and Microsoft Excel (Microsoft Inc., USA). 
Statistical significance was accepted at P ≤ 0.05, with data presented as mean ± 1 SD. 
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6.3 Results 
6.3.1 Maximum and explosive voluntary contractions 
Twenty-eight days of supplementation had no effect on MVIF in fresh (P = 0.85; f (1, 14) = 
1.23,   
  < 0.1,   
  < 0.1) or fatigued skeletal muscle (P = 0.15; f (1, 14) = 2.30,   
  = 0.1,   
  = 0.1; 
Fig. 6.1A). The mean CV in the placebo group was 5 and 6% in fresh and fatigued skeletal muscle. 
MVIF was significantly lower following the completion of the IKET (P < 0.001; f (1, 14) = 
30.54,   
  = 0.7,   
  < 0.1), with no differences between sessions (P = 0.51; f (1, 14) = 0.45,   
  < 0.1, 
  
  < 0.1) or groups (P = 0.90; f (1, 14) = 0.02,   
  < 0.1,   
  < 0.1) (β-alanine: 14 – 18%; placebo : 
11 - 12%; Fig. 6.1A). There was no effect of supplementation on force measures at 25 ms intervals 
during explosive voluntary contractions in fresh (P = 0.71; f (5, 70) = 0.59,   
  < 0.1,   
  < 0.1 
(group × session × time point); P = 0.45; f (1, 14) = 0.60,   
  < 0.1,   
  < 0.1 (group × session)) or 
fatigued skeletal muscle (P = 0.90; f (5, 70) = 0.32,   
  < 0.1,   
  < 0.1 (group × session × time 
point); P = 0.37; f (1, 14) = 0.87,   
  < 0.1,   
  < 0.1 (group × session); Fig. 6.1A). The percentage 
change in explosive force between fresh and fatigued conditions was not altered between sessions 
(P = 0.27; f (1, 14) = 1.34,   
  < 0.1,   
  < 0.1) with no group × session interaction (P = 0.80 f (1, 
14) = 0.07,   
  < 0.1,   
  < 0.1). The mean CV in the placebo group during explosive contractions 
was 12 - 18% at 25 - 50 ms and 5 - 10% from 75 - 150 ms during a fatigued condition and 17 - 
19% at 25-50 ms and 6 - 17% from 75 - 150 ms during the fatigued condition. 
 
Agonist EMG normalised to Mmax during MVICs and explosive contraction remained 
uninfluenced by supplementation in fresh (P = 0.30; f (3, 42) = 1.26,   
  < 0.1,   
  < 0.1 (group × 
session × time point); P = 0.85; f (1, 14) = 0.04,   
  < 0.1,   
  < 0.1 (group × session)) and fatigued 
skeletal muscle (P = 0.98; f (3, 30) = 0.05,   
  < 0.1,   
  = 0.1 (group × session × time point); P = 
0.68; f (1, 10) = 0.18,   
  < 0.1,   
  < 0.1 (group × session); Fig. 6.1B). The mean CV values in the 
placebo group for agonist EMG in fatigued skeletal muscle were 44% at 0 - 50 ms, 33% at 50 - 100 
ms and 41% at 100 - 150 ms time windows, and 39% at MVIF. The mean CV values in the placebo 
group for agonist EMG in fatigued skeletal muscle were 20% at 0 - 50 ms, 30% 50 - 100 ms and 
21% at 100 - 150 ms time windows, and 25% at MVIF. The percentage change in agonist EMG 
normalised to Mmax during MVICs and explosive contraction was not significantly altered between 
sessions (P = 0.24; f (1, 14) = 1.53,   
  < 0.1,   
  < 0.1), with no group × session interaction (P = 
0.73; f (1, 14) = 0.12,   
  < 0.1,   
  < 0.1). 
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Fig. 6.1: Explosive and maximal isometric voluntary force (MVIF) (A), and agonist surface 
electromyography (EMG) normalised to maximum muscle action potential (Mmax) during explosive 
contractions (0 - 50, 50 - 100 and 100 - 150 ms from onset) and at MVIF (B) for the β-alanine (BA) 
and placebo (PLA) groups pre- and post-supplementation, in fresh and fatigued skeletal muscle. 
RMS: Root mean square. Data are mean ± 1SD. 
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6.3.2 Twitches  
Resting twitches: Supplementation did not significantly influence fresh or fatigued skeletal 
muscle twitch force (Fresh: P = 0.07; f (2, 28) = 2.89,   
  < 0.1,   
  = 0.1 Fatigued: P = 0.94; f (2, 
28) = 0.06,   
  < 0.1,   
  < 0.1 (group × session × time point); Fresh: P = 0.25; f (1, 14) = 1.45,   
  < 
0.1,   
  < 0.1; Fatigued: P = 0.39; f (1, 14) = 0.80,   
  < 0.1,   
  < 0.1 (group × session); Table 6.3). 
There was no significant group × session interaction for EMD (Fresh: P = 0.67; f (1, 14) = 0.16,   
  
< 0.1,   
  < 0.1; Fatigued: P = 0.62; f (1, 14) = 0.26,   
  < 0.1,   
  < 0.1; Table 6.3), TPT (Fresh: P = 
0.60; f (1, 14) = 0.28,   
  < 0.1,   
  < 0.1; Fatigued: P = 0.54; f (1, 14) = 0.39,   
  < 0.1,   
  < 0.1; 
Table 6.3) or HRT (Fresh: P = 0.27; f (1, 14) = 1.32,   
  = 0.1,   
  < 0.1; Fatigued: P = 0.43; f (1, 
14) = 0.09,   
  < 0.1,   
  < 0.1; Fig. 6.2). Under fresh conditions, HRT within the β-alanine group 
declined by 6 ± 14% (6 ± 14 ms) pre- to post-supplementation, whilst the placebo group increased 
by 4 ± 16% (3 ± 19 ms). Under fatigued conditions, HRT within the β-alanine group declined by 5 
± 18% (10 ± 31 ms) pre- to post-supplementation, whilst the placebo group increased by 15 ± 58% 
(5 ± 37 ms). Mean CV values for fresh skeletal muscle in the placebo group: force at 25 and 50 ms 
and peak were 12, 15 and 12%, EMD was 15%, TPT was 5% and HRT was 9%. Mean CV values 
for fatigued skeletal muscle in the placebo group: force at 25 and 50 ms and peak were 15, 17, and 
15%, EMD was 16%, TPT was 16% and HRT was 7%. 
 
The percentage difference in resting twitch force pre- to post-supplementation was not 
affected (P = 0.75; f (1, 14) = 0.13,   
  < 0.1,   
  < 0.1) with no group × session interaction (P = 
0.80; f (1, 14) = 0.07,   
  < 0.1,   
  < 0.1). Resting twitch TPT was unaffected by the completion of 
the IKET (P = 0.19; f (1, 14) = 1.94,   
  < 0.1,   
  < 0.1; Table 6.3) with no group × fatigue (P = 
0.81; f (1, 14) = 0.06,   
  < 0.1,   
  < 0.1) or group × session × fatigue interactions (P = 0.82; f (1, 
14) = 0.05,   
  < 0.1,   
  < 0.1). EMD remained similar following the IKET (P = 0.72; f (1, 14) = 
0.13,   
  < 0.1,   
  < 0.1) with no group × fatigue (P = 0.94; f (1, 14) = 0.06,   
  < 0.1,   
  < 0.1) or 
group × session × fatigue interactions (P = 0.49; f (1, 14) = 0.51,   
  < 0.1,   
  < 0.1; Table 6.3). 
Resting twitch HRT significantly increased following the completion of the IKET (P = 0.04; f (1, 
14) = 5.42,   
  = 0.3,   
  = 0.1; Fig. 6.2). There was no group × fatigue (P = 0.09; f (1, 14) = 
3.42,   
  = 0.2,   
   0.1) or group × session × fatigue interactions (P = 0.71; f (1, 14) = 0.14,   
  < 
0.1,   
  < 0.1). 
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Potentiated twitches: Supplementation did not significantly influence fresh or fatigued 
skeletal muscle twitch force (Fresh: P = 0.46; f (2, 28) = 0.81,   
  < 0.1,   
  < 0.1; Fatigued: P = 
0.48; f (2, 28) = 0.76,   
  < 0.1,   
  < 0.1; (group × session × time point); Fresh: P = 0.59; f (1, 14) = 
0.30,   
  < 0.1,   
  < 0.1; Fatigued: P = 0.80; f (1, 14) = 0.07,   
  = 0.1,   
  < 0.1 (group × session); 
Table 6.3). There was no significant group × session interaction for EMD (Fresh: P = 0.66; f (1, 
14) = 0.20,   
  < 0.1,   
  < 0.1; Fatigued: P = 0.95; f (1, 14) = 0.005,   
  < 0.1,   
  < 0.1; Table 6.3), 
TPT (Fresh: P = 0.94; f (1, 14) = 0.007,   
  < 0.1,   
  < 0.1; Fatigued: P = 0.95; f (1, 14) = 0.005,   
  
< 0.1,   
  < 0.1; Table 6.3) or HRT (Fresh: P = 0.59; f (1, 14) = 0.32,   
  < 0.1,   
  < 0.1; Fatigued: 
P = 0.38; f (1, 14) = 0.84,   
  < 0.1,   
  < 0.1; Fig. 6.2). In fresh skeletal muscle, there was a 
significant decline in EMD pre- to post-supplementation (P = 0.03; f (1, 14) = 6.13,   
  = 0.1,   
  = 
0.1), this was evident in both conditions with no group × session effect. Mean CV values for fresh 
skeletal muscle in the placebo group: force at 25 and 50 ms and peak were 14, 16, and 12%, EMD 
was 11%, TPT was 3% and HRT was 6%. Mean CV values for fatigued skeletal muscle in the 
placebo group: force at 25 and 50 ms and peak were 12, 20, and 14%, EMD was 13%, TPT was 4% 
and HRT was 5%. 
 
The percentage change in potentiated twitch force was unaffected by supplementation (P = 
0.38; f (1, 14) = 0.81,   
  < 0.1,   
  < 0.1) with no group × session interaction (P = 0.66; f (1, 14) = 
0.20,   
  < 0.1,   
  < 0.1). Potentiated twitch TPT declined following completion of the IKET (P = 
0.07; f (1, 14) = 3.85,   
  = 0.2,   
  < 0.1; Table 6.3), with no group × fatigue (P = 0.50; f (1, 14) = 
0.49,   
  < 0.1,   
  < 0.1) or group × session × fatigue interactions (P = 0.90; f (1, 14) = 0.02,   
  < 
0.1,   
  < 0.1). Potentiated EMD significantly prolonged following the IKET (P = 0.03; f (1, 14) = 
6.38,   
  = 0.3,   
  < 0.01) with no group × fatigue (P = 0.17; f (1, 14) = 2.15,   
  = 0.1,   
  = 0.1) or 
group × session × fatigue interactions (P = 0.82; f (1, 14) = 0.05,   
  < 0.1,   
  < 0.1; Table 6.3). 
Potentiated HRT remained similar following the IKET (P = 0.87; f (1, 14) = 0.03,   
  < 0.1,   
  < 
0.1). There was no group × fatigue (P = 0.61; f (1, 14) = 0.27,   
  < 0.1,   
  < 0.1) or group × 
session × fatigue interactions (P = 0.94; f (1, 14) = 0.007,   
  < 0.1,   
  < 0.1; Fig. 6.2). 
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6.3.3 Doublet force  
In both fresh (P = 0.82; f (2, 28) = 0.20,   
  < 0.1,   
  < 0.1 (group × session × time point); 
P = 0.93; f (1, 14) = 0.009,   
  < 0.1,   
  < 0.1 (group × session)) and fatigued (P = 0.83; f (2, 28) = 
0.19,   
  < 0.1,   
  < 0.1 (group × session × time point); P = 0.81; f (1, 14) = 0.06,   
  < 0.1,   
  < 0.1 
(group × session)) skeletal muscle, supplementation did not significantly alter doublet force at 25, 
50ms and peak (Table 6.3). The percentage change in doublet force between fresh and fatigued 
conditions was not significantly affected by supplementation (P = 0.44; f (2, 28) = 0.85,   
  < 0.1, 
  
  < 0.1), with no group × session interaction (P = 0.32; f (1, 14) = 1.07,   
  < 0.1,   
  < 0.1). Mean 
CV values for fresh skeletal muscle in the placebo group were 11, 14 and 13% for force at 25, 50 
ms and peak. Mean CV values for fatigued skeletal muscle in the placebo group were 11, 5 and 5% 
for force at 25, 50 ms and peak. 
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Fig. 6.2: Electrically evoked half relaxation time of β-alanine (BA) and placebo (PLA) groups pre- 
and post-supplementation, in fresh and fatigued skeletal muscle during: resting twitch (a), 
potentiated twitch (b), and doublets (c). Data are mean ± 1SD.  
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Table 6.3: Electrically evoked force responses, time-to-peak tension (TPT) and electromechanical delay (EMD) of β-alanine and placebo groups pre- and 
post-supplementation, in fresh and fatigued skeletal muscle.  
   
Pre-supplementation Post-supplementation 
   
Force (N) 
EMD  
(ms) 
TPT  
(ms) 
Force (N) 
EMD 
 (ms) 
TPT  
(ms)       25 50 Peak 25 50 Peak 
Resting Twitch Fresh β-alanine 14 ± 5 42 ± 16 60 ± 12 11 ± 1 89 ± 17 16 ± 6 46 ± 17 68 ± 15 10 ± 2 86 ± 19 
 
Fresh Placebo 13 ± 4 41 ± 13 57 ± 16 13 ± 3 87 ± 12 14 ± 4 43 ± 12 57 ± 11 13 ± 2 88 ± 13 
 
Fatigued β-alanine 16 ± 7 49 ± 20 64 ± 24 11 ± 2 84 ± 21 19 ± 6 55 ± 16 66 ± 22 11 ± 3 82 ± 21 
 
Fatigued Placebo 16 ± 7 52 ± 19 65 ± 23 13 ± 4 82 ± 16 15 ± 6 52 ± 18 63 ± 19 13 ± 2 86 ± 25 
Potentiated Twitch Fresh β-alanine 26 ± 13 71 ± 38 97 ± 35 12 ± 3 84 ± 16 29 ± 14 79 ± 33 96 ± 39 10 ± 2 81 ± 23 
 
Fresh Placebo 26 ± 16 75 ± 27 97 ± 30 12 ± 3 79 ± 11 27 ± 11 88 ± 35 110 ±42 11 ± 3 77 ± 18 
 
Fatigued β-alanine 23 ± 10 58 ± 31 77 ± 28 12 ± 2 76 ± 9 24 ± 12 63 ± 25 73 ± 28 11 ± 3 76 ± 20 
  Fatigued Placebo 22 ± 11 60 ± 27 79 ± 27 14 ± 4 75 ± 12 21 ± 10 65 ± 16 84 ± 28 12 ± 3 75 ± 16 
Doublet Fresh β-alanine 28 ± 10 92 ± 31 126 ± 33 14 ± 3 100 ± 31 34 ± 9 108 ± 28 142 ± 32 14 ± 2 96 ± 19 
 
Fresh Placebo 30 ± 7 100 ± 24 135 ± 29 14 ± 3 105 ± 37 31 ± 6 116 ± 26 152 ± 36 14 ± 1 108 ± 35 
 
Fatigued β-alanine 30 ± 12 95 ± 33 122 ± 36 15 ± 2 93 ± 23 33 ± 11 101 ± 29 128 ± 35 15 ± 1 92 ± 22 
  Fatigued Placebo 30 ± 11 99 ± 32 130 ± 34 15 ± 4 98 ± 42 33 ± 10 104 ± 32 140 ± 27 15 ± 3 97 ± 25 
Data are mean ± 1SD.
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6.3.4 Force-electromyography relationship  
The slope and y-intercept of the force-EMG relationship were unaffected by 
supplementation in both fresh (slope: P = 0.86; f (1, 14) = 0.03,   
  < 0.1,   
  < 0.1; y-intercept: P = 
0.20; f (1, 14) = 1.77,   
  = 0.1,   
  < 0.1 (group × session)) and fatigued skeletal muscle (slope: P = 
0.43; f (1, 14) = 0.67,   
  < 0.1,   
  < 0.1; y-intercept: P = 0.31; f (1, 14) = 1.10,   
  < 0.1,   
  < 0.1) 
(Fig. 6.3 and Table 6.4). There was also no influence of the IKET on the slope and y-intercept of 
the force-EMG relationship (slope: P = 0.62; f (1, 14) = 0.26,   
  < 0.1,   
  < 0.1; y-intercept: P = 
0.94; f (1, 14) = 0.006,   
  < 0.1,   
  < 0.1), with no group × fatigue interaction (slope: P = 0.41; f (1, 
14) = 71,   
  < 0.1,   
  < 0.1; y-intercept: P = 0.70; f (1, 14) = 0.16,   
  < 0.1,   
  < 0.1). The mean 
CV in the placebo group for the slope of the force-EMG relationship was 31% (fresh skeletal 
muscle) and 1% (fatigued skeletal muscle). 
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Fig. 6.3: Force-surface electromyography (EMG) relationship measured during submaximal 
voluntary contractions (15 - 90% MVIF) for the β-alanine (BA) and placebo (PLA) groups pre- and 
post-supplementation, in fresh and fatigued skeletal muscle. Mmax: Maximum muscle action 
potential; RMS: Root mean square. Data are mean ± 1SD. 
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6.3.5 Force-frequency relationship 
Supplementation did not significantly influence peak force at each frequency of stimulation 
(fresh: P = 0.99; f (9, 108) = 0.2,   
  < 0.1,   
  < 0.1; fatigued: P = 0.52; f (9, 108) = 0.91;   
  < 0.1, 
  
  < 0.1 (group × session × frequency); fresh: P = 0.61; f (9, 108) = 0.28,   
  < 0.1,   
  < 0.1; 
fatigued: P = 0.64; f (9, 108) = 0.23;   
  < 0.1,   
  < 0.1 (group × session); Fig. 6.4). The frequency 
at 50% of the force response (Table 6.4) in fresh (peak force: P = 0.98; f (1, 14) < 0.01,   
  < 0.1, 
  
  < 0.1; frequency at 50%: P = 0.31; f (1, 14) = 1.12,   
  < 0.1,   
  < 0.1 (group × session)) and 
fatigued skeletal muscle was unaffected by supplementation (peak force: P = 0.81; f (1, 14) = 
0.06,   
  < 0.1,   
  < 0.1; frequency at 50%: P = 0.30; f (1, 14) = 1.15,   
  < 0.1,   
  < 0.1). Peak 
force significantly declined following the completion of the IKET (P = 0.03; f (1, 14) = 6.39,   
  = 
0.3,   
  = 0.3), with no group × fatigue interaction (P = 0.48; f (1, 14) = 0.52,   
  < 0.1,   
  < 0.1). 
The frequency at 50% of the force response remained unaffected by the IKET (P = 0.46; f (1, 14) = 
0.57,   
  < 0.1,   
  < 0.1), with no group × fatigue interaction (P = 0.68; f (1, 14) = 0.18,   
  < 0.1, 
  
  < 0.1). 
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Fig. 6.4: Force-frequency relationship assessed during submaximal percutaneous stimulation for β-
alanine (BA) and placebo (PLA) groups pre- and post-supplementation, in fresh and fatigued 
skeletal muscle. Data are mean ± 1SD.  
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Table 6.4: Characteristics of the force-frequency and force-electromyography (EMG) relationships of β-alanine and placebo groups in fresh and fatigued 
skeletal muscle, pre- and post-supplementation. 
 
 
Pre-supplementation Post-supplementation 
 
β-alanine Placebo  β-alanine Placebo  
 
Fresh Fatigued Fresh Fatigued Fresh Fatigued Fresh Fatigued 
Force-frequency relationship 
Frequency at 50% of response, Hz 13.6 ± 2.8 14.0 ± 2.4 12.9 ± 2.4 13.8 ± 3.3 14.3 ± 3.6 14.1 ± 3.4 15.0 ± 4.2 14.7 ± 3.0 
Force-EMG relationship 
Intercept (RMS:Mmax) -0.16 ± 0.62 -0.33 ± 0.56 -0.13 ± 0.52 -0.67 ± 0.69 -0.44 ± 0.87 -0.02 ± 0.56 -0.10 ± 0.55 0.29 ± 1.79 
Slope (RMS:Mmax/N) 0.023 ± 0.012 0.027 ± 0.014 0.019 ± 0.006 0.024 ± 0.012 0.027 ± 0.020 0.020 ± 0.013 0.025 ± 0.014 0.021 ± 0.015 
Data are mean ± 1SD. Mmax: Maximum muscle action potential; RMS: Root mean square.
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6.3.6 Sustained isometric knee extensor endurance test  
There was no group × session interaction for TTF (β-alanine: pre: 131 ± 65 s; post: 148 ± 
63 s; Placebo: pre: 133 ± 46 s; Post: 154 ± 79 s; P = 0.82; f (1, 14) = 0.05,   
  < 0.1,   
  < 0.1; Fig. 
6.5). Based upon the recorded TTF, the Rohmert equation (Rohmert, 1960) was used to calculate 
an estimated percentage of MVIF. Individuals within both the β-alanine and placebo group were 
holding the IKET at ~31% MVIF (~14% lower than asked), as denoted by longer hold times of ~65 
s. There was no group × session interaction for impulse values (β-alanine: pre: 19 ± 8 kN.s-1; post 
21 ± 7 kN
.
s
-1
; Placebo: pre: 19 ± 6 kN
.
s
-1
; post 21 ± 7 kN
.
s
-1
; P = 0.68; f (1, 14) = 0.18,   
  < 0.1,   
  
< 0.1).  
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Fig. 6.5: Time to task failure (s; A) and impulse (kN
.s; B) of β-alanine (BA) and placebo (PLA) 
groups pre- and post-supplementation. Data are mean ± 1SD. Individual data are presented as 
squares (BA), and triangles (PLA).  
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6.4 Discussion 
The current investigation demonstrated that increased skeletal muscle carnosine content 
via β-alanine supplementation in healthy older adults (60 - 80 y) does not significantly influence 
force production capacity in either fresh or fatigued skeletal muscle conditions. In contrast to 
previous findings in young adults (Studies 1 and 2; Chapters 4 and 5), there was no decline in 
skeletal muscle HRT following 28-days of β-alanine supplementation in either fresh or fatigued 
skeletal muscle conditions. The current research indicated that increased skeletal muscle carnosine 
content in older healthy adults, does not alter Ca
2+
 kinetics, a proposed mechanism associated with 
improved exercise performance (Dutka & Lamb, 2004; Dutka et al., 2012; Everaert et al., 2013). 
These data extend the limited literature focused on increasing skeletal muscle carnosine content via 
β-alanine supplementation in older individuals, and is the first to comprehensively examine the 
effect of β-alanine supplementation on voluntary and electrically evoked contractile properties of 
in-vivo human skeletal muscle in older adults.  
 
In-line with the findings in young healthy adults reported in Studies 1 and 2 (Chapters 4 
and 5), β-alanine supplementation did not significantly influence voluntary force production, 
including maximal and explosive force variables, with similar neural drive responses during 
contractions, pre- and post-supplementation. Based on the current data it is proposed that 28-days 
of β-alanine supplementation (4.8 g.d-1) does not significantly influence skeletal muscle Ca2+ 
related function in older healthy adults. There was no leftward shift of the force-frequency curve, 
the associated measure of intracellular Ca
2+
 levels (Balnave & Allen, 1996) in either fresh or 
fatigued conditions following β-alanine supplementation. These in-vivo data contrast previously 
reported in-vitro research, where increased carnosine content improved the sensitivity of the 
muscle contractile apparatus to Ca
2+
 conducted in animal and human skeletal muscle fibres 
(Lamont & Miller, 1992; Dutka et al., 2012). The current investigation, along with the research in 
young healthy adults (Studies 1 and 2; Chapter 4 and 5) suggests that the reported alterations to 
skinned muscle fibre and associated Ca
2+
 kinetics evident with increased carnosine content 
(Lamont & Miller, 1992; Dutka et al., 2012), are not substantial enough to alter whole skeletal 
muscle contraction in either young or older healthy adults.  
 
Surprisingly, increased skeletal muscle carnosine content via β-alanine supplementation 
in older adults did not significantly alter twitch concentration HRT, in either fresh or fatigued 
skeletal muscle conditions. These data contrast previous in-vivo research in younger adults (Studies 
1 and 2; Chapters 4 and 5), where 28-days of β-alanine supplementation (6.4 g.d-1) resulted in 
significant reductions in skeletal muscle HRT in both fresh and fatigued muscle conditions (Studies 
1 and 2; Chapters 4 and 5). It was hypothesised that the older adults would experience a similar, if 
not greater, reduction in skeletal muscle HRT following 28-days of β-alanine supplementation 
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compared to younger counterparts, due to the already apparent detrimental influence of the ageing 
process. The ageing process is associated with a negative impact on twitch contraction time and 
HRT in skeletal muscle (Allman, Cheng & Rice, 2004; Vandervoort & McComas, 1986; Narici, 
Bordini & Cerretelli, 1991; Hunter et al., 1999), with HRT increased by 20 – 43% in older adults 
(Vandervoort & McComas, 1986; Cupido et al., 1992; Doherty & Brown, 1997; Hunter et al., 
1999). Alterations to these phases of skeletal muscle concentration can influence the efficiency of 
the older adult to perform muscular activities (Kirkendall & Garrett, 1998), are functional 
parameters directly attributed to SR function (Coyle et al., 1979; Larsson & Salviati, 1989) and 
indicate a reduction of SR efficiency to re-uptake Ca
2+
 (Klitgaard et al., 1989; Petrella et al., 1989). 
In-line with the declined skeletal muscle relaxation speed, there is also a reduction in the maximal 
rate of SERCA uptake and activity in older individuals (Hunter et al., 1999). The apparent lack of 
alteration to skeletal muscle HRT following increased skeletal muscle carnosine content, via β-
alanine supplementation, may be attributed to the supplementation protocol. The current 
investigation supplemented older individuals over 28-days with a daily dose of 4.8 g
.
day
-1 β-alanine, 
currently the largest daily dose of β-alanine in this older population (del Favero et al., 2012; Glenn 
et al., 2015; 2016). No feelings of paraesthesia were reported following supplementation, 
supporting the ingestion of this larger 4.8g
.
d
-1
 dose of β-alanine in older adults (60 y). Yet, it is 
important to note that there are no direct measurements of skeletal muscle carnosine content. 
Although participants were supplemented with β-alanine at a daily dose of 4.8 g.day-1, the total β-
alanine dose over the 28-days was ~134 g, around half of that reported previously (del Favero et al., 
2012). Due to the dose-dependent effect of β-alanine supplementation on carnosine content, and the 
reported 85% increase in skeletal muscle carnosine content following ingestion of ~280 g of β-
alanine (del Favero et al., 2012), the expected increase in skeletal muscle carnosine concentration 
following 134 g β-alanine would be approximately 40%. Older adults ingesting 28-days β-alanine 
supplementation, albeit at a lower daily and total doses (3.2 g
.
d
-1
; total dose; 89.6 g), have shown 
improvements in muscular performance, as indicated by peak torque and work completed during an 
isokinetic performance task (Glenn et al., 2016). There were no direct measurements of skeletal 
muscle carnosine content, however, the authors proposed that increased skeletal muscle carnosine 
content from exogenous β-alanine consumption were responsible for the beneficial effects on 
performance (Glenn et al., 2016). Based on the existing, although limited research, in older 
individuals it can be hypothesised that β-alanine supplementation resulted in increased skeletal 
muscle carnosine content, yet the exact extent of this increase warrants further investigation.  
 
There was not effect of supplementation on IKET performance, with similar hold times 
reported pre- and post-supplementation for both the placebo and β-alanine groups. The lack of 
change in IKET hold times in older healthy individuals following β-alanine supplementation is 
consistent with the data previously reported in young healthy adults (Study 2; Chapter 5). The 
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IKET hold times in the older participants were ~70 s (~53%) greater than those reported in young 
healthy adults (Study 2; Chapter 5), implying that the older individuals were not completing the 
IKET at 45% MVIF. At 45% MVIF occlusion of the contracting skeletal muscle occurs, resulting 
in maximal accumulation of lactate, pyruvate, and H
+
 (Ahlborg et al., 1972). Due to the longer hold 
times, it can be estimated with the Rohmert equation (Rohmert, 1960), that the older participants 
were completing the IKET at around 30% MVIF, much lower than that instructed (45% MVIF). 
Completion of the IKET at 30% MVIF would not result in the same physiological responses as 
those evident during a contraction at 45% MVIF, indicating that the current IKET was not 
generating the same levels of muscle fatigue in these older adults, as evident in the younger adults. 
As such, it remains unlikely that the IKET protocol in older adults allowed examination of the 
effect of β-alanine supplementation on electrically evoked contractile properties and voluntary 
force production of fatigued in-vivo skeletal muscle in older adults. The IKET hold times in healthy 
older adults (Study 3; Chapter 6) and those in younger individuals (Study 2; Chapter 5) are in-line 
with IKET performance times reported by McPhee et al., (2014). Older individuals completing an 
IKET at 50% MVIF, demonstrated hold times ~20 s longer in duration than those of younger adult 
(Young: 71.2 ± 5 s; Older: 91.5 ± 5 s; P = 0.001; McPhee et al., 2014). The authors proposed that 
the differences in IKET hold times were associated with dissimilar contractile properties of the two 
populations (McPhee et al., 2014), with older individuals having a greater proportion of slow 
contracting Type I muscle fibres compared to their younger counterparts (Lexell et al., 1988). 
During the current investigation, the Rohmert equation (Rohmert, 1960) was used to estimate IKET 
hold times, in-line with previous research within this thesis (Study 2; Chapter 5). It should be 
highlighted, however, that the Rohmert equation (Rohmert, 1960) was designed to evaluate skeletal 
muscle contraction performance in young healthy adults. Therefore, the Rohmert equation 
(Rohmert, 1960) may not be applicable to accurately predict IKET performance times in older 
individuals, especially due to the potential impact of the ageing process, and declines in both the 
size and number of Type II muscle fibres (Lexell et al., 1995), key contributors to skeletal muscle 
performance.  
 
6.5 Conclusion 
The present investigation was the first to comprehensively examine the effect of 28-days of 
β-alanine supplementation on intrinsic in-vivo isometric knee extensor force production and muscle 
contractility in fresh and fatigued human skeletal muscle in an older population (60 – 80 y). In-line 
with previous research in young adults (Study 2; Chapter 5), 28-days of β-alanine supplementation 
in older individuals reported no significant alterations to voluntary force responses or electrically 
evoked resting or potentiated twitches and octets variables (EMD, peak force and TPT). 
Surprisingly, there was no significant beneficial effect of β-alanine supplementation on skeletal 
muscle HRT, unlike that reported in young adults (Study 2; Chapter 5). These data imply that β-
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alanine supplementation did not alter skeletal muscle the amount of Ca
2+
 released and/or sensitivity 
of the contractile properties to Ca
2+ 
in older adults. These data extended the limited research 
examining the impact of β-alanine supplementation on skeletal muscle performance in older adults. 
Based on the present data, it can be proposed that older adults (60 – 80 y) can undertake β-alanine 
supplementation protocols, with a daily dose of 4.8 g
.
d
-1
, without experiencing paraesthesia, 
maintaining the double-blind nature of the investigation.  
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Chapter 7: The examination and 
manipulation of skeletal muscle 
carnosine content in rat tissue, and the 
effect on ATPase activity 
 
 
 
 
 
 
 
 
 
The research reported within the current chapter are supported by the development of several 
methodological processes, as reported in appendix 1   
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7.1 Introduction 
The research previously reported within the current thesis was the first to examine the 
effect of increased skeletal muscle carnosine content via 28-days of β-alanine supplementation, on 
the electrically evoked contractile properties and voluntary force production of human skeletal 
muscle in-vivo. This research proposed that in young healthy adult males (18 – 30 y) 28-days of β-
alanine supplementation reduced skeletal muscle HRT (relative to equivalent placebo times) in 
fresh (Studies 1 and 2; Chapters 4 and 5) and fatigued (Study 2; Chapter 5) resting and potentiated 
twitch and octet contractions. These data were extended, examining the influence of 28-days β-
alanine supplementation in older individuals (60 - 80 y), surprisingly there were no significant 
changes in skeletal muscle HRT under fresh or fatigued conditions. As discussed in Study 3 
(Chapter 6), there were several potential reasons for the disparately in these findings. The declines 
in skeletal muscle HRT in young healthy adults (Studies 1 and 2; Chapters 4 and 5) are in-line with 
the hypothesis that increased carnosine content alters Ca
2+
 kinetics within the skeletal muscle, a 
proposed mechanism associated with the improvement in exercise performance (Dutka and Lamb, 
2004; Everaert et al., 2013; Guglielmi et al., 2013; Sale et al., 2013). Skeletal muscle relaxation 
speed can be impacted by several factors associated with Ca
2+
 kinetics (Muntener et al., 1995; 
Allen, Lamb & Westerblad, 2008; Little et al., 2011; Nogueira et al., 2013), whether that be 
adaptations to the sensitivity of the contractile properties to Ca
2+
 and/or the amount of Ca
2+
 released 
from the SR lumen to the myofibrils. Working together, Ca
2+
 pumps and Ca
2+
 release channels 
form ubiquitous Ca
2+
 regulatory systems in muscle and non-muscle cells (McMullan et al., 1997). 
The Ca
2+
-dependent ATPase, SERCA, maintains the Ca
2+
 gradient across the membrane of 
intracellular vesicles of all cells (MacLennan & Kranias, 2003; Rossi & Dirksen, 2006). SERCA 
pump activity is not only associated with the speed at which the skeletal muscle relaxes (Gafni & 
Yuh, 1989), the rate-limiting step of skeletal muscle relaxation (Dux, 1993; Gillis et al., 1985). 
 
Carnosine is historically referred to as a cytosolic dipeptide, due to its role in neutralising 
the extensive formation of lactic acid during high-intensity anaerobic exercise within the cytosolic 
of the cell (Abe, 2000), and the prominent level (98%) of carnosine synthetase activity undertaken 
in the cytosolic (Harding & Fallon, 1979). Nonetheless, for carnosine to alter Ca
2+
 kinetics of the 
skeletal muscle, there needs to be a direct or indirect connection to the Ca
2+
-dependent ATPases. 
Ca
2+
 pumps, such as the SERCA, are located on the longitudinal SR of the cardiac and skeletal 
muscle cells (MacLennan & Kranias, 2003), meaning that, to be most effective in this role 
carnosine needs to be apparent within the microsomal fraction of the skeletal muscle. Research 
examining skeletal muscle carnosine content in both humans and rats, is generally examined by 
muscle biopsy, or 
1
H-MRS techniques (Steurenburg & Kunze, 1999; Harris et al., 2006; Hill et al., 
2007; Derave et al., 2007; Kendrick et al.,2008; 2009; Baguet et al., 2010; Stellingwerff et 
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al.,2011; del Favero et al., 2012; Bex et al., 2014; Chung et al., 2014; Gross et al., 2014; Stegen et 
al., 2014; Danaher et al., 2014). These carnosine content are of the whole skeletal muscle fibre, 
there remains no research examining the distribution of the carnosine molecule across subcellular 
compartments. It can be hypothesised that if the carnosine molecule is reported within other 
subcellular compartments, in addition to the cytosolic as historically proposed (Harding & Fallon, 
1979; Abe, 2000), the potential roles of carnosine extend above that of purely an intracellular 
buffer (see review; Sale et al., 2010; 2013).  
 
Upon initiation of skeletal muscle relaxation, Ca
2+
 ions are pumped out of the cytosolic 
fraction by PMCAs and pumped into intracellular compartments by SERCAs, where Ca
2+
 is stored 
and released upon necessity (Kochegarov, 2003). The SERCA pump serves as a dual function, (a) 
lowering the cytosolic Ca
2+
 to induce muscle relaxation, and (b) concurrently restoring the SR Ca
2+
 
store required for following muscle contraction (MacLennan, 1970; Gommans et al., 2002; Rossi & 
Dirksen, 2006; Periasamy & Kalyanasundraam, 2007; Bers, 2008). Through conformational 
changes, SERCA pumps transfer two Ca
2+ 
ions from the cytoplasm into the endoplasmic lumen per 
molecule of ATP hydrolysed (Baba-Aissa et al., 1998; Moller et al., 2010). Following the transport 
of Ca
2+ 
ions into the lumen, phosphate is released as Pi, quantification of the Pi during ATP-y-P 
hydrolysis can be evaluated as a measure of SERCA activity (McMullen et al., 2012). By acting on 
Ca
2+
 kinetics proteins directly or via other molecules, Ca
2+
 signalling can be inhibited or excited 
(Swietach et al., 2013). This physiological process can, therefore, provide an understanding of the 
functionality of the Ca
2+
-dependent ATPase activity. Carnosine has already been shown to maintain 
Ca
2+
 release pump activity at a pH of 6.0, where a complete decline in activity is evident (Zaloga, 
Roberts & Nelson, 1996). Increasing the availability of carnosine around the Ca
2+
-dependent 
ATPase pumps, therefore, may impact Ca
2+
-channel activity by interacting with the Ca
2+
-channel 
itself (Batrukova & Rubstov, 1997), possibly via the existence of saturable binding site(s) for 
carnosine on the Ca
2+
-channel. 
 
The present investigation aimed to examine the distribution of the carnosine molecule 
across subcellular fractions (nucleic, mitochondrial, cytosolic and microsomal) within rat skeletal 
muscle tissue. It was hypothesised that carnosine, or its constituents, β-alanine and L-histidine, 
would need to be evident in both the cytosolic and microsomal (containing the SR) fractions of the 
skeletal muscle to support the mechanisms of carnosine as an intracellular buffer, and as a 
manipulator of skeletal muscle Ca
2+
 kinetics. Furthermore, these data investigated the impact of 
increased carnosine availability on ATPase activity, a measure associated with skeletal muscle 
relaxation, estimated by Pi generation. It was hypothesised based on the improvements in skeletal 
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muscle HRT in-vivo (Studies 1 and 2; Chapter 4 and 5), that increased carnosine availability would 
improve SERCA activity, as estimated by Pi generation.  
 
7.2 Methodology 
7.2.1 Materials and chemicals 
The current investigation complied with the operations of the Animals (Scientific 
Procedures) Act 1986 (Amendment Regulations 2012, SI 2012/3039) and did not require 
institutional ethical approval (see Section 3.2; Page 35). Skeletal muscle tissue was obtained from 
the hind limbs of nine young (10 weeks, ~300 g in weight) International Genetic Standard Wistar 
rats (Table 7.1). Rats were kept in a light-controlled (12 h light/dark cycle) temperature-controlled 
(22ºC) environment and fed a pellet rodent diet, ad libitum, and had unrestricted access to water. 
Before experiments, the animals were killed by cervical dislocation followed by decapitation, the 
skeletal muscles from the hind limbs were then dissected out and placed in phosphate buffered 
saline (PBS). The Bicinchoninic acid (BCA) assay protein assay kit was purchased from Cheshire 
Sciences Limited (Chester, UK). Amino acid lithium citrate buffers were purchased from Biochrom 
(Cambourne, UK). BIOMOL Green phosphate assay reagent was purchased from Enzo Life 
Sciences (UK) Ltd. All other chemicals were purchased from Sigma Aldrich (St. Louis, MA, USA). 
 
Table 7.1: Characteristics of the rat skeletal muscle tissue samples, weight of skeletal muscle is 
reported as wet muscle tissue in phosphate buffered saline.  
Rat Skeletal muscle 
weight (g) 
Gender Age (weeks) Date collected 
1 21.1 Male 10 8.11.16 
2 23.4 Male 10 8.11.16 
3 25.4 Male 10 8.11.16 
4 22.3 Male 10 8.11.16 
5 17.8 Male 10 8.11.16 
6 17.6 Male 10 21.11.16 
7 20.6 Male 10 21.11.16 
8 22.1 Male 10 21.11.16 
9 24.3 Male 10 21.11.16 
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7.2.2 In-vitro skeletal muscle tissue preparation  
Fresh rat skeletal muscle tissue was rinsed in a homogenisation medium (PBS), trimmed of 
fat, connective tissue and minced. The muscle tissue was homogenised in an ice-cold 
homogenisation buffer (25 mM Potassium chloride, 20 mM HEPES pH 7.4, 1 mM 
Ethylenediaminetetraacetic acid, 50 mM Sucrose, 200 mM Mannitol, 1:300 dilution of protease 
inhibitor) using an electronic homogeniser (Ultra-turrax, IKA laboratory technology England Ltd, 
Oxford, UK). Homogenisation was undertaken at maximum speed for 1.5 min (Wrzosek, 2014), 
bringing the pestle to the bottom at least eight times (Wilkie & Schirmer, 2008). The homogenate 
was filtered through layers of cheesecloth (pore size = 75 μM) to remove cellular debris and 
connective tissue (Fig. 7.1). The filtrate was centrifuged at 1000 g for 10 min at 4
o
C (Harrier 18/80 
Refrigerated benchtop centrifuge, MSE Ltd, London, UK; Fig. 7.2; Fig. 7.3). The resulting pellet 
containing the nucleic fraction, was resuspended in a storage medium (25 mM potassium chloride, 
20 mM Hepes pH 7.4, 250 mM sucrose, 5 mM magnesium chloride) and frozen at -80
o
C. Prior to 
additional analysis, the nucleic pellet was defrosted and resuspended in 1 mL of storage buffer, the 
samples were vortexed for 15 s and spun at 500 g for 15 min (Dimauro et al., 2012). The resulting 
pellet containing the nucleic fraction was re-suspended in 2 mL storage buffer, vortexed for 15 s 
and spun at 1,000 g for 15 min, the final pellet was removed and stored in 2 mL storage buffer 
(Dimauro et al., 2012). 
 
The separated supernatant was ultra-centrifuged at 20,000 g for 20 min at 4
o
C in a Fixed 
angle (Type 70 Ti) Beckman rotor (Beckman Coulter, Fullerton, CA, USA; Fig. 7.2; Fig. 7.3). The 
resulting pellet containing the mitochondrial fraction, was resuspended in a storage medium and 
frozen at -80
o
C. Prior to additional analysis, the mitochondrial pellet was defrosted and 
resuspended in 1 mL of storage buffer, the samples were vortexed for 15 s and spun at 11,000 g for 
10 min. The resulting pellet was resuspended in 2 mL of storage buffer (Dimauro et al., 2012).  
 
The remaining supernatant was ultra-centrifuged at 100,000 g for 40 min at 4
 o
C in a Fixed 
angle (Type 70 Ti) Beckman rotor (Beckman Coulter, Fullerton, CA, USA; Fig. 7.2; Fig. 7.3). This 
step pellets the microsomal fraction derived from SR membranes, reducing soluble protein content 
and lowering the volume required for subsequent fractionation (Wilkie & Schirmer, 2008). The 
supernatant containing the cytosolic fraction was carefully decanted from the pellet and frozen at -
80
o
C. The resulting pellet containing the microsomal fraction, was resuspended in a storage 
medium and frozen at -80
o
C. 
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Low–speed 
centrifugation 
Homogenate Pellet 1: Nucleic Pellet 2: Mitochondrial Pellet 3: Microsomal 
Supernatant: Cytosolic 
Medium–speed 
centrifugation 
High–speed 
centrifugation 
Fig. 7.1: Pictorial representation of the centrifugation process produces large centrifugal forces, 
causing the particles in the sample to sediment, the progressively higher the speeds and longer 
duration will pellet distinct subcellular fractions.  
Fig. 7.2: Filtration of muscle homogenate. (a) Cheesecloth in a funnel suspended in a beaker. 
(b) Homogenate poured into the cheesecloth, drained into a beaker. (c) The cheesecloth is 
squeezed (d) A large amount of fibrous material should remain in the cheesecloth after all liquid 
has been recovered. From Wilkie & Schirmer (2008).  
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7.2.3 Protein assay  
A fresh set of protein standards from 20 μg.mL-1 to 2 mg.mL-1 were diluted from the stock 
solution in the storage medium (25 mM potassium chloride, 20 mM Hepes pH 7.4, 250 mM 
sucrose, 5 mM magnesium chloride). The BCA working reagent was prepared for the standard 
protocol through the addition of 1 part of reagent B to 50 parts of reagent A, the volume of working 
reagent was calculated based on the number of standards and samples required. The working 
reagent was then allowed to reach room temperature. Once prepared, 25 μL of each standard, 
control and sample (10% dilution) were pipetted into microplate wells in triplicate where 200 μL of 
BCA assay working reagent was added. The microplate was then incubated for 30 min at 37
o
C. 
Following incubation, the microplate was cooled to room temperature and optical density was read 
at 562 nM. 
 
The values for each BCA standard were plotted against the protein concentration (μg.mL-1) 
of the sample. A curvilinear regression analysis was undertaken to produce the standard curve, in 
this case a 2
nd
 order polynomial equation. The protein concentration of the assessed sample was 
then plotted as the dependant variable (y-axis) and the absorbance as the independent variable (X-
axis), values were then placed into the equation y = ax
2 
+ bx + c, where solving y determines the 
protein concentration of the sample. The protein concentrations were then adjusted based on 
dilution value and converted to mg
.
mL
-1
.  
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Homogenisation 
Fresh rat skeletal muscle tissue 
Low- speed centrifugation 
1,000 g for 10 min at 4
o
C 
Pellet 1: Nucleic 
Frozen at -80
o
C 
Pellet 3: Microsomal 
Frozen at -80
o
C 
Supernatant: Crude Extract 
Frozen at -80
o
C 
Supernatant 
Supernatant: Cytosolic 
Frozen at -80
o
C 
Pellet 2: Mitochondrial  
Frozen at -80
o
C 
Medium- speed centrifugation 
20,000 g for 20 min at 4
o
C 
High- speed centrifugation 
100,000 g for 60 min at 4
o
C 
Fig. 7.3: The centrifugation protocol implemented within the current thesis, increasing in centrifugal forces to separate the sample into distinct subcellular fractionations.  
Pellet 1: Nucleic 
Frozen at -80
o
C 
Low- speed centrifugation 
500 g for 15 min at 4
o
C 
Low- speed centrifugation 
1,000 g for 15 min at 4
o
C 
Medium- speed centrifugation 
11,000 g for 20 min at 4
o
C 
Pellet 2: Mitochondrial 
Frozen at -80
o
C 
 
Medium- speed centrifugation 
11,000 g for 20 min at 4
o
C 
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7.2.4 Carnosine, β-alanine and L-histidine content 
The physiological samples were thawed prior to deproteinisation achieved through the 
addition of a 5% 5-Sulphosalicylic acid solution (10 nmol 5-Sulphosalicylic acid; 20 μL L-
Norleucine) to the samples. The contents were mixed and allowed to stand for 30 min at 4
o
C. The 
precipitate was centrifuged at 10,000g for 5 min at 4
o
C until the supernatant was clear, and finally 
filtered through a 0.2 μM membrane filter to remove any remaining particulate material. Solutions 
were analysed in an Amino Acid Analyser (Biochrom 30, Pharmacia Biochrom Ltd) by using ion-
exchange chromatography. The amino acids were separated by using standard lithium citrate 
buffers of pH 2.80, 3.00, 3.15, 3.50, and 3.55. The post column derivatisation was performed with 
ninhydrin. Quantitation was performed by calibrating the peak heights to the internal standard, L-
Norleucine. The programme EZ Chrom Elite (Biochrom, Cambourne, UK) was used to examine 
peak height, with ratio to internal standard calculated on Microsoft Excel 2013 (Microsoft Inc., 
Redmond, WA, USA).  
 
7.2.5 BIOMOL green phosphate assay 
Microsomal subcellular fractions were taken from nine skeletal rat muscle samples, and 
mixed with a buffer solution (100 mM Potassium Chloride, 20 mM HEPES pH 7.4 and 2 mM 
Magnesium Chloride) and varying levels of ethylene glycol-bis (β-amino ethyl ether)-N,N,N',N'-
tetra acetic acid (EGTA) and Ca
2+
. The addition of EGTA and Ca
2+
 allowed the manipulation of 
Ca
2+
 (μM) and calculated free Ca2+ (μM) values within the samples. The standards of the BIOMOL 
Green phosphate assay ranged from 0 to 2 nmol, with incubation times of 15 min, the samples were 
diluted to 25% with storage buffer (see Appendix 1). Samples were incubated for 30 min at 25
 o
C, 
following which 100 μL of sample was mixed with 100 μL of BIOMOL Green, stopping the 
reaction. The samples were incubated at room temperature for 15 min to allow development of the 
green colour. The amount of Pi released during the Ca
2+
 uptake assay was determined by reading 
sample absorbance at 640 nM. The values for each BIOMOL Green phosphate assay standard were 
plotted against the Pi concentration (nmol) of the sample. A linear regression analysis was 
undertaken to produce the standard curve. The Pi concentration of the assessed sample was then 
plotted and then placed into the equation y = ax
2 
+ b, where solving y determines the Pi 
concentration of the sample.  
 
Ca
2+
-dependent ATPase activity: To calculate the amount of Ca
2+
-dependent ATPase 
activity, the amount of Pi released during the 0 μM Ca2+ condition was subtracted from the 1 μM 
Ca
2+ 
condition. 
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SERCA activity: Thapsigargin is a non-competitive inhibitor of SERCA activity, 
preventing uptake of Ca
2+
, thereby emptying the intracellular Ca
2+
 stores (Thastrup, 1990). As such, 
thapsigargin has found popularity as an agent both to define and to manipulate intracellular Ca
2+
 
pools (Bian et al., 1991; Foskett et al., 1991; Verma et al., 1990; Kwan et al., 1990). Inhibiting 
SERCA pump activity with thapsigargin can allow the isolation of other ATPases which generate 
Pi within the microsomal fraction, including the PMCA and the Golgi apparatus secretory protein 
ATPases (McMullen et al., 2012). Thapsigargin can inhibit the PMCA, the Golgi apparatus 
secretory protein ATPases, although the concentration required to do so is 10 to 300 times greater 
than that needed to inhibit SERCA activity (Treiman et al., 1998; Harper et al., 2005). Pi generated 
from SERCA pump activity is defined as the difference between Pi generated the condition without 
thapsigargin, minus the Pi generated in the same condition in the presence of thapsigargin.  
 
7.2.6 Statistical analysis 
Dependent variable protein content was evaluated using a one-way mixed-model ANOVA. 
Dependent variables measured over several subcellular fractions (amino acid/dipeptide content 
relative to protein concentration) were analysed using a two-way mixed-model (amino 
acid/dipeptide × Subcellular fraction) ANOVA. Carnosine, β-alanine and L-histidine concentration 
relative to protein concentratin in each subcellular compartment was analysed using a one-way 
mixed-model ANOVA. Dependent variable (ATPase activity) was analysed using a three-way 
mixed-model (thapsigargin × Ca
2+
 × carnosine) ANOVA. Dependent variables (Ca
2+
-dependent 
ATPase and SERCA activity) were analysed using a two-way mixed-model (thapsigargin × 
carnosine; Ca
2+
 × carnosine) ANOVA. Effect size for multiple comparisons was calculated using 
  
  and   
  eta squared (Lakens, 2013). Providing two effect sizes is suggested to yield a greater 
understanding of a specific effect (Preacher & Kelly, 2011). An effect size of 0.2 – 0.5 was defined 
as small, 0.5 – 0.8 as medium and ≥ 0.8 as a large effect (Schünemann et al., 2008). Statistical 
analyses were completed using SPSS version 23 (SPSS Inc., Chicago, IF, USA) and Microsoft 
Excel (Microsoft Inc., USA). Statistical significance was accepted at P < 0.05, with data presented 
as mean ± 1 SD. 
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7.3 Results  
7.3.1 Protein assay 
 The protein concentration for each subcellular fraction was assessed from nine skeletal 
muscle rat samples (Fig. 7.4). All samples were recorded in triplicate with the average reported. 
There was a significant main effect of subcellular fraction on protein concentration (P = 0.004; f (3, 
24) = 40.6,   
  = 0.9,   
  = 0.9). The nucleic fraction had significantly greater protein content than 
all other subcellular fractions; mitochondrial (P = 0.008), cytosolic (P = 0.001) and microsomal (P 
= 0.002). The microsomal fraction had a similar protein concentration to both the mitochondrial 
and cytosolic fractions (P > 0.05). There were, however, significantly greater protein 
concentrations in the mitochondrial fraction compared to the cytosolic fraction (P = 0.003).  
 
Fig. 7.4: Protein concentration (mg
.
mL
-1
) for the assessed subcellular fractions from nine rat 
skeletal muscle samples; nucleic, mitochondrial, cytosolic and microsomal. Data are mean ± 1SD. 
Post hoc analysis; # significantly different to nucleic subcellular fraction (P < 0.008). * 
Significantly different to mitochondrial fraction (P = 0.003).  
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7.3.2 Carnosine, β-alanine and L-histidine content  
 There was a significant subcellular fraction × dipeptide/amino acid interaction for muscle 
content (P < 0.001; f (6, 48) = 171.85,   
  = 1.0,   
  = 0.9; Fig. 7.5). There was a significant main 
effect of both dipeptide/amino acid (P < 0.001; f (2, 16) = 291.11,   
  = 0.8,   
  = 0.5) and 
subcellular fraction (P < 0.001; f (3, 24) = 184.99,   
  = 1.0,   
  = 0.9). Pairwise comparison 
analysis showed that there was significantly more carnosine across the subcellular fractions than 
both of its components, β-alanine (P < 0.001) and L-histidine (P < 0.001), although there was no 
difference between β-alanine and L-histidine contents. Dipeptide/amino acid contents in the 
cytosolic fraction were significantly greater than the microsomal fraction (P < 0.001), with both the 
cytosolic and microsomal amino acid contents significantly greater than those in the nucleic and 
mitochondrial fractions (all P < 0.001). There was no significant difference between the nucleic and 
mitochondrial fractions for dipeptide/amino acid contents (P < 0.05).  
 
Carnosine contents were significantly different across subcellular fractions (P = 0.001; f (3, 
24) = 180.51,   
  = 1.0,   
  = 0.9; Fig. 7.5). The largest contents were shown in the cytosolic 
fraction (192 ± 109 µM.g protein), with 69% of the total carnosine evident in this compartment, 
significantly greater than all other fractions (all P < 0.001). Carnosine contents in the microsomal 
fraction (64 ± 15 µM.g protein; 27% of total carnosine) were significantly larger than the nucleic 
and mitochondrial compartments (P < 0.001). There was no significant difference in carnosine 
contents between the nucleic and mitochondrial fractions (4 ± 3 µM.g protein; 5 ± 2 µM.g protein), 
each fraction containing around 2% of total carnosine contents.  
 
There were significantly different β-alanine contents across subcellular fractions (P = 
0.001; f (3, 24) = 44.18,   
  = 1.0,   
  = 0.9; Fig. 7.5). The largest contents evident in the cytosolic 
fraction (11 ± 5 µM.g protein), with 66% of the total β-alanine evident in this compartment,, 
significantly greater than the contents in the nucleic (0.5 ± 0.2 µM.g protein; P < 0.001), 
mitochondrial (1 ± 1 µM.g protein; P < 0.001) and microsomal (4 ± 2 µM.g protein; P < 0.02) 
compartments. The microsomal fraction β-alanine contents were 25% of the total β-alanine 
contents, significantly greater than the nucleic and mitochondrial fractions (P = 0.007; P = 0.02). 
No significant difference between nucleic and mitochondrial contents, each fraction containing 
only small percentages of total β-alanine contents (3 and 5%). 
 
L-histidine contents were significantly different across subcellular fractions (P < 0.001; f (3, 
24) = 49.91,   
  = 0.9,   
  = 0.9; Fig. 7.5). Significantly greater than the nucleic and mitochondrial 
fractions (both 1 ± 1 µM.g protein; P < 0.001), the contents of L-histidine in the cytosolic fraction 
(12 ± 5 µM.g protein) contained 59% of total L-histidine contents. These were not, however, 
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significantly greater than those in the microsomal fraction (7 ± 3 µM.g protein; P = 0.21). 
Microsomal L-histidine contents were significantly greater than the nucleic and mitochondrial 
fractions (P = 0.002; P = 0.001), containing 32% of the total L-histidine contents. There was no 
significant difference between L-histidine contents in the nucleic and mitochondrial fractions, each 
compartment containing over a small percentage of total L-histidine content (3 and 6%).  
 
 
Fig. 7.5: Content of carnosine, β-alanine and L-histidine expressed (μM.g-1 protein) for the assessed 
subcellular fractions from nine rat skeletal muscle samples; nucleic, mitochondrial, cytosolic and 
microsomal fractions. Data are mean ± 1SD.  
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7.3.3 BIOMOL green phosphate assay 
ATPase activity: There was no significant thapsigargin × Ca
2+
 × carnosine interaction, or 
carnosine × thapsigargin main effect of Pi generation via ATPase activity, all data are represented 
relative to subcellular protein content (Fig. 7.6). There was a significant main interaction between 
thapsigargin and Ca
2+
 (P = 0.002; f (1, 8) = 18.87,   
  = 0.7,   
  = 0.4), Ca2+ increased Pi generation 
with and without the addition of thapsigargin. Thapsigargin significantly decreased ATPase activity, 
with lower Pi generation via ATPase activity (P = 0.002; f (1, 8) = 19.93,   
  = 0.7,   
  = 0.4). Both 
Ca
2+
 (P = 0.004; f (1, 8) = 15.64,   
  = 0.7,   
  = 0.4) and carnosine (P = 0.004; f (1, 8) = 15.39,   
  = 
0.7,   
  = 0.4) significantly increased ATPase activity, as highlighted by increased Pi generation 
(Fig. 7.6).  
  
Fig. 7.6: Inorganic phosphate (nmol) generation under 0 μM or 1 μM calcium conditions, with and 
without the addition of 10 mM carnosine, and 1 μM thapsigargin.  
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Ca
2+
-dependent activity: There was no significant thapsigargin × carnosine interaction on 
Ca
2+
-dependent ATPase activity (P = 0.14; f (1, 8) = 1.29,   
  = 0.1,   
  < 0.1). All data was 
represented relative to subcellular protein content (Fig 7.7). The addition of both 1 μM thapsigargin 
(P = 0.005; f (1, 8) = 14.26,   
  = 0.6,   
  = 0.2) and 10 mM carnosine (P = 0.006; f (1, 8) = 14.01, 
  
  = 0.6,   
  = 0.2) significantly reduced Ca2+-dependent ATPase activity, as noted by significantly 
less Pi generation during these conditions. 
 
SERCA activity: There was no significant Ca
2+
 × carnosine interaction on SERCA activity 
(P = 0.30; f (1, 8) = 1.24,   
  = 0.1,   
  < 0.1). All data was represented relative to subcellular 
protein content (Fig 7.8). The addition of 1 μM Ca2+ significantly increased SERCA activity (P = 
0.006; f (1, 8) = 14.11,   
  = 0.6,   
  = 0.3) as expected, however, there was no influence of 
increasing carnosine concentrations by 10 mM on SERCA activity (P = 0.60; f (1, 8) = 0;.30,   
  < 
0.1,   
  < 0.1).  
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 Fig. 7.7: Inorganic phosphate generation relative to protein content from calcium ATPase 
dependent activity, with and without the addition of 10 mM carnosine, and 1 μM thapsigargin.  
 Fig. 7.8: Inorganic phosphate generation relative to protein content from 
sarcoplasmic/endoplasmic reticulum calcium ATPase activity, with and without the addition of 10 
mM carnosine, and 1 μM calcium.  
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7.4 Discussion 
The main findings from the present investigation are: a) carnosine was evident in all 
assessed subcellular fractions, predominantly located in the cytosolic compartment; b) β-alanine 
and L-histidine were reported in all assessed subcellular fractions, yet at lower content than 
carnosine (both <50 μM); c) the addition of carnosine does not affect in-vitro SERCA pump 
activity, estimated from Pi generation; and d) in the presence of carnosine, overall ATPase activity 
increased, whilst Ca
2+
-dependent ATPase activity declined. The lack of change to in-vitro Ca
2+
-
dependent ATPase and SERCA activity is unexpected, due to the previously reported declines in 
in-vivo skeletal muscle relaxation time following β-alanine supplementation (Studies 1 and 2; 
Chapters 4 and 5). The current investigation is the first to examine the distribution of carnosine, β-
alanine and L-histidine across separate subcellular fractions of the skeletal muscle. Furthermore, 
the present in-vitro analysis is the first to examine the impact of increased carnosine content on 
ATPase activity, specifically SERCA and Ca
2+
-dependent ATPases.  
 
Due to the role of carnosine as an intracellular pH buffer (see review; Sale et al., 2010; 
2013), it had been proposed that carnosine was predominantly evident within the cytosolic 
compartment of the skeletal muscle (Harding & Fallon, 1979; Abe, 2000). These data demonstrated 
that carnosine, and it constituents β-alanine and L-histidine, are indeed predominantly evident 
within the cytosolic fraction of the skeletal muscle. That said, carnosine, β-alanine and L-histidine 
were also shown across all assessed subcellular fractions. For carnosine to be apparent within these 
compartments, the molecules needs to be transported between subcellular compartments, and/or the 
carnosine synthase enzyme is present within these subcellular fractions, although this is yet to be 
determined. The distribution of carnosine across several cellular compartments, does not allow for 
any of the proposed mechanisms, associated with increased skeletal muscle carnosine concentration 
on improved exercise performance (see section 2.3; Page 21), to be contested. It does, however, 
allow for speculation about the potential roles of carnosine within the skeletal muscle. The 
presence of carnosine and its constituents within the microsomal fraction, indicates the possibility 
of these molecules interacting with the SR of the skeletal muscle, and potentially ATPase activity. 
The existence of carnosine within the mitochondrial compartment of the skeletal muscle, implies 
that carnosine may be able to alter the antioxidant abilities of the tissue, as previously proposed 
(Neifakh, 1966). Since carnosine was apparent within both the cytosolic and microsomal fractions 
of the skeletal muscle, there is the potential of carnosine to manipulate Ca
2+
 kinetics, by increasing 
the sensitivity of the contractile properties to Ca
2+
 and/or the amount of Ca
2+
 released from the SR 
lumen to the myofibrils (Lamont & Miller, 1992; Batrukova & Rubtsov, 1997; Dutka & Lamb, 
2004; Dutka et al., 2011; Everaert et al., 2013). The current data is the first to examine the 
distribution of carnosine and its components, across several subcellular fractions of the skeletal 
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muscle, indicating potential direct and indirect interactions with skeletal muscle functions. That 
said, the current data does not mean that the content of carnosine, β-alanine and L-histidine are 
physiologically relevant, and thus important to skeletal muscle function.  
 
Overall ATPase activity, estimated from Pi generation, significantly increased in the 
presence of 10 mM carnosine. Surprisingly, the alterations to overall ATP activity were not 
associated with improved Ca
2+
-dependent ATPases or SERCA activity. It could be hypothesised 
that the improvement in overall ATPase activity in the presence of carnosine, are associated with 
greater levels of Pi production by PMCA and the Golgi apparatus secretory protein ATPases. The 
current in-vitro data are unexpected, based on the reported improvements in skeletal muscle 
relaxation, following β-alanine supplementation (Studies 1 and 2; Chapters 4 and 5). The in-vitro 
data implies that the improvements to in-vivo skeletal muscle HRT (Studies 1 and 2; Chapters 4 
and 5), and might be due to improved PMCA and/or the Golgi apparatus secretory protein ATPases 
activity, rather than improved Ca
2+
 -dependent ATPase activity. As hypothesised, increasing the 
availability of Ca
2+
 significantly improved overall ATPase, Ca
2+
-dependent ATPase and SERCA 
activity. Additionally, thapsigargin, a non-competitive inhibitor of SERCA activity (Thastrup, 
1990) significantly reduced overall ATPase and Ca
2+
-dependant ATPase activity. It is important to 
consider that the current in-vitro research is performance in rat skeletal muscle tissue, and may not 
be representative of the findings in human skeletal muscle. Potential interactions with other 
molecules, such as anserine (in rodent tissue) and taurine may be apparent. Taurine is found in high 
concentrations in the skeletal muscle (Huxtable, 1992) and has been shown to increase skeletal 
muscle twitch force in rat fast-twitch skeletal muscle fibres (Goodman et al., 2000), and influence 
intracellular Ca
2+
 regulation, via increased SR Ca
2+
 uptake and total storage capacity of the SR 
vesicles (Huxtable & Bressler, 1973).  
 
The isolation of the skeletal muscle subcellular fractions was achieved using centrifugation, 
a commonly used preparative method that enables maintenance of the protein intracellular context 
(de Araujo & Huber, 2007). The current centrifugation protocol was based on previously published 
methodologies (Wilkie & Schirmer, 2008; Dimauro et al., 2012; Wilson & Walker, 2015), that said, 
no direct assessment of compartment purity was undertaken. A certain amount of contamination of 
one fraction to other may occur, in which small amounts of proteins from neighbouring 
compartments contaminate the fraction of interest. Cross-contamination of subcellular 
compartments would result in false positives being reported, (i.e., contamination of microsomal 
fraction could potentially affect ATPase activity, and impact interaction of increased carnosine on 
ATPase activity). To provide support for these in-vitro analysis purity conformational analysis is 
required to establish the degree of cross-contamination of the subcellular fractions.  
Chapter 7: The examination and manipulation of carnosine content on rat skeletal muscle tissue  
  
 
140 
7.5 Conclusion 
The current investigation was the first to report carnosine, β-alanine and L-histidine across 
the nucleic, mitochondrial, cytosolic and microsomal subcellular compartments of rat skeletal 
muscle tissue. Although in-vitro SERCA pump activity was unaffected, the presence of 10 mM 
carnosine significantly increased overall ATPase activity. Supplementary examination of PMCA 
and the Golgi apparatus secretory protein ATPases in the presence of increased carnosine content, 
provide greater understanding of the impact of carnosine on skeletal muscle ATPase activity. These 
in-vitro data does not does not allow for any of the proposed mechanisms, associated with 
increased skeletal muscle carnosine concentration on improved exercise performance to be 
contested. The current data does not mean that the content of carnosine, β-alanine and L-histidine 
are physiologically relevant, and thus important to skeletal muscle function. 
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The improvements in exercise performance following β-alanine supplementation, 
specifically those at high-intensities have been associated with the role of skeletal muscle carnosine 
as an intracellular pH buffer (Bate-Smith, 1938; Deutsch & Eggleton, 1938). This does not, 
however, exclude the possibility that carnosine may have other physiological roles. In-vitro 
research indicated that increasing the carnosine content in the skeletal muscle, via β-alanine 
supplementation, could alter the Ca
2+
 properties of the muscle (Lamont & Miller, 1992; Batrukova 
& Rubtsov, 1997; Dutka & Lamb, 2004; Dutka et al., 2011; Everaert et al., 2013). The aim of this 
thesis was to investigate the effect of β-alanine supplementation on voluntary and electrically 
evoked contractile properties of in-vivo human skeletal muscle.  
 
To examine this aim, Study 1 (Chapter 4) investigated the effect of 28-days β-alanine 
supplementation on the intrinsic contractile properties of human skeletal muscle in-vivo, as well as 
on voluntary muscle function in young (18 - 30 y) healthy males. It was hypothesised that 28-days 
of β-alanine supplementation would significantly alter the force-frequency relationship, the in-vivo 
analogue of the force-Ca
2+
 relationship (Balnave & Allen, 1996). These data, however, showed no 
significant influence of β-alanine supplementation on voluntary and electrically evoked force 
responses, or the force-frequency relationship in fresh skeletal muscle. It was suggested that 28-
days of β-alanine supplementation, to increase muscle carnosine content, does not significantly 
influence the Ca
2+
 kinetics in the skeletal muscle, and thus overall muscle performance. There was, 
however, a significant decline in skeletal muscle HRT during electrically evoked octet contractions, 
and resting and potentiated twitches. The improvements in skeletal muscle relaxation speed 
indicated that raising carnosine content may potentially alter Ca
2+
-channel activity by interacting 
with the Ca
2+
-channel itself (Batrukova & Rubstov, 1997), possibly via the existence of saturable 
binding site(s) for carnosine on the Ca
2+
-channel.  
 
Study 1 (Chapter 4) was conducted in fresh skeletal muscle, where there were no 
perturbations of pH, implying that the positive effect on HRT following increased carnosine 
content was due to altered Ca
2+
 kinetics, rather than a pH mediated effect. Swietach et al., (2013) 
suggested that there may also be a mediating effect of pH on the interaction between L-histidine 
containing dipeptides (such as carnosine) and Ca
2+
. H
+
 are also proposed to directly or indirectly 
inhibit sarcoplasmic Ca
2+
 release during skeletal muscle contraction (Laver, Eager, Taoube & 
Lamb, 2000; Laver, O’Neill & Lamb, 2004). Furthermore, carnosine has the potential to serve as a 
cytoplasmic regulator of Ca
2+
 and H
+
 coupling, since it binds to both ions (Baran, 2000). As such, it 
was hypothesised that increased muscle carnosine content, via β-alanine supplementation, would 
have a more pronounced beneficial effect on HRT when the muscle was fatigued. To investigate 
this hypothesis, Study 2 examined the effect of β-alanine supplementation on intrinsic in-vivo 
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isometric knee extensor force production and muscle contractility in both fresh and fatigued human 
skeletal muscle. An IKET at 45% MVIC was implemented to occlude blood flow to the active 
muscle, (de Ruiter et al., 2007), obstructing circulation to the contracting muscle with minimal 
efflux on lactate and H
+
 (Ahlborg et al., 1972). In-line with the findings from Study 1 (Chapter 4), 
there was no significant influence of 28-days of β-alanine supplementation on voluntary and 
electrically evoked force responses, or the force-frequency relationship under fresh conditions. 
There was also no influence of β-alanine supplementation on voluntary and electrically evoked 
force responses, or the force-frequency relationship under fatigued conditions, following 
completion of the IKET at 45% MVIC. β-alanine supplementation, however, significantly altered 
both fresh and fatigued HRT during electrically evoked octet contractions, and resting and 
potentiated twitches. In the current investigation, there was a significant benefit of β-alanine 
supplementation on skeletal muscle HRT relative to placebo, although the declines in fresh muscle 
HRT in the current investigation in resting and potentiated twitches were slightly less than those 
reported previously (Study 1; Chapter 4). These data, however, demonstrate a significantly 
valuable effect of β-alanine supplementation on skeletal muscle during both fresh and fatigued 
conditions, suggesting that raising carnosine content might alter Ca
2+
-channel activity, by 
interacting with the Ca
2+
-channel itself (Batrukova & Rubstov, 1997). The reduction in skeletal 
muscle relaxation time could be beneficial for exercise performance specifically those involving 
short, repeated muscle contractions, where muscle relaxation comprises an important proportion of 
total energy consumption (Bergström & Hultman, 1988). The improvement in skeletal muscle 
function, may also prove beneficial to older adults, were pre-existing declines in muscle function 
are evident due to the ageing process (Lexell, 1995; Stuerenburg & Kunse, 1999; Doherty 2003; 
Tallon et al., 2007; Verdijk et al., 2010). Due to the importance of maintaining lower-extremity 
muscular strength in older adults, thus preserving independence and quality of life, the effect of 28-
days of β-alanine supplementation on neuromuscular performance was investigated in older adults 
(60 – 80 y).  
 
Increased skeletal muscle carnosine content, via 28-days of β-alanine supplementation, in 
older individuals, did not benefit voluntary or electrically evoked skeletal muscle contractions, 
including HRT, in either fresh or fatigued muscle conditions (Study 3; Chapter 7). These data 
directly contrast the declines in skeletal muscle HRT evident in young adults (Studies 1 and 2; 
Chapter 4 and 5). The lack of alteration to skeletal muscle HRT may be attributed to several 
methodological factors, including the supplementation protocol with the older adults ingesting 4.8 
g
.
d
-1
 of β-alanine for 28-days, as opposed to the 6.4 g.d-1 ingested by younger adults. Based on 
previous research (del Favero et al., 2012), it was hypothesised that there was a 40% increase in 
skeletal muscle carnosine content from baseline following the current supplementation protocol. 
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That said, the expected relative 40% increase in carnosine content, may not have been adequate in 
increasing absolute carnosine levels to a content that would have resulted in improved skeletal 
muscle function, specifically HRT. It could also be suggested that older individuals may not be 
able to achieve the same carnosine content as that of younger adults, following the decline in Type 
II muscle fibres during ageing (Lexell et al., 1995). Since these Type II are the predominant store 
of skeletal muscle carnosine content (Dutka et al., 2012; Stellingwerff et al., 2011; Harris et al., 
2012), it could be proposed that that declines in absolute carnosine content in the skeletal muscle is 
irreversible. Futuremore, as part of the current investigation, all older adults completed a medical 
screening questionnaire to ensure they were ‘medically stable’ to participate (Greig et al., 1994). 
This process may have indirectly led to a bias in participant selection, with individuals whom are 
more likely to be physically active accepted, therefore the declines in skeletal muscle function in 
these individuals may not be as extensive as that of the general population, and almost certainly not 
to the declines evident in the frail elderly. It could be hypothesised that supplementing frail 
individuals with a similar amount of β-alanine would potentially improve skeletal muscle function, 
even when not apparent in healthy older adults.  
 
Previous research examining the effect of β-alanine supplementation on skeletal muscle 
carnosine content and physical exercise capacity in older adults (Stout et al., 2008; del Favero et al., 
2012; McCormack et al.,2013; Glenn et al., 2015; 2016), has been conducted with daily doses of β-
alanine between 1.6 and 3.2 g
.
d
-1
. The current investigation supplemented older individuals with a 
daily dose of β-alanine (4.8 g.day-1), currently the largest reported daily dose of β-alanine in this 
older population. Importantly, there were no symptoms of paraesthesia reported by any participant, 
a key consideration for any future research undertaken with this daily dose of β-alanine in this 
population. These data indicated that older adults (60 – 80 y) can complete β-alanine 
supplementation protocols, with a daily dose of 4.8 g
.
d
-1
, without experiencing paraesthesia, 
maintaining the double-blind nature of the investigation. It is important to note that the current 
investigation is limited by the lack of direct measurements of skeletal muscle carnosine content. 
 
Presently there is a limited number of investigations undertaking assessment of voluntary 
and electrically evoked contractions in an older population (60 – 80 y), the current investigation 
found all participants to be very compliant with the study protocol, and completed all required 
experimental tasks, with no participants withdrawing from the investigation. On reflection of the 
research process it should be noted, that the recruitment process for older adults, specifically those 
defined as medically stable (Greig et al., 1994), took a considerable amount of time, this should be 
factored into future research projects. Additionally, recruitment should be directed to more face-to-
face contact, and word of mouth, with less recruitment being successfully achieved via internet 
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resources.  That said, the participants within the current investigation were all keen to be involved 
and understood the importance of completing research within this population, and all were willing 
to complete additional research investigations, albeit not specifically those involving electrical 
stimulation to the current intensity and duration. 
 
Both younger and older individuals during studies 2 and 3 (Chapters 5 and 6) completed an 
IKET fatigue protocol to examine the effect of 28-days β-alanine supplementation on intrinsic in-
vivo isometric knee extensor force production and muscle contractility in fatigued skeletal muscle. 
Participants were instructed to complete the IKET at 45% MVIC, an intensity anticipated to 
occlude blood flow to the active muscle becomes through increased intramuscular pressure (de 
Ruitter et al., 2007). That said, the IKET hold times reported in older adults were ~70 s (~53%) 
greater than both those reported in younger adults (Study 2; Chapter 5) and those predicted by the 
Rohmert equation (Rohmert, 1960). Using the Rohmert equation, it was estimated that the older 
adults completed the IKET at a much lower intensity of 30% MVIF, rather than 45% MVIF, as 
instructed. Completion of the IKET at 30% MVIF would not result in the same physiological 
responses as those evident during a 45% MVIF hold. It can therefore, be hypothesised that the 
current IKET was not generating the same levels of muscle fatigue in these older adults, as evident 
in the younger adults. Due to the lack of change in skeletal muscle HRT in this older population, it 
was important to fully examine the declines in skeletal muscle HRT in young adults following 28-
days β-alanine supplementation.  
 
Based on the current data in young adults, reporting a reduction in skeletal muscle HRT, 
following 28-days of β-alanine supplementation (Studies 1 and 2), it was proposed that there was a 
direct or indirect mechanism associated with activity of the SERCA pump (Gafni & Yuh, 1989), 
the proposed rate-limiting step of muscle relaxation (Gillis, 1985; Dux, 1993). Acting on Ca
2+
 
kinetic proteins directly or via other molecules provides a mechanism by which Ca
2+
 signalling can 
be inhibited or excited (Swietach et al., 2013). Study 4 (Chapter 7) investigated the impact of 
increased carnosine availability on in-vitro skeletal muscle ATPase activity, through quantification 
of Pi generation. In-vitro analysis of ATPase activity revealed that SERCA activity, the pump 
associated with skeletal muscle relaxation speed, was unaffected by increased carnosine content, 
although there was a significant increase in overall ATPase activity (Study 4; Chapter 7). The 
current in-vitro data are unexpected, based on the previously reported improvements in skeletal 
muscle relaxation (Studies 1 and 2; Chapters 4 and 5). The enhanced ATPase activity evident 
following the addition of carnosine could be due to improved PMCA and/or the Golgi apparatus 
secretory protein ATPases activity, rather than altered Ca
2+
-dependent ATPases. Due to the novelty 
of these data, it is also important to consider other mechanisms that may explain the beneficial 
Chapter 8: General discussion 
  
 
146 
effect of β-alanine supplementation on skeletal muscle HRT in young adults (Studies 1 and 2; 
Chapter 4 and 5), including the potential of indirect mechanism of carnosine, such as modification 
of the protein interactions with the Ca
2+
-channels and/or binding with the proteins themselves 
(Berchtold, Brinkmeier & Muntener, 2000). It is important to also consider that these in-vitro data 
was performed in rat skeletal muscle tissue, and may not be representative of the findings in human 
skeletal muscle. 
 
There is a large body of evidence documenting skeletal muscle carnosine content in both 
humans and rats (Steurenburg & Kunze, 1999; Harris et al., 2006; Hill et al., 2007; Derave et al., 
2007; Kendrick et al.,2008; 2009; Baguet et al., 2010; Stellingwerff et al.,2011; del Favero et al., 
2012; Bex et al., 2014; Chung et al., 2014; Gross et al., 2014; Stegen et al., 2014; Danaher et al., 
2014). That said, these data were conducted on whole muscle fibres, using the muscle biopsy, or 
via 
1
H-MRS techniques. Examination of specific subcellular fractions was required to provide 
support for the roles associated with increased carnosine content, on skeletal muscle performance. 
It was hypothesised that if carnosine and/or its constituents were not present in the subcellular 
fraction, it would be unlikely that these molecules would exhibit alterations to cellular functions of 
the compartment. To investigate if carnosine, β-alanine and L-histidine, had the ability to directly 
influence the SR of the skeletal muscle, as proposed in Study 2 (Chapter 5), the distribution of 
carnosine and its constituents were examined in several subcellular fractions (Study 4; Chapter 7). 
Carnosine, β-alanine and L-histidine were ubiquitously distributed across the nucleic, 
mitochondrial, cytosolic and microsomal fractions of rat skeletal muscle, albeit in varying contents. 
β-alanine and L-histidine contents were significantly lower than those of carnosine, across all 
assessed subcellular fractions. The distribution of carnosine across several cellular compartments, 
does not allow for any of the proposed mechanisms, associated with increased skeletal muscle 
carnosine content on improved exercise performance, to be contested. It does, however, allow for 
speculation about the potential roles of carnosine within the skeletal muscle. Since carnosine was 
apparent within both the cytosolic and microsomal subcellular fractions, the current data implies 
that there is the potential of carnosine to manipulate the Ca
2+
 properties of the skeletal muscle, 
although the exact mechanism remains unclear. These data are the first to report the distribution of 
carnosine, β-alanine and L-histidine across different subcellular fractions of the skeletal muscle. 
The current data does not however, mean that the content of carnosine, β-alanine and L-histidine 
are physiological relevant, and therefore important to skeletal muscle function.  
 
The overall aim of this thesis was to investigate the effect of β-alanine supplementation on 
voluntary and electrically evoked contractile properties of in-vivo human skeletal muscle. In both 
young and older adults, 28-days of β-alanine supplementation did not significantly influence 
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voluntary and evoked force responses, or the force-frequency relationship, in either fresh or 
fatigued skeletal muscle (Studies 1-3, Chapter 4-7). In young adults, there were significant 
improvements in skeletal muscle HRT following β-alanine supplementation, during electrically 
evoked octet contractions, resting and potentiated twitches (Studies 1 and 2; Chapters 4 and 5). 
These alterations to skeletal muscle HRT following β-alanine supplementation were not evident in 
healthy older adults. Carnosine, β-alanine and L-histidine are ubiquitously distributed across the 
nucleic, mitochondrial, cytosolic and microsomal fractions of rat skeletal muscle. Nonetheless, 
carnosine was the most prominent molecule, with the largest content shown in the cytosolic 
compartment of the skeletal muscle. These data allow for speculation about the potential roles of 
carnosine within the skeletal muscle. The exact mechanism associated with the in-vivo decline in 
skeletal muscle HRT remains unclear, yet raising the availability of carnosine in-vitro, does 
improve overall ATPase activity, although not Ca
2+
-dependent or SERCA activity. 
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8.1 Overview of the key findings 
1. In young adults, 28-days of β-alanine supplementation did not significantly influence 
voluntary and evoked force responses, or the force-frequency relationship, the in-vivo 
analogue of the force-Ca
2+
 relationship, in either fresh (Studies 1 and 2; Chapters 4 and 5) or 
fatigued (Study 2; Chapter 5) skeletal muscle.  
2. There was, a significant decline in skeletal muscle HRT in young adults, during electrically 
evoked octet contractions, and resting and potentiated twitches (Studies 1 and 2; Chapters 4 
and 5).  
3. Older adults demonstrated no beneficial effect of 28-days β-alanine supplementation on 
voluntary or electrically evoked muscle contractions (Study 3; Chapter 6).  
4. Based on the in-vivo research, it was proposed that there was a direct or indirect mechanism 
associated with SERCA activity, the proposed rate-limiting step of skeletal muscle relaxation.  
5. In-vitro analysis of ATPase activity demonstrated no significant alteration in SERCA activity 
following increased carnosine content, although there was a significant increase in overall 
ATPase activity (Study 4; Chapter 7).  
6. Carnosine, β-alanine and L-histidine are ubiquitously spread across the nucleic, mitochondrial, 
cytosolic and microsomal subcellular fractions of rat skeletal muscle, albeit in varying 
contents. In-vitro findings allowed for speculation about the potential roles of carnosine within 
the skeletal muscle. 
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8.2 Future research 
Due to the highlighted limitations of the present IKET in older adults (Study 3; Chapter 6), 
future investigation should focus on the development of an isometric fatigue protocol where 
occlusion of blood flow to the active muscle is evident. It should be considered that the Rohmert 
equation (Rohmert, 1960) may not be applicable to predict IKET performance times in older 
individuals, due to the significant decline in skeletal muscle cross-sectional area, muscle fibre 
quantity and Type II fibres, evident during the ageing process.  
 
Older individuals within the current thesis (Study 3; Chapter 6), ingested β-alanine 
supplementation at a daily dose of 4.8 g
.
d
-1
, without experiencing paraesthesia. This is the first 
investigation to supplement older individuals with this dose of β-alanine. That said, it should be 
noted that there was no direct assessment of skeletal muscle carnosine content. To determine if 
older individuals experience the same dose-response relationship of β-alanine supplementation on 
skeletal muscle carnosine content, further research is required. This additional research may allow 
for the ingestion of larger daily doses of β-alanine in this population, thereby reducing the duration 
of supplementation protocols to significantly increase skeletal muscle carnosine content.  
 
The isolation of the skeletal muscle subcellular fractions in Study 4 (Chapter 7) was 
achieved using centrifugation; during this process tiny amounts of proteins from neighbouring 
compartments may contaminate the fraction of interest. To provide support for these in-vitro data, 
examination of the cross-contamination between subcellular compartments is required. Western 
blot analysis is a widely implemented and important technique used in cell and molecular biology, 
allowing the identification of specific proteins from a complex mixture of proteins extracted from 
cells (Mahmood & Yang, 2012). 
 
The ubiquitous distribution of carnosine, β-alanine and L-histidine across the nucleic, 
mitochondrial, cytosolic, and microsomal fractions of rat skeletal muscle, albeit in different content, 
provides essential information regarding the potential roles of carnosine within the skeletal muscle. 
That said, to understand the impact of increased carnosine content on human muscle performance, 
these in-vitro analysis should be continued in human skeletal muscle fibres. Additionally, due to 
the potential influencing factors of other amino acids, such as anserine (in rodents) and taurine, 
examination of these molecule contents within the subcellular fractions of the skeletal muscle is 
required  
 
In-vitro analysis demonstrated that carnosine, β-alanine and L-histidine are evident in all 
assessed subcellular fractions of rat skeletal muscle cells. It does, however, remain uncertain how/if 
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these molecules are transported throughout each subcellular fraction, and whether carnosine is 
transported across the subcellular fractions as a whole molecule, or synthesised within the fraction 
from β-alanine and L-histidine. Analysis of the molecular transporters, Tau-t and PEPT2, and the 
enzyme that catalyses the formation of carnosine, carnosine synthase, within each subcellular 
fraction would enable the examination of these mechanisms. These data would provide greater 
understanding of the how the carnosine molecule is transported and synthesised within the skeletal 
muscle. Additionally, these analyses would provide knowledge on the mechanisms associated with 
β-alanine and L-histidine, examining the potentially differing functions of these constituents in 
separate compartments.  
 
Ca
2+
 pumps together with Ca
2+
 release channels are present within the skeletal muscle and 
non-muscle cells, forming a ubiquitous Ca
2+
 regulatory system (McMullen et al., 1997). The 
addition of carnosine has been shown to interact with ATPase activity in-vitro (Study 4; Chapter 7). 
Carnosine is reported in excitable tissues, including the cardiac muscle and neuronal tissue 
(Everaert et al., 2013), it remains unclear if the current alterations to in-vitro ATPase activity 
evident with increased carnosine concentration would be apparent in other non-muscle cells. The 
ATPase, cardiac SERCA, regulates intracellular Ca
2+
 movement, fulfilling a crucial role in 
initiating cardiac contraction and relaxation, as well as facilitating the storage and distribution of 
Ca
2+
 in the SR (Frank et al., 2003). The current in-vitro data indicated the possibility of altered 
skeletal muscle ATPase activity with the addition of carnosine (Study 4; Chapter 7), extension of 
these analyses is required to examine if similar effects are shown in cardiac muscle. These data 
would be of great clinical significance, since abnormalities of the cardiac muscle contraction and 
relaxation coupling, specifically Ca
2+
 cycling, has been reported in the failing heart (Hasenfuss, 
1998; Bers, 2001; 2011). That said, carnosine may not have the same functions in different tissues 
(Boldyrev et al., 2013).  
 
Brody’s disease is a very rare inherited human muscle disorder, impacting the SR Ca2+ 
uptake (MacLennan, 2000). The main clinical feature of Brody’s disease experienced by 
individuals is impairment of muscle relaxation and muscle stiffness (Brody, 1969; Karpati et al., 
1986; Danon et al., 1988). Individuals experiencing Brody’s disease are reported to have Ca2+-
ATPase activity of around 50% compared to control individuals, examined in both whole muscle 
homogenates prepared from biopsies and muscle cell cultures (Benders et al., 1994). These 
individuals are also showed to have extremely low Ca
2+
 transport activity at around five percent 
when compared to controls (Menke & Jockusch, 1995). The in-vivo data reported within the current 
thesis indicated that increased carnosine availability, via β-alanine supplementation, improved 
young adults skeletal muscle HRT, which could be vital for individuals suffering with Brody’s 
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disease. Examining the impact of increased skeletal muscle carnosine content, via β-alanine 
supplementation, in individuals suffering from Brody’s disease, where impairment to skeletal 
muscle relaxation is evident, may provide a number of clinically relevant discoveries. 
 
It was hypothesised following in-vivo analysis, that increased carnosine content would 
improve skeletal muscle SERCA activity, the pump associated with skeletal muscle relaxation 
speed (Study 2; Chapter 5). Study 4 (Chapter 7) showed no improvement in SERCA activity 
following increase carnosine content, yet there was improved overall ATPase activity, as 
demonstrated with increase Pi generation. It was suggested that these improvements to overall 
ATPase activity were associated with increased Pi generation by PMCA and golgi apparatus 
secretory protein ATPase. Inhibition of these ATPases can been achieved using thapsigargin, 
although the content required to do so is 10 to 300 times greater than those needed to inhibit 
SERCA activity (Treiman et al., 1998; Harper et al., 2005). Isolation of SERCA, PMCA and the 
golgi apparatus secretory protein ATPases is required to fully examine the influence of carnosine 
on the activity of each ATPase. This research would provide a clearer understanding of the direct 
impact on ATPase activity in-vitro that said, any alterations of in-vitro ATPase activity may not 
result in alterations to in-vivo muscle function.  
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The research reported within the current appendix provides supporting experimental background 
and development for study 4 (Chapter 7).  
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A1.1 Introduction 
There are several protocols documented within study 4 (Chapter 7) of the current thesis, 
that needed additional support and methodological development above that reported within the 
specific chapter. The current appendix will document the development of these methodologies.  
 
A1.2 In-vitro skeletal muscle tissue preparation 
A1.2.1 Background 
The cell lysate was disrupted to disaggregate the cells and breaks them open, whilst 
applying minimal damage to the internal components of the cell (Clayton & Shadel, 2015; Pryor, 
2015). The method of cell disruption (homogenisation), blending, is ideal for the disruption in 
mammalian and plant tissue (Wilson & Walker, 2015), undertaken with the samples placed in an 
ice-cold isotonic buffer (Wilkie & Schirmer, 2008). Blending protocols are conducted based on 
duration of blending, or the number of times the blender is placed in the samples (Wilkie & 
Schirmer, 2008; Wrzosek, 2014). Following homogenisation of mammalian tissue excess material, 
such as, incompletely homogenised connective and/or vascular tissue and small fragments of non-
homogenised tissue (Wilson & Walker, 2015) need to be filtered. The filtering of the sample can be 
achieved via cheesecloth, muslin, surgical gauze or a single layer of nylon mesh (75 μM pore size) 
(Graham & Rickwood, 2002), although the use of cheesecloth is the easiest way to complete this 
process (Wilson & Walker, 2015; Fig. 7.1). The homogenisation protocol is completed with all 
samples on ice, whilst the experimenters wear protective gloves to reduce heat transfer to the 
samples (Graham & Rickwood, 2002). The remaining solution is the lysate or homogenate. 
 
The process of subcellular fractionation is flexible, adjustable (both in cell and tissues), and 
allows the analysis of proteins in their physiologic/intracellular context, therefore it is the most 
commonly used preparative/enrichment method (de Araujo & Huber, 2007). Cellular fractionation 
involves the development of pure fractions of cell components based on the density and size 
differences (Michelsen & Hagen, 2009). Fractionation of a sample can be achieved via biological 
centrifugation, a method which uses centrifugal forces to separate and purify mixtures of biological 
particles in a liquid medium (Wilson & Walker, 2015). Centrifugation occurs by the rapid rotation 
of a rotor which produces large centrifugal forces, causing the particles in the sample to sediment. 
In general, the largest units experience the largest centrifugal force and move the most rapidly in 
the sample. Repeated centrifugation at progressively higher speeds and longer centrifugation 
periods divide the muscle homogenate into distinct fractions (Wilson & Walker, 2015; Fig. 7.2). At 
relatively low speeds, large components such as the nucleic sediment to form a pellet at the bottom 
of the centrifuge tube. At slightly higher speed, a mitochondrial pellet is deposited, with even 
higher speeds and longer periods of centrifugation, isolating the small closed vesicles and then the 
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ribosomes. Fixed-angle rotors are an ideal tool for pelleting during the differential separation of 
biological particles where sedimentation rates differ significantly (Wilson & Walker, 2015). 
Protocols vary with typical centrifugation steps of 10 min for 1000 g to pellet the nucleic and 
cellular debris, 10 min for 10,000g to pellet the contractile apparatus, 20 min at 20,000 g to pellet a 
fraction enriched in mitochondria, and 1 h at 100000 g to separate the microsomal and cytosolic 
fractions (Wilson & Walker, 2015; Fig. 7.2).  
 
A1.2.2 Methodological development 
The rat skeletal muscle tissue was initially separated into nucleic, mitochondrial, cytosolic 
and microsomal fractions, using the following centrifugation protocol;  
1) The homogenised filtrate was centrifuged at 1000 g for 10 min at 4oC (Harrier 18/80 
Refrigerated benchtop centrifuge, MSE Ltd, London, UK). The resulting pellet containing the 
nucleic fraction was resuspended in 2 mL storage medium (25 mM potassium chloride, 20 
mM Hepes pH 7.4, 250 mM sucrose, 5 mM magnesium chloride) and frozen at -80
o
C. 
2) The supernatant was ultra-centrifuged at 20,000 g for 20 min at 4oC in a fixed angle (Type 70 
Ti) Beckman rotor (Beckman Coulter, Fullerton, CA, USA). The resulting pellet containing 
the mitochondrial fraction was suspended in 2 mL storage medium and frozen at -80
o
C. 
3) The remaining supernatant was ultra-centrifuged at 100,000 g for 40 min at 4 oC in a fixed 
angle (Type 70 Ti) Beckman rotor (Beckman Coulter, Fullerton, CA, USA). The supernatant 
containing the cytosolic fraction was carefully decanted from the pellet and frozen at -80
o
C. 
The resulting pellet containing the microsomal fraction was suspended in 2 mL storage 
medium and frozen at -80
o
C. 
 
Based on further examination of the current literature (Dimauro et al., 2012), following 
thawing of the nucleic and mitochondrial samples, several additional centrifugation protocols were 
undertaken (Fig. 7.3). These additional protocols were undertaken to increase the purity of these 
subcellular fractions. The nucleic pellet was defrosted and resuspended in 1 mL of storage medium, 
the samples were vortexed for 15 s and spun at 500 g for 15 min (Dimauro et al., 2012). The 
resulting pellet containing the nucleic fraction was re-suspended in 2 mL of storage medium, 
vortexed for 15 s and spun at 1,000 g for 15 min. The final pellet was removed and stored in 2 mL 
of storage medium.  
 
The mitochondrial pellet was defrosted and resuspended in 1 mL of storage medium, 
vortexed for 15 s and spun at 11,000 g for 10 min (Dimauro et al., 2012). The resulting pellet was 
resuspended in 2 mL of storage medium. The protein concentrations of these samples following the 
additional centrifugation processes were then determined (see section A1.3.2.2).  
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A1.3 Protein assay 
A1.3.1 Background 
The protein content within each subcellular fraction was quantified by the BCA 
colorimetric assay, involving the reduction of copper oxide to copper by proteins in an alkaline 
medium. Using defined time and temperature, examination of the intense purple colour produced 
through this process can allow examination of protein concentrations. Absorbance of the sample is 
directly proportional to the protein concentration, with the protein concentration calculated based 
on a reference curve obtained from a standard protein solution.  
 
A1.3.2 Methodological development 
A1.3.2.1 Standard vs. enhanced assay protocols 
The current analysis was undertaken to determine the standard protein concentration 
protocol required for the rat skeletal muscle subcellular fractions. The BCA has two sets of 
protocols; standard, with concentrations from 20 μg.mL-1 to 2 mg.mL-1, or enhanced, with 
concentrations from 500 μg.mL-1 to 2 mg.mL-1. A fresh set of protein concentrations for both the 
standard and enhanced protocols were formed, and diluted in the stock solution in the storage 
medium (25 mM potassium chloride, 20 mM Hepes pH 7.4, 250 mM sucrose, 5 mM magnesium 
chloride). The BCA working reagent was prepared for both protocols (standard and enhanced) 
through the addition of 1 part of reagent B to 50 parts of reagent A, the volume of working reagent 
was calculated based on the number of standards (8 standard points essential on a microplate assay, 
including triplicates) and samples required. The working reagent was then allowed to reach room 
temperature. Once prepared, 25 μL of each standard, control and sample were pipetted into 
microplate wells in triplicate where 200 μL of BCA assay working reagent was added. The 
microplate was then placed incubator for 30 min at either 37
o
C (standard protocol) or 60
o
C 
(enhanced protocol). Following incubation, the microplate was cooled to room temperature and 
optical density was read at 562 nM, against the average blank standard sample (water + BCA assay 
reagent).  
 
The values for each BCA standard were plotted against the protein concentration (μg.mL-1) 
of the sample. A curvilinear regression analysis was undertaken to produce the standard curve, in 
this case a 2
nd
 order polynomial equation. The protein concentration of the assessed sample was 
then plotted as the dependant variable (y-axis) and the absorbance as the independent variable (X-
axis), values were then placed into the equation y = ax
2 
+ bx + c, where solving y determines the 
protein concentration of the sample. The protein concentrations were then adjusted based on 
dilution value and converted to mg
.
mL
-1
.  
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The current experiment compared the standard and enhanced BCA protein protocols. 
Based on the current observations, the standard protocol is sufficient in examining the protein 
contents in the subcellular fractions produced in the current thesis. All additional optimisation will 
be conducted with a standard protein curve. 
 
 
Fig. A1.1: Image of the BCA assay in a microplate, with no dilution of the sample.  
 
A1.3.2.2 Sample dilution 
No dilution: A total of four rat skeletal muscle samples were analysed, with the protein 
concentrations of the nucleic, mitochondrial, cytosolic and microsomal compartments examined, 
for each skeletal muscle sample. Each sample was recorded in triplicate, with the mean reported. 
During the current experiment, the protein concentrations for the samples were much greater than 
the protein standards, above the maximum standard (2 mg
.
mL
-1
). These high protein concentrations 
were apparent visually by the very dark purple colour in the microplate wells (Fig. A1.1). Based on 
the current analysis, dilution of the subcellular fractions is required to examine protein 
concentrations within the standard range of the BCA assay.  
 
25% dilution: Subcellular compartments were diluted to a 25% dilution, one part sample, 
three parts storage media. A total of four rat skeletal muscle samples were analysed, with the 
protein concentrations of the nucleic, mitochondrial, cytosolic and microsomal compartments 
examined, for each skeletal muscle sample. Each sample was recorded in triplicate, with the mean 
reported. The protein concentration within the assessed samples remained above that of the highest 
standard (2 mg
.
mL
-1
), when examining several samples, specifically the nucleic and mitochondrial 
fractions. Several samples were within the standards range, that said, the protein concentrations 
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remained nearer the upper end of the standard range, which was not ideal. Based on the current 
data, a greater dilution of the samples is required to examine the protein concentration within the 
standard range of the BCA assay.  
 
10% dilution: Subcellular compartments were diluted to a 10% dilution, one part sample, 
and nine parts storage media. A total of four rat skeletal muscle samples were analysed, with the 
protein concentrations of the nucleic, mitochondrial, cytosolic and microsomal compartments 
examined, for each skeletal muscle sample. Each sample was recorded in triplicate, with the mean 
reported. The protein concentrations of the samples at a 10% dilution remained within the range of 
the BCA assay standards (< 2 mg
.
mL
-1
; Fig. A1.2). Based on the current analysis, all samples will 
be diluted to a 10% dilution prior to the completion of the BCA assay, to examine protein 
concentrations.  
Fig. A1.2: Protein concentration (mg
.
mL
-1
) for each assessed subcellular fraction of four skeletal 
muscle rat tissue samples. Data are mean ± 1SD.  
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10% dilution following additional centrifugation: Following the completion of additional 
centrifugation processes, as reported in Section A1.2, the protein concentrations of the subcellular 
fractions was re-examined. Samples were assessed at a 10% dilution; one part sample, nine parts 
storage media. A total of four rat skeletal muscle samples were analysed, with the protein 
concentrations of the nucleic, mitochondrial, cytosolic and microsomal compartments examined, 
for each skeletal muscle sample. Each sample was recorded in triplicate, with the mean reported. 
The protein concentrations of the samples at a 10% dilution remained within the range of the BCA 
assay standards (Fig. A1.3) 
 
 
Fig. A1.3: Protein concentration (mg
.
mL
-1
) for each assessed subcellular fraction of four skeletal 
muscle rat tissue samples following additional centrifugation of the nucleic and mitochondrial 
fractions. Data are mean ± 1SD. 
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A1.4 Fluorescence spectroscopy  
A1.4.1 Background 
Fluorescence spectroscopy is the analysis of samples via the excitation of the electrons in 
the molecules via a beam of light (photon). At room temperature, most molecules occupy the 
lowest vibrational level of the ground electronic state, on absorption of light they are elevated to 
produce excited states. When the module returns to its ground state energy is released, thus 
emission of a photon occurs carrying energy, this emission is detectable. The optical density of a 
sample can be determined using the Lambert-Beer law, in which the absorption of a material is 
defined as the logarithmic relative decrease if intensity before and after the sample. If a solution in 
a cuvette has OD = 1, this states that only 10% of the light pass (i.e. 90% are absorbed). If the 
concentration of a solution is unknown, it can be obtained by plotting the absorption against a 
series of known concentrations or a reference sample. Fluorescence spectroscopy is undertaken by 
using either cuvettes or microplates, although the optics used between each technique are different 
(Lakowicz, 2006). Additionally, although microplates are typically used to perform fluorescence 
spectroscopy, cuvettes are advantageous as they allow for right-angle observations (Lakowicz, 
2006). The microplate technique involves a Xenon flash lamp as a light source for the samples, 
with the excitation wavelength selected using an excitation monochromator. The fluorescence from 
the sample is then directed towards the detector optics. Normally, the microplate is moved to 
position each well in the observation path.  
 
A1.4.2 Methodological development 
A1.4.2.1 Carnosine absorbance spectrum  
To characterise the absorbance properties of the carnosine molecule in different pH levels 
(6.1 and 7.0), two 50 mM carnosine solutions were prepared in a phosphate buffer. Full-spectrum 
absorbance measurements were performed with filter settings of emission between 220 – 1000 nM 
at a resolution of 1 nM on a FLUOstar® Omega Microplate Reader (BMG Labtech, Ortenberg, 
Germany). All measurements were recorded at room temperature. The scanning of the samples 
gave absorption spectrum values of 3.20 nM (pH 6.1) and 3.00 nM (pH 7.0). The current analysis 
suggested that there was no clear maximum absorption for carnosine at a 50 mM concentration (Fig. 
A1.4).  
 
A1.4.2.2 Carnosine fluorescence emission 
The fluorescence emission spectra were recorded with a DeltaRAM X High Speed Random 
Access Monochromator (Photon Technology International, New Jersey, USA) equipped with a 75 
W xenon arc lamp and a photomultiplier tube R955 detection system (Hamamatsu, Japan) using a 
motorised slit band-passes for excitation and the emission monochromators, increment of 1 nM for 
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the emission monochromator, integration times of 0.1 s. The emission spectra were corrected for 
the lamp, the monochromators and the detector response. Fluorescence emission spectra at 
excitation wavelengths of 300, 350, 400, 450, 500, 550 and 600 nM were measures in a 1 cm 
quartz cuvette. The emission wavelengths ranged from 340 to 700 nM, with a total of seven trials 
(340 – 700, 390 – 700, 440 – 700, 490 – 700, 540 – 700, 590 – 700, 640 – 700 nM) for each 50 
mM carnosine solution. The fluorescence emission spectra were recorded for the phosphate buffer 
solution without any carnosine content at excitation wavelength of 600 nM and excitation 
wavelengths of 640 – 700 nM.  
 
Florescence emission spectra was produced for the phosphate buffer solution with no 
difference in emission between the 50 mM carnosine solutions and the phosphate buffer solution at 
excitation wavelength of 600 nM and excitation wavelengths of 640 – 700 nM (Fig. A1.5). 
Fluorescence emission spectra of 50 mM carnosine at pH 6.1 and pH 7.0 are shown in Fig. A1.6A 
and A1.6B. There was no spike in fluorescence emission indicating that a 50 mM carnosine 
concentration at either a pH of 6.1 or 7.0 did not emit light. The current experimental data 
suggested that the carnosine molecule on its own displays no fluorescence properties.  
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Fig. A1.4: Full-spectrum absorbance measurements performed on a 50 mM carnosine solution 
at a pH of 6.1 (red line) and 7.0 (blue line) in a phosphate buffer. OD: Optical density 
Fig. A1.4: Fluorescence emission spectra of phosphate buffer solution and 50 mM carnosine 
solutions at pH 6.1 and pH 7.0. Excitation wavelength of 600 nM and excitation wavelengths of 
640 – 700 nM. OD: Optical density 
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Fig. A1.5: Fluorescence emission spectra of 50 mM carnosine solutions at pH 6.1 (A) and pH 
7.0 (B). OD: Optical density 
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A1.4.2.3 Carnosine and calcium binding 
The fluorescence emission spectra were recorded with a FLUOstar® Omega Microplate 
Reader (BMG Labtech, Ortenberg, Germany). Fluorescence emission wavelength was 485 nM and 
excitation was 520 nM. The gain or implication of the FLUO Omega microplate reader was 
adjusted to obtain observable signals, it was found that 1318 gain was too high, whilst 400 gain 
was too low to detect a clear emission. All samples were sampled at a value of 700 gain. To all 
samples 2.5μL of a Ca2+ sensitive probe (FLUO 4 penta-potassium salt; Thermofisher, UK) was 
added.  
 
Low calcium buffer: A 2 mM carnosine concentration was added to a low Ca
2+
 cytosolic 
buffer (140 mM Potassium chloride, 10 mM Sodium chloride, 1 mM Magnesium chloride, 20 mM 
Hepes, with an overall pH of 7.2), samples containing carnosine had a decline in fluorescence 
emission properties, indicating a potential binding to Ca
2+
. An additional test was run with 0.5 mM 
and 10 mM carnosine concentrations included. Fluorescence emission was the greater in the 0.5 
mM carnosine concentration sample compared to the 2 mM and 10 mM samples. Yet, emission in 
the 2 mM carnosine sample displayed the lowest emission properties, representing the greatest 
binding of Ca
2+
 to carnosine at this concentration, greater than that reported in the 10 mM 
concentration. It should be noted that the current samples were conducted in a cytosolic like buffer, 
although Ca
2+
 was low within this buffer, there was Ca
2+
 still present. The experiment was halted 
here.  
 
Low calcium Ca
2+
 buffer with no sodium chloride or magnesium chloride: To further 
explore the relationship between carnosine and Ca
2+
, 100 mM Ca
2+
 was added to samples 
containing an intracellular-like buffer (140 mM Potassium chloride, 20 mM Hepes, with an overall 
pH of 7.2) with varying concentrations of EGTA and carnosine. EGTA is a chelating agent which 
has a lower affinity for magnesium, making it more selective for Ca
2+
, also known as a Ca
2+
 
collator, and thus it was predicted that fluorescence would decline with increasing EGTA levels.  
 
Pilot of calcium chelation: Data reported in Table A1.1 displays the fluorescence of 
assessed samples containing 200, 140 or 100 mM EGTA with the addition of 0, 2 or 10 mM 
carnosine. All samples were assessed in triplicate, with mean and SD reported. Predicted free Ca
2+
 
concentrations are reported based on the concentration of EGTA within the sample. The current 
data displayed a decline in fluorescence with increasing EGTA concentration from 100 mM to 200 
mM (Table A1.1), supporting the role of EGTA as a Ca
2+
 chelator. Based on the current data, there 
is the potential influencing factor of carnosine on Ca
2+
 chelation, as highlighted by reduction in 
fluorescence when carnosine was added to the 200 mM EGTA condition. This reduction in 
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fluorescence implies that alongside the chelation of Ca
2+
 by EGTA, the carnosine molecule is also 
chelating any free Ca
2+
 within the solution. That said, both the 100 and 140 mM EGTA conditions 
displayed no decline in fluorescence with the addition of the carnosine solution. It is likely that 
during these conditions there was too much Ca
2+
 within the system; therefore all the Ca
2+
 binding 
sites were saturated.  
 
Table A1.1: The fluorescence (OD em 385, ex 520) of samples containing 200, 140 or 100 mM EGTA 
with 0, 2 or 10 mM carnosine solution.  
  Predicted Free 
Ca
2+
 (μM) 
0 mM 
Carnosine 
2 mM 
Carnosine 
10 mM 
Carnosine 
200 mM EGTA 0.38 6616 ± 117 6424 ± 119 3852 ± 1086 
140 mM EGTA 0.93 10702 ± 1254 11239 ± 633 11522 ± 455 
100 mM EGTA 6.03 12378 ± 297 13419 ± 255 13769 ± 863 
Data are mean ± 1SD. OD: Optical density  
 
Ca
2+
 chelation: Based on the pilot data we could examine the effect of carnosine on Ca
2+
 
chelation at a predicted free Ca
2+
 level of 0.38 μM, where the addition of carnosine indicated a 
decline in fluorescence, without saturating the Ca
2+
 binding sites. To further examine these data, an 
additional 20 samples were analysed at an EGTA concentration of 200 mM, with the addition of 
either 0 mM (n=10) or 10 mM (n=10) carnosine. The addition of carnosine reduced the 
fluorescence of the assessed samples from 2714 ± 442 to 1607 ± 321 OD em 385, ex 520(P < 0.001). 
These data support the previous notion that the addition of carnosine to the sample, provides a 
greater collation of the available Ca
2+
, reducing the fluorescence, and highlighting the potential of 
carnosine to act as a Ca
2+
 buffer. It should be noted that the current experiment was conducted at a 
pH of ~7. The pH of the solutions was then adjusted to 7.4, where the analysis was repeated with a 
further 22 samples assessed at an EGTA concentration of 200 mM with the addition of either 0 mM 
(n=12) or 10 mM (n=12) carnosine. In-line with previous experimental data, carnosine significantly 
reduced the fluorescence of the samples, from 2181 ± 150 to 1639 ± 231 OD em 385, ex 520 (P < 0.001).  
 
The current analysis supports the role of EGTA as a Ca
2+
 collator, reducing the 
fluorescence of samples with increasing levels of EGTA. Interestingly, the current research 
proposes that the carnosine molecule is also able to act as a Ca
2+
 collator, decreasing fluorescence 
to a greater degree than with only EGTA. These analyses were conducted in the presence of both 
EGTA and carnosine; it could be proposed that the carnosine molecule may have additional Ca
2+
 
chelation properties, above those reported in the current analysis, since it has to compete against 
the EGTA molecule, a known Ca
2+
 chelator.  
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A1.5 Carnosine, β-alanine and L-histidine content 
A1.5.1 Background 
Amino acid analysis is a method undertaken to determine the amino acid content of amino 
acid–, peptide- and protein-containing samples (Rutherfurd & Gilani, 2009) providing an important 
quantitative parameter in the characterisation of isolated protein or peptide samples (Ozols, 1990). 
An amino acid analysis instrument will typically be a low-pressure or high-pressure liquid 
chromatograph capable of generating mobile phase gradients that separate the amino acid analytes 
on a chromatographic column. The process by which the amino acid content is determined 
involved the samples being loaded a column of cation-exchange resin, where buffers of varying pH 
and ionic strength are pumped through the column to separate the various amino acids. The 
integrity of these samples is key to the accuracy of amino acid analysis (Tyler, 2000). The retention 
time of each peak on the output from the amino acid analyser identifies the specific amino acid, the 
area under the peak indicating the quantity of amino acid present.  
 
A1.5.2 Methodological development 
Amino acid analysis is a common technique to assess amino acid concentrations of blood 
plasma and urine samples (Decombaz et al., 2012; Wilkinson et al., 2013; Mitchell et al., 2015). 
There are limited examinations of amino acid concentrations in skeletal muscle samples using an 
ion-exchange chromatography (Stuerenburg & Kunze, 1999; Hammarqvist et al., 2005; 
Hammarqvist et al., 2010; Teloh et al., 2016). There is currently no research examining the amino 
acid concentrations in rat skeletal muscle subcellular fractions, specifically the amino acids, 
carnosine, β-alanine and L-histidine. Due to the novelty of this process, several repeatability 
experiments were completed using an Amino Acid Analyser (Biochrom 30, Pharmacia Biochrom 
Ltd). Standard area and ratios, and sample concentration (uM) measurements were analysed using 
paired t-tests, intra-class correlations (ICC, 2-way fixed, repeated measures, absolute model), 
systematic bias, limits of agreement (LoA; Bland & Altman, 1986) and CV (SPSS v23, IBM, USA). 
 
Inter-reliability: Eight standards and 15 samples were assessed for inter-reliability (Table A1.2; 
Table A1.3), with measures assessed on two separate occasions. There was no significant 
difference standard ratios or samples amino acid concentrations between assessments from the 
same sample on two separate occasions, with systemic bias of between -1.5 – 16.6% for standards 
and -4.5 - 14.0% for sample concentrations. The ICC for standards ranged from 0.99 to 1.0 with all 
significance values P < 0.001, the ICC for the sample amino acid concentrations range from 0.98 to 
0.99, with all significance values below P < 0.001.  
 
Appendix 1: Methodological development  
 
 
192  
Intra-reliability: A total of eight standards and 15 samples were assessed for intra-reliability 
(Table A1.2; Table A1.3). There was no significant difference standard ratios or samples amino 
acid concentrations between repeated assessments from the same sample, with systemic bias of 
between -2 - 4.2% for standards and 2.1 - 2.5% for sample concentrations. The ICC for standards 
ranged from 0.99 to 1.0 with all significance values P < 0.001, the ICC for the sample amino acid 
concentrations range from 0.95 to 1.0, with all significance values below P < 0.001.  
 
The aim of these data was to determine the inter- and intra-reliability of a selection of 
carnosine, β-alanine and L-histidine concentrations within rat skeletal muscle subcellular fractions. 
These data indicate that this technique is appropriate to provide detailed and accurate data on 
molecular concentrations in rat skeletal muscle samples. It should be highlighted that other amino 
acids examined using the amino acid analyser have not been examined, thus, additional analysis is 
required for further analysis. Based on the current information it will also be critical to conduct 
future reliability research using human skeletal muscle tissue.  
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Table A1.2: Intra- and inter- reliability measures for the carnosine, β-alanine and L-histidine variables from the amino acid standard solution. 
.Measurement data are mean ± 1SD.  
 Standards (n=8) 
 Carnosine Area Carnosine ratio 
to Norleucine 
β-alanine Area β-alanine ratio to 
Norleucine 
Histidine Area Histidine ratio 
to Norleucine 
Measurements       
Measure 1 5094908 ± 5328802 1.2 ± 1.2 4842791 ± 4982160 1.1 ± 1.1 4664229 ± 4815631 1.1 ± 1.1 
Measure 2 4896268 ± 4948687 1.2 ± 1.3 4634278 ± 4713535 1.1 ± 1.2 4517061 ± 4647409 1.1 ± 1.2 
Measure 2 repeat 4929848 ± 5088289 1.2 ± 1.2 4897279 ± 4946592 1.1 ± 1.1 4562317 ± 4887141 1.1 ± 1.1 
Intra-reliability       
Systemic Bias 33580 (-4.2%) -0.02 (3.6%) 263001 (-2%) 0.01 (3.2%) 45256 (-7.1%) 0.03 (3.6%) 
CV (%) 8.74 7.64 9.48 6.31 6.17 7.79 
ICC (P value) 0.99 (P < 0.001) 1.0 (P < 0.001) 0.99 (P < 0.001) 1.0 (P < 0.001) 1.0 (P < 0.001) 1.0 (P < 0.001) 
t-Test 0.83 0.46 0.14 0.61 0.66 0.42 
Cohen's D 0.01 0.02 -0.04 -0.01 -0.01 -0.02 
LoA Random Error 841423 0.16 828437 0.13 513404 0.16 
LoA Lower Limit -8075003 -0.19 -565436 -0.12 -468 -0.13 
LoA Upper Limit 875002 0.14 1091438 0.15 558659 0.18 
Inter-reliability       
Systemic Bias -198640 (16.6%) -0.01 (-1.5%) -2085137 (2.6%) -0.01 (4.6%) -147167 (4.2%) -0.04 (-9.2%) 
CV (%) 10.52 8.4 7.14 4.95 4.73 7.19 
ICC (P value) 0.99 (P < 0.001) 0.99 (P < 0.001) 1.0 (P < 0.001) 1.0 (P < 0.001) 1.0 (P < 0.001) 1.0 (P < 0.001) 
t-Test 0.32 0.88 0.12 0.8 0.1 0.21 
Cohen's D 0.03 0.004 0.03 -0.004 0.03 0.03 
LoA Random Error 1030354 0.18 620128 0.1 398079 0.15 
LoA Lower Limit -1228996 -0.19 -828641 -0.1 -545247 -0.18 
LoA Upper Limit 831714 0.18 411616 0.11 250911 0.11 
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Table A1.3: Intra- and inter-reliability measures for carnosine, β-alanine and L-histidine 
concentrations from rat skeletal muscle subcellular fractions.  
 Samples (n=15) 
  Carnosine (uM) Histidine (uM) β-alanine (uM) 
Measurements        
Measure 1 338.3 ± 299.3  22.8 ± 15.3 18.2 ± 15.8 
Measure 2 329.2 ± 297.6 22.2 ± 16.4 18.8 ± 16.3 
Measure 2 repeat 331.4 ± 299.4 24.5 ± 19.3 19.0 ± 16.2 
Intra-reliability       
Systemic Bias 2.14 (2.3%) 2.38 (2.5%) 0.21 (2.1%) 
CV (%) 6.25 24.37 26.89 
ICC (P value)  1.0 (P < 0.001)  0.96 (P < 0.001) 0.95 (P < 0.001)  
t-Test 0.69 0.13 0.87 
Cohen's D -0.01 -0.11 -0.01 
LoA Random Error 39.12 10.77 9.63 
LoA Lower Limit -36.98 -8.39  -9.41 
LoA Upper Limit 41.26 13.15  9.84 
Inter-reliability       
Systemic Bias  9.09 (7.3%) 0.63 (14.0%) -0.62 (-4.5%)  
CV (%) 11.59  15.96  13.78 
ICC (P value)  0.99 (P < 0.001) 0.98 (P < 0.001)  0.99 (P < 0.001) 
t-Test  0.38 0.51  0.36 
Cohen's D  -0.02 -0.03  0.03 
LoA Random Error  73.25 6.79 4.82 
LoA Lower Limit  -64.16 -6.16  -5.44 
LoA Upper Limit 82.34  7.43  4.21 
Measurement data are mean ± 1SD.  
 
  
Appendix 1: Methodological development  
 
 
195  
A1.6 BIOMOL Green phosphate assay 
A1.6.1 Background 
The BIOMOL Green phosphate assay reagent (Enzo Life Sciences, Loerrach, Germany) is 
a non-radioactive method for assessing Pi released during enzymatic phosphatase. Highly sensitive 
methods for phosphate measurement are based on the change in the absorption spectra of basic 
dyes upon complex formation with phosphomolybdic heteropolyacid (Baykov et al., 1987). 
Phosphate is released as Pi, quantification of the Pi generated during ATP-y-P hydrolysis there can 
be evaluated as a measure of SERCA activity (McMullen et al., 2012). 
 
A1.6.2 Methodological development  
A1.6.2.1 Absorbance spectrum  
An absorbance spectrum was run between 400 and 800 nM, and although the BIOMOL 
Green phosphate assay reagent was normally undertaken at 620 nM, based on the absorbance 
spectrum of our equipment, the most appropriate absorbance was 640 nM (Fig. A1.7).  
Fig. 1.6: An absorbance spectrum optical density (OD) was assessed between 400 and 800 nM.  
 
  
Appendix 1: Methodological development  
 
 
196  
A1.6.2.2 Optimisation of the assay 
Test one: The samples were incubated for 30 min at 25
 o
C, following which 100 μL of 
sample was mixed with 100 μL of BIOMOL Green phosphate assay reagent, thus stopping the 
reaction, and allowing colour development to initiate. The samples were incubated at room 
temperature for 30 min to allow development of the green colour. The amount of Pi released during 
the Ca
2+
 uptake assay was determined by reading sample absorbance at 640 nM. The standards of 
the BIOMOL Green phosphate assay ranged from 0 to 2 nmol, with a linear curve fitted, reporting 
a R
2
 value of 0.99 (Fig. A1.8). The absorbance values within the current experiment were largely 
above the protein concentration standard values, therefore this experiment was halted.  
 
Fig. A1.7: The phosphate concentration (nmol) standard curve from test one, fitted within a linear 
curve against absorbance optical density (OD) of 640 nM.  
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Test two: The standards of the BIOMOL Green phosphate assay were increased to include 
4 and 6 nmol, thereby ranging from 0 to 6 nmol. Additionally, the room temperature incubation 
time was reduced to 20 min. Samples were incubated for 30 min at 25
 o
C, following which 100 μL 
of sample was mixed with 100 μL of BIOMOL Green, thus stopping the reaction and allowing 
colour development to initiate. The samples were incubated at room temperature for 20 min to 
allow development of the green colour. The amount of Pi released during the Ca
2+
 uptake assay 
was determined by reading sample absorbance at 640 nM. The standards of the BIOMOL Green 
phosphate assay ranged from 0 to 6 nmol, with a linear curve fitted, reporting a R
2
 value of 0.98. 
The absorbance values within the current experiment were still above the protein concentration 
standard values, even with the addition of the 6 nmol standard.  
 
Test three: The samples were diluted to 50% with storage buffer, the standards of the 
BIOMOL Green phosphate assay ranged from 0 to 4 nmol, with incubation time decreased, and 
recorded at both 15 and 20 min. Samples were incubated for 30 min at 25
 o
C, following which 100 
μL of sample was mixed with 100 μL of BIOMOL Green, thus stopping the reaction and allowing 
colour development to initiate. The samples were incubated at room temperature for 15 and 20 min 
to allow development of the green colour. The amount of Pi released during the Ca
2+
 uptake assay 
was determined by reading sample absorbance at 640 nM. The standards of the BIOMOL Green 
phosphate assay ranged from 0 to 4 nmol, with a linear curve fitted, reporting a R
2
 value of 0.87 for 
both the 15 min and 20 min readings (Fig. A1.9). From examination of the standard curve is an 
apparent plateau in the standard concentrations between 2 and 4 nmol of phosphate. Furthermore, 
the absorbance values during analysis of the current subcellular fractions, remained at the top end 
of the phosphate standard curve. The current data supports the use of a shorter (15 min) sample 
incubation period, with no difference in standard curves or calculated phosphate concentrations 
compared to those of longer incubation periods.  
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Fig. A1.8: The phosphate concentration (nmol) standard curve from test three at 15 min and 20 min 
of incubation at room temperature, fitted within a linear curve against absorbance optical density 
(OD) at 640 nM. 
 
Fig. A1.9: The phosphate concentration (nmol)
 
standard curve from test four at 15 min of 
incubation at room temperature, fitted within a linear curve against absorbance optical density 
(OD) at 640 nM. 
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 Test four: The standards of the BIOMOL Green phosphate assay ranged from 0 to 2 nmol, 
with incubation times of 15 min, the samples were diluted to 25% with storage buffer (Fig. A1.10). 
The standard range was optimised for the current samples with two of the smaller concentrations 
(0.031 and 0.063 nmol Phosphate) removed, and three additional standards included (1.6, 1.2 and 
0.8 nmol Phosphate). Samples were incubated for 30 min at 25
 o
C, following which 100 μL of 
sample was mixed with 100 μL of BIOMOL Green, thus stopping the reaction and allowing colour 
development to initiate. The samples were incubated at room temperature for 15 min to allow 
development of the green colour. The amount of Pi released during the Ca
2+
 uptake assay was 
determined by reading sample absorbance at 640 nM. The standards of the BIOMOL Green 
phosphate assay ranged from 0 to 2 nmol, with a linear curve fitted, reporting a R
2
 value of 0.99 
(Fig. A1.10). The absorbance values of the assessed skeletal muscle sample remained within the 
standards, demonstrating a clear measure of ATP activity within the microsomal samples collected 
from the rat skeletal muscle tissue.  
 
 
Fig. A1.10: Image of the BIOMOL Green phosphate assay in a microplate, with a 25% dilution of 
the sample. 
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A1.6.2.3 Calcium dependent activity 
The protocol undertaken in test four, with a 25% dilution of samples, and 15 min 
incubation period, was repeated on all remaining rat skeletal muscle microsomal fractions (n=9), 
under varying concentrations of free Ca
2+
, as predicted by the volume of EGTA within the solution. 
The absorbance OD of each samples were used to calculate phosphate concentration. All samples 
were undertaken in triplicate, with the mean reported.  
 
These data displayed a significant main effect of predicted free Ca
2+
 (P < 0.001; Fig. 
A1.12A). The solution containing 0 μM of predicted free Ca2+ released significantly less phosphate 
in comparison to all other conditions (0.097 μM, P = 0.007; 1 μM, P = 0.002, 10 μM, P = 0.003 and 
100 μM, P = 0.02). Additionally, the solution containing 0.097 μM of predicted free Ca2+ released 
significantly less phosphate in comparison to 1 μM condition (P = 0.004), yet there was no 
significant difference between the other conditions. The 1 μM predicted free Ca2+ solution was the 
only concentration to be significantly higher than the 0 and 0.097 μM solutions. 
 
These phosphate concentration data were presented relative to the protein concentration of 
the subcellular fraction (Fig. A1.12B). In-line with the above data, there was a significant main 
effect of predicted free Ca
2+
 (P < 0.001) on phosphate relative to protein concentrations. The 
solution containing 0 μM of predicted free Ca2+ released significantly less phosphate relative to 
protein concentrations in comparison to all other conditions (0.097 μM, P = 0.02; 1 μM, P = 0.008, 
10 μM, P = 0.007 and 100 μM, P = 0.03). Additionally, the solution containing 0.097 μM of 
predicted free Ca
2+
 released significantly less phosphate in comparison to 1 μM condition (P = 
0.007), yet there was no significant difference between the other conditions. The 1 μM predicted 
free Ca
2+
 solution was the only concentration to be significantly higher than the 0 and 0.097 μM 
solutions.  
 
Due to the significant increase in the phosphate released during the 1 μM condition, above 
the phosphate concentrations in the 0 and 0.097 μM conditions, the 1 μM solution was used for 
further analysis, allowing for comparison to the 0 μM condition. To calculate the amount of Ca2+-
dependent ATPase activity, the amount of phosphate released during the 0 μM condition was 
subtracted from the 1 μM condition. These data are displayed in both absolute phosphate 
concentrations (Fig. A1.13A) and phosphate concentrations relative to protein concentration (Fig. 
A1.13B).  
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Fig. A1.11: The absolute phosphate concentration (nmol; A) and phosphate concentrations 
relative to protein concentration (nmol
.
mg
-1
 protein; B) of microsomal fraction from nine rats at 
predicted free calcium concentrations from 0 to 1 μM. Bar chart data are mean ± 1SD. Line 
graph data are individual skeletal muscle samples. 
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Fig. A1.12: The absolute phosphate concentration (nmol; A) and phosphate concentrations 
relative to protein concentration (nmol
.
mg
-1
 protein; B) of the microsomal fraction from nine 
rats at 0 to 1 μM predicted free calcium concentrations. The calcium dependent ATPase activity 
is the phosphate concentrations at 1 μM predicted free calcium concentrations minus those 
generated at 0 μM predicted free calcium concentrations. Representative data from one 
microsomal sample. 
4.93 
6.65 
1.72 
0
1
2
3
4
5
6
7
8
0 1 Calcium dependent
ATPase actvity
P
h
o
sp
h
at
e 
(n
m
o
l)
 
Predicted free calcium (μM) 
4.56 
6.14 
1.58 
0
1
2
3
4
5
6
7
8
0 1 Calcium dependent
ATPase actvity
In
o
rg
an
ic
 p
h
o
sp
h
at
e 
re
la
ti
v
e 
to
 p
ro
te
in
  
(n
m
o
l. m
g
.-
1
 p
ro
te
in
) 
Predicted free calcium (μM) 
B)  
A)  
Appendix 1: Methodological development  
 
 
203  
A1.6.2.4 Controls  
Storage medium: To control for the potential effects of the storage medium on phosphate 
generation during each condition, protein concentrations were recorded in solutions where the 
sample volume was replaced with additional storage medium. ATP remained within the given 
solutions, maintaining the same solution volume. These analyses demonstrated very low levels of 
phosphate were generated during the conditions with additional storage medium (1.38 ± 0.92 nmol). 
The current experiments indicate that the storage medium was not generating phosphate, and 
therefore not influencing the samples.  
 
ATP: To control for the potential effect of the ATP on phosphate generation during each 
condition, protein concentrations were recorded in solutions where the some of the storage medium 
was replaced with additional ATP. The sample remained within the given solutions, maintaining 
the same solution volume. These analyses demonstrated slightly greater levels of phosphate 
generations during the conditions with additional ATP (2.55 ± 0.39 nmol), with a trend be 
significantly greater than those in the storage medium (P = 0.08). Therefore, based on the current 
analysis, ATP concentrations need to be maintained across all samples, since it increased the 
generation of phosphate within the samples. 
 
EGTA: To control for the potential effect of the high EGTA on phosphate generation 
during each condition, protein concentrations were recorded in solutions where some of the storage 
medium was replaced with EGTA. The sample remained within the given solutions, maintaining 
the same solution volume. In the presence of additional EGTA, additional phosphate was generated 
(4.31 ± 1.31 nmol), significantly above phosphate concentrations in the two previous conditions 
(Storage medium: P = 0.002; ATP: P = 0.003). This data indicated the EGTA need to be 
maintained across samples, since it increased the generation of phosphate within the samples.  
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-Alanine supplementation enhances human skeletal muscle relaxation speed
but not force production capacity
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Hannah R, Stannard R, Minshull C, Artioli GG, Harris RC,
Sale C. -Alanine supplementation enhances human skeletal
muscle relaxation speed but not force production capacity. J Appl
Physiol 118: 604 – 612, 2015. First published December 24, 2014;
doi:10.1152/japplphysiol.00991.2014.—-Alanine (BA) supple-
mentation improves human exercise performance. One possible ex-
planation for this is an enhancement of muscle contractile properties,
occurring via elevated intramuscular carnosine resulting in improved
calcium sensitivity and handling. This study investigated the effect of
BA supplementation on in vivo contractile properties and voluntary
neuromuscular performance. Twenty-three men completed two exper-
imental sessions, pre- and post-28 days supplementation with 6.4
g/day of BA (n 12) or placebo (PLA; n 11). During each session,
force was recorded during a series of knee extensor contractions:
resting and potentiated twitches and octet (8 pulses, 300 Hz) contrac-
tions elicited via femoral nerve stimulation; tetanic contractions (1 s,
1–100 Hz) via superficial muscle stimulation; and maximum and
explosive voluntary contractions. BA supplementation had no effect
on the force-frequency relationship, or the force responses (force at 25
and 50 ms from onset, peak force) of resting or potentiated twitches,
and octet contractions (P  0.05). Resting and potentiated twitch
electromechanical delay and time-to-peak tension were unaffected by
BA supplementation (P  0.05), although half-relaxation time de-
clined by 7–12% (P  0.05). Maximum and explosive voluntary
forces were unchanged after BA supplementation. BA supplementa-
tion had no effect on evoked force responses, implying that altered
calcium sensitivity and/or release are not the mechanisms by which
BA supplementation influences exercise performance. The reduced
half-relaxation time with BA supplementation might, however, be
explained by enhanced reuptake of calcium, which has implications
for the efficiency of muscle contraction following BA supplementa-
tion.
-alanine; muscle contractile properties; electrical stimulation; force-
frequency relationship
CARNOSINE (-ALANYL-L-HISTIDINE) is a cytoplasmic dipeptide
synthesized from -alanine (BA) and histidine and is found in
high concentrations within mammalian skeletal muscle. Car-
nosine is formed, primarily in skeletal and brain tissue, by
bonding histidine and BA in a reaction catalyzed by carnosine
synthase (23, 40). The availability of BA in the human diet is
the rate-limiting factor for carnosine synthesis in human skel-
etal muscle (for a brief review see Ref. 20). Long-term (4–10
wk) dietary supplementation with BA significantly increases
human skeletal muscle carnosine content (19, 21, 24). Interest
in elevating carnosine levels through BA supplementation has
dramatically increased since it was first shown that doing so
increased high-intensity cycling capacity (21). Since then, it
has been well established that BA supplementation can im-
prove high-intensity exercise performance (e.g., 2,000-m row-
ing performance and 100- to 200-m swimming performance)
and capacity during exercise of 1–6 min (see reviews in
Refs. 22, 34). However, the physiological mechanisms for
these ergogenic effects remain poorly understood.
Carnosine is suggested to have several physiological roles in
muscle, which are pertinent to muscle function and perfor-
mance. For example, its molecular structure makes it well
suited to act as a pH buffer (36). The pKa of its imidazole ring
is 6.83, placing it right in the middle of the pH transit range of
exercising muscle. This means that an increase in carnosine
content within the skeletal muscles also results in an expansion
of the imidazole ring content, concomitantly increasing the
muscle buffering capacity. As a result, performance improve-
ments in high-intensity exercise (particularly when hydrogen
cation accumulation is likely to limit performance) have
largely been ascribed to increases in intracellular buffering (see
review in Refs. 34, 35).
Alternative mechanisms for the enhancement of exercise
performance following BA supplementation have been pro-
posed. For example, previous work in rat skeletal muscle
suggested a role for carnosine in increasing the sensitivity of
the contractile apparatus to calcium ions (Ca2) (10). More
recent work in skinned human medialis (m.) vastus lateralis
fiber preparations showed a similar increase in Ca2 sensitivity
(11). Although only slight changes were shown in the maxi-
mum Ca2-activated force (3%), a significant leftward shift
in the force-calcium concentration relationship was shown,
indicating that force for a given submaximal Ca2 concen-
tration was increased in the presence of higher carnosine
levels in type I and II fibers. Elevated carnosine levels also
increased Ca2 release from the sarcoplasmic reticulum of
type I fibers, whereby carnosine appeared to enhance the
Ca2 sensitivity of ryanodine receptors and potentiated
Ca2-induced Ca2 release (11). Thus it was suggested that
elevated carnosine after BA supplementation could alleviate
the decline in contractile performance during fatiguing con-
tractions by countering factors that might cause reduced
calcium sensitivity and release (11).
A recent study provided the first evidence that dietary BA
supplementation may influence the muscle contractile proper-
ties of mice (13), potentially via elevated intramuscular car-
nosine and its effect on calcium sensitivity and handling (11).
BA supplementation was associated with a leftward shift in the
electrically evoked force-frequency relationship of excised
muscle, which is analogous to the force-calcium concentration
Address for reprint requests and other correspondence: C. Sale, Sport,
Health and Performance Enhancement (SHAPE) Research Group, School of
Science and Technology, Nottingham Trent Univ., UK NG11 8NS (e-mail:
craig.sale@ntu.ac.uk).
J Appl Physiol 118: 604–612, 2015.
First published December 24, 2014; doi:10.1152/japplphysiol.00991.2014.
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relationship (5, 27), eliciting a 10–31% increase in the force
produced at low stimulation frequencies (13). However, the
possibility that dietary BA supplementation might change in
vivo human muscle contractile properties, and thus voluntary
muscle performance, has not been investigated. There is a need
to examine this possibility given that we would expect a wider
range of performance effects of carnosine than has currently
been shown if improved calcium handling were the major
physiological role of carnosine in human skeletal muscle (34).
As such, we examined the effects of 28-day BA supplemen-
tation on the intrinsic contractile properties of human skeletal
muscle in vivo, as well as on voluntary muscle function.
Intrinsic contractile properties were assessed via the force-
frequency relationship in response to muscle stimulation and
the evoked twitch and octet (8 pulses at 300 Hz, which drives
the muscle at its maximum capacity for rapid or “explosive”
force production; Ref. 8) responses to supramaximal nerve
stimulation. We hypothesized that BA supplementation would
enhance intrinsic contractile properties, producing a leftward
shift in the force-frequency relationship, increasing the peak
and explosive force responses to twitch and octet stimulation,
and thus enhance explosive voluntary force production. In
addition, we hypothesized that the altered contractile properties
would lead to changes in motor control, reflected as a shift in
the force-electromyography (EMG) relationship towards lower
EMG levels for a given level of force.
METHODS
Participants
Twenty-six participants were recruited to the study and were
stratified and allocated to the two supplement groups [placebo (PLA)
or BA] on the basis of maximum knee extensor strength [maximum
voluntary force (MVF); see below] values recorded during the famil-
iarization session, such that the two groups were matched for knee
extensor strength. However, three participants withdrew from the
study (2 from PLA and 1 from BA), one during familiarization due to
a lack of tolerance of electrical stimulation and two following baseline
testing with no reason provided. As such, 23 participants completed
all aspects of the study (PLA group: n  11; age, 25.6  5.6 yr; body
mass, 79.1  13.0 kg; height, 1.80  0.07 m; BA group: n  12; age,
26.1 7.4 yr; body mass, 82.4 15.2 kg; height, 1.79 0.06 m). All
participants provided written informed consent and completed this
study, which was approved by the Institutional Human Ethical Review
Committee. None of the participants had taken any nutritional sup-
plements in the previous 6 mo. Participants had no injuries to the
lower limbs, were not involved in any systematic physical training,
and were categorized as having moderate habitual levels of physical
activity using the International Physical Activity Questionnaire Short
Format (http://www.ipaq.ki.se/ipaq.htm; Ref. 7). Throughout the
study participants were requested to maintain similar levels of phys-
ical activity and dietary intake; this was verbally confirmed at the start
of each session. None of the subjects were vegetarian or vegan, and
therefore, they would likely have encountered small amounts of BA in
their diet (1).
Study Design
This was a double-blind placebo-controlled experiment. Partici-
pants completed three experimental sessions over a 5-wk period: a
familiarization session, which preceded a baseline session by 7 days,
and a follow-up session after 28 days of supplementation with either
BA or PLA. Participants were instructed to abstain from alcohol and
strenuous/unaccustomed exercise for 36 h before measurement ses-
sions, with caffeine prohibited on the day of measurement sessions.
Compliance with these requests was confirmed verbally with each
participant before commencing each session. Measurement sessions
were completed at a consistent time of day, with recordings of force
and surface EMG during a series of voluntary and involuntary (elec-
trically evoked) isometric contractions of the knee extensors of the
dominant leg. The familiarization session involved all the voluntary
and evoked contractions, except the evoked octet contractions. The
baseline and follow-up sessions involved an identical protocol performed
according to a strict schedule. All raw data analyses, exclusions, and
statistical analyses were completed blind to supplement group.
Supplementation
Participants received 6.4 g/day of either BA (sustained-release
Carnosyn) or a matched PLA (maltodextrin) for 28 days (2 	 800 mg
tablets, ingested 4 times per day). The sustained-release formulation
used in this study has been shown to reduce or remove the paraes-
thesia often experienced by participants following doses of free BA
powder (9). We would expect the increase in muscle carnosine content
to be close to 15 mmol/kg dry muscle (an increase of 65% in a
participant eating a mixed diet), given that Harris et al. (19) reported
this level of increase following a similar but slightly lower total dose
of BA. None of the participants reported any feelings of paraesthesia
during the study. Throughout supplementation participants completed
a log to verify supplement compliance, with similar compliance
reported at 91 7% in the BA group and 88 10% in the PLA group
(independent sample t-test, P  0.60).
Supplements were provided to each participant in identical white
tubs by an individual not directly involved in testing or data analysis
to maintain the double-blind. BA tablets were tested by the manufac-
turer before release for the study and conformed to the label claim for
BA content. In addition, BA and PLA supplements were indepen-
dently tested by HFL Sports Science, UK, before use to ensure no
contamination with steroids or stimulants according to International
Organization for Standardization (ISO) 17025 accredited tests.
Experimental Setup
Knee extension force. Participants were seated in a rigid, custom-
built dynamometer, as adapted from previous studies (17, 18), with
knee and hip joint angles of 95 and 100° (180°  full extension).
Adjustable strapping across the pelvis and shoulders prevented extra-
neous movement during muscle activation. An ankle cuff was at-
tached to the dominant leg of the participant 2 cm proximal to the
medial malleolus and was in series with a linear strain gauge (615;
Tedea-Huntleigh, Herzliya, Israel) oriented perpendicular to the tibia.
Dynamometer configuration was established during the familiariza-
tion session and replicated thereafter. The force signal was amplified
(	1,000) in the frequency range of 0–500 Hz and sampled at 2,000
Hz using an external A/D converter (1401; CED, Cambridge, UK),
interfaced with a personal computer (PC) using Spike 2 software
(CED). Force data were low-pass filtered in both directions at 450 Hz
using a fourth-order zero-lag Butterworth filter before analysis. Base-
line resting force was subtracted from all force recordings to correct
for the effects of gravity.
Electromyography. EMG signals were recorded from the superfi-
cial quadriceps: m. rectus femoris (RF), m. vastus medialis (VM), and
m. vastus lateralis (VL). After preparation of the skin by shaving, light
abrasion, and cleaning with alcohol, bipolar surface electrodes
(2.5-cm interelectrode distance; silver/silver chloride, 95-mm2 area;
Ambu Blue Sensor; Ambu, Ballerup, Denmark) were attached over
each muscle at standardized percentages of thigh length, as measured
from the knee joint space to the greater trochanter: RF, 55%; VM,
25%; and VL, 45%. These sites were selected to avoid the innervation
zones of each of the assessed muscles (32). A reference electrode was
placed on the patella of the same limb. EMG signals were preampli-
fied by active EMG leads (input impedance: 100 M
; common mode
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rejection ratio: 100 dB; base gain: 500; 1st order high-pass filter set
to 10 Hz; Noraxon, Scottsdale, AR) connected in series to a custom-
built junction box and subsequently to the same A/D converter and PC
software that enabled synchronization with the force data. The signals
were sampled at 2,000 Hz. EMG data were band-pass filtered in both
directions between 20 and 450 Hz using a fourth-order zero-lag
Butterworth filter before analysis.
Electrical stimulation. A constant current variable voltage stimu-
lator (DS7AH; Digitimer, Welwyn Garden City, UK) was used to
assess knee extensor contractile properties while the participant was
voluntarily passive. Square-wave pulses (0.2-ms duration) were de-
livered via: 1) supramaximal femoral nerve stimulation to evoke
maximal resting twitch, potentiated twitch, and octet contractions; and
2) percutaneous submaximal muscle stimulation to evoke contractions
at a range of frequencies (1 to 100 Hz) to assess the force-frequency
relationship. Femoral nerve stimulation involved a cathode stimula-
tion probe (1-cm diameter; Electro-Medical Supplies, Wantage, UK)
firmly pressed into the skin over the femoral nerve in the femoral
triangle and an anode (7 	 10 cm carbon rubber electrode; Electro-
Medical Supplies) coated with electrode gel and taped to the skin over
the greater trochanter. The precise location of the cathode was
determined as the position that evoked the greatest twitch response for
a particular submaximal electrical current (typically 30–50 mA). For
percutaneous stimulation, the surfaces of two carbon rubber electrodes
(14 	 10 cm; Electro-Medical Supplies) were coated with electrode
gel and secured over the proximal and distal surface of quadriceps at
standardized percentages of thigh length, as measured from the patella
to the anterior superior iliac spine (ASIS): proximal electrode placed
20% distal to the ASIS; distal electrode placed 10% proximal to the
patella.
Protocol and Measurements
Measurements were completed in the following order, according to
a consistent time schedule including 3 min rest between successive
measurements.
Force and EMG onsets for all evoked and voluntary contractions
were identified manually using visual identification by the same
investigator, in accordance with a previously published method (16,
37). This approach is considered more valid than the use of automated
methods of identification (38).
Resting twitches. Resting twitches were evoked following15 min
passive sitting to remove any lingering potentiation, which incorpo-
rated the time for securing the participant in the dynamometer and
preparing them for EMG and electrical stimulation. Single electrical
impulses were delivered with stepwise increments in the current,
separated by 10 s to allow for neuromuscular recovery, until a plateau
in the amplitude of twitch force and compound muscle action poten-
tials (M-waves) were reached. The stimulus intensity was then in-
creased by 25% above the value required to elicit a plateau to ensure
supramaximal stimulation, and three discrete supramaximal stimuli
separated by 10 s were then delivered to elicit maximal twitch
responses and M-waves.
The time difference between M-wave onset (1st electrode site to be
activated) and twitch force onset was defined as the electromechanical
delay (EMD). Twitch force was measured at 25 and 50 ms from onset,
as markers of the explosive force production during the rising slope,
and at the peak of the force response. The time-to-peak tension (TPT)
and half-relaxation time (HRT) were also recorded. All measurements
were averaged across the three maximal twitch contractions. The
M-wave response for the three quadriceps electrodes was measured
for M-wave area, from EMG onset to the point where the signal
returned to baseline, and averaged across the three sites. The mean
M-wave area of the three supramaximal stimuli was defined as the
maximal M-wave area (Mmax) and was used for normalization of
voluntary quadriceps EMG (6).
Maximum voluntary contractions and potentiated twitches. A brief
warm-up of three submaximal knee extension contractions at 50, 75,
and 90% of the participants’ perceived maximal force were per-
formed; contractions lasted 3 s each and were separated by 20 s.
Participants then completed four maximum voluntary contractions
(MVCs) of the knee extensors 60 s apart, during which they were
instructed to contract “as hard as possible” for 3–4 s. During and after
each contraction they received strong verbal encouragement reiterat-
ing the instructions, together with online feedback of the force signal
and a marker of their maximum force during that session displayed
onscreen. Supramaximal stimulation of the femoral nerve, using the
same configuration and stimulus intensity as for resting twitches, was
used to elicit a maximal potentiated twitch 1 s after each of the
MVCs. The greatest instantaneous force during either the knee exten-
sor MVCs or explosive voluntary contractions (see below) of that trial
was defined as MVF. The root mean square (RMS) of the EMG signal
for each muscle (RF, VM, and VL) was calculated over a 500-ms
epoch surrounding MVF (250 ms either side) and normalized to the
corresponding Mmax (6), before averaging across all three sites to
calculate a mean quadriceps value. The EMD, force at 25 and 50 ms
from onset, peak twitch force, TPT, and HRT were averaged across
the four maximal potentiated twitch contractions.
Explosive voluntary contractions. The protocol followed previ-
ously published procedures (6, 16). Participants completed 10
isometric explosive voluntary knee extensions, each separated by20
s. Starting from a completely relaxed state, they were instructed to
respond to an auditory signal by extending their knee “as fast and hard
as possible” for1 s, with an emphasis on “fast.” An on-screen cursor
was used to provide online feedback on their explosive performance,
displaying the maximum rate of force development (2-ms time con-
stant) of their best attempt. Strong verbal encouragement was pro-
vided to participants to exceed this target during each subsequent
contraction. A second visual marker on the screen depicted 80% of the
peak force recorded during MVCs, which participants were expected
to achieve or exceed during each explosive contraction. Resting force
was also displayed on a sensitive scale during all explosive contrac-
tions to aid the detection of pretension or countermovement. The
explosive contractions were performed until 10 contractions, with no
prior countermovement or pretension, had been recorded.
The three contractions with the greatest maximum rate of force
development, meeting the following criteria, were used for analysis:
1) no prior countermovement or pretension, and 2) peak force 80%
MVF. Analyses involved measurement of the force-time and EMG-
time traces in short periods after their onsets. Explosive force was
measured at 25-ms intervals up to 150 ms after force onset. The RMS
of the EMG signal from each muscle was measured over three
consecutive 50-ms time periods from EMG onset of the first agonist
muscle to be activated (i.e., 0–50, 50–100, and 100–150 ms). There-
after, RMS EMG at each EMG site was normalized to Mmax and
averaged to provide a mean quadriceps value. All measurements were
averaged across the three selected contractions.
Force-EMG relationship (via voluntary incremental knee extension
contractions). A series of submaximal knee extension contractions
were performed at 15% increments of MVF, in ascending order, up to
90%. Horizontal cursors on the screen in front of participants depicted
the target levels of force. Participants were instructed to reach the
target quickly and maintain the level of force as accurately as
possible for 3 s. Contractions were separated by 20 s. The RMS
of the EMG and average force over a stable 500-ms part of the
force trace (minimal standard deviation of the force trace for that
contraction) were analyzed at each of the contraction intensities.
The EMG RMS values were normalized to Mmax and plotted against
the respective force values. Linear regression was used to evaluate the
slope and intercept of the force-EMG relationship incorporating all
data between 15 and 90% MVF.
Octet contractions. Octet contractions (8 impulses at 300 Hz; Ref.
8) were evoked via supramaximal stimulation of the femoral nerve.
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First, a brief series of single stimuli were administered, and twitch
force and M-wave amplitudes were monitored to confirm that the
stimuli were supramaximal. The current was increased if necessary to
ensure supramaximal stimulation. Then three discrete pulse trains
(15 s apart) were delivered with a supramaximal current (25%) to
evoke maximal octet contractions. The current increased by 5%
after each pulse train to confirm a plateau in both the peak force and
maximum rate of force development. On some occasions, where the
first pulse train elicited a submaximal response, a fourth pulse train
was delivered to ensure three maximal responses. The octet force
response was measured at 25 and 50 ms from force onset, as well as
at the peak. All measurements were averaged across the three ana-
lyzed contractions.
Force-frequency relationship. Surface EMG electrodes were re-
moved and carbon rubber electrodes were attached over the quadri-
ceps, taking 5 min. The force-frequency relationship was then
evaluated during tetanic contractions elicited via submaximal percu-
taneous electrical stimulation (3, 15).
Initially, 100-Hz contractions were evoked at increasing current
intensities, 30 s apart, to determine the current that elicited 50% of
MVF. This current (typically 110–200 mA) was then used for the
following force-frequency measurements. The final calibration con-
traction at 100 Hz and the subsequent measured contractions were
separated by 60 s. The force-frequency relationship contractions
consisted of two twitch contractions (1 Hz), followed by single
contractions of 1-s duration at each of nine different frequencies (5,
10, 15, 20, 30, 40, 50, 80, and 100 Hz) performed in ascending order
with 30 s between contractions. Peak force was defined as the
greatest instantaneous force. Thereafter, the force values at each
stimulation frequency were normalized to the force obtained at 100
Hz. The force-frequency relationship was fitted with a Hill curve and
evaluated for frequency at 50% of the maximum force response (11).
Statistical Analysis
Dependent variables measured over several time points/periods
(force and EMG during explosive voluntary contractions, evoked
twitch, and octet force) were analyzed using a three-way (group 	
session 	 time point) ANOVA. Similarly, the force-frequency rela-
tionship was assessed by a three-way (group 	 session 	 frequency)
ANOVA. Other dependent variables (MVF, HRT, TPT, slope and
intercept of force-EMG relationship, frequency at 50% of force
response for the force-frequency relationship) were evaluated using
two-way ANOVA (group 	 session). A Greenhouse-Geisser correc-
tion was applied when the ANOVA assumption of sphericity was
violated, and significant interaction effects were followed-up by
independent sample t-tests on the individual percentage change values
for each condition. The change in group mean values was used to
calculate the percentage change values presented. Intraindividual
variability was assessed using the mean intraindividual coefficient of
variation (CV) across the two measurement sessions for the PLA
group [(means  SD) 	 100]. Statistical analyses were completed
using SPSS version 21 (SPSS, Chicago, IL), and statistical signifi-
cance was accepted at P  0.05. Data are presented as means  1SD.
RESULTS
Electrically Evoked Contractile Properties
Resting twitches. There was no influence of supplementation
on resting twitch force (P 0.46 and 0.70 for group	 session
and group 	 session 	 time point interactions; Fig. 1A), EMD
(P 0.63; Fig. 2A), or TPT (P 0.29; Fig. 2B), although there
was a group 	 session interaction for HRT (P  0.018; Fig.
2C). Post hoc analysis showed that the change in HRT was
greater for the BA group (12  10%) compared with the
PLA group (2  11%; P  0.01). Mean CV values for the
PLA group: force at 25 and 50 ms and peak were 14, 9, and
8%; EMD was 7%; TPT was 3%; and HRT was 7%.
Potentiated twitches. There was no influence of supplemen-
tation on potentiated twitch force (P 0.44 and 0.52; Fig. 1B),
EMD (P  0.48 Fig. 2D), or TPT (P  0.32; Fig. 2E).
However, there was a group 	 session interaction for HRT
(P  0.041; Fig. 2F) and post hoc analysis showed that the
change in HRT was greater for the BA group (7  11%)
compared with the PLA group (1  8%; P  0.050). Mean
CV values for the PLA group: force at 25 and 50 ms and
peak were 6, 3, and 3%; EMD was 6%; TPT was 3%; HRT
was 4%.
Octet contractions. Supplementation did not influence
resting octet force at any time point (Fig. 1C). Mean CV
values for the PLA group: force at 25 and 50 ms and peak
were 10, 3, and 4%.
Fig. 1. Electrically evoked force of -alanine (BA) and placebo (PLA) groups
pre- and postsupplementation: resting twitch force (A), potentiated twitch force
(B), and octet force (C). Data are means  1SD.
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Force-frequency relationship. The peak force at each fre-
quency of stimulation (Fig. 3) and the frequency at 50% of the
force response (Table 1) were both unaffected by supplemen-
tation. Mean CV values for relative force (%maximum at 100
Hz) in PLA group were 6–8% at 1–10 Hz, 1–3% at 15–80 Hz,
and 6% for the frequency at 50% of force response.
Maximum and Explosive Voluntary Force Production
There was no affect of supplementation on MVF (Fig. 4A).
The mean CV for MVF in the PLA group was 3%. Similarly,
there was no influence of supplementation on force measured
at 25-ms intervals during explosive voluntary contractions
(Fig. 4A). The mean CV values for voluntary force production
in the PLA group were 13–17% at 25–50 ms and 4–7% from
75–150 ms.
Neuromuscular Activation
Agonist neuromuscular activation during maximum volun-
tary and explosive voluntary contractions. Agonist EMG nor-
malized to Mmax during MVCs and explosive contractions was
not affected by supplementation (Fig. 4B), indicating that
neuromuscular activation was consistent across measurement
sessions. The mean CV values for agonist EMG in the PLA
group were 26, 23, and 9% in the 0- to 50-ms, 50-, to 100-ms,
and 100- to 150-ms time windows, and 13% at MVF.
Force-EMG relationship. The slope and y-intercept of the
force-EMG relationship were unaffected by supplementation
(Fig. 5 and Table 1). The mean CV value for slope of the
force-EMG relationship in the PLA group was 15%. Although
the CV was very high for the intercept of the relationship
(80%) as a consequence of intercept values being close to
zero, the mean difference between sessions was actually
very low when expressed as a percentage of maximal EMG
at MVF (4%).
DISCUSSION
The present study is the first to comprehensively examine
the influence of BA supplementation on the electrically evoked
contractile properties of human skeletal muscle in vivo. BA
supplementation had no effect on the force-frequency relation-
ship, evaluated during submaximal muscle stimulation. Simi-
larly, BA did not influence the EMD, explosive force (at 25 and
50 ms), peak force or TPT of resting twitch, or potentiated
Fig. 2. Contraction times during twitch contractions
evoked via femoral nerve stimulation for BA and PLA
groups pre- and post-supplementation. Resting twitch:
electromechanical delay (EMD; A), time-to-peak ten-
sion (TPT; B), and half-relaxation time (HRT; C). Po-
tentiated twitch: EMD (D), TPT (E), and HRT (F). Data
are means  1SD. **P  0.01 and *P  0.05 for post
hoc independent t-test on %change values in BA and
PLA groups.
Fig. 3. Force-frequency relationship assessed during submaximal percutaneous
stimulation for BA and PLA groups pre- and post-supplementation. Data are
means  1SD.
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twitch or octet contractions elicited by supramaximal stimula-
tion of the femoral nerve. In line with these findings, there were
no changes in maximum or explosive voluntary force produc-
tion following BA supplementation. The only significant effect
of BA was a 12 and 7% reduction in HRT during resting and
potentiated twitch contractions.
Knee Extensor Intrinsic Contractile Properties
The force-frequency relationship of the knee extensors was
evaluated during submaximal muscle stimulation at a range of
frequencies (1–100 Hz) to evaluate potential effects of BA
supplementation on calcium handling and sensitivity, since an
association between intracellular calcium levels and force pro-
duction in response to different stimulation frequencies has
previously been shown (5). BA supplementation, however, had
no effect on knee extensor force production at relatively low
(1–15 Hz) or high (20–80 Hz) frequencies of muscle stimu-
lation, corresponding to relatively low (19–53% force at 100
Hz) and high (63–95% force at 100 Hz) levels of force.
Previous in vitro research showed that increasing cytoplasmic
carnosine levels from those normally present to levels ap-
proaching those attained after supplementation produced a
marked enhancement in Ca2 sensitivity (i.e., an increased
force response to submaximal Ca2 levels) of fibers from
human VL, as well as enhanced Ca2 release in type I fibers
(11). Thus the present data showing no effect of BA supple-
mentation on the force-frequency relationship, the in vivo
analog of the force-calcium concentration relationship (5, 27),
responses might therefore be taken to imply that supplemen-
tation did not grossly influence Ca2 sensitivity (10, 11) or
Ca2 release (11, 33).
The present force-frequency data are supported by the
findings that force and contraction time responses to supra-
maximal nerve stimulation at low (resting and potentiated
twitch) and high frequencies (300 Hz, octet) were not
affected by BA supplementation. Improved Ca2 sensitivity
or release would be expected to be particularly beneficial in
situations where calcium saturation is submaximal; during
resting twitch contractions evoked by a single nerve impulse,
for example. Combined evaluation of resting and potentiated
twitch responses might have been expected to reveal any
influence of BA supplementation on these processes, since the
mechanisms for potentiation include the phosphorylation of
myosin, which increases the sensitivity of the contractile ele-
ments to Ca2, as well as altered Ca2 handling (39). How-
ever, neither peak force, TPT, nor explosive force (force at 25
Table 1. Characteristics of the force-frequency and force-EMG relationships of BA and PLA groups pre- and
postsupplementation
Pre Post
BA PLA BA PLA
Force-frequency relationship
Frequency at 50% of force response, Hz 17.3  2.4 18.8  1.5 16.8  1.7 18.0  1.9
Force-EMG relationship
Intercept (RMS:Mmax) 0.49  0.74 0.70  0.47 0.53  0.91 0.56  0.43
Slope (RMS:Mmax/N) 0.0175  0.0054 0.0180 0.0035 0.0174 0.0037 0.0170 0.0037
Data are means 1SD. BA, -alanine; PLA, placebo; RMS, root mean square; Mmax, M-wave area.
Fig. 4. Explosive and maximum voluntary force (MVF) of BA and PLA groups
pre- and post-supplementation (A). Agonist EMG normalized to M-wave area
(Mmax) during explosive contractions (0–50, 50–100, and 100–150 ms from
onset) and at MVF for the BA and PLA groups pre- and postsupplementation
(B). RMS, root mean square. Data are means  1SD.
Fig. 5. Force-EMG relationship measured during submaximal voluntary con-
tractions (15–90% MVF) for BA and PLA groups pre- and postsupplementa-
tion. Data are means  1SD.
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and 50 ms) of resting and potentiated twitches was affected
by BA supplementation. Similarly, the resting and potenti-
ated twitch EMD, which reflects the time for excitation-
contraction coupling processes and for muscle shortening to
remove slack from the muscle tendon unit (29, 31), was
unaltered following BA supplementation. These data further
imply that BA supplementation had little influence on Ca2
sensitivity or release.
The current data appear at odds with the human single fiber
data mentioned above (11) and recent findings in mouse
muscle where 10–31% increases in force were shown at
frequencies between 25 and 125 Hz, but not at 1 Hz, following
BA supplementation (13). Several factors could explain the
present results and apparent contrast with the previous data.
Firstly, there are obvious differences with the study of Dutka et
al. (11), including the manner by which they increased carnos-
ine levels (acute exposure to a carnosine containing solution),
the conditions of the muscle (skinned fibers devoid of connec-
tive tissue and not attached to bone), and the manner in which
it was activated (exposure to Ca2-buffered solutions), all of
which bear little resemblance to the present in vivo study.
Secondly, although enhanced Ca2-induced Ca2 release was
observed following exposure to carnosine in single fiber prep-
arations (11), the authors concede that this may not occur in
vivo, since this mechanism might have limited relevance to the
control of Ca2 release through ryanodine receptors by the
dihydropyridine receptors (12, 25). Thirdly, species differences
in carnosine metabolism and histidine-containing dipeptide
content (4, 13) could explain the discrepancy between the
data of Everaert et al. (13) in mice and the data from the
present study. The potential for interspecies differences is
suggested by the fact that previous human data showed no
fiber-type differences in the carnosine-related changes in
Ca2 sensitivity (11), while there was some suggestion of
fiber type differences in mice (i.e., differences in the re-
sponse of “slow” soleus vs. “fast” extensor digitorum longus
muscles to BA supplementation) (13). It should be noted
that we did not measure muscle carnosine content in the
present study and so we cannot confirm the actual change
due to BA supplementation or whether this directly relates
to the individual responses in muscle contractile properties.
It is likely, given the previous data on the topic (e.g., Ref.
19), that the increase in muscle carnosine would be 15
mmol/kg dry muscle or 65% in these participants, with
this supplementation regimen.
While the majority of the evoked contractile properties
showed no change in response to BA supplementation, HRT
decreased by 7–12% during resting and potentiated twitch
contractions. Muscle relaxation is initiated by a reduction in
sarcoplasmic reticulum Ca2 concentration. The rate of relax-
ation may be influenced by 1) the rate of dissociation of Ca2
from troponin (26); 2) the rate of translocation of Ca2 to a site
close to the sarcoplasmic reticulum (28); and 3) the rate of
reuptake of Ca2 into the sarcoplasmic reticulum by ATPase
driven Ca2 pumps (30). At present, there do not appear
to be any reports of carnosine influencing these aspects
of excitation-contraction coupling. Interestingly, however,
Everaert et al. (13) reported an attenuation of the fatigue-
related increases in relaxation times after BA supplementa-
tion in murine soleus muscle. While their finding in this case
could be a consequence of enhanced buffering capacity,
during the repeated contractions, since BA supplementation
had no influence on resting rate of relaxation, their report
further highlights the functional implications of the present
data. During fatigue, the rate of muscle relaxation slows as
a consequence of a reduced rate of cross-bridge dissociation
or impaired Ca2 pumping into the sarcoplasmic reticulum
(2). The latter is energetically costly (30), and, as such, any
improvements in Ca2 handling with BA supplementation
could reduce the total energy expenditure during high-
intensity cyclic joint movements by reducing that energy
cost and also by improving the efficiency of joint move-
ments by reducing co-contraction. Future research should
attempt to confirm the present findings and extend them by
investigating the changes in evoked contractile properties
during fatigue to better understand the influence of BA
supplementation on muscle contractility and implications
for metabolic and movement efficiency during exercise.
Voluntary Force Production and Motor Control
BA supplementation had no effect on MVF, a finding
consistent with the lack of changes in electrically evoked
twitch or tetanic (octet) peak force in the present study.
Maximum isometric force is not affected by either increased
Ca2 sensitivity or increased myoplasmic Ca2 concentration
(27), and previous studies reported minimal effects of carnos-
ine on maximum calcium-activated force (0–3% increase) (11)
and of BA supplementation on maximal twitch and tetanic
force (13). Improved Ca2 sensitivity or release would be
expected to be beneficial for force production in situations
where calcium saturation is submaximal (e.g., during the rising
phase of voluntary force production where neuromuscular
activation is submaximal; Ref. 14) and during sustained sub-
maximal contractions. Thus one might have expected improve-
ments in explosive voluntary force and/or alterations in the
force-EMG relationship, indicative of the change in neuromus-
cular activation required to produce a given change in force, if
BA supplementation had influenced these Ca2-related func-
tions. However, in accordance with the lack of changes in the
force-frequency relationship, as well as the force responses
during twitch and octet contractions, BA supplementation did
not influence voluntary explosive force or the force-EMG
relationship. The similar neural drive during both the MVCs
and explosive voluntary contractions confirm that the voluntary
force measurements were not confounded by changes in neu-
romuscular activation over time.
Conclusions
The results of the present study showed that BA supplemen-
tation had no effect on the force-frequency relationship, im-
plying a lack of any effect on muscle Ca2 sensitivity or
release. In support of these data, there was no effect of BA
supplementation on force responses to resting and potentiated
twitches and octet contractions. As such, the study findings do
not support the idea that exercise performance and capacity
improvements after BA supplementation are due to enhanced
Ca2 sensitivity or release. We do, however, show a reduction
in HRT with BA supplementation, which might possibly be
explained by enhanced reuptake of Ca2 into the sarcoplasmic
reticulum. This has potentially important implications for the
efficiency of muscle contraction following BA that should be
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explored in future studies, since this could conceivably con-
tribute to the ergogenic potential of BA supplementation dur-
ing high-intensity exercise involving rapid muscle contrac-
tions.
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Results BA supplementation had no effect on volun-
tary or electrically  evoked isometric force production, or 
twitch electromechanical delay and time-to-peak tension. 
There was a significant decline in muscle HRT in fresh and 
fatigued muscle conditions  during both resting (3 ± 13%; 
19 ± 26%) and potentiated (1 ± 15%; 2 ± 20%) twitch 
contractions.
Conclusions The mechanism for reduced HRT in fresh 
and fatigued skeletal muscle following BA supplementation 
is unclear. Due to the importance of muscle relaxation on 
total energy consumption, especially during short, repeated 
contractions, BA supplementation may prove to be benefi-
cial in minimising contractile slowing induced by fatigue.
Trial registration The trial is registered with Clinicaltri-
als.gov, ID number NCT02819505.
Keywords Contractile properties · Electrical stimulation · 
Muscle fatigue · Carnosine
Abbreviations
휂
2
g
  Generalised eta squared
휂
2
p
  Partial eta squared
ANOVA  Analysis of variance
BA  β-alanine
Ca2+  Calcium
CV  Coefficient of variation
EMD  Electromechanical delay
EMG  Surface electromyography
H+  Hydrogen cation
HRT  Half-relaxation time
Mmax  The mean M-wave area of the three supramaxi-
mal stimuli
M-wave  Muscle action potential
MVIC  Maximal voluntary isometric contraction
MVIF  Maximal voluntary isometric force
Abstract 
Purpose In fresh muscle, supplementation with the rate-
limiting precursor of carnosine, β-alanine (BA), results in 
a decline in muscle half-relaxation time (HRT) potentially 
via alterations to calcium  (Ca2+) handling. Accumulation 
of hydrogen cation  (H+) has been shown to impact  Ca2+ 
signalling during muscular contraction, carnosine has the 
potential to serve as a cytoplasmic regulator of  Ca2+ and 
 H+ coupling, since it binds to both ions. The present study 
examined the effect of BA supplementation on intrinsic 
in-vivo isometric knee extensor force production and mus-
cle contractility in both fresh and fatigued human skeletal 
muscle assessed during voluntary and electrically evoked 
(nerve and superficial muscle stimulation) contractions.
Methods Twenty-three males completed two experimen-
tal sessions, pre- and post- 28 day supplementation with 
6.4 g.day−1 of BA (n = 12) or placebo (PLA; n = 11). Iso-
metric force was recorded during a series of voluntary and 
electrically evoked knee extensor contractions.
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PLA  Placebo
RF  Rectus femoris
RMS  Root mean squared
TPT  Time-to-peak tension
TTF  Time-to-task failure
VL  Vastus lateralis
VM  Vastus medialis
Introduction
Carnosine (β-alanyl-L-histidine) is a cytoplasmic dipep-
tide, synthesised from β-alanine (BA) and histidine and is 
found in high concentrations in skeletal muscle. The syn-
thesis of carnosine is limited by the availability of BA from 
the diet, while supplementation with BA over a number of 
weeks results in significant increases in the skeletal muscle 
carnosine content (Harris et al. 2006; Hill et al. 2007). BA 
supplementation has been shown to consistently increase 
human skeletal muscle carnosine concentrations, and by 
an equal amount in both type I and II muscle fibres (Hill 
et  al. 2007), with increases of 40–80% evident depending 
upon dose (3.2–6.4 g day−1) and duration of administration 
(4–10 weeks) (Harris et al. 2006; Hill et al. 2007). Increas-
ing skeletal muscle carnosine concentrations via BA sup-
plementation in both upper and lower limbs has consist-
ently been shown to benefit high-intensity exercise capacity 
and performance, as highlighted by several reviews (Sale 
et al. 2010, 2013) and a recent meta-analysis (Hobson et al. 
2012).
With a pKa of 6.83 for the histidine imidazole ring when 
combined with BA and the abundance of carnosine within 
skeletal muscle, it has been proposed that the improve-
ments in high-intensity exercise outcomes following BA 
supplementation are the result of increased muscle buffer-
ing capacity over the exercise pH transit range (Hill et al. 
2007). Whilst the role of carnosine as an intracellular pH 
buffer is undisputable, other physiological roles for carno-
sine underlying high-intensity exercise improvements fol-
lowing BA supplementation have been proposed (Sale et al. 
2010). Carnosine can increase the sensitivity of the calcium 
 (Ca2+) release channels in the sarcoplasmic reticulum and/
or the sensitivity of the contractile apparatus in chemi-
cally skinned muscle fibres from frogs (Lamont and Miller 
1992), mechanically skinned rat muscle fibres (Dutka and 
Lamb 2004) and type I and type II human skeletal muscle 
fibres (Dutka et  al. 2012). Muscle  Ca2+ release channels 
contain saturable binding sites for carnosine, indicating that 
carnosine has the potential to alter the  Ca2+ channel itself 
(Batrukova and Rubstov 1997). Until recently, however, 
research has been limited to rodent and in-vitro models.
Recent work (Hannah et  al. 2015) examined the 
effect of BA supplementation on human skeletal muscle 
contractile properties and force production capabilities 
in-vivo. BA supplementation did not alter maximal or 
explosive voluntary isometric force production, or the 
force–frequency relationship (Hannah et  al. 2015), this 
relationship is the in-vivo analogue of the force–cal-
cium concentration relationship (Batrukova and Rubstov 
1997). These findings were in-line with the hypothesis 
arising from our previous exercise performance studies 
(Sale et  al. 2010, 2013) proposing that the main physi-
ological role for carnosine in improving high-intensity 
exercise performance related to intracellular pH buffering 
and not to increased  Ca2+ sensitivity of the in-vivo con-
tractile apparatus. An unexpected result was a significant 
decline in half-relaxation time (HRT) during both rest-
ing and potentiated twitches following BA supplementa-
tion, making it important to confirm these findings before 
exploring potential underlying mechanisms. Muscle 
relaxation speed can be impacted by the rate of: (1) disso-
ciation of  Ca2+ from troponin (Little et al. 2011); (2) the 
rate of translocation of  Ca2+ to near the site of entry into 
the sarcoplasmic reticulum (Muntener et al. 1995); (3) re-
uptake of  Ca2+ into the sarcoplasmic reticulum by  Ca2+ 
pumps (Nogueira et  al. 2013) and cross-bridge detach-
ment (Allen et  al. 2008). Slowing of skeletal muscle 
relaxation decreases power output and shortening veloc-
ity (Allen et al. 2008), thus limiting performance during 
dynamic exercise where rapidly alternating movements 
are performed (Allen et al. 1995). Improving the relaxa-
tion of skeletal muscle can be energetically beneficial by 
increasing the efficiency of joint movements by reduced 
co-contraction (Nogueira et  al. 2013). This would be 
expected to contribute to enhanced dynamic exercise 
performance, especially where rapidly alternating move-
ments are performed.
High-intensity exercise leads to a more pronounced 
accumulation of hydrogen cation  (H+), a metabolic fac-
tor which might be involved in skeletal muscle fatigue, 
but in combination with other fatigue-induced changes or 
in an indirect manner (Westerblad 2016). It should also be 
highlighted that muscle fatigue is multi-factorial phenom-
enon. Skeletal muscle fatigue is generally accompanied by 
a marked slowing of relaxation (Allen et al. 2008).  H+ are 
proposed to directly or indirectly inhibit sarcoplasmic  Ca2+ 
release during skeletal muscle contraction (Laver et  al. 
2000, 2004). Carnosine has the potential to serve as a cyto-
plasmic regulator of  Ca2+ and  H+ coupling, since it binds to 
both ions (Baran 2000). As such, it could be hypothesised 
that increasing muscle carnosine content, via BA supple-
mentation, would have a more pronounced beneficial effect 
on HRT when the muscle is fatigued (Bergstrom and Hult-
man 1988).
The present study aimed to examine the effects of 28 
days of BA supplementation on intrinsic in-vivo isometric 
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knee extensor force production and muscle contractility in 
both fresh (rested conditions) and fatigued human skeletal 
muscle.
Methods
Ethical approval
All participants were fully informed of any risks and dis-
comforts associated with the study. Participants provided 
written informed consent and completed a health screen 
questionnaire prior to taking part in the study, which was 
first approved by the Nottingham Trent University Ethical 
Advisory Committee.
Participants
Twenty-four male participants were allocated to the two 
supplement groups [placebo (PLA) or BA] on the basis of 
maximal voluntary isometric force (MVIF) values recorded 
during familiarisation. One participant withdrew from the 
study (PLA group; n = 11) with no reason provided, and 
consequently, 23 participants completed all aspects of 
the study (PLA; age, 22 ± 1 years, height, 1.83 ± 0.06  m, 
body mass, 81.4 ± 14.2  kg, MVIF, 600 ± 149  N; and 
BA; age, 22 ± 2 years, height, 1.80 ± 0.05  m, body mass, 
76.0 ± 7.3  kg, MVIF, 565 ± 86 N). Participants had not 
ingested any nutritional supplements, had no injuries of the 
lower limb, and were not involved in any systematic physi-
cal training in the 6 months prior to the study. Participants 
were requested to maintain similar levels of physical activ-
ity and dietary intake, which was verbally confirmed at the 
start of each session. None of the participants were vegetar-
ian or vegan, and therefore, they would likely have encoun-
tered small amounts of BA in their diet.
Study design
This was a double-blind, placebo-controlled study with 
all raw data analyses, exclusions, and statistical analyses 
undertaken blind to the supplement group. Participants 
undertook three experimental sessions; a familiarisation 
session, which preceded a baseline session by ~7 days, 
and a follow-up session after 28 days of supplementation. 
Participants were instructed to abstain from alcohol and 
strenuous/unaccustomed exercise for 36 h before measure-
ment sessions, with caffeine prohibited on the day of test-
ing. Compliance with these requests was confirmed ver-
bally with participants before commencing each session. 
Measurement sessions recorded force and surface electro-
myography (EMG) during a series of voluntary and invol-
untary (electrically evoked) isometric contractions of the 
knee extensors of the dominant leg. All participants were 
first familiarised with the protocol measures, both baseline, 
and follow-up sessions involved an identical protocol per-
formed according to a strict schedule.
Supplementation
Participants were provided with 6.4 g day−1 of either BA 
(sustained-release CarnoSyn™; NAI, Inc. San Marcos, 
USA) or a matched PLA (maltodextrin; NAI, Inc. San 
Marcos, USA) for 28 days (2 × 800 mg tablets, ingested 4 
times per day). Based on similar BA supplementation pro-
tocols muscle carnosine content was expected to increase 
to ~ 38 mmol·kg−1 dry muscle (based upon a 65% increase 
from a baseline concentration of 23  mmol·kg−1 dry mus-
cle) or 65% above the typical carnosine content of indi-
vidual eating a mixed diet (Harris et  al. 2006; Sale et  al. 
2013). The sustained-release formulation used in this study 
has been shown to reduce or remove the paraesthesia often 
experienced by participants following doses of free BA 
powder (Decombaz et  al. 2012). Supplement compliance 
was verified with participant logs. Compliance was simi-
lar in both groups and was reported as 91 ± 6% (BA) and 
92 ± 9% (PLA; independent sample t test, P = 0.68); no 
feelings of paraesthesia were reported. Supplements were 
provided in identical white tubs by an individual blind to 
the supplement groups. BA tablets were tested by the man-
ufacturer before release for the study and conformed to the 
label claim for BA content. To ensure no contamination 
with steroids or stimulants according to the International 
Organization for Standardization (IOS) 17,025 accredited 
tests, the BA and PLA supplements were independently 
tested by HFL Sports Science.
Experimental setup
The experimental setup for the determination of isomet-
ric knee extension force, EMG, and electrical stimulation 
in our laboratory has been described in detail previously 
(Hannah et al. 2015).
Isometric knee extension force
The participant was strapped into a custom-built dynamom-
eter with knee and hip joint angles of ~95 and 100° (180° 
= full extension), and with an ankle cuff attached ~2  cm 
proximal to the medial malleolus secured around the par-
ticipant’s dominant leg, and which was in series with a 
linear strain gauge (Model 615; Tedea-Huntleigh, Her-
zliya, Israel). The chair position, strain gauge position, and 
strapping setup were recorded during the familiarisation 
session and replicated identically during subsequent test-
ing sessions. Force signals were amplified (×1,000) in the 
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frequency range of 0–500  Hz, sampled at 2000  Hz using 
an external A/D converter (Model 1401; CED, Cambridge, 
UK), interfaced with a personal computer (PC) using the 
Spike 2 software (CED). Force data were low-pass filtered 
in both directions at 450 Hz using a fourth-order zero-lag 
Butterworth filter before analysis. Baseline resting force 
was subtracted from all force recordings to correct for the 
effects of gravity.
Electromyography
EMG signals were recorded from the superficial quadri-
ceps: m. rectus femoris (RF), m. vastus medialis (VM), and 
m. vastus lateralis (VL). EMG signals were pre-amplified 
by active EMG leads (input impedance: 100 MΩ; com-
mon mode rejection ratio: >100 dB; base gain: 500; first 
order high-pass filter set to 10  Hz; Noraxon, Scottsdale, 
AR) connected in series to a custom-built junction box and 
subsequently to the same analogue–digital converter and 
PC software that enabled synchronisation with the force 
data. The signals were sampled at 2000  Hz. EMG data 
were band-pass filtered in both directions between 20 and 
450  Hz using a fourth-order zero-lag Butterworth filter 
before analysis.
Electrical stimulation
Knee extensor contractile properties were assessed using 
a constant current variable voltage stimulator (DS7AH; 
Digitimer, Welwyn Garden City, UK). Square-wave pulses 
(0.2  ms duration) were delivered via: (1) supramaximal 
femoral nerve stimulation to evoke maximal resting twitch, 
potentiated twitch, and octet contractions; and (2) percu-
taneous submaximal muscle stimulation to evoke contrac-
tions at a range of frequencies (1 to 100 Hz) to assess the 
force–frequency relationship. A cathode stimulation probe 
(1  cm diameter; Electro-Medical Supplies, Wantage, UK) 
and an anode (7 × 10  cm carbon rubber electrode; Elec-
tro- Medical Supplies) were used to elicit femoral nerve 
stimulation. Two carbon rubber electrodes (14 × 10  cm; 
Electro-Medical Supplies) were used to elicit percutaneous 
stimulation.
Protocol and measurements
Identification of force and EMG onset for all evoked and 
voluntary contractions was conducted manually using 
visual identification (Hannah et  al. 2012, 2015), which is 
considered more valid than the use of automated identifi-
cation methods (Tillin et al. 2013). Voluntary and evoked 
contractions were elicited in accordance with a previously 
published method (Hannah et  al. 2012, 2015; Tillin et  al. 
2013) and are described below in brief.
Resting twitches
A single electrical impulse was delivered with stepwise 
increments in the current to evoke a twitch response, until 
a plateau in the amplitude of twitch force and compound 
muscle action potentials (M-waves) was reached. To ensure 
supramaximal stimulation, stimulus intensity was increased 
by 25% above the value required to evoke a plateau. Three 
discrete supramaximal stimuli were then evoked to elicit 
maximal twitch responses and M-waves. Electromechanical 
delay (EMD) was defined as the time difference between 
M-wave onset (1st electrode site to be activated) and force 
onset. Twitch force at 25 and 50 ms from force onset, was 
measured as markers of the explosive force production, 
peak force, time-to-peak tension (TPT), and half-relaxation 
time (HRT) were also reported. All measurements were 
averaged across the three maximal twitch contractions. 
The M-wave response for the three quadriceps electrodes 
was measured for M-wave area, from EMG onset to the 
point where the signal returned to baseline, and averaged 
across the three sites. The mean M-wave area of the three 
supramaximal stimuli was defined as the maximal M-wave 
area (Mmax) and was used for normalisation of voluntary 
quadriceps EMG.
Maximum voluntary contractions and potentiated twitches
Participants were instructed to produce four maximal vol-
untary isometric contractions (MVIC), “as hard as possi-
ble” for 3–4 s. Strong verbal encouragement reiterating the 
instructions was provided during and after each contraction, 
together with visual onscreen feedback. Following each 
MVIC, supramaximal stimulation of the femoral nerve at 
the same configuration and stimulus intensity as the resting 
twitches was elicited to evoke maximal potentiated twitch. 
MVIF was defined as the greatest instantaneous force dur-
ing either the knee extensor MVICs or explosive voluntary 
contractions (see below). The root mean square (RMS) of 
the EMG signal for each muscle (RF, VM, and VL) was 
calculated over a 500 ms epoch surrounding MVIF (250 ms 
either side) and normalized to the corresponding Mmax. All 
sites were then averaged to calculate a mean quadriceps 
value. EMD, force at 25 and 50 ms from onset, peak twitch 
force, TPT, and HRT were averaged across the four maxi-
mal potentiated twitch contractions.
Explosive voluntary contractions
Participants completed isometric explosive voluntary con-
tractions, starting each contraction completely relaxed, 
contracting their knee “as fast and hard as possible” for 
~1  s, with an emphasis on “fast”. The three contractions 
with the greatest maximum rate of force development, 
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achieving the following criteria, were used for analysis: 
(1) no prior countermovement or pretension, and (2) peak 
force >80% MVIF. Explosive force was measured at 25 ms 
intervals up to 150 ms after force onset. The RMS of the 
EMG signal from each muscle was measured over three 
consecutive 50  ms time periods from EMG onset of the 
first agonist muscle to be activated (i.e., 0–50, 50–100, and 
100–150 ms). Thereafter, RMS at each EMG site was nor-
malized to Mmax and averaged to provide a mean quadri-
ceps value. All measurements were averaged across the 
three selected contractions.
Force–EMG relationship (via voluntary incremental knee 
extension contractions)
Submaximal knee extensor contractions were completed 
at 15% increments of MVIF, in ascending order, separated 
by ≥20 s. Force target levels were displayed on screen by 
horizontal cursors, with participants instructed to reach the 
target as quickly as possible, and then maintain this target 
force level as accurately as possible for ~3 s. During each 
contraction intensity, the RMS of the EMG and average 
force over a stable  500  ms part of the force trace (mini-
mal standard deviation of the force trace for that contrac-
tion). The EMG RMS values were normalized to Mmax and 
plotted against the respective force values. Linear regres-
sion was used to evaluate the slope and intercept of the 
force–EMG relationship incorporating all data between 15 
and 90% MVIF.
Octet contractions
Octet contractions (8 impulses at 300 Hz) were evoked via 
supramaximal stimulation of the femoral nerve. In sum-
mary, three discrete pulses (≥15  s apart) were delivered 
with a supramaximal current (+25%) to evoke maximal 
octet contractions. The octet force response was measured 
at 25 and 50 ms from force onset, as well as at the peak. 
All measurements were averaged across the three analysed 
contractions.
Force–frequency relationship
Tetanic contractions were elicited via submaximal percu-
taneous electrical stimulation of the quadricep to exam-
ine the force–frequency relationship (Lamont and Miller 
1992). 100 Hz contractions were evoked at increasing cur-
rent intensities, ≥30 s apart, to determine the current that 
elicited 50% of MVIF. This current was then used for the 
following force–frequency measurements. The final cali-
bration contraction at 100  Hz and the subsequent meas-
ured contractions were separated by ≥60 s. The force–fre-
quency relationship contractions consisted of two twitch 
contractions (1 Hz), followed by single contractions of 1 s 
duration at each of nine different frequencies (5, 10, 15, 20, 
30, 40, 50, 80, and 100 Hz) performed in ascending order 
with ≥30 s between contractions. Peak force was defined as 
the greatest instantaneous force. Thereafter, the force val-
ues at each stimulation frequency were normalized to the 
force obtained at 100 Hz. The force–frequency relationship 
was fitted with a Hill curve and evaluated for frequency 
at 50% of the maximum force response (Dutka and Lamb 
2004).
Sustained isometric knee extensor hold
To induce  H+ accumulation within the quadricep muscles, 
participants were instructed to perform a voluntary isomet-
ric contraction at 45% of MVIF for “as long as possible”. 
The start of the sustained fatigue hold was defined as the 
time when force was greater than 40% of MVIF, and ter-
minated when force fell below 5% of the target force for 
more than 3  s, despite strong encouragement. Strong ver-
bal encouragement was provided alongside visual feedback 
displayed onscreen. The time between start and end of 
the sustained fatigue was defined as the time-to-task fail-
ure (TTF), with average force recorded across this time. 
Impulse (kN.s) was calculated as the product of the aver-
age force and TTF. It has been estimated that TTF would 
be ~78 s for a contraction held at 45% of MVIC force (Ahl-
borg et al. 1972). Immediately upon completion of the sus-
tained fatigue hold, participants repeated all voluntary and 
evoked contractions.
Blood samples
Fingertip capillary blood samples were taken at rest, imme-
diately prior to and 5 min following the sustained fatigue 
hold. Fingertip capillary blood lactate measured 5  min 
post-exercise provides an estimate of lower limb blood lac-
tate contractions (Comeau et al. 2011). Sampling involved 
the collection of 80 µL of whole blood into a heparin-
coated clinitube; all samples were analysed immediately 
post-sampling (Radiometer Ltd, UK).
Statistical analysis
Based on an a priori power calculation, a minimum of 
22 participants were required to achieve 92% power at 
P < 0.05. Calculations were based on the previous findings 
(Hobson et al. 2012), with 24 participants being recruited 
to allow for dropouts. Statistical analyses were completed 
using SPSS version 22 (SPSS Inc., Chicago, IL, USA), 
with statistical significance accepted at P ≤ 0.05. Data are 
presented as means ± 1 standard deviation (SD). Depend-
ent variables (MVIF, EMD, HRT, TPT, slope, and intercept 
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of force–EMG relationship, frequency at 50% of force 
response for the force–frequency relationship) were evalu-
ated using a two-way mixed-model (group × session) analy-
sis of variance (ANOVA). Dependent variables measured 
over several time points (force and EMG during explosive 
voluntary contractions, evoked twitch, and octet force) 
were analysed using a three-way mixed-model (group × ses-
sion × time) ANOVA. All variables were assessed during 
both fresh and fatigued conditions. The sustained fatigue 
time-to-task failure (TTF) and impulse were analysed using 
a two-way mixed-model ANOVA.
The impact of the fatigue hold contraction on depend-
ant variables (MVIF, EMD, HRT, TPT, slope, and inter-
cept of force–EMG relationship, frequency at 50% of force 
response for the force–frequency relationship) was analysed 
using a three-way mixed-model (fatigue × group × session) 
ANOVA. Percentage change between fresh and fatigued 
values for the dependent variables measured over sev-
eral time points (force and EMG during explosive volun-
tary contractions, evoked twitch, and octet force) were 
analysed using a three-way mixed-model (percentage 
change × group × session) ANOVA. A Greenhouse–Geis-
ser correction was applied when the ANOVA assumption 
of sphericity was violated. Effect size for multiple com-
parisons was calculated using partial (휂2
p
) and generalised 
(휂2
g
) eta squared (Lakens 2013). Providing two effect sizes 
is suggested to yield a greater understanding of a specific 
effect (Preacher and Kelly 2011). Post hoc comparisons 
to explain any significant interactions are reported with 
Cohen’s d effect size. An effect size of 0.2–0.5 was defined 
as small, 0.5–0.8 as medium, and ≥0.8 as large (Schüne-
mann et al. 2008). Intra-individual variability was assessed 
using the mean intra-individual coefficient of variation 
(CV) across the two measurement sessions for the PLA 
group [(SD/mean) × 100], the current research CVs are in 
line with those reported previously using the same equip-
ment (Hannah et al. 2015).
Results
Electrically evoked contractile properties
Resting twitches
Supplementation did not significantly influence twitch 
force, EMD, or TPT (Table 1). There was, however, a sig-
nificant group × session interaction for HRT in both fresh 
(P = 0.04, n2
p
 = 0.2, n2
g
 <0.001) and fatigued (P = 0.03, 휂2
p
 = 
0.2, 휂2
g
 = 0.1; Figs. 1, 2) muscle. Post hoc analysis showed 
that the percentage change in fresh muscle HRT was not 
significantly different between the BA (−2 ± 10 ms; −3 ± 
13%) and PLA group (+8 ± 16 ms; 8 ± 16%) with a large 
effect reported (P = 0.06; Cohen’s d = 0.9). In fatigued 
muscle, post hoc analysis showed that HRT percentage 
change was significantly different between the BA (−25 ± 
34 ms; −19 ± 26%) and PLA (8 ± 16 ms; 0 ± 15%) group 
with a large effect reported (P = 0.05, Cohen’s d = 0.9).
Table 1  Electrically femoral nerve evoked force responses, time-to-peak tension (TPT), and electromechanical delay (EMD) of β-alanine (BA) 
and placebo (PLA) groups pre- and post-supplementation, in fresh and fatigued muscle. Data are means ± 1SD
Pre-supplementation Post-supplementation
Force (N) EMD (ms) TPT (ms) Force (N) EMD (ms) TPT (ms)
25 50 Peak 25 50 Peak
Resting twitch
 Fresh BA 23 ± 5 73 ± 14 88 ± 17 10 ± 1 79 ± 11 24 ± 6 73 ± 17 90 ± 19 10 ± 1 81 ± 9
 Fresh PLA 28 ± 4 79 ± 19 99 ± 26 11 ± 1 82 ± 8 29 ± 5 82 ± 16 104 ± 24 10 ± 1 83 ± 9
 Fatigued BA 22 ± 7 61 ± 22 68 ± 25 11 ± 2 72 ± 16 26 ± 8 71 ± 22 79 ± 23 10 ± 1 74 ± 13
 Fatigued PLA 25 ± 6 58 ± 20 65 ± 24 11 ± 1 69 ± 8 24 ± 4 60 ± 15 67 ± 18 10 ± 2 71 ± 9
Potentiated twitch
 Fresh BA 55 ± 13 142 ± 24 159 ± 26 9 ± 1 79 ± 6 53 ± 8 136 ± 14 155 ± 9 9 ± 1 81 ± 6
 Fresh PLA 60 ± 16 138 ± 37 163 ± 43 9 ± 1 79 ± 9 59 ± 10 142 ± 34 167 ± 38 9 ± 1 82 ± 8
 Fatigued BA 37 ± 11 92 ± 27 101 ± 29 11 ± 1 74 ± 9 40 ± 9 101 ± 19 110 ± 18 10 ± 1 73 ± 10
 Fatigued PLA 42 ± 10 93 ± 25 105 ± 30 10 ± 1 74 ± 4 38 ± 9 93 ± 23 106 ± 28 10 ± 1 74 ± 8
Octet
 Fresh BA 52 ± 15 165 ± 42 223 ± 47 7 ± 2 117 ± 25 64 ± 18 196 ± 37 274 ± 53 7 ± 2 120 ± 24
 Fresh PLA 66 ± 17 190 ± 62 285 ± 94 6 ± 1 127 ± 19 64 ± 17 199 ± 60 296 ± 94 7 ± 2 137 ± 7
 Fatigued BA 62 ± 23 191 ± 49 221 ± 72 7 ± 2 100 ± 23 62 ± 17 182 ± 47 244 ± 68 7 ± 2 114 ± 25
 Fatigued PLA 69 ± 20 191 ± 49 273 ± 72 7 ± 1 123 ± 14 64 ± 16 198 ± 49 283 ± 79 7 ± 2 125 ± 15
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The percentage difference between fresh and fatigued 
resting twitch force remained similar between sessions for 
both supplementation groups. Resting twitch TPT declined 
following completion of the sustained fatigue hold 
(P = 0.001, 휂2
p
휂
2
p
 = 0.4, 휂2
g
 = 0.2), although EMD remained 
similar with no difference between sessions or groups 
(Table 1). Resting twitch HRT significantly increased fol-
lowing the completion of the sustained fatigue hold (P 
<0.001, n2
p
 = 0.7, n2
g
= 0.3; Fig. 1) with no group × fatigue 
or group × session × fatigue interactions.
Potentiated twitches
Supplementation did not significantly influence twitch 
force, EMD or TPT (Table 1). There was, however, a sig-
nificant group × session interaction for HRT in both fresh 
(P  =  0.03, n2
p
= 0.2, n2
g
 <0.001) and fatigued muscle 
(P = 0.03,휂2
p
= 0.2, 휂2
g
 < 0.001; Figs. 1, 2). Post hoc analy-
sis showed that the percentage change in fresh muscle HRT 
was not significantly different between the BA (0 ± 9 ms; 
+1 ± 15%) and PLA group (+7 ± 10 ms; +12±15%) with 
a medium effect reported (P = 0.10, Cohen’s d = 0.7). In 
fatigued muscle, post hoc analysis showed that the percent-
age change in fatigued muscle HRT was significantly dif-
ferent between the BA (−2.7 ± 16 ms; −2 ± 20%) and PLA 
group (12 ± 12 ms; 16 ± 17%) with a large effect reported 
(P = 0.03, Cohen’s d = 1.0).
The percentage difference between fresh and fatigued 
potentiated twitch force remained similar between ses-
sions for both supplementation groups, with only a sig-
nificant effect of time (P = 0.001, 휂2
p
 = 0.5, 휂2
g
 = 0.5). 
Potentiated twitch TPT declined following completion of 
the sustained fatigue hold (P < 0.001, 휂2
p
 = 0.5, 휂2
g
 = 0.5; 
Table 1). Potentiated EMD significantly prolonged follow-
ing the fatigue hold (P = 0.001, 휂2
p
 = 0.45, 휂2
g
 = 0.2) with 
no group × fatigue or group × session × fatigue interactions. 
Potentiated HRT significantly increased following the com-
pletion of the sustained fatigue hold (P < 0.001, 휂2
p
= 0.7, 
휂
2
g
 = 0.4; Fig.  1), with no group × fatigue or group × ses-
sion × fatigue interactions.
Octet contractions
In both fresh and fatigued muscle, supplementation did not 
significantly alter octet peak force, EMD or TPT (Table 1). 
There was, however, a significant group × session interac-
tion for octet HRT in both fresh (P = 0.05; n2
p
 = 0.2; 휂2
g
 = 
0.1) and fatigued (P = 0.01; n2
p
 = 0.3; 휂2
g
 = 0.2; Figs.  1, 
2) skeletal muscle. Post hoc analysis showed that the per-
centage change in fresh muscle was significantly differ-
ent between the BA (−26±30  ms; −20  ±  22%) and PLA 
(0 ± 32 ms; 1 ± 34%) group with a large effect reported 
Fig. 1  Electrically evoked 
half-relaxation time of 
β-alanine (BA) and placebo 
(PLA) groups pre- and post-
supplementation, in fresh and 
fatigued muscle during: resting 
twitch (a), potentiated twitch 
(b), and octets (c). Data are 
means ± 1SD. **P ≤ 0.01 and 
*P ≤ 0.05 for post hoc inde-
pendent t-test between BA and 
PLA groups
Fig. 2  Representative records of the force response during an elec-
trically evoked resting twitch contraction pre- and post-supplemen-
tation with β-alanine under fresh conditions. These records are aver-
aged records from three participants to provide an illustration of the 
decline in twitch half-relaxation time
 Eur J Appl Physiol
1 3
(P = 0.05, Cohen’s d = 0.8). In fatigued muscle, post hoc 
analysis showed that HRT percentage change was sig-
nificantly different between the BA (−11 ± 20 ms; −11 ± 
20%) and PLA (12 ± 19 ms; 7 ± 13%) groups with a large 
effect reported (P = 0.01, Cohen’s d = 1.2).
Octet force percentage change between fresh and 
fatigue was not significantly affected by supplementa-
tion. Octet TPT (P = 0.05, 휂2
p
 = 0.2, 휂2
g
 = 0.1; Table 1) and 
HRT (P = 0.008, 휂2
p
 = 0.3, 휂2
g
 = 0.2; Fig. 1), declined fol-
lowing completion of the sustained fatigue hold with no 
group × fatigue or group × session × fatigue interactions. 
Octet EMD was not significantly influenced following 
the fatigue hold, with no group × fatigue or group × ses-
sion × fatigue interactions (Table 1).
Force–frequency relationship
Supplementation did not significantly influence peak force 
at each frequency of stimulation, and the frequency at 50% 
of the force response (Table 2) in either fresh or fatigued 
muscle. Following the fatigue hold, peak force significantly 
declined (P = 0.001, 휂2
p
 = 0.8, 휂2
g
 = 0.2), although the fre-
quency at 50% of the force response remained unaffected.
Maximum and explosive voluntary force production
Supplementation had no effect on MVIF in fresh or fatigued 
muscle (Fig. 3a). Following the fatigue hold, MVIC signifi-
cantly declined (P < 0.001, 휂2
p
 = 0.9, 휂2
g
 = 0.2), with no dif-
ferences between session and groups (BA: 17–18%; PLA: 
21%; Fig. 3a). There was no effect of supplementation on 
force measures at 25  ms intervals during explosive vol-
untary contractions in fresh and fatigued states (Fig.  3a). 
Explosive force percentage change between fresh and 
fatigue of force remained unaffected by supplementation.
Neuromuscular activation
Agonist neuromuscular activation during maximal 
and explosive voluntary contractions
Agonist EMG normalized to Mmax during MVICs and 
explosive contraction remained uninfluenced by supple-
mentation in fresh and fatigued muscles (Fig. 3b).
Force–EMG relationship
The slope and y-intercept of the force–EMG relationship 
were unaffected by supplementation in both fresh and 
fatigued muscles (Fig. 4; Table 2). The percentage change 
in agonist EMG normalized to Mmax during MVICs and 
explosive contraction was not significantly altered between 
sessions. Ta
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Sustained isometric knee extensor hold
TTF was unaffected by BA (pre: 63.2 ± 13.0  s; post: 
63.4 ± 15.3 s) or PLA supplementation (pre: 77.3 ± 24.8 s; 
Post: 75.3 ± 18.9  s). Impulse was also not significantly 
influenced by BA (pre: 16.1 ± 3.5 kN  s−1; post 16.4 ± 4.6 
kN  s−1) or PLA supplementation (pre: 19.6 ± 4.4 kN  s−1; 
post 19.4 ± 3.2 kN  s−1). Blood lactate concentrations at 
rest and prior to the sustained fatigued hold were not sig-
nificantly different (Table 3). Blood lactate concentrations 
significantly increased 5  min following the sustained iso-
metric knee extensor hold compared to both rest and prior 
to values (P < 0.001, 휂2
p
 = 0.8, 휂2
g
 = 0.6), with no difference 
between sessions or group (Table 3).
Discussion
The key findings from the present study are: (a) no effects 
of BA supplementation on isometric force production 
capacity in either fresh or fatigued skeletal muscle, (b) the 
confirmation of our previous findings (Hannah et al. 2015) 
showing altered fresh muscle relaxation speed following 28 
days of BA supplementation, and (c) that the skeletal mus-
cle relaxation speed is also reduced by BA supplementation 
following muscle fatigue in the absence of any change to 
peak force production or contraction time compared to the 
PLA group. The current investigation examined the influ-
ence of BA supplementation on neuromuscular perfor-
mance measures, associated with  Ca2+ handling within the 
skeletal muscle, a proposed mechanism associated with the 
improvements in exercise performance (Dutka and Lamb 
2004; Everaert et  al. 2013; Guglielmi et  al. 2013; Sale 
et al. 2013) in fresh and fatigued muscle conditions. These 
data are the first to comprehensively examine the effect of 
BA supplementation on voluntary and electrically evoked 
contractile properties of in-vivo fatigued human skeletal 
muscle.
During both fresh and fatigued conditions, BA supple-
mentation has no effect on voluntary isometric force pro-
duction including maximal and explosive force variables. 
Voluntary force peak data are consistent with the lack of 
change in electrically evoked peak force responses noted 
during twitch and octet contractions under both fresh 
and fatigued conditions. There were similar neural drive 
responses during both MVICs and explosive contractions 
pre- and post-supplementation in fresh and fatigued mus-
cle. The current findings in fresh muscle are in-line with the 
previous findings (Hannah et al. 2015), it was proposed that 
if BA supplementation had influenced  Ca2+ related func-
tion, improved explosive voluntary force and/or alterations 
in the force–EMG relationship would have been evident.
Fig. 3  Explosive and maximal voluntary isometric force (MVIF) 
responses (a), and agonist EMG normalized to M-wave area  (Mmax) 
during explosive contractions (0–50, 50–100, and 100–150  ms 
from onset) and at MVIF (b) for the BA and PLA groups pre- and 
post-supplementation, in fresh and fatigued muscles. Data are 
means ± 1SD
Fig. 4  Force–EMG relationship measured during submaximal volun-
tary contractions (15–90% MVIF) for the BA and PLA groups pre- 
and post-supplementation, in fresh and fatigued muscles. Data are 
means ± 1SD
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In both fresh and fatigued in-vivo human skeletal mus-
cles, there was no leftward shift of the force–frequency 
curve, the associated measure of intracellular  Ca2+ levels 
(Batrukova and Rubstov 1997). Thus suggesting that eleva-
tion of carnosine concentrations did not significantly alter 
 Ca2+-related function. That said,  there may have been a 
decline in sarcoplasmic reticulum  Ca2+ release which was 
not documented in the force–frequency curve, due to an 
associated increase in  Ca2+ sensitivity of the myofibrils, 
resulting in the same skeletal muscle force. The current 
research in fresh muscle is in line with the previous in-vivo 
research (Hannah et al. 2015), where increased muscle car-
nosine concentration following a similar 28-day BA supple-
mentation protocol did not alter the force–frequency curve. 
One potential limitation of both studies is that neither 
measured intracellular carnosine concentrations directly. 
That said there are many studies displaying increased mus-
cle carnosine following BA supplementation, almost with-
out exception, on an individual-by-individual basis (Har-
ris et al. 2006; Hill et al. 2007). Thus, we are confident in 
assuming that a significant increase in muscle carnosine 
content would have occurred with the BA supplementation 
protocol implemented in the present study.
The lack of an effect of BA on TPT and force produc-
tion following increased carnosine concentrations is inter-
esting. Based on the previous in-vitro studies in chemi-
cally skinned muscle fibres from frogs (Lamont and Miller 
1992), mechanically skinned rat muscle fibres (Dutka and 
Lamb 2004) and type I and type II human skeletal mus-
cle fibres (Dutka et al. 2012), an alteration to submaximal 
action potential-mediated force responses via increased 
 Ca2+ sensitivity could have been expected. Furthermore, 
the current investigation reported no alteration to potenti-
ated twitch contractions. Given that the phosphorylation 
of the myosin head during these twitches is impacted by 
 Ca2+ sensitivity, any impact of increased carnosine con-
centrations would have been displayed as a resultant effect 
on these measures. In-vitro data following BA supplemen-
tation in mice reported increased carnosine (+156%) and 
anserine content (+46%) in the extensor digitorum lon-
gus muscle and a marked leftward shift of the force–fre-
quency relationship (Everaert et al. 2013). These alterations 
to skinned muscle fibre  Ca2+ handling when exposed to 
increased carnosine concentrations are interesting, although 
both the previous (Hannah et al. 2015) and current in-vivo 
studies suggest that these responses might not be signifi-
cant enough to be evident during whole muscle contraction. 
It might be that the differences between these in-vitro data 
(where carnosine can be indirectly elevated to a consistent 
level) and the data from the current study reflect differ-
ences in the magnitude of intramuscular carnosine eleva-
tion, which we, unfortunately, cannot confirm in the cur-
rent study. It is also important to note that in-vitro research 
is conducted outside the normal intracellular environment, 
and importantly, a number of protocols include the use of 
free magnesium, an inhibitor of skeletal muscle ryanodine 
receptors (Laver et al. 2004). Furthermore, during in-vitro 
studies solutions are added to control pH levels allowing 
examination of the direct effect of carnosine, although this 
is important, these investigations have yet to examine the 
influence of carnosine concentration and varying pH levels. 
The current body of in-vivo research is completely separate 
from the in-vitro data, which might make it unrealistic to 
expect similar findings between research designs.
Increasing muscle carnosine concentrations with 28 
days of BA supplementation resulted in a shorter HRT 
(relative to equivalent PLA times) in fresh and fatigued 
skeletal muscle during both resting and potentiated twitch 
contractions. These are in contrast with HRT in fresh and 
fatigued resting and potentiated twitch contractions follow-
ing PLA supplementation. The altered muscle HRT values 
in the current investigation are in-line with those previously 
reported following the same BA supplementation protocol 
(7–12%; Hannah et al. 2015). Muscle relaxation speed has 
been associated with both  Ca2+ removal from the myo-
plasm  (Ca2+ component) and  Ca2+ dissociation from tro-
ponin followed by cross-bridge detachment (cross-bridge 
component) (Westerblad et  al. 1997). Research conducted 
by Westerblad and Allen (1993),  in fatigued mouse mus-
cle fibres, suggested that the slowing of muscle relaxation, 
apparent under fatigued conditions, was a reflection of 
slowed cross-bridge kinetics, rather than a reduction in the 
rate of  Ca2+ decline at the end of the stimulation train. Yet, 
when these data were repeated in Xenopus muscle fibres, 
the slowing of muscle relaxation was associated with a 
combination of altered cross-bridge kinetics and impaired 
Table 3  Blood lactate concentrations (mmol·l− 1) for the BA and PLA groups pre- and post-supplementation, at rest, prior to, and 5 min follow-
ing the completion of the sustained fatigue hold (+5 min)
Significant differences between concentrations are denoted by * (rest and +5 min) and X (prior to and +5 min). Data are means ± 1SD
Pre-supplementation Post-supplementation
Rest (mmol·l− 1) Prior to (mmol·l− 1) +5 min (mmol·l− 1) Rest (mmol·l− 1) Prior to (mmol·l− 1) +5 min (mmol·l− 1)
BA 1.0 ± 0.3 1.1 ± 0.2 3.8 ± 1.1* X 1.2 ± 0.3 1.3 ± 0.4 3.7 ± 1.3* X
PLA 1.0 ± 0.3 1.1 ± 0.4 3.8 ± 1.3* X 1.3 ± 0.3 1.2 ± 0.2 4.2 ± 1.0* X
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 Ca2+ handling, rather than just slowed cross-bridge kinet-
ics alone. As such, the decline in skeletal muscle HRT fol-
lowing 28 days of BA supplementation shown in the cur-
rent investigation may be associated with alterations to 
skeletal muscle cross-bridge kinetics. Alternatively, the 
decrease in HRT may be associated with the  Ca2+ com-
ponent of skeletal muscle relaxation speed, given that it 
has been proposed that  Ca2+ re-uptake by the sarcoplas-
mic reticulum  Ca2+-ATPase (SERCA) is the rate-limiting 
step in muscle relaxation (Gillis 1985; Dux 1993). The 
transfer of  Ca2+ into the SR lumen by the SERCA pump 
is accompanied by a counter-transport of  H+ out into the 
cytosol (Tran et al. 2009), by acting on  Ca2+-handling pro-
teins directly or via other molecules,  Ca2+ signalling can be 
inhibited or excited (Swietach et al. 2013). The presence of 
carnosine has already been shown to improve isolated rat 
heart muscle contraction and increases free intracellular 
 Ca2+ concentrations (Zaloga et  al. 1996). At a pH of 6.0, 
where a complete decline in  Ca2+ release pump activity 
was evident, the presence of carnosine maintained ~30% 
of pump activity at the same pH. Although speculative, 
these data suggest that increasing carnosine concentrations 
might alter  Ca2+-channel activity by interacting with the 
 Ca2+-channel itself (Batrukova and Rubstov 1997), possi-
bly via the existence of saturable binding site(s) for carno-
sine on the  Ca2+-channel. These data are, however, limited 
by a number of methodological factors, including but not 
limited to, the lack of a  Ca2+ buffer, the overloading of the 
sarcoplasmic reticulum with  Ca2+ concentrations approxi-
mately ten times greater than normal, and the addition of 
un-physiological magnesium concentrations. As such, care 
needs to be taken over the interpretation of these find-
ings. Alternatively, the decrease in HRT may be mediated 
through improved pH control in the microenvironment of 
the  Ca2+ release pump where rapid ATP hydrolysis will 
result in increased release of protons. There could also be 
an indirect mechanism to explain the beneficial effects dis-
played within the current investigation in regards to mus-
cle relaxation. Given the number of other proteins that bind 
to  Ca2+-channels (Berchtold et  al. 2000), carnosine may 
alter the protein interactions with the  Ca2+-channels and/
or bind with the proteins themselves; both of these mecha-
nisms could influence the activity of the  Ca2+-channel via 
increased carnosine concentrations.
Although the mechanism for reducing skeletal muscle 
relaxation time following BA supplementation remains 
unclear, such an outcome might be beneficial to exercise 
performance, especially during short, repeated muscle con-
tractions where muscle relaxation comprises an important 
proportion of total energy consumption (Bergstrom and 
Hultman 1988). During concentric contractions, improve-
ment of muscle recovery time has been shown to be criti-
cal to the amount of post-shortening force decrease (Edman 
1975). Reducing relaxation rates may improve muscle 
power output and exercise performance. These findings 
are particularly important for activities where fast, repeti-
tive contractions, and relaxations occur with no period of 
rest. Future research is essential to confirm an effect of 
BA supplementation and/or muscle carnosine accumula-
tion on SERCA activity and to better understand how these 
isolated muscle effects might relate to repetitive sport-
ing movements and overall performance. It would be of 
benefit to repeat these data in elite athletes where small 
changes to HRT might be advantageous. Equally we might 
speculate that benefits may occur in clinical populations 
such as Brody disease (where SERCA1 activity is signifi-
cantly reduced; Guglielmi et  al. 2013) or Duchenne Mus-
cular Dystrophy (where an excess of cytosol  Ca2+occurs; 
Ohlendieck 2000).
Within the current investigation, isometric knee exten-
sor fatigue hold times were not significantly influenced by 
BA or PLA supplementation, in direct contrast to our previ-
ous findings that showed a 13.2% (9.7 ± 9.4 s) increase in 
45% hold times following BA supplementation (Sale et al. 
2012). The reason for a lack of a significant effect in the 
current study is unclear, given that isometric knee exten-
sor hold times reported by both investigations were similar 
and aligned to times predicted by the Rohmert equation at 
a 45% MVIC (78 s; Ahlborg et al. 1972). At 45% MVIC, 
blood flow is occluded and thus the active muscle fibres are 
largely dependent upon anaerobic energy provision (Ahl-
borg et  al. 1972). Blood lactate sampled from the finger 
5 min post-exercise is indicative of the lower extremity lac-
tate release (Comeau et al. 2011), with groups in the cur-
rent study displaying similar levels of lactate accumulation 
in the lower limb. To greater understand the relationship 
between skeletal muscle HRT, increased carnosine concen-
trations and muscle fatigue, further investigations imple-
menting a dynamic fatiguing protocol are required, since 
contractile slowing (i.e., prolonged half-relaxation time) 
would affect shortening velocity and power output (Jones 
et al. 2006).
Conclusion
The current investigation showed that 28 days of BA sup-
plementation enhanced muscle relaxation time in both 
fresh and fatigued skeletal muscle. Whilst this finding is 
of interest, it remains unclear as to whether it would be 
sufficient to result in improved exercise performance, par-
ticularly in the absence of any changes to the force–fre-
quency relationship, peak force production, or contraction 
time. The mechanism for the ergogenic effect on muscle 
relaxation following increased carnosine content remains 
unclear. It could however, be proposed that  Ca2+ re-uptake 
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via direct or indirect mechanisms associated with SERCA 
pump activity is involved, as this is the rate-limiting step of 
muscle relaxation.
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